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Abstract
Modern medical practice and science involve complex phenotypic definitions. Understand-
ing patterns of association across this range of phenotypes requires co-analysis of high-
dimensional association studies in order to characterise shared and distinct elements. In this
thesis I address several problems in this area, with a general linking aim of making more
efficient use of available data. The main application of these methods is in the analysis of
genome-wide association studies (GWAS) and similar studies.
Firstly, I developed methodology for a Bayesian conditional false discovery rate (cFDR)
for levering GWAS results using summary statistics from a related disease. I extended an
existing method to enable a shared control design, increasing power and applicability, and
developed an approximate bound on false-discovery rate (FDR) for the procedure. Using
the new method I identified several new variant-disease associations. I then developed a
second application of shared control design in the context of study replication, enabling
improvement in power at the cost of changing the spectrum of sensitivity to systematic errors
in study cohorts. This has application in studies on rare diseases or in between-case analyses.
I then developed a method for partially characterising heterogeneity within a disease
by modelling the bivariate distribution of case-control and within-case effect sizes. Using
an adaptation of a likelihood-ratio test, this allows an assessment to be made of whether
disease heterogeneity corresponds to differences in disease pathology. I applied this method
to a range of simulated and real datasets, enabling insight into the cause of heterogeneity
in autoantibody positivity in type 1 diabetes (T1D). Finally, I investigated the relation of
subtypes of juvenile idiopathic arthritis (JIA) to adult diseases, using modified genetic risk
scores and linear discriminants in a penalised regression framework.
The contribution of this thesis is in a range of methodological developments in the
analysis of high-dimensional association study comparison. Methods such as these will have
wide application in the analysis of GWAS and similar areas, particularly in the development
of stratified medicine.
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Chapter 1
Introduction
1.1 Foreword
The scientific background to this thesis involves several scientific and mathematical dis-
ciplines, including genetics, pathology, probability theory and computer science. In this
introduction I give an overview of the parts of these disciplines relevant to my project. Each
chapter begins with a more specific introduction to the topics and literature it covers.
I begin with a discussion of the history of association testing in medicine, landmarked
by the successive introduction of epidemiological methods and increase in the number
of independent variables (dimensionality). As part of this, I discuss the motivation for
conducting and comparing association studies, and the reasons behind the development of
statistical methods for their analysis.
A major application and testing ground for my methods is the field of genome-wide
association study (GWAS). I discuss the motivation for conducting these studies, and describe
some of the relevant statistical procedures. I then categorise and discuss procedures for
comparing association studies, and describe some heuristic arguments regarding efficiency
of data use. Finally, I give an overview of the structure of the remainder of this thesis, and
give an indication of the position of each chapter of this thesis in the wider field of statistical
genetics.
The major contribution of my work has been the development of new statistical methods
for joint analysis of GWAS and other association studies, with a focus on making the best
use of input data. In general, the chapters of this thesis are independent linked experiments
of similar prominence, rather than a single linear narrative in which one experiment directly
leads to another. In the spirit of computational biology, I have represented this below as an
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undirected graph, with vertices representing chapters and edges representing linking ideas
(figure 1.1).
Shared
controls
cFDR
procedure
Leverage
Small
control
cohort
Subgroup
analysis
Ch. 2/3:
 cFDR
Ch. 4:
Replication
Ch. 5:
Subgroups
Ch. 6:
Risk scores
Fig. 1.1 Diagram of chapters of this thesis, with linking ideas.
1.2 Association testing and case-control studies
1.2.1 Philosophy
The question of whether two variables of interest are dependent - in practical terms, whether
information about one can tell us something about the other - is the essence of many
questions in quantitative science, particularly medicine. Establishing association between
observable phenomena is the first step in most investigative processes, usually analysed prior
to investigating more specific phenomena such as causality [Hill, 1965]. A range of statistical
procedures can be used to test for independence, commonly in a frequentist framework
in which the joint distribution of the variables in question can be predicted under a null
hypothesis of independence.
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This area of applied statistical theory is, in a sense, a formalisation of intuition. For much
of the history of medicine, association analyses were interpreted ‘by eye’, with rigorous
probabilistic procedures only established in the past several centuries [Hacking, 1990]. More
precise analytic procedures enable more subtle associations to be found or reduce of the
amount of data required to assert a result. An important analytic procedure devised for this
purpose is the case-control study [Paneth et al., 2004].
A critical step in conducting a case/control study is the assembly of a representative group
of patients with similar illnesses [Paneth et al., 2004]. In order to maximise the power of
association studies, it is sensible to combine patients with only subtle differences in disease
into general case cohorts, seeking to understand the common elements of the disease in
question. The question of what patients and their illnesses have in common (and, by proxy,
what makes them unwell) invites the parallel question of why their illnesses differ. The
analysis of differences takes several forms, and includes searching for similarity between
nominally distinct diseases as well as for heterogeneity in diseases historically considered
homogenous. Studies of this type are becoming more feasible as phenotype characterisation
improves and study sizes increase [Robinson et al., 2014]. Both the comparison of case-
control studies on separate diseases and the analysis of heterogeneity within-diseases present
new statistical challenges, some of which I consider in this thesis.
1.2.2 Historical development
Early association tests
The use of association testing to guide medical practice was widespread long before for-
malised procedures were developed, and evidence of some form of association analysis
is found even in the earliest medical texts. Ancient records such as the Edwin Smith
Papyrus [Feldman and Goodrich, 1999] and the Babylonian Sakikku (diagnostic hand-
book) [Heeßel, 2004] both detail collections of case histories with a view towards identifying
commonalities in presentation. For example, Smith’s papyrus, an incomplete copy of a
document dating from c. 3000BC, demonstrates awareness of an association between trau-
matic spinal injury and limb paralysis. This knowledge effectively arose from a rudimentary
observational study of injured patients.
The use of patient cohorts implied the expectation that patients with similar clinical
conditions would show similar response to interventions, and the assumption that such
cohorts were representative of wider populations with the disease. This was acknowledged by
the tenth-century Persian scholar Avicenna, who, in a protocol for determining drug efficacy,
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included the directive that an observed effect in a patient cohort must occur in repeated
samples from a population to distinguish a potential effect from randomness [Shoja et al.,
2011].
Formalisation of the hypothesis testing procedure took place relatively recently. The
first use of an explicit ‘null hypothesis’ was probably by Laplace [Laplace, 1781], who
assessed the difference in frequency ∆F of sexes amongst children born in London and
Paris. By considering the distribution of ∆F under the null hypothesis H0 that the population
frequencies were equal, Laplace demonstrated that a deviance from equality as large as that
observed was unlikely under H0, and thus generated the first known example of a p-value:
p = Pr(|∆F | ≥ Observed|H0) (1.1)
Development of the case-control study
The first case-control study is difficult to identify, with different elements of the procedure
being introduced separately. Case-control studies are mainly concerned with the aetiology of
diseases rather than their management, and hence diverge from Avicenna’s and the ancient
Egyptian’s primary aims [Paneth et al., 2004]. Early studies were incentivised by epidemics,
during which determining aetiology was of particular importance.
An early success of epidemiology was John Snow’s investigation into causes of cholera in
1854. By considering the location of a group of cases, Snow determined that a likely source
for the outbreak was a water pump, eventually leading to the understanding of the water-
borne nature of cholera. Snow’s study notably lacked a control set; however, a corresponding
investigation by Reverend Henry Whitehead considered controls instead, validating Snow’s
findings and constructing a case/control odds ratio for exposure to the water pump [Paneth
et al., 2004].
The first case-control study in the modern sense was probably Janet Lane-Claypon’s 1920s
study on breast cancer [Lane-Claypon et al., 1926]. In a study of 500 women from across
England with a breast cancer history and 500 matched controls, Lane-Claypon identified
several obstetric and gynaecological risk factors for the disease, many of which have held up
to modern analyses. Even at this early stage in the field, the importance of controlling for
potential biases was acknowledged and discussed [Paneth et al., 2004, Press, 2008].
The study was a landmark in many respects. It combined the existing approaches of case-
series analysis with the procedure of anamnesis (focused and systematic history-taking) and
systematic comparison of differences between groups [Paneth et al., 2004], and demonstrated
the potential contribution such studies could make to public health. A subsequent replication
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study in the USA [Wainwright, 1931] helped set a precedent for accurate description of
research methods in the interests of subsequent replication [Paneth et al., 2004].
1.2.3 Statistical hypothesis testing
The modern procedure of frequentist hypothesis testing begins with identifying a ‘null
hypothesis’ H0, which may be rejected or not. In the context of association studies this
hypothesis is typically of statistical independence between variables. An observed dataset is
quantified with a univariate test statistic associated with a random variable X which has a
known distribution under H0, and the p-value of an observation x of X is then generically
defined as
Pr(X ≥ x|H0) (1.2)
where ‘≥’ is taken abstractly to mean ‘is at least as extreme as’. The p-value can be associated
with a random variable P in its own right, defined by a function f : X(Ω)→ [0,1] (where
X(Ω) is the image of the X) such that
P = f (X)|H0 ∼U(0,1) (1.3)
This second definition is useful when considering p-values from multiple tests, which may
be considered as observations of P, and when reconstructing test statistics x as the (usually
unique) pre-image f−1(p).
Under the Neyman-Pearson approach to hypothesis testing, the acceptance or rejection of
H0 is decided according to whether p < α for some predetermined α . An important quantity
associated with this procedure is the type-1 error rate:
Pr(P < α|H0) (1.4)
which, given equation (1.3), is equal to α . A second important quantity is the type-2 error
rate, associated with a specific alternative hypothesis H1 under which P has some known
distribution ̸=U(0,1).
Pr(P > α|H1) (1.5)
The complement of the type-2 error rate (1−Pr(P > α|H1)) is also called the ‘power’ of
the test, and is typically associated with a ‘true’ value of the original test statistic X . In most
statistical applications, a testing procedure is chosen to control the type-1 error rate at α
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while minimising the type-2 error rate. A type-1 error is the corresponding event in which
H0 is incorrectly rejected, and a type-2 error the event in which H1 is incorrectly rejected.
The null-hypothesis significance testing procedure can be thought of as as a probabilistic
application of Descartes’ Reductio ad absurdum, which may have been what Laplace had
in mind. To prove a statement in this framework, the contrary is assumed (H0) and the
researcher attempts to derive a contradiction, which is necessarily a probabilistic one when
using observations from finite samples. The concept of quantifying evidence against a null
hypothesis exemplifies the importance of falsifiability in the scientific method [Popper, 1957].
This framework of hypothesis testing has however come under criticism [Wasserstein
and Lazar, 2016], generally relating to the difficulty of interpretation of the p-value. The
p-value does not directly quantify the effect size of an association, although this may be
reconstructible using both the p-value and the sample size. The p-value is also notably not
equal to the probability that H0 is true given observation x; indeed, this quantity has no
meaning in the frequentist interpretation of probability.
The Bayesian interpretation of probability does allow meaning to be assigned to such
events; namely the posterior probability of H0 given X
Pr(H0|X > x) = Pr(X > x|H0)Pr(H0)Pr(X > x) (1.6)
requiring the assignment of a prior Pr(H0) on H0 before x is observed. The degree of support
for a specific alternative H1 over the null H0 after observing X can be compared using a
Bayes factor or likelihood ratio:
BF =
Pr(X |H1)
Pr(X |H0) (1.7)
The frequentist and Bayesian approaches to assessment of hypotheses each have advan-
tages [Efron and Tibshirani, 2002] and are both readily susceptible to misinterpretation, but
ultimately seek to answer different questions and are not generally comparable.
In this thesis, I use both frequentist and Bayesian interpretations of probability, generally
due to the use of a combination of statistical methods. In chapter 2, a Bayesian probability is
computed for each of a large number of tests, but the probabilities are then interpreted as test
statistics in a frequentist multiple-testing procedure. It should generally be clear from the
context which interpretation of probability is intended.
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1.2.4 Increasing dimensionality
New scientific approaches
A common trend in many areas of applied statistics is a move toward higher-dimensional
studies, with many variables being measured in parallel across a sample set, to the extent that
the number of variables may substantially exceed the number of samples. A major driver of
this trend has been a move towards ‘omics’ approaches [Bühlmann et al., 2014], in which all
variables potentially contributing to the variance of some trait are exhaustively scanned for
associations with the expectation that only a minority will be causally associated.
The omics approach has the advantage of near-agnosticism to prior hypotheses on
association. This can be particularly useful in the analysis of complex traits in biomedicine,
in which many variables may contribute small effects to the overall variance [Pearson and
Manolio, 2008, Hirschhorn and Daly, 2005]. Targeted studies on a limited number of
variables can be thought of as incorporating an implicit prior giving a vanishing weight to
all variables not measured, which may be driven by incorrect assumptions on the biological
pathways involved as well as being driven by cost and convenience considerations [Pearson
and Manolio, 2008]. Implicit use may lead to high type-2 error rates.
A degree of subjectivity is still generally present in the analysis of genomic data. An
important example relevant to the aims of this thesis is the assignment of SNP associations
to local candidate causal genes, which is complicated by the possibility of SNPs modulating
distal genes (trans-QTLs). An important area of current research is the formalisation of
candidate gene selection; in chapter 3, an approach based on interaction DNA regions in
relevant cell lines [Schofield et al., 2016] was used for this purpose.
An obvious difficulty of omics approaches is the management of type 1 error in the
context of the large number of variables tested [Pearson and Manolio, 2008]. This means
that a larger observed effect size is needed in order to differentiate an associated variable
from a non-associated one. Importantly, this is not a disadvantage of omics approaches, but a
consequence of preferring a non-informative prior across a greater number of variables.
In genomics, this difficulty is exacerbated in traits for which genetic causality is mainly
determined by rare genetic variants. Variance in observed odds ratios is greater for rare
variants, and consequently a larger observed odds ratio is needed to reject the null for a rare
variant compared to a common one. Determining associations of rare variants is also made
more difficult by the multiplicity of such variants in the genome, and greater susceptibility to
quality-control problems [Hirschhorn and Daly, 2005]. The importance of rare variation in
complex disease is an active topic of current debate [Morris et al., 2012].
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Controlling type 1 errors
High-dimensional statistics requires careful control of errors, and determination of how error
rates should be quantified. The choice of the best error rate to control may reflect the relative
cost of type 1 and type 2 errors and the expected prevalence of true associations.
An analogue of the type-1 error rate if more than one hypothesis is tested is the family-
wise error rate (FWER). If a series of independent tests against n null hypothesis H10 , H
2
0 ,
... , Hn0 are conducted, with resultant p-values represented by random variables P1, P2, ... Pn
respectively (noting Pi|H i0 ∼U(0,1)), the FWER is given by:
FWER = Pr(
n∨
i=1
Pi ≤ α0|H10 ,H20 , ...) (1.8)
To control the FWER at a value α , a p-value threshold α0 on individual hypothesis tests may
be attained by the Sidak correction:
α0 = 1− (1−α)
1
n
=
α
n
+O(α2) (1.9)
where the first-order approximation represents the familiar Bonferroni correction.
However, the quantification of error rate using a single metric loses inherent meaning
when more than one test is conducted, due to the absence of total ordering of Euclidean
spaces of dimension > 1 compatible with the natural field structure1. The FWER, being
the disjunction of all individual tests, is considered conservative as a metric; it effectively
measures the probability of making at least one type-1 error.
An important drawback of the use of FWER-controlling methods is that they do not
change with the observed distribution of p-values. For example, if a hundred parallel studies
led to one of the two sets of p-values in figure 1.2, a Sidak correction would indicate a cutoff
of ≈ α/100 to maintain a FWER ≤ α . However, the non-uniform distribution of p-values in
the right panel would suggest that there are more non-null observations amongst the hundred
than in the scenario on the left, and (in practical terms) we may attain more information from
the data with a less stringent threshold for association.
1The absence of a total ordering on the plane in the consideration of bivariate test statistics will be
reconsidered in chapter 1, when analysing the false-discovery rate of the cFDR method
1.2 Association testing and case-control studies 9
llll
llll
llllll
llllll
ll
lll
lll
lllllll
lllll
llll
ll
lllll
ll
0.0 0.4 0.8
0.
0
0.
4
0.
8
Exp. quantile
P−
va
lu
e
llllllllllllllll
llll
lllll
lll
llll
l
lllll
llll
llll
lll
lll
0.0 0.4 0.8
0.
0
0.
4
0.
8
Exp. quantile
P−
va
lu
e
Fig. 1.2 Q-Q plots for two sets of observed p-values for which the associated random variable
(equation (1.3)) has different distributions. Approaches to multiple hypothesis testing may or
may not be responsive to such differences in distribution.
False discovery rates
The FWER considers only the probability of making ‘at least one’ type-1 error. Alternatives
to the FWER generally involve considering the probabilities of making multiple type 1 errors,
and limiting the rate at which errors are made. A useful such metric is the false-discovery
rate (FDR) [Benjamini and Hochberg, 1995]. If a set of hypotheses are tested, R are rejected,
and F are rejected falsely (that is, H0 holds) the false-discovery-rate is defined as
FDR = E
(
F
R
∣∣R > 0)Pr(R > 0) (1.10)
A useful theorem due to Benjamini and Hochberg [Benjamini and Hochberg, 1995] enables
control of the FDR in a way which is responsive to the overall p-value distribution. If n
independent or positively-dependent p-values p1, p2,... pn are observed, and the relevant null
rejected whenever
pi
1
n |{ j : p j ≤ pi}|
≤ α (1.11)
then the FDR associated with the procedure is bounded above by α .
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A related quantity is the ‘positive’ false discovery rate (pFDR) [Storey, 2002] defined as
pFDR = E
(
F
R
∣∣R > 0) (1.12)
Defining π0 as the true proportion of null hypotheses that are false, definition 1.12 has the
disadvantage that it is uniformly 1 if π0 = 1, which can be problematic [Benjamini and
Hochberg, 1995]. In this thesis, I will generally assume Pr(R > 0)≈ 1, and use the FDR and
pFDR interchangeably.
Bayesian interpretation
The quantity 1.12 may be interpreted in a Bayesian sense [Storey, 2002]. Assume m hypothe-
ses H1,H2..Hm ∈ {0,1} are tested by means of p-values P1,P2...Pm and consider the Hi as iid
Bernoulli-distributed random variables with P(H = 0) = π0. For a given threshold α , denote
R(α) as the number of Pi with Pi < α and V (α) as the number of Pi < α with Hi = 0. If
Pi|Hi has CDF F = F0Hi +F1(1−Hi) and F1(x)/x is decreasing in x, then for fixed α we
have [Storey, 2002]
FDR(α) = E
(
V (α)
R(α)
∣∣R(α)> 0)
=
E{V (α)}
E{R(α)}
= Pr(H = 0|P < α)
= π0
F0(α)
F(α)
(1.13)
The left-hand side of inequality 1.11 is an estimator of this quantity with F0(pi) = pi, π0 ≈ 1,
and F(pi)≈
∣∣{ j:p j≤pi}∣∣
n [Efron et al., 2008]. This suggests the use of quantities of this form
for each SNP as a marker of association in place of the p-value (termed the q-value) [Storey,
2002] an estimator for Pr(H0|P≤ pi),
A more useful posterior (the ‘local’ FDR [Efron et al., 2008]) evaluates the posterior
probability of association for variables with p-value exactly α ; defining f , f0, f1 as the PDFs
corresponding to the CDFs F0, F1, F , the local FDR is defined as:
Pr(H0|P = α) = π0 f0(α)f (α) (1.14)
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however, the estimation of f0, f can be difficult. Potential methods include Lehmann
alternatives (in which the assumption is made that F1(z) = F0(z)γ ) [Efron et al., 2008] or
estimation of f from the dataset using empirical Bayes methods [Zablocki et al., 2014].
1.3 Genome-wide association studies
1.3.1 Motivation and development
The methods in this thesis were predominantly developed for use in datasets from genome-
wide association studies (GWAS), and this is the application generally discussed.
Genome-wide association studies are attempts to discover the genetic causes of human
traits in a hypothesis-free manner. They represent a generalisation of earlier candidate-gene
studies (in which the effects of variants in putatively disease-associated genes are analysed in
isolation), effectively involving computing multiple such studies in parallel and explicitly
acknowledging the multiplicity of hypotheses being tested.
GWAS can contribute to medical knowledge and practice in several ways. An important
motivation is the discovery of new disease-associated processes, and thus new targets for
therapeutic drugs. A recent example is the identification of autophagy processes as a potential
target in Crohn’s disease [Zhang et al., 2008]
A second important application is the development of stratified medicine. Critical to this
is understanding the causes and pathways driving disease heterogeneity, with the eventual aim
of stratifying patients into sub-categories of disease. This may enable improved treatment
efficiency by identifying patients in which treatments are more likely to be effective; for
example, the identification of determinants of effectiveness of anti-TNFα therapy in multiple
sclerosis [Gregory et al., 2012].
GWAS-driven patient stratification may also aid in identification of patients at risk of
developing a disease; for example, the use of MHC-typing to identify patients at high risk
of type 1 diabetes (T1D) [Noble and Valdes, 2011, Atkinson and Eisenbarth, 2001, Barrett
et al., 2009]. Individuals with the highest-risk MHC genotype have a risk of developing T1D
of approximately 5%, compared to a background risk of 0.3% in the general population [Aly
et al., 2005]. Children identified as being at a high T1D risk can theoretically be more closely
monitored for the onset of early signs and symptoms of the disease.
An extremal application of disease stratification is the development of personalised
medicine; effectively the determination of the most effective treatment protocols on an
individual scale. Although GWAS may not enable strong predictive ability, even when
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disease heritability is high [Clayton, 2009], there may be scope for the modulation of
individual treatment based on genetic risk assessment, although the field is controversial in
its current form [Annas and Elias, 2014].
GWAS can be considered complete when the confirmed associations account for all of the
observed the observed heritability (see section 1.3.4). For many common diseases, confirmed
disease-associated variants only explain a small fraction of the overall genetic variance. There
are many possible reasons for this including a high burden of rare variants [Fuchsberger
et al., 2016], or a large number of common variants with small (non-zero) undetectable effect
sizes [Golan et al., 2014], or a high burden of epistatic (non-additive) variation [Manolio
et al., 2009]. Explaining all of the heritability of a trait may involve intractably large sample
size; even for GWAS with sample sizes exceeding half a million, observed associations may
not account for all of the variance of a trait [Wood et al., 2014]. A range of statistical methods
have been developed for the analysis of rare variation [Lee et al., 2014], but in this thesis I
generally only consider common variation (MAF > 1% or > 5%).
As well as aiming to increase sample size, an important future direction of the GWAS
field is an expansion into rarer and more specific traits. More specific phenotypes may
have easier-to-observe associations, beneficial both for understanding such phenotypes and
treating them.
In this chapter and throughout this thesis, I will refer to the ‘genetic architecture’ of a
disease as the set of causal variants for that disease along with their effect sizes, in a typical
British population unless otherwise stated. Occasionally I will use the term to instead mean
the set of associated variants and their associated effect sizes; the specific meaning should be
clear from the context.
1.3.2 Statistical methodology
In the GWAS design, a set of samples are genotyped at some large set of known variant sites
(typically single-nucleotide polymorphisms, or SNPs ) across the genome. In general, SNPs
are assumed to be biallelic, meaning that the nucleotide at a given position in a chromosome
may take one of two forms (of (A,C,G,T )). This thesis will generally consider autosomal
(diploid) SNPs, for which the genotype of an individual may take one of three values: for
alleles a, A, these are aa, AA (homozygous) and aA (heterozygous). For a variant under
minimal selection and de novo mutation and with random mating, the frequencies f (aa),
f (Aa), f (AA) of aa, aA and AA in a population of size N satisfy
f (aa) = p2 f (aA) = 2pq f (AA) = q2 (1.15)
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as N → ∞, where p is the frequency of allele a and q = 1− p the frequency of A (figure 1.3).
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Fig. 1.3 At a SNP of interest, genotypes at biallelic SNPs are coded as 0,1,2, or M (missing)
with heterozygosity corresponding to 1 and homozygosity in one allele (usually the rarer of
the two) to 2. Genotypes at variants in close chromosomal proximity are often correlated, a
phenomenon termed ‘linkage disequilibrium’. Genotypes of samples may be correlated due to
close relatedness. Column-wise averages (divided by two) from the submatrices for cases and
controls are termed the allele frequencies, which serve as test statistics. Summary statistics
derived from columns also include SNP-wise call rate (proportion of M’s) and deviance
from Hardy-Weinberg equilibrium, both used in quality control. Summary statistics derived
from rows include sample-wise call rate, and heterozygosity rate. Principal components of
the matrix (considering samples as observations of N random variables) are often used as
covariates in genomic control (see section 1.3.3) and for identifying population structure
A case-control GWAS broadly compares observed allelic frequency between two groups
of samples. Assume an observed allelic frequency m0 in a ‘control’ group with 2n0 haplotypes
and observed allelic frequency m1 in a ‘case’ group with 2n1 haplotypes, with E(m0) = µ0,
E(m1) = µ1 (see figure 1.3). In general, SNPs with two alleles are characterised by the lesser
(‘minor’) of the two allele frequencies (MAF). Allelic difference is commonly characterised
by either the direct difference m1−m0 or the odds ratio
OR(m1,m0) =
m1(1−m0)
m0(1−m1) (1.16)
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Several test statistics may be used to test the hypothesis H0 : µ0 = µ1, the simplest being a
contingency-table based test statistic (equivalent to a comparison of binomial proportions).
If ni j copies of allele j are observed in cohort i, the statistic is:
∑
i∈(case,control)
j∈alleles
(ni j−E(ni j|H0))2
E(ni j|H0) =
 m1−m0√
m¯(1−m0)
2n0
+ m¯(1−m1)2n1
2 (1.17)
where m¯ is the overall observed MAF, n0m0+n1m1n0+n1 , and the factor of 2 arises due to most
chromosomes being diploid in humans (alternative methods are used for sex chromosomes).
This test statistic converges in distribution to a χ21 random variable, and hence an approximate
Z score Zˆ can be derived from the square root of this test statistic, with sign determined by
the sign of m1−m0. Under H0, as n1,n0 → ∞ with n0/n1 positive and finite, Zˆ and each of
the test statistics
m1−m0
SE(m1−m0)
log{OR(m1,m0)}
SE(log{OR(m1,m0)})
m1−m0√
m¯(1− m¯)
√
1
2n0
+ 12n1
(1.18)
(where SE denotes standard error) are asymptotically equal and converge in distribution to
N(0,1).
As with any case-control study, a major consideration is the potential for confounding
variables also affecting µ1, µ0. For a vector z of covariates, a more appropriate null hypothesis
may be µ1(z)≡ µ0(z), in which µ0,µ1 are considered as functions of covariates.
For categorical covariates, a Cochran-Mantel-Hanszel test is typically used - effectively a
meta-analysis of a series of sub-analyses on each covariate level. For continuous covariates,
tests typically use a logistic regression model on disease status Y :
logit(Pr(Yi = 1)) = α+β z+ γGi+ εi (1.19)
where Gi is the genotype for sample i, β and γ are vectors corresponding to the covariate
and genotype effects, and εi ∼ N(0,σ2I) is an error term. Another popular approach is
a linear mixed model [Yu et al., 2006, Zhang et al., 2010, Lippert et al., 2011] in which
ε ∼ N(0,KK′σ2g + Iσ2e ), where K is a normalised version of the genotype matrix G of the
form in figure 1.3:
Ki j =
Gi j−2mi√
2mi(1−mi)
(1.20)
1.3 Genome-wide association studies 15
where mi is the observed allele frequency for SNP i. K is termed a ‘genetic similarity’ or
‘kinship’ matrix, and can also be estimated by other means [Speed et al., 2012],[Zhang et al.,
2010].
The detection of variant-disease associations under the GWAS methodology generally
requires sample sizes of several thousand. This large sample size is partly because of the
dimensionality of the problem, and partly due to the nature of genetic architecture of common
diseases. Variants with large effects on a disease phenotype are likely to be under negative
selection, and hence at a low allelic frequency in the population. Large GWAS on common
diseases [Barrett et al., 2009, Morris et al., 2012, Okada et al., 2014] have nonetheless found
a large proportion of disease heritability to arise from common (high MAF) variants. The
question of the relative contributions to genetic disease risk from low-frequency variants of
large effect and from high-frequency variants of low effect is a continuing debate [Gibson,
2012] but both genetic architectures are problematic in that the types of variants responsible
for disease causality are statistically difficult to find.
1.3.3 Quality control
A vital part of GWAS is ascertainment of data quality. Studies are susceptible to a multitude
of potential confounders, both due to subtle effects on genotype accuracy due to sample
storage or processing and differential population sampling, and failure of type-1 error rate
control is costly due to unnecessarily wasted resources in downstream analyses. Many
aspects of GWAS quality control are specific to the particular study at hand [Anderson et al.,
2010], and hence development of new methodology such as that in this thesis must include
consideration of appropriate quality control procedures. I include an introduction here to
several standard procedures for conventional GWAS.
Quality control in GWAS is generally involves both systematic procedures across all
variants, and specific procedures on variants identified as putatively associated. For analyses
of patterns of effect sizes across large numbers of SNPs, only the first of these is possible,
and hence must be somewhat more stringent. This is relevant to chapters 5 and 6, in which
genome-wide effects are quantified.
Systematic quality control effectively has three main steps - the exclusion of variants, the
exclusion of samples and the management of residual inflation. Variant exclusion is typically
on the basis of poor call-rate, low allele frequency or deviation from Hardy-Weinberg
equilibrium [Anderson et al., 2010]. Sample exclusion is typically on the basis of poor call
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rate, incongruence of reported sex (a mismatch between observed and expected heterozygosity
on chromosome X), or ethnicity outside of the study population (see figure 1.3).
Confounder-driven inflation in test statistics after removal of samples and variants in this
way is usually quantified using the formula [Devlin et al., 2001]
λ =
median(χ21 (i))
Qχ21
(1
2
) (1.21)
where χ21 (i) is a χ
2 test statistic for SNP i and Qχ21 is the quantile function of the χ
2
distribution with 1 degree of freedom . This may not be appropriate if a high proportion of
the genome is associated with the trait [Wood et al., 2014] or in GWAS-like analyses on only
areas of the genome with a high prior for association [Cortes and Brown, 2011, Stahl et al.,
2010]. In this case, the inflation factor λ may be estimated by only using a set of variants
specifically chosen so that H0 is expected to hold [Eyre et al., 2012].
Management of inflation may involve accounting for more covariates, either by further
stratifying samples or inclusion of more covariates in a logistic model. A common approach
is to include several principal components of the genotype matrix as covariates (where
principal components correspond to weighted sums of alleles) [Price et al., 2006]. Principal
component covariates index the main axes of polygenic variation in the dataset, which are
usually assumed not to be the sources of variation under investigation in the study; however,
the use of principal components as covariates cannot generally correct for unexplained
(cryptic) relatedness between individuals in a study. An alternative way to manage inflation
from population structure and manage cryptic relatedness at the cost of some statistical power
is to fit a linear mixed model [Zhang et al., 2010] (see section 1.3.2). Both approaches are
imperfect: they may not completely control type 1 error (that is, not remove all inflation) and
may induce type 2 error by ‘blindly’ correcting for true genetic signals, especially on very
polygenic traits such as height. Residual inflation after these steps is typically removed by
simply dividing observed χ2 statistics by the inflation factor λ , with the effect of forcing the
value of λ to 1. Since this procedure also reduces the observed effect size at true associations,
it reduces the power of the study, so it is generally desirable to reduce λ as much as possible
before this step.
1.3.4 Heritability and genetic correlation
It is possible in many cases to infer useful information from GWAS without the need to
specifically identify disease-associated variants. One important metric in genomics is the
1.3 Genome-wide association studies 17
heritability, which is colloquially considered ‘the proportion of variance in a trait attributable
to genetic variation’.
In a more formal sense, for a trait Y with non-zero prevalence in a population P, let G
denote a random variable associated with the complete genotype of an individual in P. The
heritability H2 is defined as
H2 = max
f :G→R
var( f (G))=1
lim
|P|→∞
cor( f (G),Y ) (1.22)
The narrow-sense heritability h2 restricts f to linear functions of G [Bulik-Sullivan et al.,
2015], and the SNP heritability further restricts G to some subset of the SNPs in the genome
(typically those on a genotyping chip). Both wide and narrow-sense heritability depend on
the population being sampled and the environment that population is in.
The definition of h2 invites an interpretation of the genetic architecture of a disease as a
point in a high-dimensional space, with the co-ordinate βi of a variant i corresponding to the
proportion of var(Y ) attributable to it. The correspondence of the value
h2 =∑β 2i ≤ 1 (1.23)
to the 2-norm of the vector invites consideration an inner product on this space characterising
the similarity between two traits; the obvious such being the ‘genetic covariance’, ρg between
vectors α , β :
ρg =∑αiβi (1.24)
usually considered in the form of the ‘genetic correlation’
rg =
∑αiβi√
∑α2i
√
∑β 2i
(1.25)
The genetic correlation measures pleiotropy (association of the same variant with > 1
phenotypes) between α and β in a sense, but importantly responds differently when effects
are in the same direction for both traits (αiβi > 0) than when they are both nonzero but in
opposite directions (αiβi < 0). This distinction is discussed further in chapter 5 in the context
of characterising shared and distinct genetic associations with disease subtypes.
Common methods for estimation of SNP h2 and rg include estimates from linear mixed
models (implemented as ‘genome-wide complex trait analysis’ (GCTA) [Yang et al., 2011] )
and LD-score regression (LDSC) [Bulik-Sullivan et al., 2015] . In the model implemented in
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GCTA, the trait y is modelled as
y =Wu+Xβ + ε (1.26)
where W is a matrix of numeric genotypes normalised so each row has zero mean and unit
variance, u is a vector of random effects with variance σ2u I, X is a matrix of covariates with
fixed effects β , and ε ∼ N(0,σ2e I). Given
var(y) = XX tσ2u +σ
2
e I (1.27)
the variance components σu, σe can be estimated by the restricted maximum likelihood
approach [Patterson and Thompson, 1971] with the estimate of narrow-sense heritability
given by Nσ2u , for N SNPs.
If two traits y1, y2 are measured in some population of size n on N SNPs (possibly with
missing observations, as for two separate studies), narrow-sense heritabilities [Yang et al.,
2011] and genetic correlation [Lee et al., 2012] between y1 and y2 can be estimated using a
bivariate LMM:
y1 =Wu1+Xβ1+ ε1
y2 =Wu2+Xβ2+ ε2 (1.28)
where X is a matrix of covariates with fixed effects β1, β2 in y1 and y2, W is a N×n matrix
of numeric genotypes normalised so each column has zero mean and unit variance, u1,u2 are
vectors of random effects and ε1, ε2 vectors of random residuals with
var
(
u1
u2
)
=
(
INσ2u1 1Nσu12
1Nσu12 INσ2u2
)
, var
(
ε1
ε2
)
=
(
Inσ2e1 1nσe12
1nσe12 Inσ2e2
)
var
(
y1
y2
)
=
(
WW tσ2u1+ Inσ
2
e1 WW
tσu12+ Inσe12
WW tσu12+ Inσe12 WW tσ2u2+ Inσ
2
e2
)
(1.29)
The variance components σ2u1, σ
2
u2, σ12, σ
2
e1, σ
2
e2, σe12 can be estimated by the restricted
maximum likelihood approach [Patterson and Thompson, 1971]. Estimates of narrow-sense
heritability for y1 and y2 are given by Nσ2u1, Nσ
2
u2, and an estimate of genetic correlation is
given by σu12/(σu1σu2). The model specification u ∼ N(0,σ2u ) implies that all SNPs con-
tribute to the trait, which is inconsistent with several models of genetic architecture [Gibson,
2012]. Alternative models inducing sparsity have also been proposed [Zhou et al., 2013].
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GCTA can underestimate narrow-sense heritability when applied to case-control studies in
which the prevalence of cases in the study is higher than the prevalence of cases in the general
population [Golan et al., 2014].
The LDSC method is an alternative approach which uses the assumption that causal
variants in LD with each other will have inflated observed effect sizes [Bulik-Sullivan et al.,
2015]. If the LD between SNPs i and j is r2i j, the LD-score for a SNP i is defined as
li = ∑
SNPs j
r2i j (1.30)
Define z1i, z2i as the z-scores for SNP i for quantitative traits y1 and y2 on N1, N2 samples
respectively, with Ns samples in common and M SNPs in total. The narrow-sense genetic
correlation ρ12 between y1, y2 satisfies
E(z1iz2i) =
√
N1N2ρ12
M
+
Ns√
N1N2
cor(y1,y2) (1.31)
A similar equation holds for case-control studies. If the two studies are the same, then
N1 = N2 = Ns and ρ12 is the heritability h2 of the trait, and hence
E(z2i ) =
N
M
h2+var(yi) (1.32)
By regressing LD-scores on z-scores, the heritability and narrow-sense genetic correlation
can thus be estimated. LDSC typically needs more samples than GCTA, but only requires
summary statistics for the estimation procedure [Bulik-Sullivan et al., 2015].
Broad-sense heritability (H2) is typically estimated from twin studies, which are outside
the scope of this thesis.
1.3.5 Genetic risk scores
As well as determining the set of variants associated with a trait of interest, it can be useful
to attempt to recover the underlying (usually additive) genetic risk model. Models derived in
this way can give rise to ‘genetic risk scores’ (GRS) which function as a invariant lifetime
risk predictor of the trait.
Unfortunately, predictive accuracy of such a score may be poor even when heritability is
high [Clayton, 2009]. However, in some cases GRS can contribute meaningfully to clinical
disease prediction, making use of the polygenicity of common traits [Abraham et al., 2014].
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Under the additive risk model of narrow-sense heritability, a genetic risk score for
individual i with genotype Gs(i) at SNP s typically takes the form
S(i) = ∑
s∈genome
βsGs(i) (1.33)
where βs is the coefficient of SNP s in the model, typically an estimator for the true effect
size of the SNP. The values βs may be 0 for most s if a sparse model is needed.
Genetic risk scores may be fit only using known disease-associated SNPs [Yarwood et al.,
2015] or on SNP sets for which only a proportion are assumed to be disease-associated [Abra-
ham et al., 2014].
In the latter case, machine-learning methods are typically used to impose sparsity and
prevent overfitting. A popular choice is lasso (L1-penalised) regression (for example [Barrett
et al., 2009]), although non-linear approaches such as support-vector machines may be more
effective in some circumstances [Abraham et al., 2014].
1.4 Comparison of association studies
1.4.1 General considerations
The history of association studies has been marked by the assembly of similar cases, and
analysis of similarities of the resultant cohorts. As discussed earlier, a major disadvantage
of this approach is the necessary agnosticism to phenotypic heterogeneity in order to attain
large enough sample sizes. This shortcoming has been recognised since the first such
studies [Feldman and Goodrich, 1999].
This invites the possibility of learning more from GWAS by subdividing diseases. In the
opposite direction, there may be information to be gained by comparing studies on related
diseases together. This is made practically difficult by variant definitions of phenotypes and
a wide range of genotyping platforms. Another major obstacle is reluctance of research
groups to share data [Piwowar et al., 2008] both for reasons of patient anonymity and
monopoly on research outputs. For the former reason, frequently only summary statistics are
made available from GWAS rather than genotypes (eg [ImmunoBase, 2013]), and available
summary statistics may not include effect directions.
Both of these shortcomings in disease heterogeneity in GWAS studies and the difficulties
with comparisons of association analyses are gradually being alleviated; the former by
enlargement of sample cohorts and improved phenotypic characterisation (eg [UK Biobank,
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2007]), the latter by homogenisation of association study design and independent variables
(especially in genomics) and better-facilitated data-sharing. This has necessitated a range of
statistical methods for comparing association studies.
Such methods may seek to answer several questions. Denoting HA0 /H
A
1 , H
B
0 /H
B
1 , X
A, XB
as null/alternative hypotheses and test statistics for association with diseases A, B respectively,
a commonly estimated (Bayesian) probability is
Pr(HA1 ∨HB1 |XA,XB) (1.34)
Computation of this quantity effectively corresponds to a meta-analysis of A and B as if they
were the same disease (so HA0 = H
B
0 ) and hence it is of limited use if A ̸= B and individual
association with A and B is of interest rather than association with A∨B. A more useful
quantity in many cases is
Pr(HA1 ∧HB1 |XA,XB) (1.35)
with the aim to identify shared association. This quantity is of use in the two-stage replication
procedure [Wason and Dudbridge, 2012] when A and B nominally represent the same
phenotype; this is discussed in chapter 4. Finally, the asymmetric posteriors
Pr(HA1 |XA,XB) Pr(HB1 |XA,XB) (1.36)
are useful in ‘leverage’; using information about one disease to inform another. This is
discussed in chapters 3 and 6. Assessing the pattern of distribution of associations between
two phenotypes is a more complex problem, one aspect of which is discussed in chapter 5
The optimal procedure for comparing association studies depends on the aims of the
comparison. In particular, procedures differ according to whether the two studies being
compared are on the same nominal disease, in which case the sets of associated variables
in each study are assumed to be the same, or on different diseases, in which case some
associations may be unique to one of the studies being compared. This section is organised
on this basis.
Comparison of association studies is frequently done in an informal way; for instance,
observing that the same region appears to be associated with several different diseases [The
Wellcome Trust Case Control Consortium, 2007]. For low-dimensional association studies
with reasonable power, this has sufficed; indeed, as discussed in section 1.2.2, intuition
historically sufficed for all analyses of disease cohorts until relatively recently. However, in
the same way that modern medicine has necessitated more complex studies and more precise
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analysis, the future of medicine may come to require equivalent standards of precision in the
co-analysis and comparison of studies.
1.4.2 Studies of different diseases
Identifying pleiotropy
An important question in joint analysis of two disease phenotypes is determination of which
variables are associated with both of them. This is of interest in the understanding of disease
pathophysiology, as a shared association indicates some degree of sharing in the causal
pathways of both diseases. It is also useful in designing therapeutic approaches, as a shared
association suggests drugs targeting a shared pathway may be of use in the treatment of both
phenotypes; for example, the recent investigations in the use of anti-inflammatory drugs in
depression [Köhler et al., 2014].
In the context of GWAS, the phenomenon of shared associations is broadly termed
‘pleiotropy’. Throughout this thesis, I will consider a variant to be pleiotropic for two
diseases if it is associated with both (without necessarily being causal for both) and two
diseases to ‘show pleiotropy’ if their corresponding sets of associated variants overlap. This
definition is common in GWAS and related studies [Andreassen et al., 2013] although the
term does not have a fixed meaning and various interpretations are used in the field according
to context [Paaby and Rockman, 2013]. The definition above necessitates an acceptance of
the ‘two-groups’ model [Efron et al., 2008] in which variants may be partitioned into those
associated with the disease and those not associated, usually with the implicit assumption
that most variants are in the latter category. The definition used in this thesis is troublesome
under the ‘universal pleiotropy hypothesis’ [Paaby and Rockman, 2013] in which all variants
have a small effect on all phenotypes; for example, the random-effects model in [Yang et al.,
2011].
Pleiotropy is common in human diseases: even when exclusively considering single
nucleotide polymorphisms (SNPs) with strong evidence of association, around 15% of those
associated with at least one trait are associated with multiple traits [Sivakumaran et al.,
2011]. Elements of shared genetic aetiology may be suspected in diseases with similar
symptomatology, such as bipolar disorder and schizophrenia [Lichtenstein et al., 2009] or
in diseases with common risk factors, such as type 2 diabetes and obesity [Hasstedt et al.,
2011]. If two diseases are known or suspected to share associated genetic variants, a degree
of association of a locus with one disease may increase the likelihood of association with
the other. This suggests that incorporating datasets from diseases related to the disease of
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interest may help alleviate some of the effect of multiple testing, meaning that phenotypic
similarity may lead to improved detection of disease-associated variants [Galesloot et al.,
2014]. Correspondingly, discovery and specification of shared genetic aetiology between
two diseases may suggest some shared pathophysiology [Hasstedt et al., 2011].
The genetic correlation of two traits (equation (1.25)) quantifies pleiotropy in a sense,
but can be misleading if effect sign differences are inconsistent between variants (discussed
in chapter 5). Non-zero genetic correlation does, however, provide sufficient evidence for
pleiotropy between two traits, and there is evidence of widespread pleiotropy between many
common autoimmune and metabolic diseases using this method [Bulik-Sullivan et al., 2015].
On a SNP-by-SNP basis, there are several approaches to the determination of shared
association with more than one phenotype [Galesloot et al., 2014, Shriner, 2012], a common
theme to many being the combination of multiple traits into a single generic trait to reduce
dimensionality [O’Reilly et al., 2012, Klei et al., 2008]. Most methods are designed for
the case when all phenotypes are measured on the same individuals, although some can be
be adapted to circumstances where this is not the case. However, when analysing multiple
studies on different individuals, the most widely applied approach is to simply compare
the sets of variants reaching genome-wide significance (GWS) in two studies (for instance,
[The Wellcome Trust Case Control Consortium, 2007]), which suffices for large effects
although is problematic if pleiotropic variants have markedly different effect sizes between
diseases. A similar method is to specifically analyse SNPs associated with one disease of
interest in a GWAS for a separate disease, typically using a somewhat relaxed threshold for
significance [Plagnol et al., 2011, Ramos et al., 2011]. Both of these methods are susceptible
to inflated type-1 error rates if samples are shared between studies and appropriate corrections
are not made [Bhattacharjee et al., 2012].
A similarly important question in the symmetric assessment of pleiotropy is whether
two diseases share a causal SNP in a region of interest (termed ‘colocalisation’), a stronger
statement than the sharing of association. The assessment of colocalisation is a complex
procedure which may be approached in a Bayesian model averaging framework [Giambar-
tolomei et al., 2014, Fortune et al., 2015]. Methods are not discussed in this thesis; however,
an assertion of pleiotropy in a region must be further assessed with colocalisation analysis
before conclusions on causality can be drawn.
Leverage
Even if we are unable to assert association with both of two phenotypes of interest, joint
analysis of both diseases may be useful in identifying association with each individual
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disease. As an example, assume that for two phenotypically related phenotypes A and B,
independent GWAS found p-values PA = 1×10−7, PB = 1×10−4 against H0 at some variant.
A meta-analysis of A and B (as though the diseases were identical) would probably conclude
that the variant was likely to be associated with A∨B; but this does not entail association
with A∧B. While neither p-value is small enough to assert GWS at the standard threshold
(p < 5×10−8), we may intuitively assert that there is good evidence for association with A,
given the additional low p-value for B. However, the intuitive evidence for association with
B is considerably poorer.
In this way, more information may be extractable from a joint dataset by considering
association with each disease individually, potentially gaining some of the advantages of a
meta-analysis in power while avoiding compromising specificity of the phenotype, a process
which I generally refer to in this thesis as ‘leverage’. The most widely-used method of
leverage is probably the analogy of the method described in the section above to demonstrate
pleiotropy: the restriction of variants analysed for disease B to those with some level of
association with disease A. However, this approach loses information from variants associated
with disease A at sub-significant effects, which may still contribute useful information [Park
et al., 2010] (as in the example above). A useful extension to this method is the Bayesian
conditional false discovery rate (cFDR) which uses an analogy of the Benjamini/Hochberg
procedure to two phenotypes [Andreassen et al., 2013]. This is discussed in detail in chapter 2.
An important application of association study comparison is in the analysis of rare
diseases. The field of GWAS and other omic- studies has the advantage of being hypothesis-
free at the cost of power. For rare phenotypes, the assimilation of the thousands of cases
typically necessary to power a GWAS is often impractical, and GWAS are of limited use.
In order to analyse the phenotypes at all, some leverage on larger case datasets needs to be
performed. Chapters 3 and 6 describe several procedures of this type.
1.4.3 Studies of the same disease
Meta-analysis
The procedure of meta-analysis is important in the systematic assessment of evidence. Meta-
analytic procedures have been developed for genetic association studies, and has enabled
effective sample sizes of > 105 for some traits [Wood et al., 2014]. In a contrary trend to
that of finer phenotype specification, it is also frequently useful to meta-analyse different but
related phenotypes, estimating the quantity in equation (1.34), generally followed by analysis
of the individual associations with the constituent phenotypes [Li et al., 2015].
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An important consideration in meta-analysis of association studies is the presence of
shared control samples between groups. Several methods for adapting meta-analyses to
shared-control designs have been developed [Lin and Sullivan, 2009, Bhattacharjee et al.,
2012], which provided a basis for the methods developed in chapters 2 and 4.
GWAS replication
A common exercise in high-dimensional association studies is replication, which has became
standard practice in GWAS [Anderson et al., 2010]. The procedure typically involves
conducting an initial study A on a disease of interest, and re-analysing putative associations
in a second follow-up study A′. Given P-values PA and PA′ for A and A′ and P for a meta-
analysis, a typical replication procedure [Wason and Dudbridge, 2012] would declare a
variant associated with A if
PA ≤ α PA′ ≤ β P < γ (1.37)
for some thresholds α , β , γ , where γ is typically the GWS threshold, 5× 10−8. Effect
directions are also required to be consistent across A, A′.
The replication procedure has the advantage of increasing the type-1/type-2 error rate
profile to that of a meta-analysis for variables measured in both cohorts, and is cheaper
since not all variables are generally measured in A′. Given the extensive potential for
confounders and other errors in GWAS, the requirement for evidence of association in both
A and A′ is generally considered necessary [Anderson et al., 2010], with the understanding
that unrecognised confounders affecting A will not affect A′, and vice versa.
This is easiest to ensure if A and A′ are independent; that is, share no samples. However,
in some cases, it may be advantageous to share controls (or share one group) between studies.
This is explored in chapter 4.
1.4.4 Investigating heterogeneity
As discussed previously, GWAS analysis of complex phenotypes is difficult due to a typi-
cal genetic architecture of rare variants with large effects or common variants with small
effects [Gibson, 2012]. This difficulty is prominent in syndromes with diagnosis based on
symptom clusters, such as schizophrenia [Ripke et al., 2014]. Accounting for phenotypic
heterogeneity can improve the power of association analyses in these circumstances [Morris
et al., 2009].
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However, a division of a disease into subtypes will only yield information over an
analysis in which the disease is considered homogeneous if effect sizes for disease-associated
variants are different between the subtypes. More generally, the best mode of analysis for a
heterogeneous disease will depend on the relations between the genetic architectures of the
disease subtypes, which in turn relates to the underlying cause of disease heterogeneity. The
joint genetic architectures of two disease subtypes can be modelled as a bivariate distribution
of effect sizes, which gives a framework in which different causes of disease heterogeneity
can be distinguished. This is discussed in chapter 5. In chapter 6, I analyse the genetic
architecture of a disease with more than two subgroups using genetic risk scores of various
types.
Searching for subtypes
The process of identifying genetic differences amongst subtypes of a disease invites the
question of whether the process may be inverted to find clinically interesting subtypes of a
disease in a genetically-driven way. There has been success in this area using multivariate
clinical data [Siroux et al., 2014] and transcriptomic data [Bullinger et al., 2004] but it is a
difficult problem using genomic data.
Attempts to find ‘maximally separated’ subtypes in a phenotype is difficult due to the
diversity of causes of variation in the genome. Many observable variant human traits have
some degree of heritability; including quantifications of anthropometry, behaviour and
metabolic state [SNPedia, 2017]. Finding a ‘maximally separated’ partitioning of a case
group thus broadly corresponds to finding the trait for which the genetically-driven variance
is greatest, and this is very unlikely to correspond to the variance in disease pathology; it
should generally be population structure (non-uniform patterns of identity-by-descent). This
is supported by the regular use of principal components as quality-controlling covariates in
GWAS logistic regression models [Price et al., 2006]; PCs characterise the axes of maximum
variance within a dataset, and generally correlate strongly with ethnicity [Anderson et al.,
2010, Price et al., 2006].
This problem may be alleviated by either restricting the set of variants considered to
those likely to correspond to variation in the disease of interest, or restricting the space of
potentially allowable subdivisions of a sample cohort into subtypes, which would otherwise
have size 2N for N samples. An obvious way to find such variants is to consider those with
confirmed or putative association with the disease, but clinically-important subtypes may be
differentiated by genetic variants not associated with the disease under investigation [Lee
et al., 2017]. Other options are to use variants associated with a second disease, an approach
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suggested in [Han et al., 2016b]. Chapter 6 describes an investigation into ‘meaningful’
subtypes of juvenile idiopathic arthritis (JIA) using both of these restrictions.
1.4.5 Efficient use of data
The general theme of this thesis is an aim to increase the amount of information attained
from a given dataset, allowing greater economy of sample size. Historically, this has been
relevant for all GWAS studies, due to low sample sizes and restricted access to data (for
instance, GWAS summary statistics only). As datasets have grown larger, the use of efficiency
- gaining methods such as sharing control samples or making use of leverage has become
relatively less useful.
In the current setting and in the future, however, the trend toward finer and finer pheno-
types may mean that studies on small cohorts remain common. It is frequently useful to com-
pare small subgroups of samples against each other (for example, [Lee et al., 2017, Plagnol
et al., 2011]; also see chapter 5), and in such studies shortcomings in power will arise both
from undersized ‘case’ and ‘control’ cohorts. In this setting, I believe that statistical options
to improve efficiency of data use and reduce the cost of recruitment are likely to remain
important.
Shared controls
Particular care is required in comparison of association studies if the studies being com-
pared have samples in common; for example, controls sourced from a common population
source [The Wellcome Trust Case Control Consortium, 2007]. If controls are shared between
studies on two traits, observed effect sizes between the studies will be correlated even for
variants not associated with either trait [Bhattacharjee et al., 2012]. A common solution is to
simply split the available control cohort into two independent sub-cohorts, each of which
is only used for one of the two studies [Andreassen et al., 2013, Yang et al., 2011]. This
procedure is is only possible if individual genotypes are available. More importantly, how-
ever, this ‘split-control’ approach is inefficient. In many study designs in which either shared
controls or ‘split controls’ are usable [Skol et al., 2006, Bhattacharjee et al., 2012, Fortune
et al., 2015, Lin and Sullivan, 2009], splitting a control group leads to a loss of power at the
same type-1 error rate (also see chapters 2 and 4).
The inefficiency of splitting a control dataset is predictable from a heuristic argument.
Assume that two association studies are performed, one comparing cohort C1 to cohort C0, the
other comparing C′1 to C
′
0, where C0 and C
′
0 are drawn from an identical control population.
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Denote by m1, m0, m′1, m
′
0 the observed values of a variable of interest (for instance, allele
frequencies) in each cohort. In a split control design, the association statistics depend on m1,
m0, m′1, m
′
0 only through the differences
m1−m0 m′1−m′0 (1.38)
This makes no use of the information that E(m0) = E(m′0) - whereas a shared control design,
with C0 and C′0 pooled together, does make use of this information.
In general, if association studies are to be compared and it is reasonable to assume (in the
above notation) that E(m0) = E(m1), procedures enabling controls to be shared should be
considered. This generally requires some modification of statistical methods.
Information in a genotype matrix
A second important theme of this thesis is the comparison of motives for combining case
groups (‘lumping’) and for separating case cohorts into different subtypes (‘splitting’). This
is a commonly recognised dichotomy in biomedicine [McKusick, 1969], possibly dating to
Charles Darwin [Simpson et al., 1945]. In general, the best approach to take depends on the
circumstances of the study, including the sample size, the phenotype in question, the study
design, and the study objectives.
An important consideration is that GWAS and similar studies are highly reductionist,
using only a small proportion of the available input information. Considering a standard
genotype matrix G with each row corresponding to a sample, a GWAS effectively only com-
pares allele frequencies, or column-sums. This only encompasses a linear-order proportion
of the quadratic-order information the genotype matrix contains. Although information
independent of these column-sums is used for quality control (call rates, PCA) and in pruning
by LD, it is not generally used to directly modify the study design; for instance, by suggesting
subgroup analyses.
There are many forms a genotype matrix may take while holding column-sums constant.
For instance, if the phenotype consists of two completely non-pleiotropic subtypes, the
genotype matrix will have a markedly different form to that of a cohort from a homogeneous
phenotype, even though the column-sums (and hence GWAS results) may be the same
(figure 1.4). The form of the matrix will also vary depending on the degree to which the
phenotype is governed by common variants with small effect or rare variants with large
effect [Gibson, 2012].
1.4 Comparison of association studies 29
SNPs
Sa
m
pl
es
Ca
se
Co
nt
ro
l
SNPs
Sa
m
pl
es
Ca
se
Co
nt
ro
l
Fig. 1.4 GWAS analyses based only on allele frequencies use only a small proportion of
the information the matrix contains. This figure demonstrates two genotype matrices with
the same case/control allelic frequencies, and hence the same result from a GWAS analysis,
but differing substructures. In the matrix on the left, the genetic architecture of the disease
consists of two independent sets of associations, each set affecting one underlying subtype
of the trait. A GWAS analysis taking the subtype structure into account would be more
powerful than an analysis of the trait as a whole. However, in the matrix on the right, no
such substructure is present (the phenotype is homogeneous), and analyses accounting for
subgroups of the case group would only introduce noise, potentially lowering power.
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The variation of GWAS methodology on the basis of the structure of the genotype
matrix may enable the use of more information. This is difficult to do in a general sense as
discussed in section 1.4.4, but when used appropriately could enable more powerful analyses
than conventional GWAS on the same datasets, possibly with incorporation of external
information. Examples of usage of external and column-sum independent information to
understand disease structure are discussed in chapters 5 and 6.
1.5 Overview of chapters
As discussed in the foreword to this introduction, chapters 2-6 describe a series of projects
with common themes rather than a continuous narrative. Two chapters (chapter 2 and
chapter 5) have been published, and two others (chapter 4 and section 3.3 of chapter 3) have
each undergone at least two rounds of peer-review. In all cases the chapters in question are
not identical to the publications or submissions, but they do contain transcribed passages
from papers for which I wrote the first draft. Sections from manuscripts may have been
modified by co-authors from my original drafts in wording, but not in substance. I was the
sole author for the manuscript based on chapter 3. In general, all work presented in this thesis
and its appendices is my own unless directly specified.
Chapter 2 describes the extension of a Bayesian conditional false discovery rate to a
shared-control design, and describes an approximate bound on overall false-discovery rate
when using the procedure. The chapter also includes an application to ten autoimmune
diseases, considered two at a time. The chapter was published in [Liley and Wallace, 2015].
Chapter 3 describes two further applications of the cFDR method: firstly, to (JIA),
conditioning on T1D and RA, and secondly to a rare form of vasculitis, EGPA, conditioning
on asthma and physiological eosinophil count. This chapter also serves as an exploration of
the practicalities of applying the cFDR method. The second part of this chapter (on EGPA)
is under review ([Lyons et al., 2017], on which I am joint first author).
Chapter 4 describes a different application of the shared-control design in the context
of study replication. This includes suggested applications of the new method. The chapter
underwent two rounds of peer-review at the journal Genetic Epidemiology, but was ultimately
rejected (with potential to resubmit) on the grounds of the absence of a specific application.
It is currently on arXiv [Liley, 2017].
Chapter 5 describes an exploration into the characterisation of genetic architectures of
disease subtypes, with application to T1D. This chapter incorporates an application of the
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cFDR method and is itself a potential application for the methods discussed in chapter 4.
This chapter was published in [Liley et al., 2016].
Chapter 6 describes recent work into the subtypes of JIA. It is similar in aim to chapter 5,
but differs in several ways. The analysis is largely exploratory but includes discussion of
predictability of arthritic extension (worsening) and the relative genetic similarity of the
seven major JIA subtypes.
Chapter 7 is a discussion of the linking themes in this thesis, and includes some sugges-
tions for future work. Each chapter includes a more specific discussion with a more technical
focus.
The format of chapters differs slightly depending on the stage of publication. In general,
complex methods are presented at the end of the chapter, and simple methods are presented
as they are used. Mathematical derivations and heuristic arguments are generally found in
the relevant appendices.

Chapter 2
Phenotypic leverage with shared controls
2.1 Introduction
GWAS have enabled identification of genetic variants associated with a wide range of
complex phenotypes, but in many cases these variants explain only a proportion of the known
heritability [Hirschhorn and Daly, 2005]. It may be possible to improve variant discovery
by re-analysis of existing data [Yang et al., 2011]. One promising strategy is to co-analyse
GWAS results from similar phenotypes to exploit potential similarities in genetic aetiology.
This has been attempted using several different methods [Cotsapas et al., 2011, Smyth et al.,
2008, Ferkingstad et al., 2008].
A technique for improved discovery of disease variants using pleiotropy between pairs of
diseases has been successfully developed and applied by Andreasson et al [Andreassen et al.,
2013, Andreassen et al., 2014, Andreasson et al., 2014]. The technique extends the empirical
Bayesian false discovery rate [Efron and Tibshirani, 2002] to a two-phenotype scenario, in
which association with one phenotype is tested conditional on varying degrees of association
with another. I denote the phenotype for which association is being tested as the ‘principal
phenotype’ and the other as the ‘conditional phenotype’.
By successively restricting attention to SNPs with a given strength of association in
the conditional phenotype, the number of parallel tests to perform for association with the
principal phenotype is reduced. If the two phenotypes share common associated variants,
this restriction will retain disease-associated SNPs at a higher rate than null SNPs, resulting
in a higher proportion of disease-associated SNPs in the restricted group than in the whole.
The ‘conditional false discovery rate’ (cFDR), defined as the probability that a SNP is
not associated the principal phenotype given its p values for the principal and conditional
phenotypes are below some thresholds, exploits this effect. By computing cFDR values for
34 Phenotypic leverage with shared controls
schizophrenia conditioned on bipolar disorder and vice versa, Andreasson et al [Andreassen
et al., 2013] identified multiple previously undiscovered loci for both. In a separate study
computing cFDRs for hypertension conditioned on 12 related traits [Andreassen et al., 2014],
42 new loci associated with hypertension were reported. These constituted considerable
improvement on existing results using single GWAS, although using a liberal threshold of
estimated cFDR≤ 0.01.
A major disadvantage of the algorithm developed and used by Andreasson et al is the
requirement that control groups for the two GWAS be distinct, in order to ensure that observed
effect sizes are uncorrelated at null SNPs. This requires splitting a pool of potential controls
between studies, with the summary statistics for each GWAS computed from only the controls
allocated to that study. This may be impractical as it requires access to raw genotype data.
More importantly, accuracy of effect size estimates improves with larger control groups, and
consequently splitting controls in this way weakens the effect size estimates for individual
studies. For this reason, many researchers employ a study design in which controls are
pooled into a large group; for example, the Wellcome Trust Case Control and ImmunoChip
consortia [The Wellcome Trust Case Control Consortium, 2007, Cortes and Brown, 2011].
In this chapter I extend the cFDR approach to studies with overlapping control groups,
exploiting an approach developed by Zaykin et al, following Lin et al [Zaykin and Kozbur,
2010, Lin and Sullivan, 2009] to adjust for the effect of shared controls. This allows the
strongest available estimates of effect sizes to be used for calculation, and consequently
strengthens the power of the technique. My method retains the ability of cFDR values to be
computed from summary statistics alone, without the need to recalculate effect sizes after
re-allocating controls. I demonstrate the improvement arising from sharing controls using
data from a GWAS on T1D.
I also identify a previously un-discussed difficulty with the cFDR method in general
potentially leading to a falsely low estimate of the false discovery rate amongst SNPs declared
non-null. Multiple overlapping sets of SNPs may be defined, each of which has cFDR≤ α .
However, the union of these sets does not necessarily have a false-discovery rate less than α ,
and in general it is higher. An implication of this is that if we declare non-null all SNPs for
which estimated cFDR is less than α , the overall false-discovery rate amongst SNPs declared
non-null is greater than α . I describe an approximate upper bound on the false discovery rate
amongst such SNPs based on areas of regions of the unit square.
I apply the method to summary SNP association statistics for ten variably phenotypically
distinct autoimmune diseases: type 1 diabetes (T1D) [Onengut-Gumuscu et al., 2014],
autoimmune thyroid disease (ATD) [Cooper et al., 2012], coeliac disease (CEL) [Trynka
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et al., 2012], multiple sclerosis (MS) [Beecham et al., 2013], narcolepsy (NAR) [Faraco
et al., 2013], primary biliary cirrhosis (PBC) [Liu et al., 2012], psoriasis (PS) [Tsoi et al.,
2012], rheumatoid arthritis (RA) [Eyre et al., 2012], ulcerative colitis [Jostins et al., 2012],
and Crohn’s disease [Jostins et al., 2012]. All were genotyped using a common SNP array:
the ImmunoChip, designed to provide dense genotype coverage of regions associated with
autoimmune disease. Many autoimmune traits are known to have significant heritability,
much of which remains unexplained [Cotsapas and Hafler, 2013]. I hypothesised that my
method could improve detection of disease-associated variants in these diseases without the
need for distinct control groups.
2.2 Results
2.2.1 Overview of method
Assume that each of the set of variants in question is either null (H(i)0 ) or non-null for
association with the principal phenotype i. I consider observed p-values for phenotype i as
observations of a random variable Pi with Pi|H(i)0 ∼U(0,1). Given a p-value threshold α ,
the positive false-discovery rate (equation 1.12 in chapter 1) is equivalent to Pr(H0|Pi < α)
under reasonable assumptions [Storey, 2002]. For each variant, we associate a test statistic
termed the ‘unconditional’ false discovery rate on the basis of its observed p-value pi as
uFDR(pi) = Pr(H
(i)
0 |Pi < pi). This can be interpreted as ‘the probability that a random SNP
with Pi < pi is null for phenotype i’. The estimate of this quantity (identical to the left-hand
side of inequality 1.11 in chapter 1) is denoted ûFDR(pi).
The conditional false discovery rate (cFDR) [Andreassen et al., 2013, Andreasson et al.,
2014] is the probability that a random SNP is null for a phenotype i given that the observed p
values at that SNP for phenotypes i and j are less than (pi, p j); that is, Pr(H
(i)
0 |Pi ≤ pi,Pj ≤
p j), where H
(i)
0 is the null hypothesis that the SNP is not associated with phenotype i. This
quantity is denoted cFDR(pi|p j) and the estimate as ̂cFDR(pi|p j). As above, phenotype i is
termed the ‘principal phenotype’ and phenotype j the ‘conditional phenotype’.
I first apply genomic control to allow the assumption that, globally, P values for null SNPs
are uniformly distributed on [0,1]. I compute an estimate ĉFDR(pi|p j) of the cFDR in a sim-
ilar manner to that proposed by Andreasson et al, but incorporating expected non-uniformity
in the distribution of Pi due to the sharing of controls. As ûFDR(pi) is monotonically related
to pi, I set a significance cutoff for ûFDR(pi) at the maximum value of ûFDR(pi) with
pi < 5×10−8. Correspondingly, I set a significance cutoff for ĉFDR(pi, p j) at the maximum
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ĉFDR(pi, p j) with pi < 5× 10−8 1 Implementation of these steps in R is available from
https://github.com/jamesliley/cFDR-common-controls.
2.2.2 Procedures for uFDR and cFDR
Assume that the p-values for a phenotype i across all SNPs are instances of a random variable
Pi. If pi is an instance of this random variable corresponding to a SNP of interest, the
unconditional false discovery rate uFDR(pi) is defined as
uFDR(pi) = Pr(H
(i)
0 |Pi ≤ pi)
= Pr
(
H(i)0
) Pr(Pi ≤ pi|H(i)0 )
Pr(Pi ≤ pi)
= Pr
(
H(i)0
) pi
Pr(Pi ≤ pi)
where H(i)0 is the null hypothesis that the SNP of interest is not associated with phenotype i.
Given a set of observed p values {p1i , p2i ...pNi } for a phenotype i at N different SNPs, and an
observed p value pi for a SNP of interest, this quantity is estimated as
ûFDR(pi) =
pi
#(p values pki with p
k
i ≤ pi)/N
(2.1)
=
Expected quantile of pi under H
(i)
0
Observed quantile of pi
Because of the approximation Pr(H i0) = 1, the estimate ûFDR is a an upwards-biased
estimate of uFDR; that is, its expected value is greater than the true uFDR, making it a
conservative estimate.
I compute the quantity (2.1) for each SNP at each phenotype, declaring any SNP for
which ûFDR(pi)≤ α as non-null for phenotype i. Defining V as the number of SNPs falsely
declared non-null, R as the total number of SNPs declared non-null, and Q =V/R, a theorem
of Benjamini and Hochberg [Benjamini and Hochberg, 1995] shows the false discovery rate
E(Q) among SNPs with ûFDR≤ α is less than α .
1This cutoff is liberal relative to the genome-wide significance threshold, but is conservative relative to that
previously used in cFDR-based studies. In subsequent work discussed in chapter 3, I argue that the threshold
used here is too liberal and propose a more appropriate one. However, the choice of threshold is a matter of
preference rather than necessity, and in this chapter I have retained the choice of threshold used in the relevant
publication.
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The cFDR constitutes a natural extension of this idea. I assume that the p-values for two
phenotypes i and j across all SNPs are instances of a pair of random variables Pi,Pj. If pi and
p j are instances of these variables corresponding to a SNP of interest then the conditional
false discovery rate cFDR is defined for the set of SNPs with p values for each phenotype
less than or equal to those at this SNP (as per Andreasson et al [Andreassen et al., 2013]) as
cFDR(pi|p j) = Pr(H(i)0 |Pi ≤ pi,Pj ≤ p j)
= Pr(H(i)0 |Pj ≤ p j)
Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 )
Pr(Pi ≤ pi|Pj ≤ p j) (2.2)
The estimation of this quantity proceeds in a similar way to uFDR. Given a set of observed
p value pairs {(p1i , p1j),(p2i , p2j)...(pNi , pNj )} for two phenotypes i and j at N different SNPs,
and an observed p value pair (pi, p j) for a SNP of interest, define N1 as the number of p
value pairs with Pj ≤ p j, and estimate the cFDR as
ĉFDR(pi|p j) =
Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 )
#(pairs (pki , p
k
j) ∈ (Pi,Pj) with pki ≤ pi and pkj ≤ p j)/N1
(2.3)
=
Expected quantile of pi under H
(i)
0 amongst p
k
i with k satisfying p
k
j ≤ p j
Observed quantile of pi amongst pki with k satisfying p
k
j ≤ p j
Again, this estimate is conservative, due to the approximation Pr(H(i)0 |Pj ≤ p j) = 1.
I compute the quantity (2.2) for each SNP at each pair of phenotypes, declaring any SNP
for which ĉFDR(pi|p j) ≤ α ′ as non-null for phenotype i. However, as noted earlier, this
does not guarantee that the expected false discovery rate amongst such SNPs is less than α ′.
I show that the FDR is approximately controlled at a higher level dependent on the region of
the unit square defined by rectangles for which ĉFDR(x|y)≤ α ′.
My method here diverges from the original method proposed by Andreasson et al, in the
use of the expected quantile Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) in place of the p-value pi. If studies
share no controls, it can be reasonably assumed that, for a SNP which is null for phenotype
i, the p values (pi, p j) are independent, so p′i = Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) = pi. This is the
approach taken by Andreasson et al [Andreassen et al., 2013]. I propose a method for
computing p′i when controls are shared between studies, and the independence assumption
above is not valid.
My approach is to compute the related quantity Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ,H( j)η ), where
η is the (unobserved) effect size we would observe for a given SNP for phenotype j if the
observed MAFs agreed exactly with the population MAFs for that SNP, and H( j)η is the
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hypothesis that Z j ∼ N(η ,1) for that SNP. This quantity can be thought of as the ‘expected
quantile’ of pi; that is, the proportion of p values we expect to be less than pi.
2.2.3 Sharing of control subjects
If no controls are shared between studies, it is reasonable to assume that observed effect sizes
for the two phenotypes are independent under a null hypothesis for the principal phenotype.
This implies that the expected quantile of a given SNP’s p value for the principal phenotype
is simply the p value itself regardless of its p value for the conditional phenotype. However,
when control samples are shared, this assumption is invalid. Shared controls induce a positive
correlation on estimated effect sizes for the principal and conditional phenotype [Zaykin
and Kozbur, 2010, Lin and Sullivan, 2009], meaning that when attention is restricted to
SNPs with a given degree of association with the conditional phenotype, the p values for the
principal phenotype will be falsely low; that is, the probability Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) will
not in general be equal to pi (= Pr(Pi ≤ pi|H(i)0 )); in fact it will usually be higher.
When controls are shared, the distribution of p values for the principal phenotype given p
values for the conditional phenotype depends on the underlying effect of each SNP on the
conditional phenotype. For any given SNP, this underlying effect size, which I denote η , is
not known. However, across all SNPs, η may be considered to be realisations of a random
variable H whose distribution is mirrored by the distribution of observed effect sizes for the
conditional phenotype. By integrating over this unknown true effect size for the conditional
phenotype, allowance can be made for shared controls, and the ‘expected quantile’ of a p
value for the principal phenotype, defined as Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ), can be calculated
(section 2.4).
Assume that H has a mixture distribution defined by two parameters (π0,σ2), such that
H = 0 with probability π0 and H ∼N(0,σ2) with probability 1−π0. The parameters (π0,σ2)
are estimated from the observed distribution of effect sizes for the conditional phenotype.
In order to show the effect of the p value adjustment, I simulated p values for 20,000 SNPs
for a principal and conditional phenotype, with controls shared between simulated studies.
All SNPs were null for the principal phenotype, and were variably null or non-null for the
conditional phenotype with probability 0.9, 0.1 respectively. Z scores at non-null SNPs for
the conditional phenotype were distributed as N(0,σ2), as per our assumption. I used a value
of σ = 3, which was similar to the values of σ in real data estimated by our E-M algorithm.
Consider the set of simulated SNPs with p values for the conditional phenotype less
than 0.05 (Figure 2.1). In the absence of shared controls, the distribution of pi amongst
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this set is expected to be uniform, and hence in figure 2.1 the black dots would be expected
to lie along the x-y line. However, with shared controls the principal p values are biased
downward in this set (black dots, figure 2.1). Our computed expected quantile (blue dots)
agrees closely with the observed quantile. In a sense, this constitutes ‘adjusting’ the p
values for the principal phenotype so that the expected distribution is uniform under the null
hypothesis. Software to generate this simulation is available at https://github.com/jamesliley/
cFDR-common-controls.
The formula for adjusting p-values can easily be adapted to arbitrary distributions of
H at the cost of increased computational time, but the form of the distribution of H is not
generally known. I show in appendix A, section A.1.1 that, even for distributions of H which
differ markedly from our assumption of normality, the error in the estimate is not large, and
generally translates to a negligible difference in the set of SNPs declared non-null using the
ĉFDR method. While my assumption of normality has the potential to be anti-conservative if
the true distribution of H is bimodal, non-parametric estimates for distributions of effect sizes
suggest they have a uni-modal distribution centred on zero [Park et al., 2010]. Reassuringly,
the assumption of normality is conservative if H has heavier tails than a normal.
2.2.4 Comparison to split control approach
I compared Andreasson’s approach to SNP discovery which advocated splitting controls into
non-overlapping subsets to my extended shared-control approach using a type 1 diabetes
dataset with a total of 12,175 cases and 15,171 controls. Controls and cases were each split
into two sets (control sets had size 7,585 and 7,586, cases 6087 and 6088). ‘Split’ p values
were computed using one set of controls and one set of cases and corresponding ‘shared’ p
values were computed using the complete set of controls. As expected, more shared p values
reached genome-wide significance than did split p values (Figure 2.2).
I computed cFDR values by labelling one set of cases ‘conditional’ and the other ‘princi-
pal’ using the split-control p values using Andreasson et al’s approach and using the shared
control p values using our method. For reference, I compared these to a naive application of
Andreasson et al’s method on the shared-control p values (Figure 2.2, lower panel). More
SNPs can be declared significant according to cFDR using the shared-control than split-
control approach at all reasonable thresholds, and naive application of Andreasson et al’s
approach to shared-control p values again increases the number declared significant.
Because the quantity Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) is systematically underestimated when
using this naive method (by assuming it is equal to pi) as shown in appendix A, section A.1.3,
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Fig. 2.1 Correction of cFDR for shared controls. Simulation of GWAS summary statistics
for 20000 SNPs, all null for phenotype i and variably null or non-null for phenotype j, with
association tested using a shared control group. Black dots show p values for phenotype i
at all SNPs with p value for phenotype j less than 0.05, with evident downward bias. Blue
dots show the adjustment to expected quantile of p values. The red dots show the expected
quantile we would compute if we were to assume incorrectly that all SNPs were null for the
conditional phenotype i. This quantity overestimates the true quantile.
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Fig. 2.2 Validation of the shared-control approach and p-value adjustment due to shared
controls. Panel A shows the effect of splitting controls on power to detect association.
The number of SNPs with p values less than a given cutoff are shown for split-control
and shared-control approaches. For all p-value cutoffs, fewer SNPs reach significance
when using a split-control design. Panel B shows the number of SNPs with ĉFDR values
less than a given cutoff using the existing method on a split-control design, our extended
method on a shared control design with the adjustment for shared controls, or using the
split-control approach naively on the shared-control design; that is, assuming incorrectly that
Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) = pi. The second figure shows that failing to correctly calculate
Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) = pi leads to a subtle increase in the number of SNPs declared
non-null at all cutoffs, due to the incorrect underestimation of ĉFDR.
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it leads to a falsely low ĉFDR. The increase in observed number of SNPs declared significant
when using the naive method shows that it can indeed lead to false discoveries.
For principal phenotype p values in the range 5×10−6 - 5×10−8 - effectively the region
from which ‘new’ SNPs may be discovered by cFDR rather than p value alone - the naive
cFDR is frequently underestimated by 2-3 fold (appendix A, figure A.5, left panel). For
lower p values, the naive cFDR may underestimate by hundreds- or thousand-fold, with the
potential fold underestimation increasing with decreasing p value (appendix A, figure A.5,
right panel). Because of the relatively high ratio of number of controls to number of cases, the
correlation between effect sizes is lower in this constructed case (c. 0.22) than between most
phenotypes in our study (c. 0.5). The underestimation of cFDR using the ‘naive’ method
worsens with higher correlation, so we would expect that the fold-underestimate we see here
is less severe than that which would be observed if applying this to other studies.
2.2.5 False discovery rate
An important consideration in any GWAS procedure is control of the type-1 error rate. This
can be done in several ways, as discussed in chapter 1, section 1.2.4. A major advantage
of the ûFDR statistic is the control it allows over the FDR by the Benjamini-Hochberg
procedure: if H(i)0 is rejected for all SNPs with ûFDR less a given threshold α , the FDR
amongst these SNPs is bounded above by α .
This is not true for the ĉFDR. This can be seen most easily by considering an extreme
case in which all non-null SNPs for phenotype i have Pi = Pj = 0 (figure 2.3). Assume no
controls are shared and no SNPs are non-null for phenotype j and null for phenotype i, so
Pi|H(i)0 and Pj|H(i)0 have independent U(0,1) distributions. Assume also that the total number
of SNPs N is large but a fixed positive proportion of SNPs π1 = 1−π0 are non-null. For
fixed pi, p j, the number of non-null SNPs with Pr(Pi < pi,Pj < p j) = pi p j so as N → ∞
ĉFDR(pi|p j)→A.S pi π0 p j +π1π0 pi p j +π1 (2.4)
For a region X of the unit square, define (as per Storey et al [Storey et al., 2003]) the random
variables V (X), S(X) and R(X) as the number of null SNPs, non-null SNPs and the total
number of SNPs for which observed p-values fall in X . Defining X as the rectangle with
corners (0,0), (pi,0), (0, p j), (pi, p j), as N → ∞, we have
V (X)/R(X)→A.S pi p jπ0pi p jπ0+π1 < pi
π0 p j +π1
π0 pi p j +π1
(2.5)
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so for large enough N the ĉFDR overestimates the FDR for the rejection region X . Indeed,
if p′j is fixed and H
(i)
0 is rejected whenever Pj < p
′
j and ĉFDR(pi|p′j) < α , the FDR is
controlled at α by the main result of Benjamini and Hochberg [Benjamini and Hochberg,
1995]. However, as N → ∞ the region for which ĉFDR < α tends to the region L defined by
(pi, p j) : pi
π0 p j +π1
π0 pi p j +π1
< α
⇔ p j < π1π0(1−α)
(
α
pi
−1
)
(2.6)
and, by integrating over this region, we have
V (L)→A.S N π1α
(1−α)π0 log
(
1−απ0
π1
)
R(L)→A.S N
(
π1+
π1α
(1−α)π0 log
(
1−απ0
π1
))
V (L)
R(L)
→A.S
α log
(
1−απ0
1−π0
)
π0(1−α)+α log
(
1−απ0
1−π0
) (2.7)
which is not generally < α (in fact, it is usually substantially > α , and may be larger than α
by an arbitrarily large factor) so the procedure in which H(i)0 is rejected whenever ĉFDR < α
does not asymptotically control the FDR at α (or at kα for any fixed k).
This is demonstrated in figure 2.3. For any preset p′j, the region defined by Pj < p′j,
ĉFDR(pi|p′j)< α is a rectangle with a corner on the boundary of L. Since any such rectangle
M contains all non-null SNPs (and thus as many as L itself) and fewer null SNPs, each
rectangle has a lower value of V/R than does L. Intuitively, the Benjamini-Hochberg result
only guarantees FDR control over regions like M, not over regions like L.
In the original method [Andreassen et al., 2013], SNPs were declared significant if they
were contained within any rectangular regions with a ĉFDR value of less than 0.01. Our
reasoning demonstrates that the false-discovery rate of this procedure was likely to have been
considerably higher than 0.01.
It is a difficult problem to find a bound on FDR for the procedure in which SNPs are
rejected if ĉFDR < α . However, given a rejection region L for p-value pairs (pi, p j), we
can compute a bound on the positive FDR of the region L, Pr(H(i)0 |(pi, p j) ∈ L); that is, the
FDR if we were to repeatedly re-generate and re-test Pi, Pj values while retaining the same
rejection region L.
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Fig. 2.3 FDR control on SNPs reaching cFDR threshold. L is the locus of a set of points
with ĉFDR = α , and M∗ is a rectangle within L. If all the non-null SNPs were concentrated
in the lower left corner, then the number of non-null SNPs in L would be equal to that in
any individual rectangle with vertices at the origin and on L, but the number of null SNPs
would be greater, meaning that V (L)/R(L) would be greater than V (M)/R(M), and generally
greater than α . The value E{V (L)/R(L)|R(L) > 0} is asymptotically bounded above by
α∗v(L)/v(M), where v(L) and v(M∗) are the expected number of null SNPs in L and M∗
respectively (appendix A, section A.1.2).
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From Storey et al [Storey et al., 2003], we assume that we are performing N identical
hypothesis tests to generate bivariate test statistics (Pik,Pjk), k = 1..N. Denote H
(i)
0k as the
null hypothesis for test k and assume that H(i)0k has a Bernoulli distribution with parameter
1−π0, and that the tri-variate random variables (Pik,Pjk,H(i)0k ) are independent and identically
distributed with (Pik,Pjk)|H(i)0k ∼ (1−H(i)0k )F0+H(i)0k F1. Further assume that F0 is known, and
for each region X denote
v(X) =
∫
X
dF0 (2.8)
Set M as a rectangle contained within L with vertices (0,0), (p∗i ,0), (0, p∗j) and (p∗i , p∗j). Now,
twice using the result that E
(
V (X)
R(X)
∣∣R(X)> 0) = E{V (X)}E{R(L)} = Pr(H(i)0 |(pi, p j) ∈ X) [Storey
et al., 2003], we have
Pr(H(i)0 |(pi, p j) ∈ L) = E
(
V (L)
R(L)
∣∣R(L)> 0)
=
E{V (L)}
E{R(L)}
=
π0v(L)
π0v(L)+(1−π0)E{S(L)}
<
π0v(L)
π0v(M)+(1−π0)E{S(M)}
=
v(L)
v(M)
π0v(M)
π0v(M)+(1−π0)E{S(M)}
=
v(L)
v(M)
E{V (M)}
E{R(M)}
=
v(L)
v(M)
E
(
V (M)
R(M)
∣∣R(M)> 0)
=
v(L)
v(M)
Pr(H(i)0 |(pi, p j) ∈M) (2.9)
The value α∗ = ĉFDR(p∗i |p∗j) is an estimate for Pr(H(i)0 |(pi, p j)∈M) which is almost surely
conservative as N → ∞ (under reasonable conditions on F0, F1). Thus v(L)v(M)α∗ provides an
asymptotic bound for Pr(H(i)0 |(pi, p j) ∈ L), and a rough bound for the FDR for the ĉFDR
procedure.
By the definition of L in our procedure, α = α∗, and it is desirable to choose the rectangle
M∗ in L which minimises v(L)v(M) . Importantly, this bound is not strict for finite N, since the
region L is not independent of the observations of Pi,Pj. It will, however, hold almost surely
for fixed α , π0, F0, F1 as N → ∞ (since the rejection region will converge almost surely to a
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limit L∞, in a similar way to equation 2.6, and αv(L∞)/v(M∗) is almost surely asymptotically
conservative) under reasonable assumptions on F0, G0. For the remainder of this thesis, I
will refer to this as a ‘bound’, with these caveats assumed.
The estimation of F0 and hence v(X) with shared controls and Pi|H(i)0 ≁ U(0,1) is
discussed in appendix A, section A.1.2.
2.2.6 Application to ten immune mediated diseases
I obtained summary statistics in the form of p values for ten immune mediated diseases
from ImmunoBase (www.immunobase.org, accessed 19/3/14). For each pair of diseases,
the number of shared controls was estimated according to the description of the control
samples in each paper. The numbers of cases, controls and our estimated numbers of shared
controls for each study are shown in Table 2.1. Uniform quality control criteria were applied
to all SNPs, and the MHC region, which exhibits both strong LD and strong association
with immune mediated diseases was excluded. P values were corrected within each trait for
genomic inflation using a standard algorithm [Devlin et al., 2001] applied to SNPs included
on the ImmunoChip to replicate a GWAS study of reading and maths ability (Steve Eyre and
Cathryn Lewis, personal communication), unlikely to be related to any immune mediated
disease studied here.
P values for each principal phenotype were adjusted to p′ as described above in order to
account for the effect of shared controls. For each ordered pair of phenotypes, a Q-Q plot
was generated as per Andreasson et al [Andreassen et al., 2013]. A Q-Q plot is a graph of
the observed distribution of a random variable against the expected distribution. I overlaid
Q-Q plots for log10(p
′) values for the principal phenotype for subsets of SNPs exhibiting
successively smaller p values for the conditional phenotype. Figure 2.4 shows QQ plots for
T1D conditional on RA and PSO; plots for all other pairwise comparisons may be found
in appendix A, figure A.8 onwards. Notably, if lines shift further left with more stringent
cutoffs on association with the conditional phenotype, then SNPs which are associated with
the conditional phenotype are more likely to be associated with the principal phenotype,
indicating pleiotropic effects of SNPs on the two phenotypes. In many cases, the Q-Q plots
demonstrate considerable leftward shift with conditioning on association with a second
disease, and we see strong evidence for pleiotropy for T1D conditioned on RA and little or
no evidence for pleiotropy for T1D conditioned on PSO.
I estimated the unconditional and conditional false discovery rates, ûFDR(pi) and
ĉFDR(pi|p j), at each SNP for each phenotype and each ordered pair of phenotypes re-
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Fig. 2.4 Q-Q plots for T1D conditional on RA (Panel A) and PSO (Panel B). Y axes show
log10(p
′
T 1D); X axes show log quantile (rank) of p values in various sets of SNPs. The degree
of leftward shift of a black point from the diagonal is monotonic with the unconditional FDR
of that p value for the principal phenotype, and the degree of leftward shift of a coloured
point is monotonic with the conditional FDR of the p value for the principal phenotype
and the p-cutoff corresponding to the colour for the conditional phenotype. As expected, a
leftward shift is seen even for the unconditional Q-Q plots (black line) owing to the use of
the ImmunoChip, which focuses on potential autoimmune-associated regions. Each colour
corresponds to the Q-Q plot for pT 1D amongst a subset of SNPs with pRA or pPSO less than
the indicated cutoff. P values for T1D are adjusted for the effect of shared controls between
studies. A leftward shift with decreasing pRA or pPSO cutoff indicates that SNPs which are
associated with the conditional phenotype (RA or PSO) are more likely to be associated
with the principal phenotype (T1D), presumably due to pleiotropic effects on phenotypes.
Good enrichment is seen for T1D conditioning on RA (Panel A), and little or no enrichment
conditioning on PSO (Panel B).
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Table 2.1 Number of cases and controls for each study, and relevant references, together with
our estimates of the number of controls shared between studies. P values for T1D are from a
meta-analysis of case-control and TDT data, with effective numbers of cases computed as
shown in the methods section
Disease Controls Cases
T1D [Onengut-Gumuscu et al., 2014] 12175 15171
ATD [Cooper et al., 2012] 9364 2733
CEL [Trynka et al., 2012] 12228 12041
MS [Beecham et al., 2013] 24091 14498
NAR [Faraco et al., 2013] 10421 1886
PBC [Liu et al., 2012] 8514 2861
PSO [Tsoi et al., 2012] 22806 10588
RA [Eyre et al., 2012] 15870 11475
UC [Jostins et al., 2012] 15977 10920
CRO [Jostins et al., 2012] 15977 14763
Estimated number of pairwise shared controls
T1D ATD CEL MS NAR PBC PSO RA UC CRO
T1D - 9364 12228 8430 4289 8514 4822 8430 4020 4020
ATD - 9364 8430 4289 8514 4822 8430 4020 4020
CEL - 8430 4289 8514 4822 8430 4020 4020
MS - 4289 8430 4822 8430 10102 10102
NAR - 4289 4289 4289 4020 4020
PBC - 4822 8430 4020 4020
PSO - 4822 4020 4020
RA - 4020 4020
UC - 15977
CRO -
spectively. Figure 2.5 shows ĉFDR for T1D conditioned on RA. The advantage gained by
ĉFDR can be seen in the left-shift of the region in which a SNP can be declared significant
(blue dots), corresponding to a higher p-value cutoff for significance for T1D among SNPs
with low p values for RA. Indeed, if only SNPs with a p value for RA less than some threshold
ζ are considered, a p value cutoff for significance for T1D is given by the leftmost border of
the blue dots on the line Pj = ζ .
The degree of leftward shift in the Q-Q plots clearly contains information about the
degree of pleiotropy between diseases. I defined a statistic summarizing some aspects
of this evidence for pleiotropy and used it to visualise the set of pairwise relationships
between diseases as a network (Figure 2.6). The network encouragingly reflects several
pathophysiological associations: UC is linked to CRO, and T1D to ATD. Strong linkage is
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Fig. 2.5 Plot of ĉFDR (red-yellow) for T1D conditioned on RA. White dots signify the region
for which ûFDR is less than α corresponding to p < 5×10−8. Blue dots signify the region
for which cFDR is less than the same α . Note the leftward shift of blue points and the general
leftward shift of colours corresponding to an increased p-value threshold for association with
T1D for SNPs with low p values for RA. Black dots show a random sample of the observed
p value pairs.
50 Phenotypic leverage with shared controls
also seen both ways for MS and PBC, and between T1D and RA, findings which can also be
seen in the Q-Q plots ( A, figure A.8 onwards). One way relationships suggest the presence
of a larger total number of associated SNPs for the disease at the start of the arrow than at
the end.
2.2.7 Discovery of novel associations
The numbers of SNPs deemed significant for each phenotype by analysis using unconditional
and conditional approaches are shown in table 2.2, with details in A, table A.2 onwards.
ĉFDR allows certain SNPs with p values as high as 3×10−6 to be declared significant while
controlling the false discovery rate at a relatively low value. Fifty-one of the 59 SNPs we
identify uniquely through ĉFDR have previously been reported to be associated with the
relevant disease through use of alternative significance thresholds, other genomic control
procedures, other GWAS or additional samples not genotyped by ImmunoChip, a useful
verification of our technique. Eight of the SNPs we discover uniquely through cFDR were
in regions not previously known to be associated with the corresponding disease (table 2.3).
These will require replication in independent samples to be declared truly associated, but they
contain some potentially interesting signals, such as an association for RA at SNP rs72928038
near existing MS, ATD and T1D associations in BACH2, a transcriptional regulator involved
in transcription repression and activation by MAFK [Dubois et al., 2010]. The biological
plausibility of new findings is somewhat expected, given the restricted coverage of the
ImmunoChip to potentially immune-associated regions.
The SNP rs1034290 in region 1p13.1, which we found to be associated with PBC, is
in intron three of CD58, which is a surface receptor involved in binding and activation of
T-lymphocytes. The protective effect of the MS-associated allele is postulated to arise from
upregulation of the transcription factor FOXP3 [De Jager et al., 2009] and the patterns of
association in the region suggest the two diseases may share a causal variant here (http:
//www.immunobase.org).
2.3 Discussion
In this chapter, I extended a technique for computing conditional Bayesian False Discovery
Rates to GWAS for independent diseases with shared control groups. This technique enables
improved detection of disease-associated SNPs compared to conventional methods. By
enabling larger control groups for each study, my method uses data more efficiently than in
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T1D
ATD
CELMS
NAR
PBC
PSO
RA
UC
CRO
Fig. 2.6 Network of degree of pleiotropy between phenotypes (CRO: Crohn’s disease; UC:
Ulcerative colitis; PBC: primary biliary cirrhosis; MS: multiple sclerosis; CEL: coeliac
disease; T1D: type 1 diabetes; RA: rheumatoid arthritis; ATD: autoimmune thyroid disease;
NAR: narcolepsy; PSO: psoriasis). An arrow runs from vertex i to vertex j if and only if by
conditioning on p < 5×10−6 for the conditional phenotype j we can increase the threshold
for significance for the p value for the principal phenotype i from 5×10−8 to 4×10−7 or
greater. Edges are thickened if the cutoff could be increased more than this. The threshold
4×10−7 was selected as the minimum value for which the network is weakly connected;
that is, having an arrow to or from each edge.
52 Phenotypic leverage with shared controls
Table 2.2 Number of SNPs with p≤ 5×10−8 after genomic found by analysis of the principal
phenotype alone and the estimated equivalent FDR for this set of SNPs. Conditional analysis
shows the number of additional SNPs found through conditional FDR analysis, and the upper
bound for the FDR of all SNPs selected by this method, including adjustment for the multiple
phenotypes conditioned upon. Finally, we summarise the performance of the cFDR approach
by the FDR ratio - the ratio of the upper bound for the FDR for all SNPs selected by the
cFDR approach, and the estimated FDR of all SNPs with p less than the maximum p value
within this set if we had not conditioned. Note, we list only the most associated SNPs in each
LD block by pruning according to LD, as described in Methods.
Disease Univariate Conditional Efficiency ratio
N.SNPs FDR N.SNPs FDR
T1D 44 3.79×10−6 4 7.32×10−6 0.11
ATD 3 1.04×10−5 4 1.02×10−5 0.03
CEL 46 3.97×10−6 7 5.77×10−6 0.24
MS 43 5.97×10−6 12 1.19×10−5 0.15
NAR 3 1.61×10−4 0 3.05×10−4 0.83
PBC 25 8.86×10−6 2 2.09×10−5 0.12
PSO 44 2.33×10−5 2 5.45×10−5 0.06
RA 16 2.04×10−5 10 6.00×10−5 0.11
UC 49 4.49×10−6 6 6.73×10−6 0.14
CRO 80 2.08×10−6 12 2.73×10−6 0.28
corresponding study designs in which control groups are independent, and is applicable to a
wider range of GWAS datasets for which only summary statistics are available.
Combination of GWAS by analysis of pleiotropy in this sense has several attractive advan-
tages over single-phenotype analysis. The most obvious advantage is improved detection of
disease-associated SNPs using GWAS without the need for additional samples. A secondary
advantage arises from understanding of the pleiotropic structure between phenotypes: if a
SNP is known to exhibit pleiotropy between two conditions, it may be causative for a shared
risk factor or pre-disease state. Analysis of such SNPs has the potential to yield informa-
tion on disease aetiology, with implications for preventative medicine and development of
treatment.
A further potential use for this technique could be the genomic analysis of diseases with
phenotypes which are difficult to differentiate; for instance, Crohn’s disease and Ulcerative
Colitis [Farmer et al., 2000]. Additionally, many diseases (such as narcolepsy [Association
et al., 1990]) are definitively diagnosed on clinical grounds. This implies that these diseases
may constitute a range of biochemical and genetic states. Inclusion criteria based on objective
biochemical grounds, such as that used for narcolepsy in the context of this paper [Faraco
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Table 2.3 Eight SNP associations with the indicated disease discovered by cFDR but not pre-
viously published to our knowledge, together with the phenotype upon which they have been
conditioned (C. phen.) and nearby genes. SNPs are shown by RSID: major>minor alleles.
The disease (principal phenotype) p value has been corrected for genomic inflation. Note
that a SNP reaching significance by ĉFDR for the principal phenotype does not constitute
evidence of association with the conditional phenotype (C. phen.). Chr = chromosome, Pos
= position (build GRCh37), SNPs are shown with major>minor alleles, MAF = minor allele
frequency in UK controls.
SNP Chr Pos Disease p value
rs6691768: A>G 1p31.3 61791863 CEL 8.56×10−8
rs1034920: T>C 1p13.1 117076399 PBC 1.43×10−6
rs6705577: G>C 2p21 43359275 CEL 3.61×10−7
rs79248157: T>C 2q32.1 185501065 UC 1.53×10−7
rs72928038: G>A 6q15 90976768 RA 5.89×10−7
rs12924003:C>T 16q12.1 51080214 CRO 5.82×10−8
rs6032606:G>C 20q13.12 44596207 CEL 1.31×10−7
rs9610686:G>A 22q13 37633851 CEL 1.90×10−7
SNP Chr Disease C. phen. MAF Nearby Genes
rs6691768: A>G 1p31.3 CEL CRO 0.373 NFIA
rs1034920: T>C 1p13.1 PBC MS 0.100 CD58
rs6705577: G>C 2p21 CEL MS 0.272 THADA
rs79248157: T>C 2q32.1 UC CRO 0.031 ZNF804A
rs72928038: G>A 6q15 RA T1D 0.176 BACH2
rs12924003:C>T 16q12.1 CRO NAR 0.321 NOD2
rs6032606:G>C 20q13.12 CEL MS 0.052 ZNF355, MMP9
rs9610686:G>A 22q13 CEL ATD 0.387 RAC2
et al., 2013] are unlikely to characterise all patients with these diseases, and conclusions drawn
from studies will not necessarily be medically applicable to the whole patient population.
Given this, diseases defined phenotypically with potential genomic diversity may be better
analysed by separate consideration of biochemically-defined subtypes, with a collective
analysis performed by a method such as ĉFDR, avoiding the assumption that the genomic
bases of disease subtypes are identical.
I identify a somewhat counter-intuitive property that the FDR in the union of all regions
with ĉFDR less than a given α tends to be greater than α , and propose a method to overcome
this problem. They are complex to apply, but could be much simplified if interest was directed
to SNPs with conditional p values less than some threshold p0, in which my method for
allowing for shared controls would ensure that the expected false discovery rate at SNPs
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with ĉFDR(pi|p0)≤ α would indeed be controlled at α . My more complicated method to
control FDR is necessary if the variable p j is used in place of the constant p0. However, I
argue in chapter 7, section 7.1.4 that the full ĉFDR procedure (with variable p j) is preferable
on grounds of efficient information use.
An important consideration in both our method and the original method is that a
ĉFDR(pi|p j) value which reaches significance does not constitute genome-wide evidence of
association with the conditional phenotype j; indeed, the probability of association with the
conditional phenotype relates to ĉFDR(p j|pi) and in general ĉFDR(pi|p j) ̸= ĉFDR(p j|pi).
In some cases, where the principal p value is very close to genome-wide significance, even
conditioning on p j ≤ 0.5 can theoretically be enough to reach the relevant ĉFDR threshold.
This is not a weakness of the ĉFDR method as such, but a consequence of introducing another
source of randomness (Pj) to the overall procedure. Principal p values greater than 5×10−8
which can be declared significant conditioning on large conditional p value cutoffs correspond
to an increase in the area of the region L (see results section), which is accounted for by our
FDR-controlling method. This problem is discussed further in chapter 3, section 3.4.
My method enables improved detection of SNPs compared to analysis of unconditional
FDR (principal p value alone). However, the improvement is smaller than that reported by
Andreasson et al [Andreassen et al., 2013, Andreassen et al., 2014, Andreasson et al., 2014],
who detected almost twice as many SNPs using cFDR as they would have detected with
uFDR. This is expected for two reasons. Firstly, the gain in power from cFDR essentially
comes from an increase in the total number of controls and the effective number of cases.
If controls are already shared, the only information gain can come from increasing the
number of effective cases. Consequently, the difference in power between cFDR and uFDR
will not be as large when controls are shared, although both outperform their counterparts
when controls are split. Secondly, we were careful to use stringent cutoffs for FDR which
were chosen to mirror the established genome-wide significance threshold of p≤ 5×10−8,
generally equivalent to a false discovery rate around 5×10−6 to 5×10−5, compared to the
more liberal thresholds used by Andreasson et al.
One alternative way to exploit pleiotropic relationships is by meta-analysing two related
diseases together, as though the diseases were the same. Our method confers several advan-
tages over this approach. The most important of these is that our method borrows strength
from other SNPs according to the level of genome wide pleiotropy between diseases; that is,
if the two GWAS suggest extensive pleiotropy (such as Figure 2.4 for T1D | RA), a low p
value for a conditional phenotype will ‘sway’ our judgement of association with the principal
phenotype more than the same p value for a conditional phenotype with poor pleiotropy (such
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as Figure 2.4, for T1D | PSO). A meta-analysis would not distinguish these two scenarios. A
secondary advantage of my technique is that SNP detection is not systematically weakened if
the two diseases do not exhibit pleiotropy, as would be the case in meta-analysis; this arises
because I am testing association with only one of the two phenotypes at a time.
2.4 Methods
2.4.1 Datasets
I obtained SNP summary statistics from ten studies on autoimmune diseases from Im-
munoBase (www.immunobase.org). Inclusion and exclusion criteria for the studies are
described in detail in the original publications ([Onengut-Gumuscu et al., 2014, Cooper et al.,
2012, Trynka et al., 2012, Beecham et al., 2013, Faraco et al., 2013, Liu et al., 2012, Tsoi
et al., 2012, Eyre et al., 2012, Jostins et al., 2012, Jostins et al., 2012]. Generally, some or
all controls from different studies were obtained from common data sources, resulting in
overlapping control groups. All studies used the ImmunoChip array [Cortes and Brown,
2011].
P values for type 1 diabetes were from a meta-analysis of a case-control study and
familial study using the transmission disequilibrium test (TDT). In order to calculate the
correlation between p values for different diseases, it was necessary to calculate effective
numbers of cases and controls for the combined T1D study. For a case control study, under
the assumptions of Hardy-Weinberg and the null hypothesis, the variance of the log odds
ratio may be expressed as
n0+n1
2n0n1
1
f (1− f )
where n0 and n1 are the numbers of cases and controls and f is the minor allele frequency in
controls.
Given the standard error of a log OR for the TDT study, σˆ , and a minor allele frequency,
we estimated M = σˆ2 f (1− f ) for all ImmunoChip SNPs which did not show deviation from
the null hypothesis (p > 0.5). The distribution of log(M) is shown in appendix A, figure A.7.
By equating the median of M with n0+n1n0n1 , and assuming that each TDT family contributed
the equivalent information to one control in a case-control study, ie n0 = 2943, an equivalent
number of cases was estimated to be 4126. This seemed reasonable, given that there were a
total of 5505 (dependent) cases across those families.
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SNPs were excluded on the basis of QC summaries calculated on 12,888 common
controls: call rate less than 99%, minor allele frequency less than 0.02, or deviation from
Hardy-Weinberg equilibrium (|Z|> 5). Given the strong association of immune mediated
diseases with the MHC and the extended LD in the region, we were concerned that MHC
SNPs might cause inaccurate estimation of pleiotropy. I therefore excluded SNPs in a wide
band around the MHC region on chromosome 6 (co-ordinates 24500000: 34800000, build
NCBI36). After quality control, genotype data was available for at least one phenotype at a
total of 110677 SNPs.
2.4.2 Genomic control
P values were corrected for genomic inflation using a genomic control algorithm [Devlin
et al., 2001]. A set of SNPs known to be un-associated with autoimmune disease was
obtained from the Wellcome Trust Case Control Consortium (WTCCC) study on reading
and mathematics ability. These SNPs were pruned so that none were in LD with r2 > 0.2,
and any SNPs within 500 kb of known autoimmune-associated regions were removed. The
average degree of inflation was computed for each disease at the remaining 1761 SNPs, and
all effect sizes and p values were adjusted accordingly.
2.4.3 Computation of expected quantile
From the first part of (2.2), we have:
cFDR(pi|p j) =
Pr(H(i)0 |Pj ≤ p j)Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 )
Pr(Pi ≤ pi|Pj ≤ p j) (2.10)
As per Andreasson et al [Andreassen et al., 2013], the quantity Pr(H(i)0 |Pj ≤ p j) is set
conservatively at 1, and the quantity Pr(Pi ≤ pi|Pj ≤ p j) is estimated empirically as the
proportion of pairs of observed p values (p′i, p′j) with p′j ≤ p j which also satisfy p′i ≤ pi.
For a given SNP, let η denote the standardised mean allele frequency (MAF) difference;
that is, the Z value we would compute if the observed MAFs agreed exactly with the
population MAFs. I consider η for a random SNP as being an instance of a random variable
H, and that the observed z value for that SNP Z|H = η is distributed as
Z|H = η ∼ N(η ,1) (2.11)
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We further assume that H follows a mixture distribution taking the value 0 with probability
π( j)0 and a normal pd f with probability 1−π( j)0 :
H ∼
0, p = π
( j)
0
N(0,σ2), p = 1−π( j)0
(2.12)
This implies
Z j ∼
N(0,1), p = π
( j)
0
N(0,1+σ2), p = 1−π( j)0
(2.13)
Thus, given the observed distribution of Z j, the parameters π
( j)
0 and σ j may be estimated by
an expectation - maximisation algorithm (https://gist.github.com/chr1swallace/11421212).
We assume as per Zaykin [Zaykin and Kozbur, 2010] that the distribution of pairs of
observed z values (Zi,Z j) for a single given SNP is bivariate normal. Denote by H
( j)
η the
event that, for a given SNP, the values Z j are distributed as N(η ,1), with η depending on the
SNP.
Under our assumption of the null hypothesis H(i)0 for the principal phenotype and a
population MAF difference corresponding to η for the conditional phenotype, we have
(Zi,Z j|H(i)0 ,H( j)η )∼ N
((
0
η
)
,
(
1 ρ
ρ 1
))
(2.14)
The correlation ρ arises from the shared controls between groups [Zaykin and Kozbur,
2010, Lin and Sullivan, 2009] and is asymptotically equal to
ρ =
1√(
1+ N0iN0
)(
1+ N0 jN0
)(
1+ N0iNi +
N0
Ni
)(
1+ N0 jN j +
N0
N j
) (2.15)
where Ni and N j are the numbers of cases, N0i and N0 j are the numbers of non-shared
controls, and N0 is the number of shared controls for the original GWAS for the principal and
conditional phenotypes respectively. There is good agreement with the asymptotic correlation
when group sizes are greater than 100 [Zaykin and Kozbur, 2010].
Given equations (2.12)–(2.15), the joint distribution of Zi and Z j can be computed under
only the assumption H(i)0 . The value of the partial PDF of (Zi,Z j|H(i)0 ) at (x,y) can be derived
in a similar way to (2.13):
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(
Zi,Z j|H(i)0
)
∼
N
((
0
0
)
,
( 1 ρ
ρ 1
))
, p = π( j)0
N
((
0
0
)
,
( 1 ρ
ρ 1+σ2
))
, p = 1−π( j)0
(2.16)
We now compute the final probability in equation (2.10). Define
Pη(X) = Pr(X |H(i)0 ,H( j)η ) (2.17)
as the probability of observing events X for a particular SNP with true effect size η (which
may be 0, corresponding to the general null). Then,
Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) =
Pr(Pi ≤ pi,Pj ≤ p j|H(i)0 )
Pr(Pj ≤ p j|H(i)0 )
=
π( j)0 P0(Pi ≤ pi,Pj ≤ p j)+(1−π( j)0 )
∫ ∞
−∞Pη(Pi ≤ pi,Pj ≤ p j) f (η)dη
π( j)0 P0(Pj ≤ p j)+(1−π( j)0 )
∫ ∞
−∞Pη(Pj ≤ p j) f (η)dη
. (2.18)
If the distribution of H is estimable by other means, quantity (2.18) can be calculated
numerically without the assumption that the non-null component of H be normally distributed,
at the cost of higher computation time. Under our assumptions, equations (2.13) and (2.16)
enable the fast computation of quantity (2.18) by normal CDFs; writing
Λ(ρ,σ2)(zi,z j) =
∫
|x|>|zi|,|y|>|z j|
N(0
0
)
,
( 1 ρ
ρ 1+σ2
)(x,y)dxdy
λσ2(z j) =
∫
|y|>|z j|
N(0,1+σ2)(y)dy (2.19)
we have
Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) =
π( j)0 Λ(ρ,0)(zi,z j)+(1−π( j)0 )Λ(ρ,σ2)(zi,z j)
π( j)0 λ0(z j)+(1−π( j)0 )λσ2(z j)
(2.20)
2.4.4 Point expected quantile
Because the formula for Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) is differentiable on the unit square, an
expression for the expected quantile of pi given an exact value for p j can be computed by
taking the partial derivative with respect to p j:
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Pr(Pi ≤ pi|Pj = p j,H(i)0 ) =
∂
∂ p j
Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) =
A+B
C
where
A = π( j)0 N(0,1)(z j)
∫
|x|≥zi
N(ρz j,1−ρ2)(x)dx
B = (1−π( j)0 )N(0,1+σ2)(z j)
∫
|x|≥zi
N( ρz j
1+σ2
, 1−ρ
2+σ2
1+ρ2
)(x)dx
C = π( j)0 N(0,1)(z j)+(1−π( j)0 )N(0,1+σ2)(z j)
where Nµ,σ2(x) denotes the value of the normal pd f with mean µ and variance σ2 at x.
2.4.5 Significance thresholds
Because ûFDR values are monotonically related to p values, the widely accepted GWAS p
value cutoff of 5×10−8 corresponds naturally to a cutoff for ûFDR. For each phenotype i,
I set a significance threshold β i for ûFDR(pi) as the lowest possible value of γ for which
ûFDR(pi)≤ γ ⇔ pi ≤ 5×10−8.
I then applied an analogous approach to ĉFDR. For each pair of phenotypes (i, j), I set a
significance threshold α ij as the value of γ
′ for which ĉFDR(pi|p j) ≤ γ ′⇔ pi ≤ 5×10−8.
Given the distribution of Pj, it is possible that this could lead to declaring SNPs with
pi > 5×10−8, p j ≈ 1 as significant. To avoid this, if α ij was larger (less stringent) than β i, I
set α ij = β
i.
For each ordered pair of phenotypes (i, j), I declared all SNPs with ĉFDR(pi|p j)≤ α ij
as non-null for phenotype i. This included all SNPs with ûFDR(pi)≤ β i. I then computed
bounds c(i)j on the false discovery rate amongst SNPs for which ĉFDR(pi, p j)≤ α ij as per
section 2.2.5. For each phenotype, this gave nine upper bounds, corresponding to each of the
nine conditional phenotypes.
2.4.6 Network and heatmap representation of pleiotropy
I compared the degree of pleiotropy between diseases by considering how much the p-value
threshold for significance for the principal phenotype changed when conditioning on a small
p-value threshold for the conditional phenotype. I used the ĉFDR algorithm to compute
the number p j∗i such that P(H
(i)
0 |Pi ≤ p j∗i , p j ≤ 5×10−6) = P(H(i)0 |Pi ≤ 5×10−8); that is,
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ĉFDR(p j∗i |5×10−6) = ûFDR(5×10−8). I then considered the ratio p j∗i /5×10−8; that is,
the fold increase in significance cutoff after conditioning.
I visualised the ratio p j∗i /5× 10−8 as a heat-map (appendix A, figure A.6). I also
produced a network (Figure 2.6), with an edge from vertex i to vertex j if and only if, by
conditioning on Pj ≤ 5× 10−6, the cutoff for significance for Pi could be increased from
5×10−8 to 4×10−7. This cutoff was chosen as the smallest value such that the network was
weakly connected; that is, each vertex had an arrow either to it or from it.
2.4.7 Discovery of novel SNP associations
SNPs were deemed significant for each principal phenotype i if ĉFDR(pi|p j)≤ α ij for any
conditional phenotype j and α ij ≤ β i. The list of SNPs declared non-null for phenotype i was
pruned to allow for linkage disequilibrium (LD) by listing all SNPs in increasing order of
min j(ĉFDR(pi|p j) and stepping through the list from left to right, at each stage removing all
SNPs in LD with r2 ≥ 0.1 to the right of the current SNP. This ideally leads to the inclusion
of at most one SNP from each LD block.
2.4.8 Multiple Testing
A multiple testing problem arises from considering p values for one disease conditioned
separately on nine others. Specifically, if the criterion for declaring a SNP non-null for
phenotype i is that ĉFDR(pi|p j)≤ α ij for at least one of the nine possible values of j, then
the FDR for all SNPs declared non-null will be greater than the FDR among the smaller set
of SNPs for which ĉFDR(pi|p j)≤ α ij for only one value of j, due to multiple testing.
However, this excess FDR is not enough to warrant a Bonferroni (Sidak) correction; the
ĉFDR(pi|p j) values for a phenotype i are highly correlated, as all are in turn highly correlated
with pi. A Bonferroni correction tends to remove any advantage in SNP detection gained
from ĉFDR, though an advantage may still be seen when only considering one conditional
phenotype j.
A method proposed by Nyholt [Nyholt, 2004] was used to correct for multiple testing
in SNPs with high LD. I estimated a correlation matrix Ω for potentially non-null cFDR
values using Spearman’s rank correlation. The variance of the eigenvalues of Ω, var(λobs),
was computed and used to estimate the effective number of variables Me f f according to the
equation
Me f f = 1+9
(
1− var(λobs)
9
)
(2.21)
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Note that var(λobs) is at most 9 (completely correlated variables, effectively one test) and
at least 0 (completely uncorrelated variables, essentially a Bonferroni correction).
Denoting by nij the number of SNPs with ĉFDR(pi|p j)≤ α ij, corresponding to an upper
bound on the FDR of cij, an upper bound for the FDR among all SNPs declared significant
for phenotype i was then computed as
ci0 = Me f f
∑ j=1..10, j ̸=i cijn
i
j
∑ j=1..10, j ̸=i nij
, (2.22)
intuitively, multiplying the expected average number of false discoveries across conditional
phenotypes (cijn
i
j) by the effective number of tests. Values of Me f f and c
i
0 are shown in
appendix A, table A.2.

Chapter 3
Applications of cFDR method
3.1 Introduction
The cFDR method and the extensions derived in the previous chapter are widely applicable,
requiring only genome-wide summary statistics. However, the method is still relatively new,
particularly the application to shared control designs and control of overall FDR introduced in
chapter 2. This chapter details two additional applications of cFDR on new disease datasets.
Firstly, I reapplied the method on a previously published genetic dataset for juvenile
idiopathic arthritis (JIA) [Hinks et al., 2013] , conditioning on the clinically related diseases
RA and T1D. Application of the cFDR method enabled improved genetic discovery while
maintaining FDR control. Section 3.2.1 gives an overview of the JIA phenotype, and avenues
for investigation which could lead to improved treatment strategies. Genetic analysis of JIA
is discussed further in chapter 6.
Secondly, I applied the cFDR method to a new GWAS dataset on the phenotype of
Eosinophilic Granulomatosis with Polyangiitis (EGPA), levering on large GWAS for eosinophil
count [Astle et al., 2016] (EC) and asthma [Moffatt et al., 2010], and a smaller concurrent
GWAS on anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). This was able to
substantially improve discovery of SNP-disease associations, thus improving understanding
of the pathophysiology of EGPA and related conditions.
These two analyses represent different areas of application for the cFDR method. In
the analysis of JIA in section 3.2, the traits for leverage (RA and T1D) were chosen due
to known comorbidity and several known similarities in genetic basis, although they are
notably distinct diseases from JIA itself1. In EGPA (section 3.3), I was able to lever on traits
1The nomination of ‘similar’ traits to study is obviously subjective, but the systematic selection of levering
traits is beyond the scope of this thesis
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which were more related to the disease; in effect, constituents of the disease itself (strictly,
the diagnosis of EGPA requires a pathologically raised eosinophil count, and EC considers
only normal eosinophil counts). The traits used for leverage also differed in their type; EC is
a haematological measurement in healthy individuals rather than a disease trait such as T1D
and RA.
Both applications were on GWAS in diseases of relatively lower prevalence than typical
GWAS traits, and hence had limited sample size, incentivising the use of methods such as
cFDR. As well as improving the potential for SNP discovery, these applications gave further
insight into the practicalities of applying the cFDR method, particularly regarding the choice
of threshold for association. The analysis of EGPA illustrated the potential for using cFDR
to study rare phenotypes by levering on very large datasets for common related traits.
3.2 Applications to juvenile idiopathic arthritis
3.2.1 JIA and traits for conditioning
JIA is an autoimmune disorder of childhood (onset at age < 16) affecting around one in
1000 children per year. It is diagnosed symptomatically based on the onset of non-infective
joint inflammation persisting for six weeks without an established alternative cause. Patients
frequently present with symptoms typical of inflammation, including fever and lethargy.
Extra-articular autoimmune processes may also be present, including onycholysis, dactylitis,
and iridocyclitis [Ravelli and Martini, 2007]. Collectively, these characteristics of the disease
and its symptomatic diagnosis suggest that a range of inflammatory and other processes
are implicated in JIA pathogenesis. The disease is sub-classified into a range of subtypes,
discussed in chapter 6, section 6.1. The differential pathology of JIA subtypes is an important
topic explored in chapter 6, but within-disease genetic heterogeneity is not considered in this
chapter.
As a degenerative disease of childhood, JIA has a significant disease burden on patients
and on the healthcare system. The disease can be painful and debilitating, and greatly reduce
quality of life. Children with JIA frequently have retarded growth and failure to thrive, due
to both articular damage and systemic inflammation [Ravelli and Martini, 2007], and are
more likely to develop other inflammatory conditions including uveitis and coronary vascular
disease [Raab et al., 2012]. Children with JIA are restricted in their ability to undertake
activities of daily living, frequently into adulthood, placing considerable stress on parents
and other carers [Packham and Hall, 2002].
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Despite a recently improved recent range of treatment options, there is potential for
considerable development in the evidence-based management of JIA, both in the development
of new pharmacological therapies and the improved determination of which treatments are
likely to be effective in a given patient [Ravelli and Martini, 2007]. Timely effective therapy
is of particular importance in JIA given the long-term impact of the disease on the patient’s
joint function and development. Understanding risk factors for JIA and identifying patients
at risk of the disease also has therapeutic benefit. A promising line of investigation towards
these aims is in studying the genetic architecture of the disease.
Genetics of JIA
Determination of genetic associations of JIA has been slower than for phenotypes with
comparable childhood incidence such as type 1 diabetes, partly because of difficulties in
recruitment due to the relatively recent diagnostic criteria and the comparative heterogeneity
of the phenotype, and partly because of lower prevalence (0.1-0.2% [Duurland and Wedder-
burn, 2014] compared to around 0.6% in T1D [Hex et al., 2012]). A GWAS published in
2012 on 814 cases was the largest at that time, and was restricted to oligoarticular and RF-
negative polyarticular subtypes in order to generate homogeneous study cohorts [Thompson
et al., 2012]. No loci reached genome-wide significance. A range of candidate-gene studies
associated the PTPN2, PTPN22, and MHC regions with JIA [Hinks et al., 2013]
The genomic investigation of JIA was continued with an ImmunoChip study [Hinks
et al., 2013] on 2,816 cases and 13,056 controls. Although the ImmunoChip was not
explicitly designed to cover putative JIA-associated regions, the fine-mapping of general
autoimmunity-associated loci was expected to cover several undiscovered JIA regions. Like
the earlier GWAS, the ImmunoChip study was restricted to the oligoarthritis and RF-negative
polyarthritis subtypes. The study found 14 additional JIA-associated loci at genome-wide
significance.
JIA is known to have comorbidity with T1D [Hermann et al., 2015], with which the
PTPN22, PTPN2 and MHC regions are also known to be associated [Bottini et al., 2004, Todd
et al., 1987, Barrett et al., 2009]. A non-parametric comparison of p-value rankings [Burren
et al., 2014] found that, based on ImmunoChip data, JIA was more similar to T1D than
14 other autoimmune conditions [Onengut-Gumuscu et al., 2014]. This suggested that
leverage on T1D may improve genetic discovery. The same could be expected of RA given
the phenotypic similarity of the disease to JIA. Given this potential, I used the data from
the JIA ImmunoChip study to conduct an analysis using cFDR, conditioning on data from
ImmunoChip studies on T1D [Onengut-Gumuscu et al., 2014] and RA [Eyre et al., 2012].
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My aim was to examine whether additional JIA-associated variants could be identified by
levering these three related diseases.
3.2.2 Methods
Quality control
SNPs were included in each pairwise analysis (JIA|T1D, JIA|RA) if they passed quality
control criteria in both of the original studies (of [Onengut-Gumuscu et al., 2014, Eyre et al.,
2012, Hinks et al., 2013]). In addition, SNPs were excluded from the analysis if their MAF
across cases and controls was ≤ 2%, if their overall call rate in either cases or controls was
≤ 99%, or if they deviated from Hardy-Weinberg equilibrium across cases and controls with
p-value ≤ 2Φ(−4) = 6.3× 10−5 in either of the two datasets used in each analysis. The
MHC region was removed from the analysis with wide margins (24.5-34.8 Mb, chromosome
6; NCBI build 37). After quality control, 111,406 SNPs were available for the JIA/T1D
analysis and 100,611 for the JIA/RA analysis.
Observed summary statistics were substantially inflated (JIA: λ = 1.67, T1D: λ = 1.64,
RA: λ = 1.54); however, due to the restricted cover of the ImmunoChip, these values were
likely to be overestimates of inflation due to a high frequency of genuine associations.
Following earlier work with the ImmunoChip [Trynka et al., 2012, Onengut-Gumuscu et al.,
2014], inflation factors were computed using a set of SNPs expected to have no effect for
autoimmune phenotypes (see chapter 2, section 2.2.6). Using this restricted set of SNPs, the
inflation statistics were more reasonable (JIA: λ = 1.16; T1D: 1.11; RA: 0.98). The dataset
was adjusted for this residual inflation by scaling χ2 test statistics [Devlin et al., 2001].
Adjustment for shared controls
The presence of shared controls between studies was adjusted for using the procedure
described in chapter 2. Total sample sizes and estimated parameters of Z-score distributions
were as follows:
Table 3.1 Study sizes and parameters of effect size distributions for JIA, T1D and RA
ImmunoChip studies
Controls Cases Est. π0 Est. σ
JIA 13056 2816 0.68 1.89
T1D 12228 6670 0.78 2.98
RA 15870 11475 0.78 5.77
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I estimated an overlap of 8530 controls in both analyses, leading to correlations of 0.17
and 0.16 between Z-scores for null SNPs in the JIA|T1D and JIA|RA analyses respectively.
Conditioning on type 1 diabetes and rheumatoid arthritis
I drew Q-Q plots showing observed and expected distributions of summary statistics for
each of the four analysis (JIA|T1D, T1D|JIA, JIA|RA, RA|JIA) using an adaptation of the
procedure described in [Andreassen et al., 2013] and used in chapter 2, section 2.2.6. As in
the previous chapter, I chose to show observed and expected quantiles of ‘adjusted’ p-values
p′JIA, p
′
T 1D, p
′
RA rather than raw p-values pJIA, pT 1D, pRA (using the notation and method
from chapter 2, sections 2.2.3, 2.4.3):
p′JIA = Pr(PJIA < pJIA|PT 1D < pT 1D,HJIA0 ) / Pr(PJIA < pJIA|PRA < pRA,HJIA0 )
p′T 1D = Pr(PT 1D < pT 1D|PJIA < pJIA,HT 1D0 ) / Pr(PT 1D < pT 1D|PRA < pRA,HT 1D0 )
p′RA = Pr(PRA < pRA|PJIA < pJIA,HRA0 ) / Pr(PRA < pRA|PT 1D < pT 1D,HRA0 )
noting that the definitions of p′JIA, ... differ between analyses. P-values for the conditional
phenotype were unadjusted. Although in practice making only a very subtle difference to the
appearance of the plots, this corrects the Q-Q plots for shared controls between studies. Q-Q
plots showed good evidence for increasing inflation with conditioning for all four analyses
(figures 3.1).
Two thresholds for cFDR significance were considered, each of which corresponded
to the standard genome-wide p-value significance threshold of 5×10−8 in different ways.
Denoting by pAi , p
B
i the p-values for SNP i for traits A, B respectively, the cutoff α
A|B
1 on the
cFDR values in the analysis A|B, ĉFDR(pA|pB), was set as
αA|B1 = max
i|pAi ≤5×10−8
(
ĉFDR(pAi |pBi )
)
(3.1)
The FDR of the procedure in which SNPs are declared non-null by ĉFDR(pA|pB)≤ αA|B1
is generally higher than the FDR of the procedure in which SNPs are declared non-null by
pi ≤ 5×10−8 (and larger than αA|B1 itself) so the second, more conservative threshold αA|B2
was declared such that upper bounds on the FDR values
Pr
(
HA0 |ĉFDR(pA|pB)≤ αA|B2
)
(3.2)
Pr
(
HA0 |pAi ≤ 5×10−8
)
(3.3)
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Fig. 3.1 Conditional Q-Q plots showing inflation of summary statistics for one phenotype
conditioning on another. If there are a body of SNPs which show pleiotropy between
the principal and conditional phenotypes, the deviation of the Q-Q plot leftward of the
X-Y line should increase with conditioning on successively lower p-value thresholds for
the conditional phenotype. Inflation of summary statistics is evident in all cases when
conditioning on p-value thresholds in the conditional phenotype.
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were equal. An upper bound on quantity 3.2 was estimated using the procedure described in
chapter 2, section 2.2.5, and an upper bound on quantity 3.2.2 using the Benjamini-Hochberg
procedure. Thresholds are given in table 3.2 below.
Table 3.2 Thresholds on ĉFDR for analysis of JIA, T1D and RA
αA|B1 FDR bound α
A|B
2 FDR bound
JIA|T1D 1.00×10−5 5.59×10−5 2.97×10−6 1.79×10−5
JIA|RA 1.36×10−5 7.28×10−5 2.55×10−6 1.71×10−6
T1D|JIA 3.96×10−6 9.04×10−6 1.95×10−6 4.94×10−6
RA|JIA 1.26×10−5 5.47×10−5 4.48×10−6 2.06×10−5
SNPs with ĉFDR values less than the threshold were pruned to remove SNPs in LD with
r2 ≥ 0.1 using the protocol described in chapter 2, section 2.4.7, prioritising SNPs by ĉFDR
value.
3.2.3 Results
The analysis of JIA conditioning on T1D yielded 12 non-MHC variants for which ĉFDR≤
αJIA|T 1D1 and 8 for which ĉFDR≤ αJIA|T 1D2 . Five variants with ĉFDR≤ αJIA|T 1D1 and 1 with
ĉFDR≤ αJIA|T 1D2 were not genome-wide significant by p-value alone (P(JIA)> 5×10−8).
Results are shown in table 3.3.
Table 3.3 Results for cFDR analysis of JIA|T1D. Only results for SNPs not in LD with a
SNP reaching GWS-by-p-value in JIA by p-value are shown. * - ĉFDR≤ αJIA|T 1D2
rsID Chr. Pos. P(JIA) P(T1D) ĉFDR
rs7808122 7 22764605 5.8×10−08 0.0551 6.35×10−06
rs34132030 13 41954036 1.77×10−07 0.0164 9.78×10−06
rs79893749* 3 46228654 1.88×10−07 1.54×10−05 2.58×10−06
rs66718203 16 11336144 4.46×10−07 2.36×10−07 3.68×10−06
rs6740838 2 100179931 8.83×10−07 3.29×10−06 8.31×10−06
SNP rs79893749 is near the genes encoding CCR1 and CCR3, which are chemokine
receptors and are good candidates for JIA association. SNP rs66718203 (16p13.13) is near
the CLEC16A region, known to be associated with T1D, MS, CEL, PSO, IBD and PBC. SNP
rs6740838 is near the AFF3 gene, known to be associated with RA, T1D, and CEL.
The analysis for JIA|RA yielded six SNPs not in LD with SNPs reaching GWS-by-p-value
for JIA, shown in table 3.4. SNP rs7993214, in the COG6 region, is in LD (r2 > 0.2) with the
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imputed SNP rs9532434, which reached genome-wide significance for JIA (p= 4.52×10−8).
SNP rs79893749 is in a region associated with CEL and T1D, containing the CCR1/CCR3
genes. SNP rs6740838 is in a region associated with RA, T1D and CEL, containing the
AFF3 gene. SNP rs2364480 is in a region containing an imputed SNP (rs10849448) reaching
genome-wide significance for JIA (p= 4.54×10−9). SNP rs5029924 is in a region associated
with multiple autoimmune conditions containing the genes OLIG3 and T NFAIP3. Finally,
SNP rs4755450 is in a region containing the imputed SNP rs7127214 reaching genome-wide
significance (p = 1.90×10−8).
Table 3.4 Results for cFDR analysis of JIA|RA. Only results for SNPs not in LD with a SNP
reaching GWS-by-p-value in JIA by p-value are shown. * - ĉFDR≤ αJIA|RA2
rsID Chr. Pos. P(JIA) P(RA) ĉFDR
rs7993214* 13 39248912 1.61×10−07 1.02×10−4 1.18×10−06
rs79893749 3 46228654 1.88×10−07 1.92×10−3 2.86×10−06
rs6740838 2 100179931 8.83×10−07 5.48×10−06 4.5×10−06
rs2364480 12 6365536 5.1×10−08 7.14×10−2 4.98×10−06
rs5029924 6 138229191 2.86×10−06 3.52×10−07 8.71×10−06
rs4755450 11 36320151 3.35×10−07 2.16×10−2 1.16×10−05
Results for the T1D|JIA analysis yielded three SNPs with ĉFDR≤ αT 1D|JIA1 not in LD
with SNPs reaching GWS-by-p-value for T1D, two with ĉFDR≤ αT 1D|JIA2 . All three SNPs
were in regions which reached genome-wide significance in the published paper, which
included additional TDT families [Onengut-Gumuscu et al., 2014] although none did in the
(reduced) case-control dataset used in this analysis.
Table 3.5 Results for cFDR analysis of T1D|JIA. Only results for SNPs not in LD with a
SNP reaching GWS-by-p-value in T1D by p-value are shown. * - ĉFDR≤ αT 1D|JIA2
rsID Chr. Pos. P(T1D) P(JIA) ĉFDR
rs72727394 15 36634314 5.22×10−08 0.0163 1.34×10−06
rs12150079 17 35278943 1.88×10−07 0.0118 3.74×10−06
rs113010081 3 46432416 3.43×10−07 8.11×10−07 1.23×10−06
In the RA|JIA analysis, eight SNPs not GWS-by-p-value reached significance by ĉFDR<
αRA|JIA1 , three of which satisfied ĉFDR < α
RA|JIA
2 . Results are shown in table 3.6. All SNPs
in the RA|JIA analysis are in regions found to be RA-associated in a more recent meta-
analysis [Okada et al., 2014].
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Table 3.6 Results for cFDR analysis of RA|JIA. Only results for SNPs not in LD with a SNP
reaching GWS-by-p-value in RA by p-value are shown. * - ĉFDR≤ αRA|JIA2
rsID Chr. Pos. P(RA) P(JIA) ĉFDR
rs3087243* 2 204447164 1.36×10−07 2.68×10−04 1.81×10−06
rs35677470* 3 58158676 1.74×10−07 2.48×10−05 1.58×10−06
rs9979383* 21 35637631 5.23×10−07 1.06×10−08 1.58×10−06
rs595158 11 60666157 1.79×10−07 4.9×10−03 5.87×10−06
rs12936409 17 35297175 3.72×10−07 6.76×10−04 6.00×10−06
rs28532547 1 2551146 2.28×10−07 4.72×10−03 7.23×10−06
rs75351767 7 37393876 2.94×10−07 4.36×10−03 8.87×10−06
rs39984 5 102625191 9.29×10−08 1.06×10−01 1.25×10−05
3.3 Applications to EGPA
3.3.1 EGPA and traits for conditioning
EGPA, formerly called Churg-Strauss syndrome, is characterised by eosinophilic tissue
infiltration. The disease typically has a clinical prodrome of asthmatic symptoms, with more
serious symptoms developing months to years later. It is a rare condition, with an incidence
in Europe of approximately 0.5-0.8 per million per year and a prevalence of 10.7–13 cases
per million [Gioffredi et al., 2014].
EGPA is typically considered a small-vessel autoimmune vasculitis. However, many
patients have no evidence of vascular involvement and do not have raised levels of anti-
neutrophil cytoplasmic antibodies (a marker of systemic vasculitis). This suggests a distinc-
tion between vasculitic EGPA, characterised by conditions such as glomerulonephritis and
purpura due to small-vessel damage, and eosinophilic EGPA, in which tissue damage such as
pulmonary infiltration and cardiomyopathy arise due to tissue eosinophilia.
The recommended treatment for initial occurrence of the disease is typically glucocorti-
coids, or dual therapy with cyclophosphamide in serious cases. Remission is typically man-
aged with methotrexate or azathioprine [Bosch et al., 2007]. All first-line drugs have marked
systemic toxicity, and there is considerable incentive for development of new therapies. This
could be facilitated by better understanding of disease pathology through investigation of its
genetic basis. In light of the heterogeneous nature of the disease, there may also be scope for
precision medicine approaches targeting individuals with particular subtypes.
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Eosinophils and eosinophilic disease
Eosinophils are immune cells involved in defence against multicellular parasites, and are in-
volved in the mechanisms of atopy. Typically, eosinophils make up 1-5% of circulating leuko-
cytes, corresponding to a plasma concentration of < 0.4×109L−1 in adults. Eosinophilia
is a state of raised circulating eosinophil count, typically > 0.45× 109L−1. This may be
idiopathic, secondary to another condition, or in response to outside insult such as an aller-
gen [Simon and Simon, 2007]. Eosinophilia is associated with several clinical syndromes
depending on the site of eosinophilic infiltration.
Eosinophil-modulated syndromes can occur even when eosinophils are within the normal
range [Straumann et al., 2012]. This suggests that amongst asymptomatic patients, sub-
clinical manifestations of eosinophil-moderated syndromes may be indexed by high-normal
eosinophil counts, and hence information may be obtainable about the genetic basis of
such syndromes by analysis of genetic determinants of eosinophil count within the normal
range; that is, only using nominally healthy patients without overt eosinophilia. This has the
advantage of a much larger potential study size. This suggested the leverage of an EGPA
dataset with a large GWAS on EC in asymptomatic individuals.
Asthma and AAV
Asthma is an inflammatory disease of the bronchi, characterised by recurrent reversible
obstruction of the airways. It is typically treated with long-term inhaled corticosteroids
and symptomatically managed with beta-agonists. Asthma is frequently associated with
eosinophilic airway infiltration, and is genetically associated with many immunomodulatory
genes [Moffatt et al., 2010]. It is a common disease, with a prevalence of approximately 5%
in the UK [Anderson et al., 2007] and substantial mortality. Given the asthmatic prodrome of
EGPA, and the commonality of the phenotype, asthma was a clear option for leverage for
genetic discovery.
Another candidate for leverage was non-EGPA AAV, given the partly vasculitic nature
of EGPA. AAV refers to a class of rare vasculitides all characterised by inflammatory cell
infiltrates and vascular necrosis, generally involving small and medium-sized arteries. They
are usually treated with immunosuppressive therapy, often cyclophosphamide. A GWAS
on non-EGPA AAV was conducted in parallel with the current study, providing another
potentially useful dataset for leverage.
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Genetics of EGPA
Prior to this study, data on genetic associations of EGPA was limited. Previous case-control
studies [Vaglio et al., 2007, Wieczorek et al., 2008] found associations with HLA-DRB04
and DRB07, neither at genome-wide significance. This suggests a degree of heritability of
EGPA, potentially with shared contributions from other autoimmune-associated loci.
The current study was designed as the first GWAS of EGPA, with the aim of developing
understanding of the genetic basis. Because of the rarity of the phenotype, a relatively small
cohort of 542 samples were able to be recruited.
3.3.2 Methods
Quality control
Quality control and the primary GWAS analysis were largely undertaken by my collaborators,
although I helped in some areas. Notes on quality control are reproduced from the manuscript
currently in preparation for this work.
599 individuals with a clinical diagnosis of EGPA were recruited from 17 centers in 9
European countries (UK, Ireland, Germany, Czech republic, Poland, France, Italy, Spain
and Sweden). 9 individuals were excluded because of uncertain diagnosis. Genotype data
for 6000 UK controls was obtained from the European Prospective Investigation of Cancer
(EPIC) Consortium. Additional controls were also recruited and genotyped in parallel with
the EGPA samples. 496 individuals with a history of asthma were excluded.
Samples with a sex mismatch, abnormal heterozygosity or proportion of missing geno-
types >5%, or which were duplicated, were removed. SNPs were removed if they were
monomorphic, had missing calls >2%, or deviated substantially from Hardy-Weinberg
equilibrium (p-value < 1×10−6).
All quality control criteria for samples and SNPs were applied firstly to each batch
of samples and secondly across the combined dataset. After combining samples, SNPs
with differential missingness between cases and controls were removed (Fisher’s exact
test, FDR < 5% by Benjamini-Hochberg procedure). Principal components of the post-
QC genotype calls combined with calls from 1000 Genome individuals (downloaded from
http://www.1000genomes.org) were computed and, on the basis of the first three components,
samples of non-European ancestry were excluded. After quality control, 542 EGPA cases
and 6717 controls remained, with 543,639 genotyped SNPs.
Principal components were calculated for the genotype matrix including both cases and
controls. Summary statistics were computed using the first 20 principal components as
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covariates. The resultant summary statistics showed some residual inflation (λ = 1.09). In
the primary GWAS analysis and the cFDR analysis, the unadjusted p-values were reported,
along with indication of the SNPs which met an adjusted level of significance α equivalent
to p < 5×10−8, using an analogous method to standard scaling of χ2 scores [Devlin et al.,
2001]:
α = 2Φ
(
−
√
λΦ−1
(
5×10−8
2
))
≈ 1.26×10−8 (3.4)
SNPs were included in each cFDR analysis if they met QC criteria for both the constituent
studies. QC criteria for the EC and asthma GWASs can be found in the relevant papers
([Astle et al., 2016, Moffatt et al., 2010]). The GWAS on AAV included 609 cases, with the
same control set and quality control procedures as used for the EGPA study. For the cFDR
analysis, the MHC region was removed with wide boundaries (chr6:28.7-34.5 Mb, build
hg19). Although imputation was performed for the GWAS analysis, only directly genotyped
SNPs were used for cFDR. Sample sizes and available SNPs in the cFDR analyses are shown
in table 3.7.
Table 3.7 Number of cases and controls for conditional phenotypes, shared controls and
number of SNPs in cFDR analyses of EGPA
Analysis Controls Cases Shared controls N SNPs
EGPA|EC 173480 0 513,801
EGPA|Asthma 16110 10365 0 74776
EGPA|AAV 6717 609 6717 543,117
No adjustment for shared controls was necessary in the EGPA|Asthma and EGPA|EC
analyses; the shared controls in the EGPA|AAV analysis led to a correlation of 0.08 between
Z-scores for null SNPs. The parametrisation of the distribution of Z-scores for AAV found
(π0,σ) = (0.71,1.09).
Thresholds on cFDR were chosen to match FDR bounds with the GWAS analysis
(αEGPA|·2 ; see equation 3.2.2) in the previous section, using the threshold adjusted for genomic
inflation (equation 3.4) and noting that the GWAS had higher dimensionality than the cFDR
analysis. Cutoffs are shown in table 3.8. Bounds are substantially higher than in table 3.2
due to a higher false-discovery rate bound in the EGPA GWAS than in the JIA GWAS.
3.3.3 Results
Q-Q plots showing observed and expected distributions of summary statistics for EGPA|EC
and EGPA|asthma are shown in figure 3.2. I used adjusted pEGPA values for the EGPA|AAV
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Table 3.8 Thresholds on ĉFDR for analysis of EGPA (FDR < 6.4×10−3 for all three analyses)
αEGPA|·2
EGPA|EC 2.8×10−3
EGPA|Asthma 1.5×10−3
EGPA|AAV 6.3×10−4
plot. Inflation of summary statistics with conditioning is evident in the EGPA|Asthma and
EGPA|EC analyses, but not in the EGPA|AAV analysis. Analysis of EGPA|Asthma yielded
two SNPs reaching GWS by ĉFDR not in regions reaching GWS for EGPA alone, shown
in table 3.9. SNP rs11745587 is near the IRF1/IL5 genes, in a region of chromosome 5
associated with CRO, UC, JIA, PSO and alopecia areata. IL5 (interleukin-5) is an important
mediator of eosinophil activation [Sehmi et al., 1992], suggesting that variation in this region
is a good candidate for mediating EGPA risk.
Table 3.9 Results for cFDR analysis of EGPA|Asthma
rsID Chr. Pos. P(EGPA) P(Asthma) ĉFDR
rs11745587 5 131796922 1.10×10−06 1.83×10−03 1.05×10−04
rs6454802 6 90814199 4.72×10−07 2.16×10−03 5.05×10−05
rs1623646 10 9076230 1.49×10−05 1.98×10−03 6.05×10−04
SNP rs6454802 is near BACH2, in a region of chromosome 6 with multiple autoimmune
associations. SNP rs1623646 is in a relatively un-annotated region of chromosome 10
associated with RA [Okada et al., 2014]. The top EGPA SNP in the region, rs7898135 (not
genotyped in the asthma dataset), had a p-value of 5.75×10−7. In a chromatin conformation
analysis, rs7898135 interacted with the GATA3 gene in foetal thymus tissue and CD4+ cells
in naive and non-activated states [Javierre et al., 2016, Schofield et al., 2016].
None of the SNPs found in the EGPA|Asthma analysis appeared to be strongly associated
with asthma. However, other SNPs in the same regions were more strongly asthma-associated:
rs1295686, near IRF1/IL5, had p= 1.4×10−7; rs4142967 near BACH2, had p= 1.57×10−5,
and rs1242987, near rs1623646, had p= 1.03×10−4. This suggests that if asthma and EGPA
are both associated at these regions, they are likely to have different causal architecture.
The EGPA|EC analysis found association with eight regions not reaching GWS by p-
value for EGPA. These are shown in table 3.10. These findings replicated the associations
found in the EGPA|Asthma analysis on chromosomes 5,6, and 10. SNP rs9290877 is in a
region on chromosome 3 near LPP. SNP rs42041 is in a region on chromosome 7 associated
with RA, near CDK6. SNP rs187564398 on chromosome 12 in a relative gene desert. SNP
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Fig. 3.2 Conditional Q-Q plots showing inflation of summary statistics for one phenotype
conditioning on another (EGPA|Asthma on left, EGPA|EC on right, EGPA|AAV below). Note
different cutoffs for p-value for the conditional phenotype.
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rs2033784 on chromosome 15 is in a CRO and UC associated region near SMAD3. SNP
rs4781047 on chromosome 16 is in a region associated with multiple autoimmune conditions
near CLEC16A and DEXI.
Table 3.10 Results for cFDR analysis of EGPA|Asthma
rsID Chr. Pos. P(EGPA) P(EC) ĉFDR
rs9290877 3 188442480 3×10−05 9.06×10−14 1.25×10−03
rs11745587 5 131796922 1.1×10−06 1.65×10−29 1.62×10−04
rs6454802 6 90814199 4.72×10−07 1×10−18 4.76×10−05
rs42041 7 92246744 6.36×10−07 4.56×10−08 1.55×10−04
rs1444782 10 9058671 3.53×10−06 1.01×10−27 2.95×10−04
rs187564398 12 115934855 2.32×10−07 6.94×10−03 8.78×10−04
rs2033784 15 67449660 4.35×10−05 5.49×10−11 1.92×10−03
rs4781047 16 11318537 2.04×10−05 7.78×10−14 9.21×10−04
No SNPs reached genome-wide significance by cFDR in the EGPA|AAV analysis, likely
due to the relatively small size of the study for the conditional phenotype.
3.4 Discussion
This chapter extends chapter 2 by applying the cFDR method in new contexts and by using
it in a new study to directly improve discovery of disease associations. These applications
demonstrate the scope of the method, and explore the behaviour of the test statistic and
associated false discovery rate in a wider variety of circumstances.
An important question which was pertinent in this chapter was why a complex procedure
such as cFDR should be performed for leverage, as opposed to simply considering SNPs
reaching a pre-set threshold for association for the conditional phenotype and determining
association with the principal phenotype using a Bonferroni correction or similar (such as
the analysis in [Plagnol et al., 2011]). Indeed, conditioning on genome-wide significance
for eosinophil count in the EGPA|EC analysis may lead to similar results, with an easier
interpretation. In general, however, the cFDR should in general be a more powerful tool for
SNP discovery, despite being more complicated. The main reason for this is that an analysis
conditioning on a single threshold disregards most of the information the conditional GWAS
may contribute. This is discussed further in chapter 7, section 7.1.4
A second reason is that the choice of single threshold to condition on is difficult. If it
is chosen in a truly a priori way, before any data is observed, then the choice is somewhat
arbitrary; the genome-wide significance threshold of p < 5×10−8 is relatively conservative,
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especially if the conditional GWAS is small. If the single threshold is chosen after observing
the data, as probably happens often in practice, this introduces bias to the analysis. By not
requiring any predefined threshold on association in the conditional phenotype, the cFDR
circumvents these problems.
Conditioning on a single p-value threshold for the conditional phenotype may be appeal-
ing in its simplicity. It is still, however, susceptible to an inflated false-positive rate from that
suggested by the Benjamini-Hochberg procedure if controls are shared, and appropriate ad-
justments should be made in this case. A recent example of such an adjustment was made in
a GWAS for T1D [Onengut-Gumuscu et al., 2014] levering on celiac disease; while previous
analyses had declared SNPs associated with T1D with pT 1D < 1×10−4 if pceliac < 5×108,
the presence of shared controls required tightening the threshold on pT 1D to pT 1D < 1×10−5
to maintain a Bayesian posterior probability of T1D association greater than 0.9. Adaptations
of the methodology in chapter 2, sections 2.2.3, 2.4.3 could be used in a similar way.
Another subtle area in which shared controls may improperly suggest inflation is in
conditional Q-Q plots; it is possible to use either raw p-values or adjusted p-values p′. In
general, I consider it appropriate to replace the p-values for the principal phenotype with the
expected quantile (see chapter 2, sections 2.2.3, 2.4.3 for details) when controls were shared.
A major consideration in the analysis of EGPA is the choice of which phenotypes (and
more generally, how many phenotypes) to use for leverage by cFDR. Different diseases may
share different causative processes with the disease of interest, suggesting that leverage on a
greater number of phenotypes could aid in the discovery of more associations than levering
on a small number of phenotypes. However, leverage on a large number of phenotypes
necessitates a complex multiple-testing correction; one example of this is discussed in
section 2.4.8, although I have not tested this procedure on a larger scale (≫ 10 conditional
phenotypes). If phenotypes used for leverage only minimally improve the power of the
analysis, then the need to control for multiple testing may outweigh the advantage gained
from including such phenotypes. This could be resolved with the use of a prior on the
expected contribution of each conditional phenotype on the analysis (derived from phenotype
ontologies [Robinson et al., 2008] or similar) but I did not explore this approach in this
context.
If there is no pleiotropy between phenotypes, then (considering observed p-value pairs
(pi, p j) as iid observations of a bivariate random variable (Pi,Pj) and using the notation in
chapter 2, section 2.2.2) we have
E(ĉFDR(pi|p j)) = E(ûFDR(pi) = piPr(Pi ≤ pi) (3.5)
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since Pr(Pi ≤ pi) is independent of p j. If there is pleiotropy, then in general
E(ĉFDR(pi|p j)) ̸= E(ûFDR(pi)
and the expected ranking of SNPs by p-value (or ûFDR) will differ from the expected ranking
of SNPs by ĉFDR.
This leads to a second important point arising from this chapter. A practical consideration
in the analysis of cFDR is the question of which SNP to report as the ‘top SNP’ in a region
declared associated by cFDR - the SNP with the best ĉFDR value, or the SNP with the
best p-value for the principal phenotype. In this chapter and chapter 2, I generally took the
former option, following the first paper in the field [Andreassen et al., 2013]. However, in
consideration of the results from the EGPA|Asthma analysis, in which the SNP rs7898135
had a markedly lower p-value for EGPA association than did the SNP rs1623646 (which
had the lowest ĉFDR score in the region), I would recommend for future analysis that both
SNPs be reported, as well as the top SNP in the region for the conditional phenotype. The
cFDR method is only able to find associations on the scale of regions (LD-blocks) of the
genome, and different diseases may have different patterns of causal variants in the same
region. Indicating only the variant with lowest ĉFDR may understate the association of the
principal and conditional phenotype with the region. Furthermore, the expected ranking
of SNPs by observed p-value may differ from the ranking by true effect size for technical
reasons (for instance, poor imputation quality) which may also lead to errors if the ‘top’ SNP
in a region is chosen on the basis of minimum cFDR score.
A GWAS and follow-up analyses can be considered to be attempting to find two things:
firstly, the subset of variants in the genome associated with the trait, and secondly, the genetic
architecture’ of the trait; specifically the relative effect sizes of all causal variants. Because
of the changed expected ordering implied by equation 3.6, the cFDR procedure disturbs
the observed genetic architecture of the phenotype on both single-region and genome-wide
scales. In a standard GWAS, effect sizes can be recovered from p-values and observed MAF,
and more specifically, for variants of a given AF, the effect size is monotonic to the p-value.
Moreover, if a single variant in an LD block is causal, the probability that the causal variant
has the lowest p-value tends to 1 as sample sizes tend to infinity.
In cFDR analyses with pleiotropy between phenotypes, this is not the case: E(ĉFDR) is
responsive to the p-value for both the principal and the conditional phenotype. If the set of
causal variants in a region differ between the principal and conditional phenotypes, then the
minimum cFDR value will not be monotonic to the p-value, and even with a single causal
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variant for each phenotype will not have minimal expected value at the causal variant for
the principal phenotype. The same consideration holds across the whole genome; unless
the genetic architectures of the conditional and principal phenotype are identical, the cFDR
will not generally order variants of equal MAF according to their relative effect sizes in
the way that a standard GWAS analysis would. This point is discussed further in chapter 7,
section 7.1.1.
In several of the cFDR analyses presented, some SNPs reaching genome-wide significance
by ĉFDR when they did not by p-value did not appear to have a low enough p-value for the
conditional phenotype to justify the apparent improvement in evidence for association (for
example, SNPs rs7808122 and rs34132030 in the JIA|T1D analysis (table 3.3) and SNPs
rs2364480, rs79893749 and rs4755450 in the JIA|RA analysis (table 3.4)). This is an effect
which can occur even when no pleiotropy is present. Although the expected values of ĉFDR
and ûFDR are the same (equation 3.5), and hence their expected order is the same (and the
same as the order of expected p-values), the deviation from this ordering differs between
ĉFDR and ûFDR. If thresholds γ1, γ2 are chosen for ĉFDR and ûFDR in order to control the
false-discovery rate at the same level between procedures, some variants with ûFDR < γ1
may ‘move’ such that ĉFDR > γ2 and vice versa, despite the overall FDR bound being
maintained. The chances of a SNP moving ‘up’ or ‘down’ this way are approximately equal.
However, if α(·|·)1 is used as a ĉFDR threshold, no SNPs can move ‘out’ of genome-wide
significance by ûFDR < γ/pi < 5× 10−8, although SNPs can move in. For this reason, I
consider that the cutoff α(·|·)2 is a more appropriate approximation of GWS by p-value.
The EGPA result suggests that EGPA could be primarily driven by high eosinophil
count, or caused by some external process which also causes high-normal count in healthy
individuals. An interesting subsequent analysis if possible would be to consider whether the
disease has any evidence of causative variants not associated with physiological eosinophil
count.
The idea of levering an association analysis for a rare disease using a much larger dataset
for an associated trait is an interesting avenue for future research. One such avenue may be to
lever on a meta-analysis of multiple diseases, making use of shared associations. This could
lead to difficulty discovering variants with both deleterious and protective effects across the
disease spectrum (which are common; see [Cotsapas and Hafler, 2013]) due to ‘averaging’
across diseases, so meta-analysis by p-value may be necessary. This is discussed further in
chapter 7, section 7.2.1.
The results presented here give information on the set of genetic associations of the
diseases in question additional to that attainable by p-value analysis alone, although as
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expected, the ability to discover new associations is limited if the dataset used has already
been superseded in size or power by subsequent studies. In particular, these results highlight
the pervasive sharing of genetic associations between autoimmune phenotypes. One striking
point is the effectiveness of conditioning on a non-disease trait, namely eosinophil count in
healthy individuals, in understanding disease aetiology. The dataset of blood cell traits [Astle
et al., 2016] is a particularly exciting one in this respect. Other BioBank data sets (eg [Canela-
Xandri et al., 2017]) will also be interesting for leverage purposes.

Chapter 4
Two-stage testing with shared controls
4.1 Introduction
High-dimensional case-control studies have become a mainstay of investigation of patho-
physiology in complex diseases and traits. An important part of their analysis is the process
of replication [Wason and Dudbridge, 2012], in which the results of a high-dimensional study
are used to inform the design of a second study at a subset of the original variables, with a
joint analysis used to determine overall association.
Replicating studies in this way has the advantage of increasing the effective study sam-
ple sizes without requiring measurement of all variables in all samples. It also serves to
protect against false-positives due to systematic errors in the original datasets, by re-testing
association in a second nominally independent dataset.
Replication has a significant cost, and can require large numbers of samples, especially
when associated variables have small effects (ie [Fuchsberger et al., 2016]). There is
therefore a need to minimise the number of additional samples which need to be analysed.
This paper presents a method to perform replication by combining controls in both the
original ‘discovery’ and second ‘replication’ datasets, potentially reducing the number of
new samples required. Shared-control approaches can improve study efficiency in many
related applications in which studies are compared [Lin and Sullivan, 2009, Han et al.,
2016a, Bhattacharjee et al., 2012, Zaykin and Kozbur, 2010, Liley and Wallace, 2015, Fortune
et al., 2015].
Results from original and replication datasets for which some or all controls are shared
cannot be directly compared due to the correlation between test statistics directly resulting
from shared controls even under the null hypothesis [Bhattacharjee et al., 2012]; use of
the same thresholds in a shared-control design as used in an independent-controls design
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will lead to higher type-1 error rates. In this chapter I demonstrate a simple adaptation to a
standard design to account for the changed correlation structure and retain control of type-1
error rate, only requiring a change to one p-value threshold.
The action of sharing control samples results in a different spectrum of sensitivity to
confounding in study groups. It necessitates a sacrifice of type-1 error rate control in variables
affected by confounding in the discovery-phase control cohort, but improves type-1 error
rate control in variables affected by confounding in the replication-phase control cohort.
Performance is largely equivalent to an independent-controls design for variables affected by
confounding in either case cohort.
The new spectrum of false positive rates can be advantageous in circumstances where
control samples in the replication cohort are less well-ascertained than those in the discovery
cohort. This may be the case in studies on degenerative disease, where control ascertainment
is generally uncertain, and population-sourced controls may be used for replication. The
shared-control design can reduce power losses from mis-specified controls in the replication
cohort, as well as reducing false-positive rates caused by confounding in the cohort.
When used with shared cases instead of controls, this method can be adapted to a ‘partial
replication’ procedure where only a new control set is used. Although not equivalent to a
full replication in an independent dataset, the procedure enables improvement in type-1 error
rates and control over confounding. This is applicable in studies on rare traits, where all
available samples need to be included in the discovery analysis for adequate power.
Throughout this chapter I use GWAS terminology (SNPs, allele frequency, variants etc)
although the method is applicable to any high-dimensional case control study. ‘Controls’ will
be considered to generally be samples unaffected by a disease or trait of interest, although
the method can be applied with case/control labels swapped, or applied to comparisons
between subgroups of a case group. Asymptotic analytical results are established where
possible, but all type 1/type 2 error rates are readily tractable empirically to good accuracy
given study sizes and proposed p-value thresholds, and a tool is provided to do this at
https://wallacegroup-liley.shinyapps.io/replication_shared/.
4.2 Results
4.2.1 Overview of method
Assume a GWAS dataset of a set of cases C1 and controls C0 used in a ‘discovery’ phase of a
GWAS or similar study, and corresponding sets of cases and controls C′1, C
′
0 in the replication
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phase. Further assume that C0 and C1 are genotyped at a set of SNPs S and C′0, C
′
1 at a set
S′ ⊆ S.
For each SNP designate µ1, µ0, µ ′1, µ
′
0 as the population minor allele frequency in the
corresponding group, and m1, m0, m′1, m
′
0 as the observed allele frequency (so E(mi) = µi).
Designate two null hypotheses; H∪0 : (µ1 = µ0)∪ (µ ′1 = µ ′0) and H∩0 : (µ1 = µ0 = µ ′1 = µ ′0),
noting that H∩0 ⇒ H∪0 . In a typical conservative GWAS approach, we seek to test against H∪0 ,
since µ1 ̸= µ0 or µ ′1 ̸= µ ′0 may hold at non-disease associated SNPs due to confounding in
the original or replication studies respectively.
A typical two-stage genetic testing procedure [Wason and Dudbridge, 2012], which I
will refer to as method A, begins by comparing genotypes of C1 and C0 at SNPs S generating
p-values pd (discovery). A subset S′ of SNPs reaching putative significance level pd < α
are genotyped in C′0 and C
′
1, with genotypes compared to generate p-values pr (replication
stage). Finally, genotypes are compared between C0∪C′0 and C1∪C′1 at SNPs S′ to generate
p-values pm (meta-analytic stage). SNPs are designated as ‘hits’ if pd < α, pr < β , pm < γ
for some β , γ , and all effects have the same direction.
The main modification proposed in this chapter, denoted as method B, differs at the
replication stage in that C′1 is compared with C0∪C′0 at S′ instead of just C′0 (figure 4.1). The
p-values resulting from the modified replication stage are termed ps, and the criterion to
designate a hit changed to pd < α, ps < β ∗, pm < γ , with all effects in the same direction.
The threshold β ∗ is chosen to conserve type-1 error rate between methods (see section 4.4
and appendix B.1.1).
A second modification, denoted method C, combines C0 and C′0 at both the discovery and
replication phase (figure 4.1). This is analogous to a situation in which only a single control
cohort is available, and a choice must be made to split it between discovery and replication
procedures or to use it for both. In this case, C0∪C′0 is compared with C1 at SNPs S in the
discovery phase to produce p-values pc, then C0∪C′0 is compared with C′1 at SNPs S′ at the
replication phase and compared with C1∪C′1 at the meta-analytic stage to produce p-values
ps and pm as before. A hit is determined by pd < α, ps < β⊥, pm < γ , with all effects in the
same direction. Again, β⊥ is chosen to maintain the type-1 error rate between methods.
4.2.2 General properties
For SNPs in H∩0 , the overall type-1 error rate is conserved between methods by the definition
of β ∗, β⊥ (equation 4.2) at a level P0. I show in appendix B, section B.1.2 that β > β ∗ > β⊥.
For SNPs in H∪0 \H∩0 the type-1 error rates differ between methods. Such SNPs may be
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Fig. 4.1 Diagram of methods A, B, and C. Method B differs by comparing C′1 to pooled C0
and C′0 at the replication stage to generate p-value Ps instead of Pr. Method C also pools
controls at the discovery phase, comparing C1 to pooled C0 and C′0 to generate p-values Pc
instead of Pd . A ‘hit’ is declared in method A if Pd < α , Pr < β , Pm < γ , in method B if
Pd < α , Ps < β ∗, Pm < γ and in method C if Pc < α , Ps < β⊥, Pm < γ .
characterised by the group(s) amongst C0, C1, C′0, C
′
1 in which their expected MAF is
aberrant from the expected MAF in the population which the group ostensibly represents.
‘Aberrance’ is taken to mean an incorrect expected value from systematic measurement error
or uncorrected confounding, rather than random deviance around a correct expected value.
Bounds on type-1 error rates with aberrance in each group are shown in table 4.1.
Methods B and C necessitate sacrificing bounds on error rates with aberrance in C0 and C0,C′0
respectively. The bound on error with aberrance in C′1 improves through methods A-C. I
show in section 4.4.5 that the type-1 error with aberrance in C′0 decreases from methods A to
B, and the error with aberrance in C′1 increases from A through C, although the upper bound
is the same for both.
Table 4.1 Upper bounds on type 1 error rates with aberrance in cohorts, noting that β > β ∗ >
β⊥
Aberrant cohort
None C0 C′0 C1 C
′
1
M. A P0 β α β α
M. B P0 1 α β ∗ α
M. C P0 1 1 β⊥ α
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4.2.3 Simulation
I analysed the power difference between methods B and A systematically across a range of
values of (n0,n1,n′0,n
′
1). I compared both average power difference and maximum power
difference (see section 4.4.4). Figure 4.2 shows power difference at various study sizes
for typical α , β , γ values (α = 5× 10−6, β = 5× 10−4, γ = 5× 10−8) and minor allele
frequency 0.1. The difference is typically highest when the ratio of controls to cases is high
in the discovery cohort and low or equal in the replication cohort, and the number of cases in
the discovery cohort is larger than the number in the replication cohort. Power to detect SNPs
in H1 is typically highest in method C, second-highest in method B, and lowest in method A.
4.2.4 Recommended applications
To demonstrate areas where this approach is applicable, several examples are constructed
or sourced from the GWAS field in which the procedure of sharing controls or cases will
improve power or type-1 error profile of the two-stage testing procedure or enable some form
of orthogonal replication to be performed.
Assumptions
In order to use method B or C, it must be assumed that cohort C0 and C′0 are sampled from
similar enough populations to be comparable to C1 and C′1 (possibly with the inclusion of
strata or covariates in the genetic risk model). An important caveat of methods B and C is
sacrifice of control over errors arising from aberrance in C0 (method B) or C0∪C′0 (method C),
so an assumption must be made that variables affected by confounding or measurement error
in these cohorts are understood to be distinguishable from true associations by quality-control
measures only.
Post-hoc assessment of all putative hits should be performed to check for genotyping
errors [Anderson et al., 2010] and assess whether the hit could have arisen from aberrance in
C0.
Conventional GWAS
Method B is applicable in several cases in large conventional GWAS, particularly when then
ratio of controls to cases in the discovery cohort is larger than that in the replication cohort.
In a relatively recent GWAS on rheumatoid arthritis [Stahl et al., 2010] with comparable
sample populations for discovery and replication cohorts, method B could be used to attain
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Fig. 4.2 General power differences (%) between methods A and B. Mean power difference is
taken as the integral of power difference between methods B and A (see methods section)
over R with respect to log-odds ratio. In all cases, 20 000 samples are used overall for a
SNP with MAF 0.1, with cutoffs α = 5×10−6, β = 5×10−4, γ = 5×10−8. Mean power
difference is determined as the integral of the power difference with respect to the log-odds
ratio over the real line.
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greater power than method A for a fixed type-1 error rate. Assuming that summary statistics
are well-approximated by binomial tests of allelic differences (so covariates and strata used
in computation of summary statistics have only small effects), the improvement in power
is around 4% for SNPs with an odds-ratio of 1.3, MAF 0.1, and is positive across all odds
ratios. More than 2000 additional controls in C′0 would be needed to increase power by this
amount (figure 4.3a).
Small power advantages such as this may make minimal difference in a single study,
although since they require no extra cost, are worth attaining if possible. The power of
method B is generally considerably higher than method A when n0 > n1 and n′0 ≈ n′1, which
corresponds to a scenario in which cases are comparatively harder to recruit, but control
recruitment and genotyping also carries cost (in that minimising the number of controls
needed for replication is of interest). Power advantages may be more substantial in some
cases; for example, a study with (n0,n1,n′0,n
′
1) = (15000,5000,5000,5000), method B
enables a power increase of up to 8% (Figure 4.3b). To achieve comparable performance
with method A, around 2000 additional controls would be necessary in the replication cohort.
Method B with (n0,n′0) = (15000,5000) is also more powerful than method A would be if
controls were divided equally between C0 and C′0 (see Figure 4.3b).
Difficult control ascertainment
An important application of the method presented in this paper is in studies for which ‘control’
samples are expensive or difficult to ascertain. This is often the case in comparative studies
between disease subtypes. In such studies, sharing controls can improve power substantially,
especially if a proportion of samples in the replication cohort are falsely assigned to the
control cohort (see methods section).
An international GWAS on fronto-temporal dementia in 2014 [Ferrari et al., 2014]
is an example in which sharing controls may be beneficial. The study had sample sizes
(n0,n1,n′0,n
′
1) = (4308,2154,5094,1372). Control samples in the discovery phase were
assessed for current neurological disease, and were used in previous studies on Parkinson’s
disease, indicating a high degree of reliability. Control samples in the replication phase were
collected from the same geographic distribution as cases, but were not explicitly used in
previous neurological studies, suggesting better control ascertainment amongst the discovery
cohort.
In this study, sharing controls could allow for a more strongly-ascertained control cohort,
and reduce the effects of confounders affecting C′1. At typical values α = 1× 10−4, β =
1×10−3, γ = 5×10−8, power is nearly equivalent between the two methods assuming all
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controls are genuine. However, with 10% mis-ascertainment in C′1, the power advantage of
method B is up to 5%. Given the near-identical distribution of cases in the discovery and
validation cohort, cases could alternatively be shared, leading to a power increase of up to
6%.
4.2.5 Prospective study design
Studies may be planned and powered with the assumption that samples may be shared. For
certain restrictions on sample numbers, this can provide the potential for greater power than
would be attainable by restricting to an independent-controls design. For instance, if we seek
to validate hits on a GWAS with 10000 controls and 5000 cases, and can afford to genotype
a further 10000 samples, power is higher after recruiting 4000 additional controls and 6000
additional cases and sharing controls than can be achieved from any independent-control
study design (Figure 4.3d).
This may be a common scenario if controls are sourced from a known database rather
than specifically recruited for the study.
Partial replication
In circumstances where case recruitment is difficult, as in studies of rare diseases, an
assessment of repeatability may be made by re-testing results from a discovery phase with a
new control set only. This can enable the use of control cohorts which only partially match
the case cohort.
In a GWAS on pemphigus vulgaris [Sarig et al., 2012], a rare disease primarily affecting
individuals of Ashkenazi Jewish ethnicity, the discovery cohorts were sampled from Jewish
populations, with age- and population- matched controls. Control cohorts were small
((n0,n1,n′0,n
′
1) = (100,400,59,285)), potentially due to difficulty recruiting both ethnically-
and geographically-matched controls.
Method C could be used in this instance to enable a larger control set and greater power.
If a control cohort of Ashkenazi individuals could be assembled without requiring geographic
matching with the case set, it would be inappropriate to use as a sole control cohort against the
existing case cohort, due to the potential for geographic confounding. However, such a cohort
could be used as either C0 or C′0 in method C, with the existing ethnically- and geographically-
matched controls serving as the other cohort. In this way, the power advantage of the larger
cohort could be used while maintaining control over potential aberrance in the larger control
group.
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Fig. 4.3 Examples of comparison of power of methods A and B. In all panels, a posi-
tive odds ratio corresponds to a deleterious mutation and average MAF is 10%. The top
two panels show comparisons of method B with n′0 fixed against method A with varying
n′0. Panel 4.3a has (n0,n1,n
′
0,n
′
1) = (20169,5539,8806,6768) (values from a GWAS on
RA [Stahl et al., 2010]), and panel 4.3b (n0,n1,n′0,n
′
1) = (15000,5000,5000,5000). Both
panels use (α,β ,γ) = (5×10−6,5×10−4,5×10−8). Panel 4.3c demonstrates the effect of
false-ascertainment (F.A) in C′0; when cases are mis-ascertained as controls. In this case,
(α,β ,γ) = (1×10−4,1×10−3,5×10−8), reflecting values used in the paper [Ferrari et al.,
2014]. Panel 4.3d demonstrates a prospective scenario with 10000 samples for replication.
Method B with (n0,n1) as above, (n′0,n
′
1) = (4000,6000) is more powerful than any design
using method A (grey region; n′0 ∈ (1000,9000); n′1 = 10000−n′0).
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Method C enables computation of power and type-1 error rates, and comparison to
alternative designs with cases split into smaller independent discovery and validation cohorts
(method A). Testing a case cohort against two separate control cohorts is almost always more
powerful for a fixed type-1 error rate than splitting the case cohort in two and performing
method A (see supplementary figures B.1,B.2).
4.3 Discussion
This paper proposes a method to improve efficiency of data use in a replication procedure,
adding to the body of methods for comparison of high-dimensional case-control studies. For
many common study sizes, the method can reduce the cost of replication, or increase power
of discovery. The adapted method is simple to apply, only requiring modification of a single
association threshold. A standard replication procedure (or more general comparison of
case-control studies) with independent control datasets does not make use of the information
that expected values of variables in control datasets are, in principle, the same. In this way,
the same dataset can in theory yield more information when controls are shared.
The most important caveat of these methods is the loss of systematic type-1 error rate
control for null SNPs which are aberrant in C0. Control of such errors must not be sacrificed
entirely, but in some circumstances it may be satisfactory to assess such errors on a SNP-by-
SNP basis. Such assessment is important and standard for all proposed GWAS hits under
any method [The Wellcome Trust Case Control Consortium, 2007] in the interests of quality
control. In method C, control over aberrance in C′0 is additionally lost; however, since this
method is largely applicable when C0∪C′0 is a single homogeneous control (or case) cohort,
there is no way that aberrance in the cohort can be systematically identified by comparison
with other cohorts.
Somewhat better control of the type-1 error rate can often be achieved for SNPs with
aberrance in C1 or C′0. This may incentivise the use of this method when confidence in the
representativeness of these cohorts is low compared to that of C0. The type 1 error rate is
somewhat increased for SNPs with aberrance in C′1, although as it remains bounded by α ,
this increase is not a major problem.
The two-stage validation procedure is similar to a meta-analysis of the discovery and
validation experiments, for which several adaptations to shared-control designs have been
proposed [Lin and Sullivan, 2009, Han et al., 2016a]. However, there are several important
distinctions which necessitate an alternative approach in this case. Firstly, not all variables
are measured in the second (replication) study; we are restricted to analysis of variables
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reaching a given observed effect size. Secondly, the studies to be ‘meta-analysed’ are not
complete, in the sense that there may be residual confounding; a strong effect size in the
meta-analysis alone is not adequate evidence for association and some level of association
(with consistent direction) is additionally required in both constituent studies.
The method is inapplicable when replication is performed on cohorts from completely
distinct geographic groups, although there can be some difference in geographic distribution
between control sets if this is controlled for in computing summary statistics. The method is
most applicable when control groups are sampled from similar populations and genotyped
on similar platforms.
The widespread discoveries of the GWAS field have led to corresponding increases
in complexity of phenotypic definitions, with ever-finer delineations of disease types of
ever-rarer prevalence. The genetic analysis of such complex phenotypes is necessarily
comparative; there is little use understanding the genetics of a rare disease subtype except in
the context of the genetics of the disease in general. Such analyses necessitate GWAS and
other comparative studies between rare phenotypic types [Liley et al., 2016], with ‘controls’
meaning the better-characterised disease sub-phenotype in this sense, as well as between
cases and controls. Rare disease subtypes are often afflicted with ascertainment difficulties,
leading to varying degrees of expected aberrance in disease cohorts. Within this paradigm,
the applicability of this method is likely to expand.
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4.4 Methods
4.4.1 Definitions
Denote zx for x ∈ {d,r,s,m,c} as the signed z-score (±Φ−1(px/2)) corresponding to px, and
zx for x ∈ α,β ,β ∗,γ as the positive corresponding threshold −Φ−1(x/2), where Φ,Φ−1 are
the standard normal CDF and quantile functions. Other than (zd,zr), all pairs of z-scores
are correlated under H∩0 , with correlation estimable from sample sizes or empirically if
covariates are used (appendix B, section B.1.1). Denote ρxy as the correlation between zx and
zy, (x,y) ∈ {d,r,s,m}2, and set
ΣA = var
(
(zd zr zm)t
)
ΣB = var
(
(zd zs zm)t
)
ΣC = var
(
(zc zs zm)t
)
(4.1)
For i ∈ {d,r,s,m,c} define ζi = E(zi), where the expectation is conditional on the SNP in
question. For SNPs in H∩0 we have ζi ≡ 0, but this may not hold for SNPs in H∪0 \H∩0 . Note
that the values ζi are proportional to the corresponding log-odds ratios for SNPs with fixed
MAF. Define RA, RB, RC as the false-positive rates for a SNP of interest in methods A, B and
C respectively.
4.4.2 General type 1 error rate
Define NΣ(z) as the PDF of the multivariate normal with mean 0 and variance Σ at z. The
values β ∗, β⊥ are chosen to satisfy
2
∫ ∞
zα
∫ ∞
zβ∗
∫ ∞
zγ
NΣB
(
(zd zr zm)t
)
dzmdzrdzd = 2
∫ ∞
zα
∫ ∞
zβ⊥
∫ ∞
zγ
NΣC
(
(zd zr zm)t
)
dzmdzrdzd
= 2
∫ ∞
zα
∫ ∞
zβ
∫ ∞
zγ
NΣA
(
(zd zr zm)t
)
dzmdzrdzd
= Pr(pd < α, pr < β , pm < γ|H∩0 ) (4.2)
thus conserving the type 1 error rate (denoted P0) against H∩0 between methods (Figure 4.4).
If no threshold is used on pm (ie, γ = 1), then β ∗, β⊥ satisfy
Pr(pd < α, ps < β ∗|H∩0 ) = Pr(pc < α, ps < β⊥|H∩0 ) = Pr(pd < α, pr < β |H∩0 ) = αβ
(4.3)
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since zd ⊥ zr|H∩0 . The definition of β ∗,β⊥ from equation 4.2 will be considered a gener-
alisation of the definitions from 4.3, with results established first for β ∗, β⊥ defined as per
definition 4.3, and extended where possible to definition 4.2.
I show in appendix B, section B.1.2 that for β ∗, β⊥ defined as per definition 4.3 we have
lim
zα→∞
zβ ∗√
1−ρ2dszβ +ρdszα
= 1 (4.4)
lim
zα→∞
zβ⊥√
1−ρ2cszβ +ρcszα
= 1 (4.5)
approaching from above, so
zβ ∗ > max
(
zβ ,
√
1−ρ2dszβ +ρdszα
)
(4.6)
zβ⊥ > max
(
zβ ,
√
1−ρ2cszβ +ρcszα
)
(4.7)
As defined by equation 4.3, zβ ∗ , zβ⊥ are also asymptotically linear in zα , zγ , zβ as the former
two tend to ∞, with some constraints (appendix B, section B.1.2), although the limit does
not necessarily approach from above. For both definitions, β⊥ < β ∗ < β (appendix B,
section B.1.2)
4.4.3 Study sizes, odds ratios and allele frequencies
Consider a study with n0 controls and n1 cases, with underlying allele frequencies µ0 and µ1
and observed allele frequencies m0, m1 in controls and cases respectively. Let Z be a signed
Z-score derived from a GWAS p-value against the null hypothesis µ0 = µ1. To first order,
E(Z) =
√
2n0n1
n0+n1
µ1−µ0√
µ¯(1− µ¯) (4.8)
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Fig. 4.4 Replication with shared controls. Red and blue shaded areas are regions where
a pair of observed Z scores are deemed a ‘hit’ in the (+,+) quadrant under method A/B
respectively. The value zm is almost linearly dependent on (zd,zr) and on (zd,zs) (appendix B,
section B.1.1). Solid red/blue ellipses indicate contours of the distribution of observed Z
scores for a typical disease-associated SNP under methods A and B, and dashed ellipses
indicate contours for a SNP in H∩0 .
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where µ¯ = n0µ0+n1µ1n0+n1 . Hence (approximately)
ζd =
√
2n0n1
n0+n1
µ1−µ0√
µ¯(1−µ¯) ζr =
√
2n′0n
′
1
n′0+n
′
1
µ ′1−µ ′0√
µ¯(1−µ¯)
ζs =
√
2(n0+n′0)n
′
1
n0+n′0+n
′
1
µ ′1−
µ0n0+µ
′
0n
′
0
n0+n
′
0√
µ¯(1−µ¯) ζc =
√
2(n0+n′0)n1
n0+n′0+n1
µ1− µ0n0+µ
′
0n
′
0
n0+n
′
0√
µ¯(1−µ¯)
ζm =
√
2(n0+n′0)(n1+n
′
1)
n0+n′0+n1+n
′
1
µ1n1+µ
′
1n
′
1
n1+n
′
1
− µ0n0+µ
′
0n
′
0
n0+n
′
0√
µ¯(1−µ¯) (4.9)
where µ¯ varies between definitions (though I generally will take it to be approximately
constant). These formulae allow ζi to be estimated in empirical computations. The estimation
of ζi is more complex if covariates or strata are used in the computation of zi (appendix B,
section B.1.1).
False ascertainment
In general, for a true association, µ0 = µ ′0 and µ1 = µ
′
1. If some proportion κ of samples in
C′0 are incorrectly assigned and come from the case population, then µ
′
0 = (1−κ)µ0+κµ1.
This lowers the absolute values of ζr, ζs and ζm, reducing the power to detect the SNP.
4.4.4 Empirical computations
The power to reject a SNP given ζd , ζr, ζs, ζc ζm in each method can be effectively estimated
in terms of zα , zβ , zγ , zβ ∗ , zβ⊥ by integrating over bivariate normals with covariance matrices
ΣA, ΣB, ΣC. Determination of these matrices is described in appendix B, section B.1.1. The
probability of rejecting the null for a given SNP using method A is∫ ∞
zα−ζd
∫ ∞
zβ−ζr
∫ ∞
zγ−ζm
NΣA
(
(zd zr zm)t
)
dzmdzrdzd
+
∫ ∞
zα+ζd
∫ ∞
zβ+ζr
∫ ∞
zγ+ζm
NΣA
(
(zd zr zm)t
)
dzmdzrdzd (4.10)
and using method B ∫ ∞
zα−ζd
∫ ∞
zβ−ζs
∫ ∞
zγ−ζm
NΣB
(
(zd zs zm)t
)
dzmdzsdzd
+
∫ ∞
zα+ζd
∫ ∞
zβ+ζs
∫ ∞
zγ+ζm
NΣB
(
(zd zs zm)t
)
dzmdzsdzd (4.11)
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Matrix ΣC is generally singular, and zm can be written as
zm =
ρcsρsm−ρcm
ρ2cs−1
zd +
ρcsρcm−ρsm
ρ2cs−1
zs = S(zd,zm) (4.12)
allowing the probability of rejecting the null in method C to be written as a two-dimensional
integral across the regions
X1 = {(zd,zc) : zd > zα ,zc > S(zd,zm)}
X2 = {(zd,zc) : zd <−zα ,zc <−S(zd,zm)}
using the covariance matrix Σ′C =
(
1 ρdc
ρdc 1
)
, as
∫∫
X1∪X2
NΣ′C
(
(zd zc)t
)
dzddzc (4.13)
If n0n1 =
n′0
n′1
, matrix ΣA is singular (appendix B, section B.1.1), in which case zm = ρdmzd +
ρvmzv and the expression above may be reduced to a two-dimensional integral over a more
complex region in the same way (Figure 4.4). If ΣB is nearly singular, the approximation
zm ≈ ρdsρsm−ρdmρ2ds−1
zd +
ρdsρdm−ρsm
ρ2ds−1
zs (4.14)
may be used in a similar way.
4.4.5 Type 1 error rates
Aberrance in C1
For SNPs aberrant in only C1 we have ζd ̸= 0, ζc ̸= 0, ζm ̸= 0, and ζr = ζs = 0. RA, RB,
RC can be considered as functions of ζd . As ζd → 0, RA,RB,RC → P0 (equation 4.2). As
ζd →±∞, RA → β2 , RB = β
∗
2 and RC =
β⊥
2 . For positive ζd both RA and RB are increasing
(and both are symmetric in ζd) so RA <
β
2 , RB <
β ∗
2 , RC <
β⊥
2 for all ζd .
Since β⊥< β ∗< β (often substantially), methods B and C are generally better at rejecting
H∩0 for such SNPs. In the simplified case where zγ = 1, RA ≥ RB universally (appendix B,
section B.1.3. This typically holds for all zγ , except for small deviations in pathological
cases.
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In general, I consider aberrance which is only still present after any strata or covariates
have been accounted for in the computation of z scores. If strata or covariates remove the
effective aberrance between groups, the type-1 error rate is equivalent to that under H∩0 .
Aberrance in C′1
For SNPs aberrant in C′1, we have ζd = 0, ζc = 0, ζr ̸= 0, ζs ̸= 0 and ζm ̸= 0.
Again, RA,RB,RC → P0 as ζr → 0. As ζr →±∞, RA,RB,RC → α2 , and both are bounded
by α2 . Although RB and RC are typically higher than RA in this case, since both have the same
(typically conservative) upper bound, this is not typically a large sacrifice in type 1 error.
In the simplified case where γ = 1, an approximate upper bound on RB−RA is given by
(appendix B, section B.1.4)
α
2
√
2π
(
k√
1−ρ2 −1
)
zβ ≪
α
2
(4.15)
where
k =
ζs
ζr
≈
√
(n0+n′0)(n
′
0+n
′
1)
n′0(n0+n
′
0+n
′
1)
(4.16)
In practice, there is typically a similarly small difference between RC, RB and RA in the
general case.
Aberrance in C′0
For SNPs aberrant in C′0, ζd = 0, ζr ̸= 0, ζc ̸= 0, ζs ̸= 0 and ζm ̸= 0. As for SNPs with
aberrance in C′1, RA,RB,RC → P0 as ζr → 0 and as ζr →±∞, RA,RB → α2 , both bounded
above by α2 . RC, however, tends to 1 as ζd → ∞.
In method B the cohort C0 has a correcting effect on the replication study, meaning
|ζs|< |ζr| and RB < RA.
For the simplified case where γ = 1, a similar bound to 4.15 holds for the difference
RA−RB (note signs are reversed) with
k′ =
ζs
ζr
≈
√
n′0(n
′
0+n
′
1)
(n0+n′0)(n0+n
′
0+n
′
1)
(4.17)
in the place of k. The improvement in type-1 error rate for a SNP with aberrance in C′0 is
generally larger than the loss with the same aberrance in C′1 (see methods), meaning that if
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aberrances are of similar prevalence and size in C′1 and C
′
0, method B will typically have a
lower type-1 error rate than method A.
Aberrance in C0
Aberrance in C0 represents a serious problem in case-control study comparison. False-
positive rates are generally worse under method B, and tend to 1 as E(z)→ ∞. If aberrances
of this type are expected to be very frequent, this may preclude use of methods B or C.
However, aberrances of this type may be best detected retrospectively by examining
aberrances between control groups at SNPs declared ‘hits’. This procedure is already
a necessary quality-control procedure in method A [The Wellcome Trust Case Control
Consortium, 2007, Anderson et al., 2010], as method A does not provide any control over
differences between C0 and C′0. The number of SNPs reaching significance in the two-stage
procedure is usually small enough that this examination is readily tractable.
Aberrance in two or more cohorts
If SNPs are aberrant in both C1 and C′1, or in both C0 and C
′
0, the effect on RA and RB is
similar. If both cohorts are aberrant in the same direction, there is no way to differentiate
the SNP from a genuine association on the basis of the genotype data alone. If cohorts are
aberrant in different directions, then in both methods, the type-1 error rate is lower than for a
null SNP with no aberration or aberration in only one cohort, as effect sizes for the discovery
and replication cohorts are biased in opposite directions. The same typically holds if C′0 and
C1, or C0 and C′1, are biased in the same direction.
If C′0 and C
′
1 or C0 and C1 are both biased in the same direction, RA is generally lower
than RB, as ζs ̸= 0. Both RA and RB are bounded by α2 in this case. In addition, a systematic
bias in both replication groups (or both discovery groups) is likely to be due to a known
confounder, the effect of which can be removed by performing a stratified test (as is typically
good practice when confounders are known). Aberrance in opposite directions leads to
RB > RA in the first case, and a scenario similar to aberrance in C0 in the second case.
Aberrance in three or more cohorts corresponds to a chaotic scenario in which neither
methods A,B, or C will reliably provide FPR control. Aberrance of this extent is typically
detectable and removable using quality control procedures.
Chapter 5
Characterising disease heterogeneity
5.1 Introduction
Analysis of genetic data in human disease typically uses a binary disease model of cases and
controls. However, many common human diseases show extensive clinical and phenotypic
diversity which may represent multiple causative pathophysiological processes. Because ther-
apeutic approaches often target disease-causative pathways, understanding this phenotypic
complexity is valuable for further development of treatment, and the progression towards
personalised medicine. Indeed, identification of patient subgroups characterised by different
clinical features can aid directed therapy [Li et al., 2015] and accounting for phenotypic
substructures can improve ability to detect causative variants by refining phenotypes into
subgroups in which causative variants have larger effect sizes [Morris et al., 2009].
Such subgroups may arise from environmental effects, reflect population variation in
non-disease related anatomy or physiology, correspond to partitions of the population in
which disease heritability differs, or represent different causative pathological processes. In
this chapter, I present a method which tests whether there exist a subset of disease-associated
SNPs which have different effect sizes in case subgroups, determining whether heterogeneity
corresponds to differential genetic pathology.
The test is for a stronger assertion than the question of whether subgroups of a disease
group exhibit any genetic differences at all, as these may be entirely disease-independent: for
example, although there will be systematic genetic differences between Asian and European
patient cohorts with type 1 diabetes (T1D), these differences will not generally relate to the
pathogenesis of disease.
Rather than attempting to analyse SNPs individually for differences between subgroups,
a task for which GWAS are typically underpowered, I model allelic differences across all
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SNPs using mixture multivariate normal models. This can give insight into the ‘geometric’
structure of the genetic basis for disease. Given evidence that there exists some subset
of SNPs that both differentiate controls and cases and differentiate subgroups, I present a
method to reassess test statistics to search for single-SNP effects.
5.2 Results
5.2.1 Summary of proposed method
I jointly consider allelic differences between the combined case group and controls, and
allelic differences between case subgroups independent of controls. Specifically, I establish
whether the data support a hypothesis (H1) that a subset of SNPs associated with case-control
status have different underlying effect sizes (and hence underlying allele frequencies) in case
subgroups. This assumption has been used previously for genetic discovery [Plagnol et al.,
2011].
H1 encompasses several potential underlying mechanisms of heterogeneity. A set of
SNPs may be associated with one case subgroup but not the other; the same set of SNPs may
have different relative effect sizes in subgroups, or heritability may differ between subgroups.
These scenarios are discussed in appendix C, section C.1.
The overall protocol is to fit two bivariate Gaussian mixture models, corresponding to
null and alternative hypotheses, to summary statistics (Z scores) derived from SNP data. I
assume a group of controls and two non-intersecting case subgroups, and jointly consider
allelic differences between the combined case group and controls, and allelic differences
between case subgroups independent of controls (figure 5.1). Heterogeneity in cases can also
be characterised by a quantitative trait, rather than explicit subgroups.
For a given SNP I denote by µ1, µ2, µ12 and µc the population minor allele frequencies
for each of the two case subgroups, the whole case group and the control group respectively,
and Pd , Pa GWAS p-values for comparisons of allelic frequency between case subgroups and
between cases and controls, under the null hypotheses µ1 = µ2 and µ12 = µc respectively
(or similarly for quantitative heterogeneity). I then derive absolute Z scores |Zd| and |Za|
from these p-values (see figure 5.1). The values |Zd|, |Za| are considered as absolute values
of observations of random variables (Zd,Za) which are samples from a mixture of three
bivariate Gaussians. Further details are given in appendix C, section C.2.
I consider SNPs to be partitioned into three categories, with each category corresponding
to a different joint distribution of Zd , Za:
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Fig. 5.1 Overview of three-categories model. Zd and Za are Z scores derived from GWAS
p-values for allelic differences between case subgroups (1 vs 2), and between cases and
controls (1+2 vs C) respectively (left). Within each category of SNPs, the joint distribution
of (Zd,Za) has a different characteristic form. In category 1, Z scores have a unit normal
distribution; in category 2, the marginal variance of Za can vary. The distribution of SNPs in
category 3 depends on the main hypothesis. Under H0 (that all disease-associated SNPs have
the same effect size in both subgroups), only the marginal variance of Zd may vary; under
H1 (that subgroups correspond to differential effect sizes for disease-associated SNPs), any
covariance matrix is allowed. The overall SNP distribution is then a mixture of Gaussians
resembling one of the rightmost panels, but with SNP category membership unobserved.
Visually, my test determines whether the observed overall Zd , Za distribution more closely
resembles the bottom rightmost panel than the top.
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1. SNPs which do not differentiate subgroups and are not associated with the phenotype
as a whole (µc = µ1 = µ2)
2. SNPs which are associated with the phenotype as a whole but which are not differen-
tially associated with the subgroups (µc ̸= µ12; µ1 = µ2 = µ12)
3. SNPs which have different population allele frequencies in subgroups, and may or may
not be associated with the phenotype as a whole (µ1 ̸= µ2)
If the SNPs in category 3 are not associated with the disease as a whole (null hypothesis,
H0), we expect Zd , Za to be independent and the variance of Za to be 1. If SNPs in category
3 are also associated with the disease as a whole (alternative hypothesis, H1), the joint
distribution of (Zd,Za) will have both marginal variances greater than 1, and Za, Zd may co-
vary. My test is therefore focussed on the form of the joint distribution of (Zd,Za) in category
3. Importantly, I allow that the correlation between Zd and Za may be simultaneously positive
at some SNPs and negative at others. This allows for a subset of SNPs to specifically alter
risk of one subgroup, and another subset to alter risk for the other subgroup. To accommodate
this, I only consider absolute Z scores and model the distribution of SNPs in category 3 with
two mirror-image bivariate Gaussians.
Amongst SNPs with the same frequency in disease subgroups (categories 1 and 2), Za
and Zd are independent and the expected standard deviation of Zd is 1. I therefore model
the overall joint distribution of (Zd,Za) as a Gaussian mixture in which the PDF of each
observation (Zd,Za) is given by
PDFZd ,Za|Θ(d,a) =π1N
(
1 0
0 1
)(d,a) (category 1)
+π2N(1 0
0 σ22
)(d,a) (category 2)
+π3
1
2
N(τ2 ρ
ρ σ23
)(d,a)+ 1
2
N( τ2 −ρ
−ρ σ23
)(d,a)
 (category 3) (5.1)
where NΣ(d,a) denotes the density of the bivariate normal PDF centred at
(
0
0
)
with covariance
matrix Σ at (d,a). Θ is the vector of values (π1,π2,τ,σ2,σ3,ρ). Under H0, we have ρ = 0
and σ3 = 1. The values (π1,π2,π3) represent the proportion of SNPs in each category, with
Σπi = 1 (see table 5.1). Patterns of (Zd,Za) for different parameter values are shown in
appendix D.1, table D.1.
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Model Interpretation
π1 H0/H1 Proportion of SNPs not associated with case/control
status and not associated with subgroup status
(category 1)
π2 H0/H1 Proportion of SNPs associated with case/control
status but not subgroup status (category 2)
π3 H0/H1 Proportion of SNPs associated with subgroup status
(category 3)
τ H0/H1 Standard deviation of observed Zd scores (effect sizes for
subgroup status) in category 3
σ2 H0/H1 Standard deviation of observed Za scores (effect sizes
for case/control status) in category 2
σ3 H1 only Standard deviation of observed Za scores (effect sizes
for case/control status) in category 3
ρ H1 only ‘Absolute covariance’ between Zd scores (effect sizes for
subgroup status) and Za scores (effect sizes for
case/control status) in category 3
Table 5.1 Interpretation of parameter values in the fitted model. Parameters τ , σ2 and σ3
are dependent on sample sizes, but can be converted to sample-size independent forms (see
appendix C, section C.4.3).
I use the product of values of the above PDF for a set of observed Zd , Za as an objective
function (‘pseudo-likelihood’, PL) to estimate the values of parameters. This is not a true
likelihood as observations are dependent due to linkage disequilibrium (LD), although
because I minimise the degree of LD between SNPs using the LDAK method [Speed et al.,
2012], the PL is similar to a true likelihood.
5.2.2 Model fitting and significance testing
Parameters π1, π2, π3 (= 1−π1−π2), σ2, σ3, τ and ρ are fit under H1 and H0. Under H0,
(ρ,σ3) = (0,1).
The fit of the two models is compared using the log-ratio of PLs, giving an unadjusted
pseudo-likelihood ratio (uPLR). A term depending only on Za is subtracted to minimise the
influence of the Za score distribution, and a term log(π1π2π3) added to ensure the model is
identifiable [Chen et al., 2001]. I term the resultant test statistic the pseudo-likelihood ratio
(PLR). The null distribution of the PLR is conservatively estimated by a distribution of the
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form:
PLR|H0 ∼
γχ21 prob = κγχ22 prob = 1−κ (5.2)
The value γ arises from the weighting derived from the LDAK procedure causing a scale
change in the observed PLR. The mixing parameter κ corresponds to the probability that
ρ = 0, (approximately 12 ).
I estimate γ and κ by sampling random subgroups of the case group. Such subgroups only
cover the subspace of H0 with τ = 1 (no systematic allelic differences between subgroups),
causing the asymptotic approximation of PLR by equation 5.2 to be poor. I thus estimate
γ and κ from the distribution of a similar alternative test statistic, the cPLR (see methods
section and appendix C, section C.3), which is well-behaved even when τ ≈ 1 and enables a
conservative estimate of a p-value under H0.
A natural next step is to search for the specific variants contributing to the PLR. An
effective test statistic for testing subgroup differentiation for single SNPs is the Bayesian
conditional false discovery rate (cFDR), introduced in chapter 2 [Andreassen et al., 2013,
Liley and Wallace, 2015] applied to Zd scores ‘conditioned’ on Za scores. However, this
statistic alone cannot capture all the means by which the joint distribution of (Za,Zd) can
deviate from H0, and we also propose three other test statistics, each with different advantages,
and compare their performance (appendix C, section C.6.1).
5.2.3 Power calculations, simulations, and validation of method
I tested the method by application to a range of datasets, using simulated and re-sampled
GWAS data. First, to confirm appropriate control of type 1 error rates across H0, I simulated
genotypes of case and control groups under H0 for a set of 5× 105 autosomal SNPs in
linkage equilibrium (appendix C, section C.4). Quantiles of the empirical PLR distribution
were smaller than those for the empirical cPLR distribution and the asymptotic mixture-χ2,
indicating that the test is conservative when τ > 1 (estimated type 1 error rate 0.048, 95%
CI 0.039-0.059) and when τ ≈ 1 (estimated type 1 error rate 0.033, 95% CI 0.022-0.045)
as expected; see figure 5.2. The distribution of cPLR closely approximated the asymptotic
mixture-χ2 distribution across all values of τ (appendix C, figure C.5).
I then established the suitability of the test when SNPs are in LD and when there exist
genetic differences between subgroups that are independent of disease status overall. First,
I used a dataset of controls and autoimmune thyroid disease (ATD) cases and repeatedly
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choose subgroups such that several SNPs had large allelic differences between subgroups.
I found good FDR control at all cutoffs (appendix D.2, figure C.6) and the overall type 1
error rate at α = 0.05 was 0.041 (95% CI 0.034-0.050). Second, I analysed a dataset of T1D
cases with subgroups defined by geographical origin. Within the UK, there is clear genetic
diversity associated with region [Leslie et al., 2015]. As expected, Zd scores for geographic
subgroups showed inflation compared to for random subgroups (appendix D.2, figure D.1).
None of the derived test statistics reached significance at a Bonferroni-corrected p < 0.05
threshold (min. corrected p value > 0.8, appendix D.2, figre D.2).
To examine the power of my method, I used published GWAS data from the Wellcome
Trust Case Control Consortium [The Wellcome Trust Case Control Consortium, 2007]
comprising 1994 cases of Type 1 diabetes (T1D), 1903 cases of rheumatoid arthritis (RA),
1922 cases of type 2 diabetes (T2D) and 2953 common controls. I established that the test
could differentiate between any pair of diseases, considered as subgroups of a general disease
case group (all < 1×10−8, table 5.2).
T1D and RA have overlap in genetic basis [The Wellcome Trust Case Control Consortium,
2007, Fortune et al., 2015, Liley and Wallace, 2015], as well as non-overlapping associated
regions. T1D and T2D have less overlap [Fortune et al., 2015] and T2D and RA less still.
This was reflected in the fitted values (table 5.2, figure 5.3). The fitted values parametrizing
category 2 in the full model for T1D/RA (π2, σ2) were consistent with a subset of SNPs
associated with case/control status (T1D+RA vs control) but not differentiating T1D/RA.
By contrast, the parametrization of category 2 for T1D/T2D and T2D/RA had marginal
variance σ2 approximately 1, suggesting that a subset of SNPs associated with case/control
status but not with ‘subgroup’ status did not exist in these cases. The rejection of H0 for
the comparisons entails the existence of a set of SNPs associated both with case/control and
subgroup status. The H0 model does not allow such a set of SNPs, forcing the parametrisation
of Zd , Za scores for such SNPs to be ‘squashed’ into a category shape permitted under H0,
with one marginal variance being 1: either category 2 (as happens in T2D/RA since π2|H0 ≈
π3|H1, σ2|H0 ≈ σ3|H1 in T2D/RA) or category 3 (as in T1D/T2D, where π3|H0 ≈ π3|H1,
τ|H0 ≈ τ|H1).
To determine the power of the test more generally, I showed that power depends on the
number of SNPs in category 3 and on the underlying parameters of the true model, depending
on the number of samples through the fitted model parameters (appendix C, section C.4.3). I
therefore estimated the power of the test for varying numbers of SNPs in category 3 and for
varying values of the parameters σ3, τ , and ρ . (Figure 5.4; appendix D.2, figure D.3). As
expected, power increases with an increasing number of SNPs in category 3, reflecting the
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Fig. 5.2 QQ plot from simulations demonstrating type 1 error rate control of PLR test. PLR
values for test subgroups under H0 with either τ = 1 (random subgroups; grey) or τ > 1
(genetic difference between subgroups, but independent of main phenotype; blue) with
cPLR values for random subgroups (black) and against proposed asymptotic distribution
under simulation (12
(
χ21 +χ
2
2
)
; solid red line; 99% confidence limits dashed red line). The
distribution of cPLR for random subgroups generally majorises the distribution of PLR
(that is, Pr(cPLR > x|H0) > Pr(PLR > x|H0) for all x), meaning the cPLR-based test is
conservative relative to testing against an empirical distribution of PLR values from random
subgroups. Further details are shown in appendix C, sections C.3 and C.4.
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Fig. 5.3 Observed absolute Za and Zd for T1D/RA. Colourings correspond to posterior
probability of category membership under full model (see triangle): grey - category 1, blue -
category 2, red -category 3. Contours of the component Gaussians in the fitted full model are
shown by dotted lines.
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Fig. 5.4 Power of PLR to reject H0 (genetic homogeneity between subgroups) depends on the
number of SNPs in category 3 and the underlying values of model parameters σ2, σ3, τ , ρ .
Dependence on number of case/control samples arises through the magnitudes of σ3 and τ
(appendix C, section C.4.3). Leftmost figure shows power estimates for various values of π3,
σ3, τ , ρ . Value N is the approximate number of SNPs in category 3, (∝ π3). Each simulation
was on 5× 104 simulated autosomal SNPs in linkage equilibrium. Value ρ/(σ3τ) is the
absolute correlation between Zd and Za in category 3. Also see appendix D.2, figure D.3.
Rightmost figure shows power of PLR to detect differences in genetic basis of T1D and RA
subgroups of a combined autoimmune dataset, down-sampling to varying numbers of cases
(X axis). PLR is compared with: power to find≥ 1 SNP with Zd score reaching genome-wide
significance (GWS, blue; p≤ 5×10−8) or Bonferroni-corrected significance (BCS, green;
p≤ 0.05/(total # of SNPs)); and power to detect any SNP with Za score reaching genome-
wide significance and Zd score reaching Bonferroni-corrected significance (sub-BCS, grey;
p≤ 0.05/(total # of SNPs with Za reaching GWS)). Error bars show 95% CIs. Circles/solid
lines for each colour show power for all SNPs, triangles/dashed lines for all SNPs except
rs17696736. Power for sub-BCS drops dramatically but power for PLR is not markedly
affected, indicating relative robustness of PLR to single-SNP effects.
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Table 5.2 Fitted parameter values for models of T1D/RA, T1D/T2D, T2D/RA, and GD/HT.
H1 is the null hypothesis (under which σ3 = 1, ρ = 0) that SNPs differentiating the subgroups
are not associated with the overall phenotype; H1 is the alternative (full model). p values for
pseudo-likelihood ratio tests are also shown.
Subgroups π1 π2 π3 σ2 σ3 τ ρ
T1D/RA H1 0.997 5.69×10−4 2.06×10−3 2.76 1.39 1.74 1.815
H0 0.997 6.26×10−4 2.48×10−3 2.71 - 1.67 -
T1D/T2D H1 0.573 0.426 9.63×10−4 1.00 2.03 2.25 1.68
H0 0.578 0.421 8.91×10−4 1.00 - 2.21 -
T2D/RA H1 0.573 0.426 8.71×10−4 1.00 2.23 1.75 1.69
H0 0.91 8.05×10−4 0.0892 2.25 - 0.97 -
GD/HT H1 0.506 0.487 0.007 1.12 2.90 1.65 2.61
H0 0.493 0.079 0.428 1.68 - 1.03 -
Subgroups p-val
T1D/RA 3.2×10−12
T1D/T2D 1.6×10−9
T2D/RA 5.1×10−9
GD/HT 2.2×10−15
proportion of SNPs which differentiate case subgroups and are associated with the phenotype
as a whole. Power also increases with increasing τ , σ3, and absolute correlation (ρ/(σ3τ))
as high values enable better distinction of SNPs in the second and third categories.
I explored the dependence of power on sample size by sub-sampling the WTCCC data
for RA and T1D (figure 5.4) and compared the power of the PLR with the power to find
any single SNP which differentiated the two diseases in several ways (see figure legend).
Although the power of the PLR-based test was limited at reduced sample sizes, it remained
consistently higher than the power to detect any single SNP which differentiated the two
diseases. I then repeated the analysis removing the known T1D- and RA- associated SNP
rs17696736. The power to detect a SNP with significant Zd score (Bonferroni-corrected)
amongst SNPs with GW-significant Za score dropped dramatically, though the power of
PLR was only slightly reduced. This illustrated the robustness of the PLR test to inclusion
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or removal of single SNPs with large effect sizes, a property not shared by single-SNP
approaches.
Estimating power requires an estimate of the underlying values of several parameters:
the expected total number of SNPs in the pruned dataset with different population MAF
in case subgroups, and the distribution of odds-ratios such SNPs between subgroups and
between cases/controls. With sparse genome-wide cover, such as that in the WTCCC study,
> 1250 cases per subgroup are necessary for 90% power (discounting MHC region). If
SNPs with greater coverage for the disease of interest are used (such as the ImmunoChip
for autoimmune diseases) values of π3, σ3 and τ are correspondingly higher, and around
500-700 cases per subgroup may be sufficient.
5.2.4 Application to autoimmune thyroid disease and type 1 diabetes
Autoimmune thyroid disease (ATD) takes two major forms: Graves’ disease (GD; hyperthy-
roidism) and Hashimoto’s Thyroiditis (HT; hypothyroidism). Differential genetics of these
conditions have been investigated. Detection of individual variants with different effect sizes
in GD and HT is limited by sample size (particularly HT); however, the T SHR region shows
evidence of differential effect [Cooper et al., 2012]. T1D is relatively clinically homogeneous
with no major recognised subtypes, although heterogeneity arises between patients in levels
of disease-associated autoantibodies, and disease course differs with age at diagnosis [Plagnol
et al., 2011]. I analysed both of these diseases.
For ATD, I was able to confidently detect evidence for differential genetic bases for GD
and HT (p = 2.2×10−15). Fitted values are shown in table 5.2. The distribution of cPLR
statistics from random subgroups agreed well with the proposed mixture χ2 (appendix D.2,
figure D.5b).
For T1D, I considered four subgroupings defined by plasma levels of the T1D-associated
autoantibodies thyroid peroxidase antibody (TPO-Ab, n=5780), insulinoma-associated anti-
gen 2 antibody (IA2-Ab, n=3197), glutamate decarboxylase antibody (GAD-Ab, n=3208)
and gastric parietal cell antibodies (PCA-Ab, n=2240). A previous GWAS study on autoan-
tibody positivity in T1D identified only two non-MHC loci at genome-wide significance:
1q23/FCRL3 with IA2-Ab and 9q34/ABO with PCA-Ab [Plagnol et al., 2011].
I tested each of the subgroupings retaining and excluding the MHC region. Fitted values
for models with and without MHC are shown in appendix D.1, figure D.2, and plots of Za
and Zd scores are shown in appendix D.2, figure D.6. Retaining the MHC region, I was
able to confidently reject H0 for subgroupings based on TPO-Ab, IA-2Ab and GAD-Ab
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(all p-values < 1.0× 10−20). Although there was evidence that SNPs in the dataset were
associated with PCA-Ab level (τ ≈ 2.5, null model), the improvement in fit in the full model
was not significant, and I conclude that such SNPs determining PCA-Ab status are not in
general T1D-associated. This can be seen by in the plot of Za against Zd (appendix D.2,
figure D.6) where SNPs with high Zd values do not have higher than expected Za values.
With MHC removed, the subgrouping on TPO-Ab was significantly better-fit by the full
model (p = 1.5×10−4). There was weaker evidence to reject H0 for GAD-Ab (p = 0.002)
and IA2-Ab (p = 0.008) (Bonferroni-corrected threshold at α < 0.05: 0.006). Fitted values
of τ in both the full and null models for GAD-Ab were ≈ 1, indicating absence of evidence
for a category of non-MHC T1D-associated SNPs additionally associated with GAD-Ab
positivity. Collectively, this indicates that differential genetic basis for T1D with GAD-Ab
and IA2-Ab positivity is driven principally by the MHC region, and although PCA-Ab
status is partially genetically determined, the set of causative variants is independent of T1D
causative pathways.
The variation in genetic architecture of T1D with age is not fully understood, but previous
studies have suggested larger observed effects at known loci in patients diagnosed at a
younger age [Hyttinen et al., 2003, Howson et al., 2009, Howson et al., 2011, Howson et al.,
2012]. I investigated whether these differences were indicative of widespread differences
in variant effect sizes with age-at-diagnosis, possibly due to differential heritability (see
appendix C, section C.1). I applied the method to T1D dataset with Zd defined by age at
diagnosis (quantitative trait). Fitted values are shown in appendix D.1, table D.3 and Za
and Zd scores in appendix D.2, figure D.7. The hypothesis H0 could be rejected confidently
when retaining or removing the MHC region (p values < 1.0×10−20 and 0.007 respectively).
Signed Zd and Za scores for age at diagnosis showed a visible negative correlation (p= 0.002)
amongst Zd and Za scores for disease-associated SNPs (rg method 2, figure 5.5). This is
consistent with a higher genetic liability with lower age at diagnosis.
5.2.5 Assessment of individual SNPs
Many SNPs which discriminated subgroups were in known disease-associated regions
(appendix D.1, tables D.6, D.9, and D.12). In several cases, the new method identified
disease-associated SNPs which have reached genome-wide significance in subsequent larger
studies but for which the Za score in the WTCCC study was not near significance. For
example, the SNP rs3811019, in the PTPN22 region, was identified as likely to discriminate
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Fig. 5.5 Za and Zd scores for age at diagnosis in T1D, excluding MHC region. Colour
corresponds to posterior probability of category 2 membership in null model (since categories
in full model are assigned on the basis of correlation), with black representing a high
probability. Zd and Za are negatively correlated (p = 8.7× 10−5 with MHC included,
p= 0.002 with MHC removed) after accounting for LD using LDAK weights, and weighting
by posterior probability of category 2 membership in the null model, to prioritise SNPs
further from the origin
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T1D and T2D (p = 3.046×10−6; appendix D.1, table D.9), despite a p value of 3×10−4
for joint T1D/T2D association.
For GD and HT, SNPs near the known ATD-associated loci PTPN22 (rs7554023), CTLA4
(rs58716662), and CEP128 (rs55957493) were identified as likely to be contributing to the
difference (see appendix D.1, table D.15). The SNPs rs34244025 and rs34775390 are not
known to be ATD-associated, but are in known loci for inflammatory bowel disease and
ankylosing spondylitis, and this analysis suggest they may differentiate GD and HT (FDR
0.003).
I searched for non-MHC SNPs with differential effect sizes with TPOA positivity in
T1D, the subgrouping of T1D for which we could most confidently reject H0. Previous
work [Plagnol et al., 2011] identified several loci potentially associated with TPO-Ab pos-
itivity by restricting attention to known T1D loci, enabling use of a larger dataset than
was available to us. I list the top ten SNPs for each summary statistic for TPO-Ab posi-
tivity in appendix D.1, table D.18. Subgroup-differentiating SNPs included several near
known T1D loci: CTLA4 (rs7596727), BACH2 (rs11755527), RASGRP1 (rs16967120) and
UBASH3A (rs2839511) [Barrett et al., 2009]. These loci agreed with those found by Plagnol
et al [Plagnol et al., 2011], but my analysis used only available genotype data, without
external information on confirmed T1D loci. I was not able to replicate the same p-values
due to reduced sample numbers.
Finally, I analysed non-MHC SNPs with varying effect sizes with age at diagnosis in T1D
(appendix D.1, table D.21). This implicated SNPs in or near CTLA4 (rs2352551), IL2RA
(rs706781), and IKZF3 (rs11078927).
5.3 Discussion
The problem I address is part of a wider aim of adapting GWAS to complex disease phe-
notypes. As the body of GWAS data grows the analysis of between-disease similarity and
within-disease heterogeneity has led to substantial insight into shared and distinct disease
pathology [Andreassen et al., 2013, Liley and Wallace, 2015, Morris et al., 2009, Traylor
et al., 2013, Wen and Lu, 2013]. I seek in this paper to use genomic data to infer whether
such disease subtypes exist. The problem is related to the question of whether two dif-
ferent diseases share any genetic basis [Bulik-Sullivan et al., 2015] but differs in that the
implicit null hypothesis relates to genetic homogeneity between subgroups rather than genetic
independence of separate diseases.
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The test strictly assesses whether a set of SNPs have different effect sizes in case sub-
groups. I interpret this as ‘differential causative pathology’, which encompasses several
disease mechanisms, discussed in appendix C, section C.1. In some cases, if subgroups are
defined on the basis of the presence or absence of a known disease risk factor, the heritability
of the disease will differ between subgroups, with corresponding changes in variant effect
sizes.
I use ‘absolute covariance’ ρ preferentially (see appendix D.1, table D.1) because I expect
that Za and Zd will frequently co-vary positively and negatively at different SNPs in the same
analysis; for instance, if some variants are deleterious only for subgroup 1 and others only
for subgroup 2. A potential advantage of the symmetric model is the potential to generate Zd
scores from ANOVA-style tests for genetic homogeneity between three or more subgroups,
in which case reconstructed Z scores would be directionless. This situation is similar to the
analysis described in section 6, although I use alternative methods in that case.
Aetiologically and genetically heterogeneous subgroups within a case group correspond
to substructures in the genotype matrix. As discussed in chapter 1, section 1.4.5, information
about such substructures is lost in a standard GWAS, which only uses the column-sums
(MAFs) of the matrix (linear-order information). Data-driven selection of appropriate case
subgroups and corresponding analyses of these subgroups can use more of the remaining
quadratic-order information the matrix contains. Indeed a ‘two-dimensional’ GWAS approach
(using Za and Zd) instead of a standard GWAS (using only Za) may improve SNP discovery,
as I found for PTPN22 in RA/T2D. However, this can only be the case if the subgroups
correspond to different variant effect sizes; for other subgroupings, a two-dimensional GWAS
will only add noise.
While it seems appealing to use this method to search for some ‘optimal’ partition of
patients, I focus on testing subgroupings derived from independent clinical or phenotypic
data. Firstly, it is difficult to characterise subgroupings as ‘better’ or ‘worse’, and no one
parameter can parametrise the degree to which two subgroups differ; parameters π3, τ , and
ρ all contribute, and attempts to test the hypothesis using a single measure such as genetic
correlation have serious shortcomings (appendix C, section C.5). Secondly, even if subgroups
could meaningfully be ranked, the search space of potential subgroupings of a case group is
prohibitively large (2N for N cases), making exhaustive searches difficult. This is explored
further in chapter 7, section 7.1.5.
I demonstrated that effect sizes of T1D-causative SNPs differ with age at disease diagno-
sis. The strong negative correlation observed (figure 5.5) was consistent with an increased
total genetic liability in samples with earlier age of diagnosis, a finding supported by can-
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didate gene studies [Howson et al., 2009, Howson et al., 2011, Howson et al., 2012] and
epidemiological data [Hyttinen et al., 2003]. Such a pattern arises naturally from a lia-
bility threshold model where total liability depends additively on both genetic effects and
environmental influences which accumulate with age (appendix C, section C.1).
The method necessarily dichotomises the multitude of mechanisms of heterogeneity,
although there are many diverse forms (appendix D.1, table D.1; appendix C, section C.1).
There is potential to further dissect the mechanisms of disease heterogeneity by incorporating
estimations of genetic correlation [Bulik-Sullivan et al., 2015] or assessing evidence for lia-
bility threshold models [Chatterjee and Carroll, 2005]. Similar mixture-Gaussian approaches
may also be adaptable to this purpose, by assessing other families of effect size distributions.
The methods in this chapter add to the current body of knowledge by extracting additional
information from a disease dataset over a standard GWAS analysis, and help to determine if
further analysis of disease pathogenesis in subgroups is justified. My approach is analogous
to the intuitive method of searching for between-subgroup differences in SNPs with known
disease associations [Plagnol et al., 2011] but does not restrict attention to strong disease
associations, enabling use of information from disease-associated SNPs which do not reach
significance. My parametrisation of effect size distributions allows insight into the structure
of the genetic basis of the disease and potential subtypes, improving understanding of
genotype-phenotype relationships.
5.4 Methods
5.4.1 Joint distribution of variables Za, Zd
I assume that SNPs may be divided into three categories, as described in the results section
(figure 5.1). Under these assumptions, Za and Zd scores have the joint PDF given by
equation 5.1.
Define Θ as the vector of values (π1,π2,π3,τ,σ2,σ3,ρ). Z scores Za and Zd are re-
constructed from GWAS p-values for SNP associations. In practice, since the model is
symmetric, I only require absolute Z scores, without considering effect direction.
If a set of SNPs have normally-distributed log-odds ratios, for which Z scores are
generated, then if α is the 97.5% quantile of the odds-ratio distribution, and we have sample
sizes n1, n2, the expected observed standard deviation of Z scores (corresponding to, σ2, σ3,
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and τ) is given by
E{SD(Z)}=
√
1+
log(α)2n1n2
12(n1+n2)
(5.3)
(appendix C, section C.4.3).
5.4.2 Definition and distribution of PLR statistics
For a set of observed Z scores (Za,Zd) I define the joint unadjusted pseudo-likelihood
PLda(Z|Θ) as
log{PLda(Zd,Za|Θ)}= ∑
Z(i)d ∈Zd ,Z
(i)
a ∈Za
wiPDFZd ,Za|Θ(Z
(i)
d ,Z
(i)
a )+C log(π1π2π3) (5.4)
where the term C log(π1π2π3) is included to ensure identifiability of the model [Chen et al.,
2001] and weights wi are included to adjust for LD (see below).
I now set
θ̂1 = arg max
θ∈H1
PLda(Zd,Za|θ)
θ̂0 = arg max
θ∈H0
PLda(Zd,Za|θ)
uPLR(Z) = log
(
PLda(Z|θ̂1)
PLda(Z|θ̂0)
)
(5.5)
recalling that H0 is the subspace of the parameter space H1 satisfying σ3 = 1 and ρ = 0.
If data observations are independent, uPLR reduces to a likelihood ratio. Under H0, the
asymptotic distribution of uPLR is then
uPLR∼ 1
2
χ21 p = 1/2χ22 p = 1/2 (5.6)
according to Wilk’s theorem extended to the case where the null value of a parameter lies on
the boundary of H1 (since ρ = 0 under H0) [Self and Liang, 1987].
The empirical distribution of uPLR may depart substantially from this asymptotic
distribution if τ ≈ 1. Indeed, if X has the above asymptotic distribution, we may have
Pr(uPLR > x)≫ Pr(X > x) when τ ≈ 1 (see appendix C, sections C.3.2, C.3.3). In the full
model, the marginal distribution of Za has more degrees of freedom (four; π1, π2, σ2, σ3) than
it does under the null model (two; π2, σ2; as σ3 ≡ 1). This can mean that certain distributions
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of Za can drive high values of uPLR independent of the values of Zd (appendix C, figure C.4,
section C.4), which is unwanted as the values Za reflect only case/control association and
carry no information about case subgroups. If observed uPLRs from random subgroups (for
which τ = 1 by definition) are used to approximate the null uPLR distribution, and a specific
uPLR value compared against this approximated null, there would be minimal power when
τ ≫ 1.
This effect can be managed by subtracting a correcting factor based on the pseudo-
likelihood of Za alone, which reflects the contribution of Za values to the uPLR. We define
PLa(Za|Θ) = ∏
Z(i)a ∈Za
(
π1N0,1(Z
(i)
a )+π2N0,σ22 (Z
(i)
a )+π3N0,σ23 (Z
(i)
a )
)
(5.7)
that is, the marginal likelihood of Za. Given θ̂1, θ̂0 as defined above, we define
f (Za|θˆ1, θˆ0) = min
(
log
PLa(Za|θ̂1)
PLa(Za|θ̂0)
,0
)
(5.8)
We now define the PLR as
PLR = uPLR− f (Za|θˆ1, θˆ0) (5.9)
Estimates πˆ2 and σˆ2 of π2 and σ2 under H0 can be made by fitting a bivariate distribution to
the marginal observed distribution of Za (see section 5.4.4). Given these estimates, I define
the similar test statistic cPLR
cPL(Zd|Za,θ) = PLda(Za,Zd|θ)PLa(Za|θ)
θ̂ c1 = arg maxθ∈H1|π2=πˆ2,σ2=σˆ2 cPL(Zd|Za,θ)
θ̂ c0 = arg maxΘ∈H0|π2=πˆ2,σ2=σˆ2 cPL(Zd|Za,θ)
cPLR = log
(
cPL(Zd|Za, θ̂ c1)
cPL(Zd|Za, θ̂ c0)
)
(5.10)
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noting that the expression PLda(Za,Zd |θ)PLa(Za|θ) can be considered as a likelihood conditioned on the
observed values of Za. Now
PLR = log
(
PLda(Zd,Za|θ̂1)
PLda(Zd,Za|θ̂0)
)
− log
(
PLa(Za|θ̂1)
PLa(Zd|θ̂0)
)
= log
(
cPL(Zd|Za, θ̂1)
cPL(Zd|Za, θ̂0)
)
(5.11)
The empirical distribution of cPLR has approximately the same form when τ = 1 or when
τ≫ 1 (appendix C, section C.4). The distribution is asymptotically the same as the empirical
distribution of PLR when τ ≫ 1. However, when τ ≈ 1 (ie, for random subgroups), cPLR
values are generally larger than PLR values (appendix C, section C.4), so in general Pr(PLR>
x) < Pr(cPLR > x). For an observed PLR value X , the approximate p-value Pr(cPLR >
X |H0) is thus a conservative estimate (overestimate) of Pr(PLR > X |H0). From the above,
however, the approximate p-value Pr(cPLR > X |H0) is more powerful than testing X against
the observed distribution of PLR for random subgroups.
5.4.3 Allowance for linkage disequilibrium
The asymptotic approximation of the pseudo likelihood-ratio distribution breaks down when
values of Za, Zd are correlated due to LD. One way to overcome this is to ‘prune’ SNPs by
hiererarchical clustering until only those with negligible correlation remain. A disadvantage
with this approach is that it is difficult to control which SNPs are retained in an unbiased
way without risking removal of SNPs which contribute greatly to the difference between
subgroups.
I opted to use the LDAK algorithm [Speed et al., 2012], which assigns weights to SNPs
approximately corresponding to their ‘unique’ contribution. Denoting by ρi j the correlation
between SNPs i, j, and d(i, j) their chromosomal distance, the weights wi are computed so
that
wi+∑
i̸= j
w jρ2i je
−λd(i, j) (5.12)
is close to constant for all i, and wi > 0 for all i. The motivation for this approach is that
∑
i̸= j
ρ2i j represents the replication of the signal of SNP i from all other SNPs.
This approach has the advantage that if n SNPs are in perfect LD, and not in LD with any
other SNPs, each will be weighted 1/n, reducing the overall contribution to the likelihood to
that of one SNP. In practice, the linear programming approach results in many SNP weights
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being 0. Using the LDAK algorithm therefore allows more SNPs to be retained and contribute
to the model than would be retained in a pruning approach.
A second advantage of LDAK is that it homogenises the contribution of each genome
region to the overall pseudo-likelihood. Many modern microarrays fine-map areas of the
genome known or suspected to be associated with traits of interest [Cortes and Brown, 2011]
which could theoretically lead to peaks in the distribution of SNP effect sizes, disrupting the
assumption of normality. LD pruning and LDAK both reduce this effect by homogenising
the number of tags in each genomic region.
I adapted the pseudo-likelihood function to the weights by multiplying the contribution
of each SNP to the log-likelihood by its weight (equation 5.4.2), essentially counting the
ith SNP wi times over. Adjusting using LDAK was effective in enabling the distributions
of PLR to be well-approximated by mixture-χ2 distributions of the form 5.2 (appendix D.2,
figures D.5a, D.5b and D.5c).
5.4.4 E-M algorithm to estimate model parameters
I use an expectation-maximisation algorithm [Dempster et al., 1977, Hastie et al., 2001] to fit
maximum-PL parameters. Given an initial estimate of parametersΘ0 =(π01 ,π
0
2 ,τ
0,σ02 ,σ
0
2 ,ρ
0)
I iterate three main steps:
1. Define for SNP s with Z scores Z(s)d ,Z
(s)
a
ζ (s)g = Pr(s ∈ category g|Θi)
∝

π i1N(1 0
0 1
)(Z(s)d ,Z(s)a ) (g = 1)
π i2N(1 0
0 (σ i2)
2
)(Z(s)d ,Z(s)a ) (g = 2)
π i3
1
2N
(
(τ i)2 ρ i
ρ i (σ i3)
2
)(Z(s)d ,Z(s)a )+ 12N((τ i)2 −ρ i
−ρ i (σ i3)2
)(Z(s)d ,Z(s)a )
 (g = 3)
(5.13)
2. For g ∈ (1,2,3) and LDAK weight ws for SNP s set
π i+1g =
∑wsζ
(s)
g +C
∑ws+3C
(5.14)
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3. Set
(τ i+1,σ i+12 ,σ
i+1
3 ,ρ
i+1) = arg max(τ,σ2,σ3,ρ)PL(Zd,Za|π i+11 ,π i+12 ,τ,σ2,σ3,ρ)
(5.15)
Step 3 is complicated by the lack of closed form expression for the maximum likelihood
estimator of ρ (because of the symmetric two-Gaussian distribution of category 3), requiring
a bisection method for computation. The algorithm is continued until |PLR(Zd,Za|Θi)−
PLR(Zd,Za|Θi−1)|< ε; I used ε = 1×10−5.
The algorithm can converge to local rather than global minima of the likelihood. I
overcome this by initially computing the pseudo-likelihood of the data at 1000 points
throughout the parameter space, retaining the top 100, and dividing these into 5 maximally-
separated clusters. The full algorithm is then run on the best (highest-PL) point in each
cluster
An appropriate choice of Θ0 can speed up the algorithm considerably; for simulations, I
begin the algorithm at previous maximum-PL estimates of parameters for earlier simulations.
Maximum-cPL estimations of parameters were made using generic numerical optimisa-
tion with the optim function in R. Prior to applying the algorithm, parameters π2 and σ2 are
estimated as maximum-PL estimators of the objective function
g(Za|π2,σ2) =∑wilog{(1−π2)N0,1(Z(i)a )+π2N0,σ22 Z
(i)
a } (5.16)
where wi is the weight for SNP i (see appendix C, section C.4 for rationale). The conditional
pseudo-likelihood (cPL) was maximised over the remaining parameters.
The algorithm and other processing functions are implemented in an R package available
at https://github.com/jamesliley/subtest
5.4.5 Properties and assumptions of the PLR test
My assumption that (Za,Zd) follows a mixture Gaussian is generally reasonable for complex
phenotypes with a large number of associated variants [Lo et al., 2015] and the adjustment
for the distribution of Za (essentially conditioning on observed Za) reduces reliance on this
assumption. If subgroup prevalence is unequal between the study group and population, my
method can still be used with adaptation (appendix C, section C.2.4).
The test is robust to confounders arising from differential sampling to the same extent as
conventional GWAS. For example, if subgroups were defined based on population structure,
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and population structure also varied between the case and control group, SNPs which differed
by ancestry would also appear associated with the disease, leading to a loss of control of
type-1 error rate. However, the same study design would also lead to identification of spurious
association of ancestry-associated SNPs with the phenotype in a conventional GWAS analysis.
As for GWAS, this effect can be alleviated by including the confounding trait as a covariate
when computing p-values (appendix C, section C.2).
5.4.6 Prioritisation of single SNPs
An important secondary problem to testing H0 is the determination of which SNPs are likely
to be associated with disease heterogeneity. I sought a way to test the association of a SNP
with subgroup status (ie, Zd), which gives greater priority to SNPs potentially associated
with case/control status (ie, high Za).
An effective test statistic meeting these requirements is the Bayesian conditional false
discovery rate (cFDR) [Andreassen et al., 2013] (see chapters 2, 3). In this context, the cFDR
is used to test against the null hypothesis H ′0 that the population minor allele frequencies of
the SNP in both case subgroups are equal (ie, that the SNP does not differentiate subgroups),
responding to association with case/control status in a natural way by relaxing the effective
significance threshold on |Zd|. As discussed in chapter 2, this relaxation of threshold only
occurs if there is systematic evidence that high |Zd| scores and high |Za| scores typically
co-occur. The cFDR is direction-independent, only considering p-values.
Given a set of observed Za and Zd values Z
(i)
a , Z
(i)
d , with corresponding two-sided p values
pai, pdi, the cFDR for SNP j is defined as
X4 = pd j
∣∣{i : pai ≤ pa j∧ pdi ≤ pd j}∣∣∣∣{i : pdi ≤ pd j}∣∣ (5.17)
≈ Pr(H ′0
∣∣Pa ≤ pa j,Pd ≤ pd j)
A false-discovery rate bound can be estimated on such SNPs as per chapter 2.
I discuss three other single-SNP test statistics in appendix C, section C.6.1, which test
against different null hypotheses. If the hypothesis H ′0 is to be tested, then I consider the
cFDR the best of these.
Contour plots of the test statistics for several datasets are shown in appendix D.2, fig-
ures D.8, D.9 and D.10.
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5.4.7 Genetic correlation testing
Given the correlation between Zd and Za in the age-at-diagnosis analysis, methods to estimate
narrow-sense genetic correlation (rg) [Bulik-Sullivan et al., 2015, Lee et al., 2012] may
be adaptable to the subgrouping question by estimating rg across a set of SNPs between
case/control traits of interest, with the potential advantage of characterising heterogeneity
using a single widely-interpretable metric. This may be between Z scores derived from
comparing the control group to each case subgroup, testing under the null hypothesis rg = 1
(method 1); or between the familiar Za and Zd , under the null hypothesis rg = 0 (method 2).
I explored these methods in appendix C, section C.5. I show that method 1 leads to
systematically high false positive rates, as rg is also reduced from 1 in subgroupings that are
independent of the overall disease process (e.g. hair colour in T2D). I show that method 2 is
considerably less powerful than my method because it tests a narrower definition of H1 which
does not take account of the marginal variances of the distribution of Zd , Za in category 3,
and requires that correlation between Zd and Za be always positive or always negative, in
contrast to my symmetric model (Figure 5.1). Indeed, parameter ρ estimates an analogue of
rg accounting for simultaneous correlation and anticorrelation.
Methods to compute rg were not explicitly proposed as methods for subgroup testing, and
my analysis does not indicate any general shortcomings. However, comparison with rg based
approaches places my method in the context of established methodology, demonstrating the
necessity of considering both variance parameters (τ , σ3) and covariance parameters (ρ) in
testing a subgrouping of interest.
5.4.8 Description of GWAS datasets
ATD samples were genotyped on the ImmunoChip [Cortes and Brown, 2011] a custom
array targeting putative autoimmune-associated regions. Data were collected for GWAS-like
analyses of dense SNP data [Cooper et al., 2012]. The dataset comprised 2282 cases of
Graves’ disease, 451 cases of Hashimoto’s thyroiditis, and 9365 controls.
T1D samples were genotyped on either the Illumina 550K or Affymetrix 500K platforms,
gathered for a GWAS on T1D [Barrett et al., 2009]. I imputed between platforms in the same
way as the original GWAS. The dataset comprised genotypes from 5908 T1D cases and 8825
controls, of which all had measured values of TPO-Ab, 3197 had measured IA2-Ab, 3208 had
measured GAD-Ab, and 2240 had measured PCA-Ab. Comparisons for each autoantibody
were made between cases positive for that autoantibody, and cases not positive for it. I did
not attempt to perform comparisons of individuals positive for different autoantibodies (for
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instance, TPO-Ab positive vs IA2-Ab positive) because many individuals were positive for
both.
To generate summary statistics corresponding to geographic subgroups, I considered the
subgroup of cases from each of twelve regions and each pair of regions against all other cases
(78 subgroupings in total). To maximise sample sizes, I considered T1D cases as ‘controls’
and split the control group into subgroups.
5.4.9 Quality control
Particular care had to be taken with quality control, as Z-scores had to be relatively reliable for
all SNPs assessed, rather than just those putatively reaching genome-wide significance. For
the T1D/T2D/RA comparison, which I re-used from the WTCCC, a critical part of the original
quality control procedure was visual analysis of cluster plots for SNPs reaching significance,
and systematic quality control measures based on differential call rates and deviance from
Hardy-Weinberg equilibrium (HWE) were correspondingly loose [The Wellcome Trust Case
Control Consortium, 2007]. Given that we were not searching for individual SNPs, this was
clearly not appropriate for my method.
I retained the original call rate (CR) and MAF thresholds (MAF ≥ 1%, CR ≥ 95% if
MAF ≥ 5%, CR ≥ 99% if MAF <5%) but employed a stricter control on Hardy-Weinberg
equilibrium, requiring p ≥ 1× 10−5 for deviation from HWE in controls. I also required
that deviance from HWE in cases satisfied p≥ 1.91×10−7, corresponding to |z| ≤ 5. The
looser threshold for HWE in cases was chosen because deviance from HWE can arise due
to true SNP effects [Anderson et al., 2010]. I also required that call rate difference not be
significant (p ≥ 1× 10−5) between any two groups, included case-case and case-control
differences. Geographic data was collected by the WTCCC and consisted of assignment
of samples to one of twelve geographic regions (Scotland, Northern, Northwestern, East
and West Ridings, North Midlands, Midlands, Wales, Eastern, Southern, Southeastern, and
London [The Wellcome Trust Case Control Consortium, 2007]). In analysing differences
between autoimmune diseases, I stratified by geographic location; when assessing subgroups
based on geographic location, i did not.
For the ATD and T1D data, I used identical quality control procedures to those em-
ployed in the original paper [Cooper et al., 2012, Barrett et al., 2009]. I applied genomic
control [Devlin et al., 2001] to computation of Za and Zd scores except for the analysis of
ATD (following the original authors [Cooper et al., 2012]) and the geographic analyses (as
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discussed above). In all analyses except where otherwise indicated I removed the MHC
region with a wide margin (≈ 5Mb either side).
5.5 Addendum: alternative methods for testing
5.5.1 Introduction
A major shortcoming of the PLR method is its complexity, in regard to both the number
of steps involved in using the method, and the computational resources required. The
determination of whether the joint distribution of (Zd,Za) contains a component with both
marginal variances > 1 appears relatively simple, to the point where it appears to be testable
more simply. The main text in this chapter and appendix C discuss the advantages and
shortcomings of using genetic correlation in several ways as a substitute for the PLR. In this
addendum, I discuss several other alternatives to testing the main hypothesis, and propose a
custom test statistic which may be more effective. This section is a description of a promising
new direction for future investigation rather than a description of completed work.
A generalised version of the null hypothesis HG0 to be tested against is as follows:
HG0 : PDFZd ,Za(x,y) = π1NI2(x,y)
+π2N1(x)F(y)
+π3N1(y)G(x) (5.18)
where F and G are univariate density functions which may have variance > 1, and π1 +
π2 + π3 = 1. In general, F and G are considered to be continuous, bounded and strictly
positive in R. The three components correspond to the three categories used throughout the
chapter. Notably, Zd and Za are conditionally independent given the category. Denote by
HG0 (π1), H
G
0 (π1,F), H
G
0 (π1 = x), H
G
0 (F = f (x))... the subspaces of H
G
0 with the appropriate
parameters fixed, taking the specified values if given.
The possibility of attempting to reject HG0 (or more specific null hypotheses) by consid-
ering correlation between Za and Zd is discussed at length in section 5.4.7. The problems
with using standard correlation or ‘absolute correlation’ are summarised in table D.1 in
appendix D.1.
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Linear functions of genotypes (genetic risk scores) can not generally reject HG0
Another potential approach to rejecting HG0 is to use genetic risk scores (GRS). If a predictive
score were developed to differentiate cases from controls, HG0 could be tested by assessing
the degree to which the score can differentiate the disease subgroups. A similar approach is
used in chapter 6 in understanding the subtypes of JIA.
While effective in some circumstances, GRS are also unsuitable for the problem in many
cases. Consider an generalised GRS to predict a genotype Y which for sample i takes the
form
GRS(i) = ∑
j∈SNPs
β jgi j (5.19)
where gi j ∈ G j ∈ G is the genotype for sample i, SNP j, and β j = f j(G,Y ) is a function
dependent on all genotypes and all case/control labels, but independent of subtype labels.
Denote the case group by C12. Suppose that the disease consists of two subtypes S1 and
S2 of equal prevalence, where subgroups have completely distinct genetic associations (this
scenario is in H1), but for which the distribution of effect sizes is the same. For a SNP s1
associated with S1 and a SNP s2 associated with S2 of the same MAF and effect size, the
coefficients β j in the GRS (equation 5.19) will have the same expected value, and indeed the
same distribution.
Since the subgroups are of equal prevalence and have the same effect size distribution, a
set of observed genotypes G′ with subtype labels Z′ has the same likelihood as the same set
G′ with subtype labels swapped. Thus, if the GRS in equation 5.19 is used to differentiate
subgroups of C12 corresponding to S1 and S2, and the difference in mean GRS score is
∆G(S1,S2) =
1
|{i ∈ S2}|∑GRS(i|i ∈ S2)−
1
|{i ∈ S1}|∑GRS(i|i ∈ S1) (5.20)
then
E (∆G(S1,S2)) = E (∆G(S2,S1))
=−E (∆G(S1,S2))
= 0 (5.21)
so the GRS will not be able to differentiate subgroups in this case. A criterion based on
whether GRS fitted to case/control status can differentiate subgroups forms a sufficient but
not necessary condition for falsehood of HG0 .
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5.5.2 Custom statistic
The main difficulty in finding a test statistic for rejecting HG0 above is determining a function
that has an estimable distribution and expected value under HG0 but whose behaviour changes
under the H1 scenarios in table D.1. Effectively, SNPs should contribute more to the test
statistic if both |Zd| and |Za| are large. A SNP with low |Zd| is of relatively little help in
rejecting H0, whatever its value of Za.
An ideal metric k(Zd,Za) to identify such pairs of (Zd,Za) scores should thus increase as
both Zd and Za increase, but have a limiting maximum value as Za → ∞ with Zd fixed. The
metric k(Zd,Za) = min(|Zd|, |Za|) is one choice, but it is too extreme; there should be some
variance in the ‘interest’ in a (Zd,Za) score with Za when |Za| ≫ |Zd|. On the X-Y plane,
k(x,y) should have contours roughly resembling plots of the function:
(x2− k)(y2− k) = a2 (5.22)
with a held constant, and k varying (shown in figure 5.6.
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Fig. 5.6 Plot of implicitly defined curves (x2− k)(y2− k) = a2 for different values of k
(shown as contour labels and colours, with blue and yellow indicating negative and positive
values of k respectively). While potentially useful as a metric for ‘interest’ in a (Zd,Za) pair
in the subgroup context, a problem is the variable behaviour when Zd = 0 or Za = 0.
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This immediately suggests the metric
k(x,y) = x2+ y2−
√
(x2− y2)2+(2a)2 (5.23)
A problem with this metric is that it is negative at and around the origin, but tends to 0 as
Zd → ∞,Za = 0 and as Za → ∞, Zd = 0. This is a problem, as (Zd,Za) pairs with one value
zero are equally (un)interesting everywhere in this context. I thus propose the non-negative
function k(x,y) parametrised by a (in the place of (2a) above) as
k(x,y) =
√
x4+a2+
√
y4+a2−
√
(x2− y2)2+a2−a (5.24)
Defining Z( j)d , Z
( j)
a as the Zd and Za scores at a SNP j, a potential test statistic K for the
subgrouping problem is then defined as a function of the sets of values {Z( j)d } and {Z( j)a }
K({Z( j)d },{Z( j)a }) =
∑w jk(Z
( j)
d ,Z
( j)
a )
γ
∑w j
(5.25)
where the sum is over all SNPs j. Weights w j may be derived from LDAK or similar
procedures. The parameter a effectively controls how curved the contours of k are near the
origin (see figure 5.7) and the parameter γ controls the degree to which individual variants
contribute to the test statistic, and the parameter a . A contour plot of k(Zd,Za) is shown in
figure 5.7.
The function k has many of the desired properties of a metric for ‘interest’ in (Zd,Za)
pairs. Firstly, since with x fixed,
lim
y→∞
(√
y4+a2−
√
(x2− y2)2+a2
)
= x2 (5.26)
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Fig. 5.7 Contour plot of alternative metric k for subgrouping problem, with an example
distribution of Zd , Za in H0. Contours of k(Zd,Za) (with a = 2) are shown in purple, with an
example of a Zd , Za in HG0 shown in grey, red and blue corresponding to categories 1, 2 and
3. The new test statistic differentiates points for which both Zd and Za differ substantially
from 0.
If HG0 is restricted to well-behaved instances where Zd|Za = y,HG0 converges surely to N(0,1)
as y→ ∞ (equation 5.18), we have
lim
y→∞E
{
k(Zd,Za)|Za = y,HG0
}
= E
{√
Z4d +a
2|HG0
}
+ lim
y→∞E
{√
y4+a2−
√(
Z2d − y2
)2
+a2−a|HG0
}
= E
{√
Z4d +a
2|HG0
}
+E
{
Z2d |HG0
}
−a
< ∞ (5.27)
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and indeed, the random variable k(Zd,Za)|Za = y,HG0 converges surely as y → ∞ (with
appropriate conditions on F , G in equation 5.18) to a random variable ψa:
ψa =
√
X4+a2+X2−a; X ∼ N(0,1) (5.28)
For y > 0
δ
δy
k(x,y) =
2y3√
y4+a2
+
2y(x2− y2)√
(x2− y2)2+a2
> 0 (5.29)
so the value of k(x,y) increases as y increases with fixed x. Hence for y1 > y2 > 0 we have
1k(x,y1)>k0 < 1k(x,y2)>k0 . Denote H
′
0 = H
G
0 (π1,π2,F,G) and fZd(x) the PDF of Zd under H
′
0.
Now
Pr(k(Zd,Za)> k0|Za = z0,H ′0) =
∫
R
1k(x,y1)>k0 fZd(x)dx
< lim
y→∞
∫
R
1k(x,y)>k0 fZd(x)dx
= lim
y→∞Pr(k(Zd,Za)> k0|Za = y,H
′
0)
= Pr(ψa > k0) (5.30)
Since this is independent of fZd , the same holds replacing H
′
0 with H
G
0 . The same also holds
with Zd and Za interchanged.
Define random variables ψa as above and Ψa:
Ψa = k(X ,Y );
(
X
Y
)
∼ N
((
0
0
)
,
(
1 0
0 1
))
(5.31)
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If ψa =
√
X4+a2+X2−a = k0 then X =±
√
k(2a+k)
2(a+k) . The region {(x,y) : k(x,y)≤ k0} is
thus contained within the region {(x,y) : |x| ≥
√
k(2a+k)
2(a+k) , |y| ≥
√
k(2a+k)
2(a+k) } and for all k0
Pr(Ψa > k0)< (Pr(ψa > k0))2
= 4Φ
(
−
√
k(2a+ k)
2(a+ k)
)2
< 2Φ
(
−
√
k(2a+ k)
2(a+ k)
)
(5.32)
PDFs and CDFs for ψa and Ψa are shown in figure 5.8. For a specific instance H ′0 =
0 1 2 3 4 5
0.
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Fig. 5.8 CDFs and PDFs for random variables ψa and Ψa. CDF plot additionally shows
1−Pr(ψa > x)2 which is strictly less than Pr(Ψa < x).
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H0(π1,π2,F,G) of H0 with π1,π2,F,G fixed,
Pr(k > k0|H ′0) =
∫∫
R2
1k(x,y)>k0PDF(Zd,Za)(x,y)dxdy
= π1
∫∫
R2
1k(x,y)>k0NI2(x,y)dxdy
+π2
∫∫
R2
1k(x,y)>k0N1(x)F(y)dxdy
+π3
∫∫
R2
1k(x,y)>k0N1(y)G(x)dxdy
< π1Pr(Ψa > k0)+(π2+π3)Pr(ψa > k0) (5.33)
< 4π1Φ
(
−
√
k(2a+ k)
2(a+ k)
)2
+2(1−π1)Φ
(
−
√
k(2a+ k)
2(a+ k)
)
< 2Φ
(
−
√
k(2a+ k)
2(a+ k)
)
(5.34)
The bound 5.34 does not depend on π1,π2,F,G and hence the bound holds when H ′0 is
replaced by H0. The bound 5.33 only depends on π1, and hence H ′0 may be replaced by
HG0 (π1). The distributions of ψa and Ψa are empirically tractable, enabling construction of
a rough bound on a p-value associated with K under HG0 or H
G
0 (π1) using the central limit
theorem.
Distribution of new test statistic under H0
The bound introduced in equation 5.34 is not very useful in practice, as it is usually sufficient
to reject weaker forms of HG0 . It is generally reasonable to make some assumptions on the
values π1,π2,F,G can take; this is effectively the approach taken with the PLR, in which the
null hypothesis has specified parameters (π1,π2,π3,τ,σ1,σ2 = 1,ρ = 0). Given an estimator
πˆ1 of π1, then bound 5.33 with πˆ1 in place of π1 can be used to accept or the null hypothesis
HG0 (π1 = πˆ1). Since for any π
′
1 < πˆ1 we have
Pr
(
k > k0|HG0 (π1 = π ′1)
)
< Pr
(
k > k0|HG0 (π1 = πˆ1)
)
(5.35)
a test against the null hypothesis HG0 (π1 = πˆ1) is conservative against H
G
0 (π1 = π
′
1) in that
the true p-value is necessarily lower. Thus for a conservative test, the value for πˆ1 should be
an upper bound on the true value.
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Further improvements to the test can be made if estimates are made of the distributions F
and G. Importantly, the estimation of these distributions only requires a one-dimensional
model; under H0, the marginals PDFs of Zd and Za are
PDFZd(x) = (π1+π2)N1(x)+π3G(x)
PDFZa(x) = (π1+π3)N1(x)+π2F(x)
(5.36)
suggesting the following procedure:
1. Estimates πˆ3 and Gˆ of π3 and (parameters of) G are made from observed values of Zd
2. Estimates πˆ2 and Fˆ of π2 and (parameters of) F are made from observed values of Za
3. The CDF of K under the Hs0 = H0(π1 = πˆ1,π2 = πˆ2,π3 = πˆ3,F = Fˆ ,G = Gˆ) is com-
puted, generally empirically
4. An observed value of K corresponding to a subtyping of interest is tested for consistency
with Hs0 by comparison to this empirical CDF
This procedure is a promising avenue for future work on this test statistic, but was not
investigated in this instance.
5.5.3 Comparison of power of new method and PLR
Application to autoimmune datasets
I tested whether the new method could reject HG0 or H
G
0 (π1 = πˆ1) on the autoimmune datasets
used to test the PLR in section 5.2.3 (considering each pair of phenotypes in (T1D,T2D,RA)
as subtypes of a wider autoimmune phenotype). These results should be interpreted cautiously
in the absence of simulations to check for appropriate type-1 error rate control.
Firstly, I computed the value of K for each set of Zd and Za scores as per equation 5.25,
using LDAK weights, considering values of γ in (1,2,4). I then considered two different
models for the distribution of k(Zd,Za) under H0, as follows:
1. k(Zd,Za)|HG0 ∼ ψa (bound 5.34)
2. k(Zd,Za)|HG0 (π1 = πˆ1)∼
ψa prob. 1−π1Ψa prob. π1 (bound 5.33)
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In model 2, the value πˆ1 was estimated from the observed distribution of Zd , Za using steps 1
and 2 and setting πˆ1 = 1− πˆ2− πˆ3.
The null hypothesis HG0 could not be rejected in any case using model 1 (p > 0.5 in all
cases). Confidence in rejecting HG0 (π1) using model 2 varied according to γ , with p-values
shown in table 5.3. Performance was markedly strongest at γ = 4.
Table 5.3 P-values for rejection of HG0 (π1) using new test statistic on datasets for T1D/RA,
T1D/T2D, T2D/RA, and GD/HT. See table 5.2 for comparison.
Subgroups γ = 1 γ = 2 γ = 4
T1D/RA > 0.5 0.34 2×10−3
T1D/T2D > 0.5 7×10−4 < 1×10−4
T2D/RA > 0.5 2×10−3 < 1×10−4
Simulations
In order to establish a comparison of the potential power of the new statistic with the power
of the PLR method, I re-simulated and re-tested the scenarios discussed in the main paper. In
each case, these reflect the power of the new statistic to reject HG0 (π1,π2,F,G) rather than
HG0 , where F and G are normal distributions with mean 0. In this sense, the power in these
simulations represents the ‘optimal’ power of the new test statistic.
For each set of parameters (π1,π2,π3,τ,σ1,σ2,ρ) I simulated 5000 sets of Zd and Za
scores under the full model and the null model (with σ2 replaced by 1 and ρ by 0). I then
estimated the power of the new test to reject the null hypothesis at α = 0.05 by computing
the proportion of simulations from the full model for which the associated test statistic K
passed the 95% quantile of test statistics K from simulations from the null model. For these
simulations, I used γ = 1; brief analyses suggested similar behaviour when γ was set to 2 or
4.
A plot of power in the same circumstances as for the PLR is shown in figure 5.9, and more
extensive plots (again in the same circumstances as for PLR) are shown in appendix D.2,
figures D.4.
Figure 5.10 compares power between the PLR and new method at all points of the space
H1 considered in appendix D.2, figures D.4. In general, the PLR tends to be more powerful,
although not in all circumstances. The greatest difference in power in favour of K over PLR
is in cases where π3 is high and τ is low, corresponding to a subgrouping trait which is
highly polygenic but with small effect sizes. In general, the power of K is sufficient that it
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appears usable as a test statistic, with the advantage of being far simpler than the PLR though
typically with somewhat lower power.
5.5.4 Discussion
The major areas for further work on this statistic are determination of an appropriate null
hypothesis and development of methods to estimate the distribution of K under this null,
whether by simulation or analytically. The null hypothesis proposed in equation 5.18 is too
broad to realistically use in practice. Other areas for consideration are the choice of value for
the parameters a and γ , and the management of situations where Zd , Za are systematically
correlated (for example, see appendix C, section C.2.4).
The major reason why the PLR-testing procedure is so complex is the difficulty in
effectively simulating under H0 by permutation testing or otherwise. Namely, it is relatively
easy to simulate with τ = 1, but very difficult to simulate with τ > 1. It may be possible to
avoid the need for permutation testing using the new method, but this needs to be tested more
extensively.
The new test statistic is often less powerful than the PLR, but not universally, and it
may be well-suited to assessing classes of phenotypes for which the genetic architecture
of the subgrouping trait involves many small effects. One example may be analysis of
subgroups corresponding to geography [Leslie et al., 2015]. Overall, the new statistic appears
to be a reasonable alternative option to testing in the subgrouping problem, which has the
advantage of being considerably simpler than the PLR. It may serve as a useful indicator for
certain types of disease heterogeneity, and contribute to the understanding of inter-phenotypic
genetic relationships.
5.5 Addendum: alternative methods for testing 137
N = 100 (pi3 = 0.002)
Underlying τ
Un
de
rly
in
g 
σ
3
ρ/(σ3τ)
1.
9
3.
7
1.6 1.9
0 0.
5
13 14
30 29
19 19
50 51
N = 500 (pi3 = 0.01)
Underlying τ
ρ/(σ3τ)
1.
9
3.
7
1.6 1.9
0 0.
5
76 79
91 91
89 89
91 91
Fig. 5.9 Power of new test statistic K depends on the number of SNPs in category 3 and the
underlying values of model parameters σ2, σ3, τ , ρ . Dependence on number of case/control
samples arises through the magnitudes of σ3 and τ (appendix C, section C.4.3). Figure shows
power estimates for various values of π3, σ3, τ , ρ . Value N is the approximate number of
SNPs in category 3, (∝ π3). Each simulation was on 5×104 simulated autosomal SNPs in
linkage equilibrium. Value ρ/(σ3τ) is the absolute correlation between Zd and Za in category
3. Also see appendix D.2, figure D.4.
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Fig. 5.10 Comparison of power of PLR and power of new test statistic K to reject
HG0 (π1,π2,F,G) at α = 0.05. Lines are drawn from each point to the x-y line to indi-
cate deviation from equal power. In general, the PLR method is more powerful, but this is
not universal.
Chapter 6
Levering phenotypes for risk prediction
6.1 Introduction
Following chapter 3, Juvenile Idiopathic Arthritis (JIA) is a clinically-diagnosed disease
characterised by a persistent arthritis in children in the absence of other known causes.
As a ‘diagnosis of exclusion’, JIA encompasses all childhood arthritis of unknown cause
and is therefore probably caused by a range of pathological processes. The standard clin-
ical sub-classification of JIA was proposed by the International League of Associations
for Rheumatology (ILAR) [Petty et al., 2004] with the understanding that subtype defini-
tions and sub-classifications would evolve as further information on the disease became
available [Ravelli and Martini, 2007].
The ILAR subtypes are based on the number of joints affected (oligoarthritis: ≤ 4; pol-
yarthritis: > 4), seropositivity to rheumatoid factor (RF), and the presence of extra-articular
symptomatology (systemic (Still’s disease), enthesitis-related, and psoriatic arthritis) [Rav-
elli and Martini, 2007], with a proportion of cases remaining undifferentiated. Population
frequencies of each subtype within JIA as a whole are shown in table 6.1. The oligoarthritis
Table 6.1 Prevalence of subtypes of JIA. Reproduced from [Ravelli and Martini, 2007]
Subtype Abbreviation Frequency (%)
Systemic arthritis Sys 4–17
Oligoarthritis EO/PO 27–56
RF-positive polyarthritis RF+poly 2–7
RF-negative polyarthritis RF-poly 11–28
Enthesitis-related arthritis ERA 3–11
Psoriatic arthritis PSA 2–11
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subtype can be further sub-categorised into ‘extended’ (EO) and ‘persistent’ (PO) subtypes
based on whether the patient remains in an oligoarthritic state or the disease progresses to
polyarthritis [Gardner-Medwin et al., 2006], an assessment which can obviously not be made
at the time of initial diagnosis of the disease.
Due the heterogeneity and relative commonality of JIA, the overall genetic architecture
would be expected to be polygenic; this is supported by GWAS/ImmunoChip findings [Hinks
et al., 2013] showing a widespread distribution of associations across the genome (also
see chapter 3). An important consideration in the genetic analysis of JIA is the individual
genetic architectures of each subtype. There may be genetic heterogeneity amongst patients
with different JIA subtypes in that the individual genetic architectures may be distinct to
the genetic architecture of JIA as a whole; indeed, this may be expected given the clinical
heterogeneity. More generally, subtype status may be driven by different pathological
processes, be driven by individual anatomical or physiological variation, or be driven by
environmental differences (see chapter 5 and table D.1 in appendix D.1), with the first two
phenomena being of particular scientific interest.
The systemic subtype of JIA (Sys) appears to have a genetic architecture largely distinct
from that of other subtypes. In an international GWAS of 770 children with Sys JIA [Ombrello
et al., 2017], genetic risk scores (GRS) trained to non-systemic JIA could not predict Sys
cases from controls, and a GRS trained to the RF-positive polyarthritis found Sys samples to
be significantly differentiated from control samples in the opposite direction to RF-positive
polyarthritis samples. The differential genetic architectures highlight the difficulties in
analysing diseases with subtypes of this sort, in that the analysis of systemic JIA is unlikely
to be strengthened by levering on general JIA vs control datasets. It is likely that further
genetic heterogeneity is present between JIA subtypes, although this is difficult to determine
using genome-wide significant SNPs only [Hinks et al., 2013]. Understanding the genetic
heterogeneity of JIA subtypes may be useful both in the development of specific treatment
and in direct clinical management, and could be used to inform more clinically-useful
sub-classifications of the disease in the future [Petty et al., 2004, Ravelli and Martini, 2007].
In this chapter I seek to develop and apply methods for assessing genetic heterogeneity
in JIA. The number of JIA samples in total is small (< 3000) and each subtype is sufficiently
rare that it is difficult to study in isolation. Given the limited power of analyses on these
sample sizes, my analyses typically involve leverage on summary statistics from higher-
powered studies. An obvious candidate phenotype to lever on is the JIA/control phenotype, in
the manner of the single-SNP analysis in chapter 5, section 5.2.2. The results from systemic
JIA above suggest that this will not be useful for understanding the basis of Sys, and this
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may also be the case for other subtypes. For this reason, I also lever on summary statistics
other genetically related autoimmune diseases.
The most obvious adult analogue of JIA is RA, with the polyarthritic subtypes of JIA
in particular sharing pathological characteristics of RA including symmetric distribution of
infected joints and elevation of rheumatoid factor [Gardner-Medwin et al., 2006, Ravelli and
Martini, 2007]. This suggests examination of the genetics of RA as a useful starting point for
determining differential genetics of JIA subtypes. A second candidate for a discriminating
GRS is T1D, which shows considerable pleiotropy with JIA as explored in chapter 3; indeed,
as discussed in section 3.2.1, among a range of autoimmune diseases, JIA is the most similar
disease to T1D on the basis of enrichment of summary statistics [Burren et al., 2014]1. I
sought to establish whether GRSs to predict disease/control status for RA and T1D could
differentiate JIA subtypes from controls to different degrees.
An example of particular importance is the prediction of extended/persistent oligoarthritis
state; children for whom extension of an existing oligoarthritis is unlikely could be treated
less aggressively than those for whom extension is probable. Resources spent in follow-up of
children with oligoarthritis could similarly be directed in a more efficient way.
In light of these clinical and scientific applications, this chapter has two main parts2 :
1. Assessment of whether EO and PO subtypes of JIA can be differentiated on the basis
of genetics, using GRS based on genotype data for EO/PO samples and other JIA
samples, and summary statistics for RA and T1D.
2. Assessment of the similarity of genetic architecture of JIA subtypes to the genetic
architecture of RA and T1D, using GRS based on genetic data from JIA and summary
statistics for RA and T1D.
1The similarity between JIA and T1D in the absence of obvious phenotypic overlap is indicative of some
uncertainty in predicting genetic overlap by phenotypic overlap, somewhat undermining the idea of levering on
phenotypically related phenotypes
2The sections are ordered to reflect the chronological order of this work. The primary aim of this exercise
was that in item 1 (discrimination of EO/PO), with item 2 (wider analysis of subtypes) as a later exploratory
analysis. I am aware that if the order of this work had been reversed; that is, if the specific analysis of EO/PO
differentiation had been incentivised by the results of the wider subtype analysis, then it would be necessary to
perform appropriate multiple-testing adjustments on the EO/PO analysis. However, this was not the case, and
multiple-testing adjustments are not used in item 1
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6.2 Common considerations
6.2.1 Notation
Throughout this chapter, subscript i will generally refer to samples and be assumed to run
from 1 to n unless otherwise specified. Subscript j will refer to variables/predictors and run
from 1 to p. Subscripts k,h will refer to cross-validation folds and run from 1 to the number
of folds. A set of values {X} will be assumed to take the form of a column vector when
appropriate.
6.2.2 Datasets
The JIA dataset consisted of 2585 JIA cases and 5181 controls from a range of recruitment
centres across the UK. The dataset was originally gathered for a GWAS on JIA, currently
in preparation. I was not involved in data gathering, sample recruitment or preparation, or
quality control procedures. The breakdown of JIA samples is shown in table 6.2. Specifically,
Table 6.2 Number of available cases in each JIA subtype
Subtype N cases Frequency (%)
Sys 283 10.9
EO 394 15.2
PO 650 25.1
RF+poly 199 7.7
RF-poly 573 22.2
ERA 185 7.2
PsA 150 5.8
Unclassified 86 3.3
Missing 65 2.5
Control 5833 -
the dataset included 1044 cases initially presenting with oligoarthritis, of which 650 (62%)
progressed to polyarthritis. Samples were genotyped on a range of platforms and imputed
to approximate genome-wide cover. SNPs were removed if they were multi-allelic, had
imputation r2 < 0.5, had minor allele frequency < 1%, or deviated from Hardy-Weinberg
equilibrium in controls with p-value < 1×10−3. Sample-wise quality control measures were
identical to those described in [Ombrello et al., 2017]. After quality control, 7292621 SNPs
(including imputed variants) were available for analysis.
Datasets used for leverage included summary statistics from GWAS on rheumatoid
arthritis [Okada et al., 2014] and type 1 diabetes [Barrett et al., 2009]. Summary statistics in
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all cases were the same as those reported in the final publications, following quality control
procedures as described therein. Since ‘cases’ and ‘controls’ both referred to JIA samples in
this case, there were no shared samples between the datasets used for leverage and the JIA
dataset used for GRS training.
6.2.3 Genetic risk scores
I briefly introduced the concept of genetic risk scores in chapter 1, section 1.3.5. In its
simplest form, a genetic risk score GRS for a sample i with numeric genotypes gi j at SNPs
j = 1..p is a linear sum:
GRS(i) =
p
∑
j=1
β jgi j (6.1)
GRS can be constructed in a variety of ways [Kooperberg et al., 2010] and have wide
application in medicine [Paynter et al., 2010, Yarwood et al., 2015, Abraham et al., 2014].
Given a standard (simplified) logistic regression model for genetic associations with a
phenotype Y ∈ {0,1}:
logit{Pr(Y = 1)}= γ0+
p
∑
i=1
γ jgi j (6.2)
where γ j is the log-odds ratio for the risk of Y given a genotype g· j, a natural set of candidate
for values of β j to predict a phenotype Y using a GRS of the form in equation 6.1 is β j ≈ γ j.
In this chapter, I use GRS firstly to differentiate two groups (the EO and PO subtypes of
clinical interest) and secondly to differentiate multiple categories (all subtypes).
Assessment of predictive accuracy of a GRS is simple if the values βi are fitted on a
dataset independent of the data on which the GRS is tested. Assessment is more difficult if
the data used for fitting the GRS overlap or coincide completely with the data used for testing
it. When this was necessary, I used various types of cross-validation. I introduce these as
they are used.
6.3 Prediction of extension in oligoarthritic JIA
6.3.1 Motivation
The general aim of this sub-project was to answer the following question:
Given an individual with newly-diagnosed oligoarthritic JIA, can GWAS data
from that individual (or a subset of SNPs derived from GWAS data) be used to
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predict, to better accuracy than a random predictor, whether they will progress
to polyarthritis?
The motivation for this question is largely clinical rather than scientific, in that a method
is sought for differentiation of patients without directly requiring understanding how it does
so. Specifically, only a risk score predictive of oligoarthritic extension is sought, rather than
explicit identification of EO/PO associated genetic variants. Although the score as a whole
may have reasonable predictive power, individual variants contributing to it may not, and
may not even be associated with EO/PO status - in the sense that the set of variants with
non-zero coefficients in the GRS may have a high FDR.
There is some evidence that extension of osteoarthritis may have some associations
with the phenotype at presentation. A retrospective study on 205 American children with
JIA found that extension was more likely in children with certain distributions of disease;
specifically, wrist or ankle involvement and a symmetric distribution of affected joints [Al-
Matar et al., 2002]. Another small study [Gardner-Medwin et al., 2006] suggested that
extended oligoarthritis may be characterised by a widespread inflammatory process to a
greater extent than persistent oligoarthritis. Evidence of anatomical or physiological variables
being predictive of oligoarthritis extension suggest at least some inherent physiological basis
to the EO/PO phenotype. If genetic predictors can be found which have independent effects
to clinical predictors, these could enable improved clinical predictability of the extension
phenotype.
6.3.2 General methods
Penalised regression
A useful set of tools in GRS are penalised regression methods [Tibshirani, 1996], which
can simultaneously perform variable selection and fitting, enable use of genomic data with
minimal need for an initial dimensionality reduction step. For a (normalised) set of n
observations (xi,yi), i ∈ 1..n, where each xi is a vector of p predictors xi j, j ∈ 1..p, the
standard ordinary linear model is
yi = xTi β + εi
εi ∼ N(0,σ2) (6.3)
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for which the best linear unbiased estimator for β is
βˆ = arg minβ∈Rp∑
i
(
yi− xTi β
)2
(6.4)
By contrast, penalised-regression estimators β include
arg minβ∈Rp
{
1
n∑i
(
yi− xTi β
)2
+λ∑
j
|β j|
}
L1-penalised, ‘Lasso’
arg minβ∈Rp
{
1
n∑i
(
yi− xTi β
)2
+λ∑
j
|β j|2
}
L2 - penalised, ‘Ridge’
arg minβ∈Rp
{
1
n∑i
(
yi− xTi β
)2
+λ1∑
j
|β j|+λ2∑
j
|β j|2
}
‘Elastic net’
where values λ/λ1,λ2 are typically chosen to minimise the cross-validated error across the
dataset. The ‘Lasso’ estimator, which is used in this chapter, has the advantage of ‘shrinking’
unused components of β to 0, imposing sparsity on the model. Lasso estimators are typically
strongly consistent if λ = o(p) [Chatterjee and Lahiri, 2011].
GRS derived from penalised regression can outperform those fit using an ordinary linear
model on variants reaching a pre-fixed threshold on association [Abraham et al., 2014].
From an information-theoretic standpoint, a penalised regression essentially corresponds to a
data-driven selection of an optimal association threshold.
Bayesian penalised regression
The maximum-likelihood estimator for β in lasso regression may be considered a posterior
mode for β with Laplace (double-exponential) priors on each β j [Park and Casella, 2008].
This invites the use of variable prior variances across elements of β (known as ‘Adaptive
lasso’ [Zou, 2006]) as a means to lever a lasso procedure on other information:
P(β ) ∝∏
j
eλ j|β j| (6.5)
leading to a maximum-likelihood (or equivalently maximum a-posteriori) estimator for β
given X = {xi j}, y = {yi}, {λ j} and λ0
MLE(β |X ,y,{λ j},λ0) = arg minβ∈Rp
{
1
n∑i
(
yi− xTi β
)2
+λ0∑
j
λ j|β j|
}
(6.6)
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In a logistic regression model, for which Pr(yi = 1) = logit(xTi β ) = (1+exp(−xTi β ))−1,
the term 1n ∑i
(
yi− xTi β
)2 is replaced with the standard objective function for logistic regres-
sion:
l(β |{xi,yi}) = log
{
∏
i|yi=1
logit(xTi β ) ∏
i|yi=0
(
1− logit(xTi β )
)}
(6.7)
A high value of λ j indicates a differential shrinkage favouring non-inclusion in the model,
and a low value favours inclusion. The values λ j are normalised so ∑ j λ j = p, and the
optimum value of λ0 (representing the overall shrinkage) is fitted using cross-validation as in
the usual Lasso procedure.
Prior distributions which are not conditional on σ2 may lead to a bimodal posterior for β .
However, while this is problematic in the estimation of the posterior distribution by Gibbs
sampling or similar [Park and Casella, 2008], it is generally not a serious problem when only
seeking the MAP estimate.
Since only the MAP estimate is sought and used, and the posterior distribution is not
otherwise considered, this exercise is not a true Bayesian analysis, and the set of values {λ j}
does not strictly define a prior. However, I consider it helpful to think of distribution 6.5 as a
prior-like initial estimate of effect size, and will refer to is as a ‘prior distribution’ throughout
this section, in a slight abuse of terminology.
Leverage strategy
Construction of a predictive GRS for EO/PO is difficult because of the relatively small
number of samples and the difficulty of phenotypic ascertainment. In a similar philosophy
to the analysis of rare diseases using cFDR in chapter 3, this can be partly alleviated by
incorporating data from related phenotypes into the procedure by which coefficients β j in the
GRS are fitted (equation 6.1). As with cFDR, this generally comes at the cost of sacrificing
consistency of effect size estimates, due to favouring of variants also associated with the
levering trait. Indeed, the estimators of coefficients of variants, and the choice of what
coefficients are included in the model, do not represent the true genetic architecture of the
EO/PO phenotype. However, in light of the clinical rather than scientific aim, this is not a
serious problem.
An important consideration in designing a GRS was how much influence the levering
trait should have over the final GRS. A GRS-fitting procedure involves a variable-selection
step and a coefficient-fitting step, and summary statistics from a levering phenotype may
be used to varying extents in either or both of these. I considered several strategies: firstly,
constructing a completely EO/PO agnostic GRS using only the levering phenotype for both
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steps (section 6.3.3); secondly, constructing a GRS using only the EO/PO phenotype for both
steps with no leverage (section 6.3.4); and thirdly, using a mixture of EO/PO phenotype and
the levering phenotype to varying degrees (section 6.3.4).
Choice of dimensionality
Many GRS used in predictive capacities use only confirmed or high-information variants
(eg [Paynter et al., 2010]) and although optimal models often include sub-genome-wide
associations [Abraham et al., 2014] these generally do not contribute a large proportion of
the overall predictive power.
The construction of a GRS using only genome-wide significant variants is an extreme
version of a method in which a generalised linear model (usually logistic regression or similar)
is used to predict the outcome variable (EO/PO) status using variants reaching some threshold
level of significance for association. Choice of the significance threshold for variants to
be included in the GRS represents a trade-off with a lower threshold corresponding to a
higher proportion of non-associated variants included in the model but a higher proportion of
heritability explained.
An ideal compromise is to make a data-informed judgement of the number of predictors to
use. For the EO/PO agnostic GRS for T1D and RA, the determination of whether a predictor
would be included in the model was entirely on the basis of its p-value for association with
the leveing phenotype; that is, all variants up to a maximum p-value were included The
absence of available genotypes for RA and T1D precluded more complex variable-selection
strategies such as penalised regression.
For EO/PO informed GRS, L-1 penalised regression was used for both variable selection
and coefficient fitting, with incorporation of some pre-selection of variables to minimise
computational load.
6.3.3 Construction of EO/PO-agnostic GRS
Initially, I constructed GRS fitted to differentiate RA, T1D, and JIA samples from controls.
The aim of this procedure was to determine if the pleiotropy between the levering phenotype
(RA, T1D, JIA/control status) and the EO/PO phenotype was sufficient that a GRS fitted to
the levering phenotype would have predictive ability in the EO/PO phenotype.
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GRS for RA
Summary statistics for RA included log-odds ratios (from which I computed p-values pRA
against the null hypothesis of no RA association) and effect directions. I identified the set
of variants common to the RA and JIA/EO/PO dataset with pRA ≤ 10−3. I pruned the set
of variants by LD to r2 < 0.2, estimating LD between variants using the JIA dataset and
prioritising variants with minimum pRA. I then ordered the resulting set of variants Vj by
increasing p-value.
Denoting gi j as the numeric genotype (taking values 0,1,2) of individual i at variant j,
and X(Vj) as the log-odds ratio of variant j, the GRS value for individual i was defined as
GRSN(RA)(i) =
N(RA)
∑
j=1
X(Vj)gi j (6.8)
In the absence of genotype data for RA, I determined the optimal value Nopt for N using
the JIA data:
Nopt = arg maxN(RA)
∣∣t(GRSN(RA)(i)|i ∈ JIA cases,GRSN(RA)(i)|i ∈ Controls)∣∣ (6.9)
where t(·, ·) refers to the t-score from a two-sample t-test against the null hypothesis of equal
means of GRS scores in EO and PO populations. Since the EO/PO dataset is independent of
the control dataset for JIA, the GRS is unbiased for EO/PO; that is, under the null hypothesis
that EO/PO and RA have no shared genetic basis, the GRS has identical expected value in
EO and PO populations. The coefficients of the GRS are not agnostic of JIA/control case
labels and the GRS is biased in assessments of predictability of JIA/control status on the
current dataset; the expected values of the GRS amongst the JIA cases and amongst the JIA
controls .
GRS for T1D
Construction of a GRS for T1D presented an additional difficulty as summary statistics were
based on score tests and hence effect directions were not available for variants in the dataset.
Firstly, absolute log-odds ratios |X | were reconstructed from p-values P and minor-allele
frequencies M using the formula
|X | ∝ −Φ
−1 (P
2
)√
M(1−M) (6.10)
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making use of the approximations (for autosomal SNPs)
X ∼ N
(
0,
√
M(1−M)
√
1
2ncontrol
+
1
2ncase
)
(6.11)∣∣∣∣Φ−1(P2
)∣∣∣∣∼ |N(0,1)| (6.12)
under the null hypothesis of no association. The set of variants common to both the T1D and
JIA dataset was identified and pruned as for the RA GRS.
The optimal number of predictors and the signs of the coefficients were estimated in
parallel from the JIA/control dataset. The optimal number of predictors cannot be determined
from the same dataset from which signs are estimated, as a greater number of predictors will
always give better discrimination if signs are determined between the groups the GRS seeks
to predict. This procedure thus required a cross-validation (XV) procedure, for which ten
folds were used.
For each fold, I estimated the signs of coefficients from the nine-tenths of the data not in
the fold, and the optimal N was determined on the remaining tenth of the data using a similar
formula to equation 6.9 above. The optimal number of predictors was then taken as the
median of the ten estimates from the XV folds, and signs for the final GRS were estimated
from the whole dataset.
Again, the resulting GRS for T1D would be biased upwards (in favour of better discrimi-
nation) for prediction of JIA/control status, but is unbiased for prediction of EO/PO status
under the null hypothesis of no shared genetic basis between EO/PO and T1D.
GRS for JIA
Construction of a GRS for JIA could use a wider range of methodologies due to the availability
of genotypic data. I used two separate methods, generating two separate sets of predictors.
Model parameters were again fitted using cross-validation.
The first GRS was fitted in a similar way to the GRS for RA. I ranked variants by
decreasing absolute log-odds ratio between JIA and control samples and pruned by LD to
r2 < 0.2. The GRS was computed with the same form as equation 6.8. The optimal number
of predictors was determined by producing, ranking and pruning ten sets of p-values pkEO,
k ∈ 1..10, each with one-tenth of the data removed, and fitting a GRS of the form of 6.8 to
each set of statistics.
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I then tested each fold-specific GRS on the remaining one-tenth of the data, and deter-
mined the number of predictors which maximally separated subgroups in a similar way to
equation 6.9. The final number of predictors was chosen as the median of these ten values.
I fitted the second GRS to the pruned set of variants using a lasso model (equation 6.6)
with equal prior variances λ j ≡ 1. I determined an optimal value of λ0 by cross-validation,
using the same ten-fold subdivision of the data as for the previous GRS.
Again, both GRS were overfitted to JIA and measures of separation would be biased
upwards if the GRSs were used to predict JIA/control status on the same set of data used to
generate the GRS.
Assessment of predictive accuracy
For all EO/PO agnostic GRS, a sufficiently large number of variants were included in the
final model that GRS scores could be assumed to be normally distributed within each JIA
subtype. Under this assumption, performance was compared using a standard two-groups
t-test, to test for difference in mean GRS between EO and PO individuals.
Predictive performance was also visually assessed using receiver-operator characteristic
(ROC) curves, and estimation of sensitivity and specificity at an optimal threshold determined
by maximal Youden’s index (sens. + spec. -1).
6.3.4 Construction of EO/PO informed GRS
The principal idea of this approach was to use a large dataset on a related disease (JIA,
RA, T1D) to set the values λ j used in the Laplace prior (equation 6.5), followed by GRS
construction using Lasso regression on the EO/PO samples.
Variable selection
The time-complexity of the LARS algorithm used for computing Lasso estimators with p
predictors on n samples is O(p3+ p2n) [Efron et al., 2004], which becomes very computa-
tionally intensive for p > 1000, and for whole-genome scale estimation in which p >> 105
the LARS algorithm is not practically applicable. Under the assumption that the proportion
of non-associated SNPs π0 is ≈ 1 (with the standard two-groups model of [Efron et al.,
2008]), some feature selection is justified before application of the LARS algorithm.
I did this by restricting to variants showing moderate evidence of association with the
levering phenotype or with the EO/PO phenotype (p < αT ; I used αT = 1× 10−3). This
required using the ten sets of summary statistics pkEO, k ∈ 1, ..10 used in fitting the GRS for
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JIA in the previous section, in which the set pkEO compares EO and PO samples with samples
in fold k removed from the analysis. Variable selection was performed separately for each
XV fold k, assessing EO/PO association using summary statistics pkEO. In order that the GRS
fitted to each nine-tenths of the data to be completely agnostic to the remaining one-tenth,
the cross-validation procedure to fit the value λ0 (see equation 6.6) was nested within each
fold of the wider cross-validation procedure.
Overall EO/PO informed GRS algorithm
The overall algorithm for fitting and assessing the GRS was as follows
Definitions
S: genome-wide set of SNPs
T 1, T 0: case/control cohorts for trait under investigation (EO/PO), genotyped at S
XT (P,Q): genotype submatrix for trait under investigation at samples P, variables Q.
yT (P): case/control indicator for trait under investigation at samples P
pL: p-values for trait used for leverage, genotyped at S
pA,B: set of p-values from comparing cohort A to cohort B
αL: cutoff p-value in trait used for leverage for SNP inclusion in lasso model
αT : cutoff p-value in trait under investigation for SNP inclusion in lasso model
prune(S′,X1,X0): function pruning set of SNPs S′ by LD, favouring high pX1,X0
Λ: set of potential values for λ0 with kth element Λk
f (.): function mapping p-values pL to prior parameters {λ j} for lasso model
MLE(β |X ,y,{λ j},λ0): MLE for β under logistic formulation of equation 6.6
m(y1,y2): metric for accuracy of GRS values y1 for predicting phenotype y2
function GENERATE UNBIASED GRS
N ← 10 ▷ Number of XV-folds
T 01 , T
0
2 ,... T
0
N ← partitioning of T 0 for XV
T 11 , T
1
2 ,... T
1
N ← partitioning of T 1 for XV
SL ←{SNPs : pL < αL} ▷ SNPs associated with levering trait
for k ∈ 1...N do ▷ Find sets of SNPs to include in each XV fold
T 1A ←
⋃
s ̸=k T 1s , T 0A ←
⋃
s̸=k T
0
s ▷ Training sets
T 1B ← T 1k , T 0B ← T 0k ▷ Test sets
SkT ←{SNPs : pT 1A ,T 0A < αT} ▷ SNPs associated with EO/PO, fold-k agnostic
Sk ← SkT ∪SL ▷ SNPs to be included in lasso model, fold-specific
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Sk ← prune(Sk,T 1,T 0)
{λk}= f (pT 1A ,T 0A (S
k)) ▷ Prior parameters for SNPs in Si
end for
initialise Y : |Y |= |T 0∪T 1| ▷ Y will be set to overall unbiased GRS
for k ∈ 1..N do
define T 1A ,T
0
A ,T
1
B ,T
0
B as above
initialise Yk : dim(Yk) = (|T 1A ∪T 0A |× |Λ|) ▷ GRS for samples not in fold k
for h ∈ {1..N}\ k do
T 1C ←
⋃
s ̸=k,h T 1s , T 0C ←
⋃
s ̸=k,h T 0s
T 1D ← T 1h , T 1D ← T 0h
for l ∈ Λ do
βkhl ←MLE(β |XT (T 1C ∪T 0C ,Sh),yT (T 1C ∪T 0C ),{λ j},Λl)
Yk(T 1D ∪T 0D, l) = XT (T 1D ∪T 0D,Sh)βkhl ▷ GRS in fold k, λ0 = Λl
end for
end for
λ k0 = {Λl : m(Yk[·, l],yT (T 1A ∪T 0A )) is maximised} ▷ Find best λ0 from XV
βk ←MLE(β |XT (T 1A ∪T 0A ,Sk),yT (T 1A ∪T 0A ),{λ j},λ k0 ) ▷ Fold-k agnostic
Y (T 1B ∪T 0B ) = XT (T 1B ∪T 0B ,Sk)βk ▷ Unbiased GRS values for samples in fold k
end for
return Y , m(Y,yT )
end function
□
Since all the inputs into generating the GRS for samples in fold k - XT (T 1A ∪T 0A ,Sk),yT (T 1X ∪
T 0X ),{λk}, and λ k0 - are agnostic of phenotype labels yT from fold k, the GRS has equal ex-
pected values across individuals with yT = 1 and individuals with yT = 0 under the null
hypothesis that yT is independent of all genetic predictors.
Choice of function f
There are several choices of the function f in the previous section, which determines the
relationship between an observed p-value pi in the trait used for leverage and the parameters
λ j (corresponding to variance 2/λ 2j ) of the Laplace prior (equation 6.5) used in fitting the
lasso model. Since the value of λ in equation 6.6 is variable and fitted by cross-validation,
the set of values {λ j}= f ({p j}) may be multiplied by an arbitrary constant. All functions f
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were thus scaled such that
∑ f (p j) =∑λ j = |{λ j}|= p (6.13)
where p is the total number of predictors in the model. I proposed three prior-generating
functions f1, f2, f3 and fitted a separate GRS using each of them.
The first and simplest form of f is a theshold function:
f1(p j) ∝
x if p j < αy if p j ≥ α (6.14)
that is, modulating variances according to whether variants reach a p-value threshold α in
the levering trait. This approach is used implicitly with x = 1, y = ∞ in the pruning step in
the algorithm. A disadvantage is that the choice of α,x,y are somewhat arbitrary. A prior
of this form was used with x = 12 , y = 1 with the value α = 5×10−8 corresponding to the
standard genome-wide significance threshold. I chose these specific values of (α,x,y) as
roughly ‘simple’ values before fitting any models.
A preferential approach is to choose the parameters λ j to match the Laplace distributions
to a presumed underlying sampling distribution for each observed unsigned Z score z j =
−Φ−1(p j/2)). If |z j| is an absolute value of a single observation from a distribution N(0,σ2j ),
the MLE for the standard deviation σ j is equal to |z j|. I sought to match the distribution
from which z j is observed to the Laplace prior, and used the Kullback-Liebler divergence
(an asymmetric measure of difference between probability distributions) to do this. The K-L
divergence of a Laplace distribution with PDF l(z;λ j) =
λ j
2 e
−λ j|z| and a normal distribution
with PDF n(z;σ j) = (
√
2πσ j)−1e−z
2/(2σ2j ) is
DKL(l||n) =
∫ ∞
−∞
λ j
2
e−λ j|z|log

λ j
2 e
−λ j|z|
1√
2πσ j
e
− z2
2σ2j
dz
= 2
∫ ∞
0
λ jlog(
√
2πλ jσ j)dz+2
∫ ∞
0
(
−λ jz+ z
2
2σ2j
)
λ je−λ jzdz
= log(λ jσ j)+
1
λ 2j σ2j
+ log
(√
π
2
)
−1 (6.15)
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which is minimised when λ jσ j =
√
2. Thus the parameter λ j leading to the closest-matched
Laplace distribution l(z;λ j) to the presumed underlying distribution N(0,σ2j ) leads to the
second form for f
f2(p j) ∝
√
2
|z j| ∝−
1
Φ−1(p j/2)
(6.16)
A disadvantage of this approach is that the prior variance is unbounded, in that SNPs
with exceptionally strong associations with the levering trait can be effectively guaranteed
inclusion in the lasso model. Since the levering trait is not the same as the trait under
investigation, this may weaken the predictive power.
A better quantity on which to base the prior variance may be the posterior probability
of association with the trait used for leverage, assuming a two-groups model [Efron et al.,
2008]. Assume Z-scores for the levering trait have the distribution
Z ∼
N(0,1) with prob. π0N(0,σ2) with prob. 1−π0 (6.17)
where values π0, σ may be set using an E-M algorithm (see chapter 2, section 2.4.3), noting
that σ has a different meaning to the SNP-specific σ j used in equation 6.15. The posterior
probability ψ j of association (with regard to the null hypothesis HL0 for the levering trait) for
SNP j with z-score z j is
ψ j = Pr(HL0 |z j) =
Pr(HL0 )p(z j|HL0 )
p(z j)
=
π0N1(z j)
π0N1+(1−π0)Nσ2(z j)
(6.18)
where Nσ2(z) denotes the PDF of N(0,σ2) at z. The observed z j can be considered a sample
from a distribution of the form 6.17 with π j in the place of π0:
z j ∼
N(0,1) with prob. ψ jN(0,σ2) with prob. 1−ψ j (6.19)
This distribution has the advantage of favouring inclusion for large z j, but with bounded
expectation equal to the overall variance σ2 of the effect size distribution across the levering
trait as ψ j → 0.
The value of λ j minimising the K-L divergence between a Laplace distribution with PDF
l(z;λ j) =
λ j
2 e
−λ j|z| and a distribution s(z;ψ j) of the form of equation 6.19 is independent of
ψ j; considering distribution s(z;ψ j) as a limit as a→ 0 of continuous distributions sa(z;ψ j)
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with PDFs
sa(z;ψ j) = (1−ψ j)Nσ2(z)+ψ j
ψ j
2a
1|z|<a (6.20)
we have
DKL(l||s) = lim
a→0
(∫ ∞
−∞
l(z;λ j)log{l(z;λ j)}dz−
∫ ∞
−∞
l(z;λ j)log{sa(z;ψ j)}dz
)
=−1−2(1−ψ j) lim
a→0
(∫ a
0
λ j
2
e−λ jz
(
Nσ2(z)+
ψ2j
2a(1−ψ j)
)
+
∫ ∞
a
λ j
2
e−λ jzNσ2(z)
)
= (1−ψ j)
(
log(λ jσ)+
1
λ 2j σ2
+ log
(√
π
2
))
−1 (6.21)
which is minimised for λ jσ =
√
2 regardless of ψ j.
In order to choose a Laplace distribution l(z;λ j) corresponding to the distribution s(z;ψ j),
the value λ j may be fitted on the basis of expectation of absolute values of random variables
between l(z;λ j) and s(z;ψ j), accounting for a ‘baseline’ possibility of association with the
levering phenotype when ψ j ≈ 1.
The expected value of |X | if X has Laplace PDF l(z;λi) = λi2 e−λi|z| is El(|X |) = 1λi . If X
has normal PDF n(z;σ) = Nσ2(z) then En(|X |) =
√
2
πσ , and if X has distribution s(z;ψ j) of
the form in equation 6.19 then Es(|X |) = (1−ψ j)
√
2
πσ . The third definition of f
f3(pi) ∝
1
1+(1−ψi)
√
2
πσ
(6.22)
sets El(|X |) = 1+Es(|X |).
Choice of function m and assessment of significance
The function m(Y,yT ) measured deviance of the GRS from the true phenotype. Given the
potential for different behaviours of yT in different XV-folds, I fitted a logistic model
logit−1(Pr(Y = 1)) =∑γk1fold=k + γ0yT (6.23)
and defined m(Y,yT ) as the p-value from a score test against the null hypothesis γ0 = 0.
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Although the value m(Y,yT ) is derived from a p-value for an observed value γobs of γ , the
value m(Y,yT ) is not equal to Pr(|γ|> |γobs|
∣∣∣∣HEO/PO0 ), where HEO/PO0 is the null hypothesis
that the EO/PO phenotype is independent of all genetic variants. Under HEO/PO0 , the values
yT and Y are independent for individuals in fold i, since the GRS is agnostic to those samples.
However, fold-specific measures of predictive accuracy are not independent between folds,
and hence values m(Y,yT ) do not have a U(0,1) distribution under H
EO/PO
0 , despite being
derived from p-values.
In order to estimate a true p-value associated with an observed value m(Y,yT ), the entire
GRS-generating procedure was repeated > 500 times with permuted phenotype labels, with
the final p-value estimated using the quantile of the observed m(Y,yT ) in the distribution of
m(Y,yT ) values from permuted phenotypes.
6.3.5 Genetic associations with EO/PO status
Initially, I sought to establish whether the dataset supported any genetic differences between
EO and PO samples at all. I performed a GWAS comparing EO- and PO- subgroups of
JIA using sex and the three principal components as covariates, generating p-values pEO.
Sex does not show evidence of association with extension [Al-Matar et al., 2002] but it is
associated both with JIA and oligoarthritis in general [Ravelli and Martini, 2007] suggesting
sex-specific mechanisms of oligoarthritis. These may be better-detected with sex adjustment,
and the inclusion of sex in the model has little effect on the power to detect sex-independent
EO/PO associations. Principal components were included in the model to account for
potential regional differences in diagnosis (for example, due to differential follow-up times).
The inflation factor λ for the set pEO was 1.02 (λ1000 = 1.03) indicating a low degree of
inflation as expected. No p-values reached genome-wide significance or Bonferroni-corrected
significance at α = 0.05 (minimum p-value 5.4×10−8; Bonferroni-corrected significance
cutoff 6.6×10−9).
A Q-Q plot demonstrated no evidence of departure from pEO ∼ U(0,1) (figure 6.1).
Collectively, isolated analyses of the EO/PO phenotype suggest a total absence of discover-
able heritability. However, GWAS Q-Q plots can also show no evidence of association for
underpowered studies (which this is likely to be), whilst larger studies on the same disease
show extensive evidence of associations.
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Fig. 6.1 Q-Q plot for p-values derived from comparison between extended and persistent
oligoarthritis. The grey region shows a pointwise 99% confidence envelope for each order
statistic of a uniform distribution. There is no evidence of departure from a pEO ∼U(0,1).
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Table 6.3 Details of GRSs fitted to T1D, RA or JIA for predicting EO/PO phenotype. Column
LP stands for levering phenotype. Column dim(GRS) is the number of variables in the GRS.
LP dim(GRS) P-value
RA 69 2.1×10−4
T1D 1113 3.2×10−4
JIA 1 (log-OR) 91 3.8×10−4
JIA 2 (lasso) 42 2.0×10−5
Conditional associations
Despite no obvious departure of pEO from U(0,1), I examined whether conditioning on
RA, T1D or JIA association revealed any inflation. As discussed in chapter 5, association
statistics from JIA/control and EO/PO are independent under the null hypothesis for EO/PO.
Figure 6.2 shows the results of this analysis. Notably, there is visible inflation in all cases
when the MHC region (chr6:25-40Mb, NCBI build 37) is included, which disappears when
the MHC region is removed, indicating that visible inflation is generally driven by the
MHC region. Given the extensive involvement of MHC in JIA and autoimmune disease in
general [The Wellcome Trust Case Control Consortium, 2007, Hinks et al., 2013] this is
reasonable evidence for some genetic basis to oligoarthritic extension, principally driven by
the MHC region.
Despite the visual evidence, analyses using cFDR found no EO/PO associations when
conditioning on any of the three phenotypes, even using liberal thresholds α1(EO/PO|·) (see
chapter 3, section 3.2.2 ) for genome-wide association.
6.3.6 GRS results
EO/PO agnostic GRS
All four EO/PO agnostic GRS (fitted to RA, fitted to T1D, fitted to JIA using odds-ratios
and fitted to JIA using lasso) could significantly discriminate EO and PO samples. Results
from the comparisons are shown in table 6.3. The best-performing GRS was the lasso-based
model fitted to JIA data. Figure 6.4 shows the respective densities of the GRS fitted to JIA
using the lasso model in EO and PO samples.
ROC curves for the four predictors showed modest predictability. Sensitivity and speci-
ficity of predictors are shown in table 6.4. These results indicated the presence of pleiotropy
between each of RA, T1D, and JIA and the EO/PO phenotype, to the extent that EO/PO is
partially predictable on the basis of genetic susceptibility to RA, T1D, or JIA alone.
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Fig. 6.2 Conditional Q-Q plot for p-values derived from comparison between extended and
persistent oligoarthritis, conditioning on JIA, T1D and RA, with MHC included (left panels)
and excluded (right panels). Note different thresholds for conditional p-values, chosen
because the studies on RA and T1D were larger than the study on JIA. There is evidence of
deviation from a uniform distribution for pEO when conditioning on association with other
phenotypes. Confidence envelopes are not shown as they differ for each conditional p-value
threshold. The deviation in distribution disappears when the MHC region is removed from
the analysis, suggesting that the inflation is MHC driven.
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Fig. 6.3 ROC curves for predicting EO/PO using GRS for T1D, RA and JIA. Modest
predictive power is seen in each case. Red dots mark the point of maximal Youden’s index
(sens. + spec. -1).
Table 6.4 Sensitivity and specificity at maximal Youden’s index of GRSs fitted to T1D, RA
or JIA for predicting EO/PO phenotype.
LP AUC Sens. (%) Spec. (%)
RA 0.57 65 50
T1D 0.56 48 62
JIA 1 (log-OR) 0.56 83 27
JIA 2 (lasso) 0.58 70 43
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EO/PO informed GRS
After pruning to only SNPs with pkEO < αT = 1× 10−3 and pruning by LD (in the same
way as described in chapter 2), a median of 1345 (range 1316-1384) SNPs were included in
the lasso model for each XV fold. A median of 3 (1-38) variants were included in the final
predictive score. The final predictive scores were essentially identical whether or not SNPs
associated with each of the levering trait were included in the lasso model, although with
different fitted values of λ due to different numbers of input variables. Results from the GRS
analysis are shown in figure 6.5. The unbiased GRS with no leverage could not discriminate
between groups (p = 0.36)
The GRS with leverage in general performed much better, in that more variants were
included in the model, and there was more discrimination between EO and PO by the unbiased
GRS (table 6.5), most strikingly when levering on T1D. Only one comparison (levering on
T1D, with prior f3) reached Bonferroni-corrected significance (p < 0.05/10 = 0.005; ten
comparisons shown in table 6.5) although several (levered on JIA with prior f1, levered
on JIA with prior f3, levered on T1D with prior f2, levered on T1D with prior f3) showed
suggestive associations at FDR≤ 0.1 (p < 0.033).
None of f1, f2, f3 were clearly dominant, although f2 appeared the weakest. A graph
of densities from a successful GRS is shown in figure 6.6. As an illustration of predictive
power, an ROC curve is shown for the GRS levered on T1D with prior f1 (figure 6.7). With
this predictor, the cutoff with optimal Youden’s index (sens. + spec. -1) had sensitivity 69%
and specificity 45%. These values are likely to be overestimates of the true performance of
this GRS on new data, since it was chosen as the best-performing GRS out of those tested.
6.3.7 Discussion
In this project, I determined that the EO/PO phenotype has a genetic component, and that
it may be predicted to a better-than-random degree using GRS. This indicates that genetic
testing of patients with newly-diagnosed oligoarthritis could provide a clinically useful
classification (if it provides independent predictive ability to clinical variables), ultimately
allowing more efficient management of patients with JIA. I also developed a generic method
for generating and testing a GRS leveraged on data from a different, related phenotype, using
standard machine-learning procedures.
This exercise serves as at best a pilot study, and is not on its own enough to suggest
changes to patient management protocols. Sample sizes were too small to identify any
individual variant associated with the EO/PO phenotype, and no independent dataset was
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Fig. 6.4 Results of GRS fitted to the JIA/control phenotype for predicting extension in
oligoarthritis. Significant discrimination is evident (p = 2.0×10−5).
Table 6.5 Details of GRSs fitted to EO/PO phenotype. Column LP stands for levering
phenotype. Columns dim(model) and dim(GRS) give the number of variables entered into
the lasso model and the number of variables in the GRS respectively. Columns dim(model),
and dim(GRS) are medians across XV-folds.
LP Prior dim(model) dim(GRS) P-value
None None 1346 (1316-1384) 3 (0-38) 0.36
JIA f1 3362 (3335-3407) 13 (9-38) 0.015
JIA f2 " 29 (0-125) 0.080
JIA f3 " 35 (0-74) 0.030
RA f1 3060 (3031-3104) 13 (1-51) 0.75
RA f2 " 6 (4,10) 0.14
RA f3 " 0 (0,23) 0.20
T1D f1 2633 (2608-2674) 19 (10-51) < 0.001
T1D f2 " 7 (5-10) 0.027
T1D f3 " 15 (4-39) 0.015
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Fig. 6.5 Results of GRS fitted to EO/PO phenotype with no leverage. Top panel shows
‘unbiased’ GRS scores for EO and PO samples. No discrimination is evident (p = 0.36).
The lower panel shows variable inclusion in the GRS, with a red line indicating a nonzero
coefficient. There is reasonable concordance in the variables included in the models for each
cross-validation fold.
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Fig. 6.6 Results of GRS fitted to EO/PO phenotype leveraged on T1D using prior form f1,
as an example of a successful model. Top panel shows ‘unbiased’ GRS scores for EO and
PO samples. Moderate discrimination is evident (p = 3.0×10−4). The lower panel shows
variable inclusion in the GRS, with a red line indicating a nonzero coefficient. There is good
concordance in the variables included in the models for each cross-validation fold.
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Fig. 6.7 ROC curve for GRS on EO/PO phenotype, levered on T1D with prior f3. At the
point of maximal Youden’s index (sens. + spec. -1), the classifier has sensitivity 69% and
specificity 45%. These values should not be interpreted as estimations of performance of the
GRS on new data, since this model was chosen as the best-fitting example.
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available for validation of the proposed risk scores. The current study has no way to determine
if between-group discrimination arises from the EO/PO phenotype or a confounder.
Generalisability and confounders
The generalisability of the GRS is dependent on the GWAS samples’ representation of of the
true population presenting with oligoarthritic JIA. This cohort has the advantage that patients
were recruited agnostic of EO/PO phenotype, on the basis of presentation with oligoarthritis
only. This reduces the chance that the observed genetic differences were due to confounding
variables. However, the presence of confounding remains a possibility. One potential such
confounder is misdiagnosis. If some number of samples had only transient arthralgia or
oligoarthritis secondary to some other disease process, we may expect that such samples
should be over-represented in the PO group, since the arthritis would not progress. This
could mean that genetic differences between EO and PO groups were due only to the higher
proportion of ‘true’ JIA cases in the former. This would be consistent with the observed
inflation of EO/PO conditioning on JIA association (figure 6.2).
It may be argued, however, that confounding of this type does not matter from a clinical
perspective. The population on whom such a classifier may be used matches that in the study
- that is, children presenting with apparent oligoarthritis - and will contain misdiagnosed
cases at a similar rate to the study cohort. In this context, the clinical usefulness of predicting
extension does not depend on what the prediction is based on. The same is true if the cohorts
are confounded by ethnicity or geographic location, although in this case the GRS would not
be independent of clinical or epidemiological predictors. Confounders are only problematic
in this application if they are unique to the current dataset, and such confounders should be
eliminated by the sampling procedure.
GRS performance
This exercise broadly used three types of predictive GRS: firstly, GRS fit entirely on the
basis of external datasets on related diseases fitting (sections 6.3.3, 6.3.3, 6.3.3); secondly,
GRS which used EO/PO data in combination with summary statistics from related diseases
(table 6.5, rows 2-10), and thirdly, GRS fitted only on EO/PO genotypes (table 6.5, row 1).
Comparisons of predictive accuracy between the first type of GRS and the second two must
be made cautiously, as the second two required use of the same dataset for both training and
testing. However, it appeared that both the first and second types of GRS performed better
than the third.
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This would not be expected to hold as sample sizes increase to infinity, as the genetic
architectures of RA, T1D and JIA are at best approximations of the genetic architecture of
EO/PO. Indeed, the coefficients of the third type of GRS should be consistent estimators of
variant effect sizes in EO/PO, the coefficients of the first type should be consistent estimators
of effect sizes in the levering phenotype, and the coefficients of the second type should
converge to some average of the two (assuming that the sample sizes in EO/PO and the
levering phenotype increase at approximately the same rate). This should result in a reversal
of the observed predictive accuracies, with the third type of GRS ultimately performing the
best, followed by the second, followed by the first.
The observed results, in conjunction with the conditional analyses in section 6.3.5, do
indicate a degree of pleiotropy between the genetic basis of EO/PO and the three levering
phenotypes, principally at the MHC locus. Notably, this only demonstrates pleiotropy in the
sense of sharing of associated, rather than causal variants. All of the GRS use implicit effect
size estimates for EO/PO for prediction, and in the current study, the improved performance
of EO/PO agnostic GRS suggest that the systematic error in these estimates in the GRSs for
T1D/RA/JIA due to the difference in phenotype is less than the random error in the estimates
from the small sample size in the EO/PO phenotype itself.
The relatively poor performance of the GRS levered on RA compared to those levered on
T1D and JIA was surprising, given the performance of the GRS for RA and the evidence of
pleiotropy with EO/PO (figure 6.2). The size and precision of the GWAS may have been a
problem; considerably more variants reached pRA < 5×10−8 than did pT 1D < 5×10−8 or
pJIA < 5×10−8, presumably including many which were specifically associated with RA.
Variants with pRA < 5×10−8 were given the same weight in prior f1 and approximately the
same prior weight in f3, and RA-specific variants may have diluted the effect of variants
which were associated with both EO/PO and RA.
Evaluation of method
The choice of methods was largely due to necessity. Penalised regression is empirically the
strongest form of GRS in typical complex-disease settings [Abraham et al., 2013, Kooperberg
et al., 2010]. Pre-selection of variables on the basis of p-value (within-fold) is a widely-used
procedure (eg [Cho et al., 2010]) but may lead to failure to identify true associations [Abraham
et al., 2013]. Since that was not an aim of this project, and pre-selection was liberal, allowing
all SNPs with p-values < 1×10−3, this is unlikely to have adversely affected the predictive
ability of the GRS in this case.
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An important consideration in the choice of cross-validation procedure is the bias-variance
trade-off [Friedman et al., 2001]. Given the small sample size and apparently small effect
sizes from the Q-Q plots, I expected that a model fit to < 80% of the data would have sub-
stantially reduced predictive power compared to one fit to the whole dataset (downward bias).
Correspondingly, the computationally complex procedure and necessity for permutation
testing to estimate the null distribution of m(Y,yT ) precluded less biased XV-procedures such
as leave-one-out cross validation. The ten-fold procedure was a reasonable compromise,
although still computationally complex, requiring several thousand hours of computational
time. The number of variants included in the GRS was chaotic across XV-folds (table 6.5),
suggesting that the sampling variance in optimal λ0 is high (equation 6.6).
Application
Even the best GRS for EO/PO prediction had modest sensitivity and specificity (table 6.4),
and these values are likely to be overestimates of performance in a new dataset. The
accuracy of predictors is likely to increase as more data becomes available, and leveraged
scores may become more accurate than EO/PO agnostic GRS. Even the small degree of
predictive accuracy observed in this study may be clinically useful, again if the GRS contains
information independent of that attainable clinically. In practical terms, children with
oligoarthritis and high GRS values could be monitored more closely for extension than those
with low GRS values.
Although GRS are not widely used in this way, many clinical measurements which are
only slightly correlated with a phenotype remain part of standard diagnostic procedures. For
example, diagnostic recommendations for rheumatic heart disease [Reményi et al., 2012]
include considerations of low-accuracy predictors such as ethnicity, geographical location
and living conditions. Indeed, the standard clinical history and physical examination - an
indispensable component of diagnosis - can be statistically considered as a collection of
a large number of variables with low individual predictive power [Wipf et al., 1999]. In
general, medical decisions are typically made on the basis of combined consideration of
many predictors, and new predictors, however small their effects, can still be useful. GRS in
particular have a cost-benefit advantage in that genotyping ideally only needs to be performed
once in the lifetime of an individual [Abraham et al., 2014].
In order to be useful as a clinical predictor, the GRS has to explain phenotypic variance
additional to that explained by existing predictors. Equivalently, it must remain correlated
with the phenotype conditional on other predictor variables. In the case of the EO/PO
phenotype, although there are some clinical associations, predictability is modest [Al-Matar
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et al., 2002, Gardner-Medwin et al., 2006] suggesting that the GRS may indeed improve
predictive accuracy. However, I was not able to assess this as further phenotypic information
was unavailable.
Summary
This project gave a promising (though not definitive) indication that EO/PO is partially
predictable from patient genotypes. While larger and more diverse datasets are needed to
confirm this predictability and enable it to be clinically useful, this provides a useful starting
point and general framework for investigation of genetic predictability of disease subtypes.
6.4 Investigation of heterogeneity in JIA subtypes
6.4.1 Motivation and general methods
As discussed in section 6.1, the classification of JIA into subtypes is largely based on
clinical presentation. Consequently it is not necessarily the case that subtypes represent
different pathological forms of the disease, or that there are systematic genetic differences
between subgroups. Understanding pathological subtypes of a disease is useful in further
investigation of the disease, and in guiding further scientific investigation. As discussed
in chapter 5, the determination of an ‘optimal’ partitioning of a phenotype on the basis
of genomic data is a difficult problem. However, it is possible to gauge how well a given
subgrouping differentiates patients genetically in various ways. Chapter 5 details one such
method which effectively assesses how well-separated two subtypes of a disease are on the
basis of associations between control samples and combined case samples for the disease.
In this section, I examine a similar problem, in analysing how well-separated disease
subgroups are on the basis of associations between either JIA and controls, T1D and controls,
or RA and controls. The aim in this chapter is different from the aim in chapter 5 in two
ways. Firstly, the question of whether subgroup differentiation is pleiotropic with JIA/control,
RA/control, or T1D/control is of minor importance. Although leverage is used to help the
analysis, the main aim is to assess whether there is genetic differentiation between subtypes
at all. Secondly, an important question is how subgroups separate, in the sense of assessing
which subgroups are most genetically similar, which cannot be easily assessed using the
model in chapter 5.
I generally considered the null hypothesis H0 that variation in all genetic variants was
independent of subtype status. For SNPs, this is equivalent to equality of expected values
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of numeric genotypes across all subgroups. It also implies that test statistics fitted using
genotype data without knowledge of subtype status are themselves independent of subtype
status. Throughout this section, H0 will refer to this hypothesis unless specified.
The main methodological idea in this section is to construct several discriminants yi of
the form
yi = ∑
j∈SNPs
w jkgi j (6.24)
where gi j is the genotype of sample i at SNP j, and k is the XV fold which i is part of. The
values w jk is agnostic to the values yi for i ∈ fold k. This ensures that for samples i within
each fold k, yi is independent of the JIA subtype of sample i under H0 I then compare the
values of yi between individuals with different subtypes of JIA to attempt to reject H0. This
also allows determination of how each discriminant ‘separates’ the subtypes by assessing the
relative directions in which the mean values of yi in each subgroup differ from the overall
mean of yi.
6.4.2 Modified GRS for RA and T1D
I derived GRS scores for RA and T1D which were agnostic to sample labelling for samples
in the JIA dataset (ie subtype/case/control). This ensured that scores were unbiased for
predicting subtype status and JIA/control status; under the null hypothesis that JIA/control
status has no genetic associations, if GRS(i) is the GRS value for sample i:
E{GRS(i)|i ∈ JIA cases}= E{GRS(i)|i ∈ controls} (6.25)
and under H0 (although heritability may be nonzero for JIA/control status), we have, for any
subtype X
E{GRS(i)|i ∈ X}= E{GRS(i)|i ∈ JIA cases} (6.26)
The second of these conditions is more important, since in this section I primarily aimed
to assess whether GRS could differentiate subtypes of JIA. The first condition additionally
enables assessments to be made of whether these GRS can predict subtype/control status. I
used similar methods to those used to develop GRS for T1D and RA in sections 6.3.3 and
6.3.3. However, the final GRS developed in those sections made use of JIA/control sample
labels, and hence did not satisfy equation 6.25, although they did satisfy equation 6.26.
In the fitting of the RA GRS in section 6.3.3, the only step involving JIA/control status
was the determination of the number of variants to include in the GRS. For this application,
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I replaced this step with the simple criterion of including all variants with pRA < 5×10−8
(after pruning variants for LD with r2 < 0.2).
The GRS scores for T1D in section 6.3.3 made use of case/control labels both in determin-
ing the number of variants to include and determining the effect directions for each variant.
For the current application, I computed GRS scores for T1D by randomly splitting the data
into ten parts, then fitting effect directions to each nine-tenths of the data and computed GRS
scores for the remaining tenth using these effect directions, again using all variants with
pT 1D < 5×10−8 after pruning for LD.
For both analyses, I computed two sets of GRSs, one including and one excluding the
MHC region (chr. 6, 25.0-40.0 Mb, NCBI build 37). In both analyses, I used a stringent
p-value threshold for inclusion (5× 10−8) since the levering GWAS were both large and
well-powered, and an effect size corresponding to pRA = 5×10−8 or pT 1D = 5×10−8 would
correspond to a much smaller pJIA value if the effect size were conserved in JIA (pJIA > 0.5
if pRA = 5×10−8, pJIA = 1.5×10−2 if pT 1D = 5×10−8).
For each subtype, I assessed subtype/control differences in GRS scores using signed
statistics from standard two-group t-tests. In order to simulate under a null hypothesis of
homogeneity of genetic effects in JIA subtypes, I repeatedly randomly permuted subtype
labels (but not JIA control labels) and recalculated summary statistics Z′ for each random
permutation. I used these sets of permuted ‘null’ Z′ to assess significance of each observed Z
score.
6.4.3 Unsupervised GRS construction
In order to capture ‘inherent’ variance within the JIA phenotype, I used a principal component
analysis (PCA) on JIA case genotypes, weighted by association with JIA/control status. In
typical genomic data, most of the variance in the first several standard principal components
corresponds to identity by descent, or population substructure [Price et al., 2006]. Allelic
differences between populations in the UK tend to be small but widespread [Leslie et al.,
2015], so in smaller sets of variants in which other sources of variation (for instance, presence
or absence of disease) lead to larger allelic differences, the contribution of population sub-
structure to the variance of the first principal component should be reduced. By weighting the
variance of each variant according to association with JIA/control, attention is concentrated
to a small set of variants for which the principal source of genetic variance may be subtype
status. Under H0, the first principal component will not be associated with subtype status. If
there is between-subtype genetic variance at the variants contributing to JIA risk, the first
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principal component should have different values between subgroups, although population
substructure and other confounders may still contribute to its variance.
In a standard PCA, the scores t for the first principal component on a genotype matrix
G = gi j (sample i, variant j) are defined as:
ti =∑
j
w jgi j (6.27)
with weights w = {w j} satisfying
w = arg max||w||=1∑
i
t2i
= arg max||w||=1w
T GT Gw (6.28)
In this application, I transformed each column g j of gi j according to z j, a z-score for SNP j
for the JIA/control comparison:
g′j =
√√√√zJIA/Controlj
var(g j)
(g j− g¯ j) (6.29)
by comparison to the standard transform for PCA to equality of sample variances for each
variable:
g′j =
g j− g¯ j√
var(g j)
(6.30)
so that each g′j had mean 0 and variance z j instead of variance 1. By doing this, I expected
that variance would correspond to genetic differences between JIA and control rather than
genetic differences due to population substructure or identity by descent.
I initially pruned SNPs by LD to r2 < 0.2, prioritising by p-value for JIA/control, and
removed all SNPs with |z j|<Φ−1
(
1×10−3
2
)
(equivalent to p j > 1×10−3). The remaining
SNPs were used to generate the first principal component t ′. I repeated the analysis with the
MHC region removed (co-ordinates as in the previous section) to generate the first principal
component t ′NMHC.
Since the construction of t ′ and t ′NMHC is agnostic to subtype labels, their distributions
are the same in each subtype under H0. I assessed deviance of each subtype by comparing
values in that subtype with values not in that subtype. I additionally assessed whether t ′ and
t ′NMHC had different means across subtypes in general using standard one-way ANOVA.
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6.4.4 Supervised GRS construction
Finally, I assessed whether a supervised predictor - a linear discriminant - could differentiate
JIA subtypes when trained to do so. While PCA heuristically finds the axis along which the
data has the greatest variance, LDA finds the axis along which the ratio of between-group
variance to within-group variance is greatest. This can lead to very different behaviour of the
two predictors (figure 6.8)
Assume that N samples are partitioned into K classes c1,c2..cK . Denote by gi the set of
genotypes of individual i, and assume that genotypes are standardised to have mean 0 across
all samples. Denote µˆk = 1|ck|∑i∈ck gi as the within-class mean genotype for class k. The
within-class covariance matrix Σw is estimated as
Σˆw =
1
N
K
∑
k=1
∑
i∈ck
(gi− µˆk)(gi− µˆk)T (6.31)
and the between-class covariance matrix Σb estimated as
Σˆb =
1
N
K
∑
k=1
|ck|µˆkµˆkT (6.32)
The (first) canonical discriminant [Rao, 1948] (CD) is a score βT gi that satisfies
β = arg maxββ
T Σˆbβ (6.33)
subject to βT Σˆwβ = 1. I scaled the genotype matrix gi j in the same way as in section 6.4.3,
so that the variance in cases of genotypes at variant j was proportional to |z j|, an absolute
z-score for the difference between cases and controls.
Since LDA is a supervised procedure, an assessment of whether an LDA fitted to the
whole dataset could discriminate subgroups within the same dataset would be severely biased
upwards (favouring discrimination), even under H0. In order to avoid this bias, I used a
ten-fold cross-validation procedure, fitting the CD to each nine-tenths of the model and using
the resultant value of β to compute values of the discriminant for the final tenth. I assessed
discrimination of each subtype in the same way as in section 6.4.3.
6.4.5 Genetic associations with subtype status
Initially, I conducted an a SNP based analysis to detect systematic differences between
subtypes of JIA. I used the same datasets as described in the previous section. I performed
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Fig. 6.8 Discriminants derived from PCA and LDA can behave markedly differently. Broadly,
PCA corresponds to the axis of greatest variation, which would be expected to differentiate
subtypes which differ in their fundamental disease mechanism. LDA finds the axis along
which subtypes are best discriminated. Although the linear discriminant in this example
roughly corresponds to the second principal component, and hence PCA alone may suffice, in
higher dimensions the number of principal components which potentially have to be analysed
to find one differentiating subtypes may be prohibitively high.
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a GWAS using a one-way ANOVA for each SNP, comparing within-subtype variance to
between-subtype variance, and computed p-values pdi f f from the resulting F-scores. Seven
subtypes were included in the analysis (those in table 6.2), considering EO and PO as separate,
and excluding unclassified samples and samples with missing subtype labels.
Multiple SNPs reached genome-wide significance (pdi f f < 5×10−8) and Bonferroni-
corrected significance (pdi f f < 6.9×10−9) in the MHC region. The lowest p-value was at
rs146683910, at which pdi f f = 5.5×10−72. The SNP rs146683910 was also associated with
JIA/control status (pJIA = 1.3×10−34) but not with EO/PO status (pEO = 0.22). No SNPs
outside the MHC region reached Bonferroni-corrected significance.
Substantial deviation from pdi f f ∼U(0,1) was evident in a Q-Q plot of −log10(pdi f f )
values with the MHC region included, but there was little evidence of inflation with the MHC
region removed 6.9. The deviation from U(0,1) increased when successively restricting
to subsets of SNPs with stronger evidence of association with pJIA, pRA, and pT 1D (see
chapter 2, section 2.2.6), more clearly when the MHC region was included. Conditional Q-Q
plots are shown in figure 6.10.
I performed cFDR analyses on directly typed SNPs for subtype differentiation conditioned
on T1D, RA and JIA. In all three analyses, a single SNP - rs2476601 - reached significance,
using a significance threshold based on conserving FDR between a GWAS analysis and
the cFDR procedure (threshold α2, chapter 3, section 3.2.2. The SNP rs2476601 is on
chromosome 1 near the PTPN22 gene. It is possibly a causal variant in the region for
RA [Stahl et al., 2010], T1D [Onengut-Gumuscu et al., 2014] and JIA [Hinks et al., 2013].
Collectively, these results indicate that there exist genetic variants differentiating JIA
subgroups, namely in the MHC region and near PTPN22. There is also evidence of pleiotropy
between subtype status and RA/control, T1D/control and JIA/control status, principally in
the MHC region.
6.4.6 GRS results
Similarity between JIA subtypes and adult diseases
Results for the GRS fitted to RA are shown in table 6.6. Both GRS were significantly
associated with JIA/control status (p = 1.4×10−9 with MHC included, p = 1.8×10−7 with
MHC excluded). Under the null hypothesis that JIA subtypes are genetically homogeneous,
the expected predictive accuracy of the GRS for determining subtype/control status should
be equal for all subtypes, and the associated p-value (column 5 of table 6.6) should be
monotonically decreasing with the number of samples in each subtype cohort. The subtype
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Fig. 6.9 Q-Q plot for p-values derived from F-scores for JIA subtype differentiation. A
99% pointwise confidence envelope is shown in grey, based on the distribution of order
statistics from a uniform distribution. There is evidence of departure from a uniform p-value
distribution when the MHC region is included, but not when it is removed.
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Fig. 6.10 Conditional Q-Q plots for inter-subtype differences in JIA, conditioned on JIA,
RA and T1D, with MHC included (left panels) and excluded (right panels). Note different
thresholds for conditional p-values, chosen because the studies on RA and T1D were larger
than the study on JIA. There is evidence of deviation from a uniform distribution for pdi f f
when conditioning on association with other phenotypes, most clearly when the MHC
regions is included. The reduced deviation when the MHC region is removed suggests that
the inflation is largely MHC driven. Confidence envelopes are not shown as they differ for
each conditional p-value threshold.
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for which the GRS most strongly separated cases from controls was EO, for which prediction
was significantly better in the observed data than under the null (p < 1×10−4; Bonferroni-
adjusted p-value threshold 3.6×10−3 over 14 tests).
The GRS with MHC included could not distinguish ERA or PsA cases from controls
(p-values for subtype/control comparisons 0.53, 0.76, 0.59 respectively), although the GRS
with MHC excluded could predict RF+poly and PsA subtypes to an extent (p-values for
subtype/control comparisons 3.28× 10−3, 3.10× 10−3). Since all variants in the second
GRS were included in the first with the same odds-ratio, this suggests that the variance of the
GRS with MHC included is dominated by the effects of SNPs in MHC which primarily affect
heritability for EO, PO and RF-poly subtypes. Both GRS predicted Sys/control status poorly,
but not much more poorly than would be expected if subtypes were genetically homogeneous.
The poor performance of both GRS on RF+poly was unexpected, as RF+poly JIA would
seem to be the most phenotypically related to RA. The substantially improved predictability
of EO/control status compared to other subtypes was also unexpected, since the subtype is
phenotypically similar to the PO, RF-poly and RF+poly subgroups.
Results from the GRS fitted to T1D are shown in table 6.7. Both GRS were significantly
associated with JIA/control status (p = 5.0×10−71 with MHC included, p = 5.2×10−10
with MHC removed). Again, the GRS with MHC included could predict EO/control status
significantly better than what would be expected if subgroups were genetically homogeneous
(p < 1×104, Bonferroni-adjusted p-value threshold 3.6×10−3 over 14 tests). Prediction
of systemic JIA was significantly worse than expected (p < 1× 104 with MHC included,
p= 3.8×10−3 with MHC excluded) indicating that in a broad sense, the genetic determinants
of Sys/control status are distinct from the determinants of T1D/control status. Given the
genetic similarity of JIA and T1D [Onengut-Gumuscu et al., 2014] and the evidence of genetic
differences between systemic and non-systemic JIA [Ombrello et al., 2017], this suggests
that similarity between JIA and T1D arises primarily from associations with non-systemic
JIA.
Unsupervised GRS
PC1 scores from the unsupervised GRS with MHC region included were significantly
different in JIA subtypes (ANOVA, p = 3.1× 10−12). This is consistent with the results
from single-SNP analyses in section 6.4.5, again indicating evidence for genetic differences
between JIA subtypes.
A plot of densities of PC1 scores by subtype is shown in figure 6.11. This visually
suggests that the between-subtype discrimination is driven to a large extent by the Sys
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Table 6.6 Details of GRS fitted to RA for differentiating JIA subtypes. Column 2 is the
number of samples in each subtype. Column 3 is the difference in mean GRS scores
(normalised to overall mean 0, variance 1) between subtypes and controls. Column 4 is
a p-value derived from a t-test against the null hypothesis that the GRS is independent of
case/control status. Column 5 is the probability that an observed t-score would be further than
the observed score from the mean of t-scores derived from random relabelling of subtypes,
and can be interpreted as a p-value against the null hypothesis implies that the accuracy of
prediction of that subtype from controls by GRS is equal to the accuracy of prediction of JIA
samples from controls on average. Column 6 indicates whether the differentiation of that
subtype from controls was worse or better than the average differentiation of JIA samples
from controls.
Subtype Cases Mean GRS dif. P (sub/ctl) P (vs pred) Dir.
MHC included
Sys 280 0.14 0.023 0.77 Worse
PO 650 0.19 1.17×10−05 0.37 Better
EO 390 0.4 5.44×10−14 < 1×10−4 Better
RF-poly 570 0.12 7.52×10−03 0.32 Worse
RF+poly 200 -0.044 0.53 3.80×10−03 Worse
ERA 180 -0.023 0.76 0.01 Worse
PsA 150 0.054 0.59 0.15 Worse
MHC excluded
Sys 280 0.062 0.3 0.2 Worse
PO 650 0.12 9.51×10−03 0.48 Worse
EO 390 0.12 0.023 0.77 Worse
RF-poly 570 0.21 3.28×10−05 0.13 Better
RF+poly 200 0.24 1.67×10−03 0.13 Better
ERA 180 6.42×10−03 0.93 0.066 Worse
PsA 150 0.24 3.10×10−03 0.12 Better
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Table 6.7 Details of GRS fitted to T1D for differentiating JIA subtypes. Column 2 is
the number of samples in each subtype. Column 3 is the difference in mean GRS scores
(normalised to overall mean 0, variance 1) between subtypes and controls. Column 4 is
a p-value derived from a t-test against the null hypothesis that the GRS is independent of
case/control status. Column 5 is the probability that an observed t-score would be further than
the observed score from the mean of t-scores derived from random relabelling of subtypes,
and can be interpreted as a p-value against the null hypothesis implies that the accuracy of
prediction of that subtype from controls by GRS is equal to the accuracy of prediction of JIA
samples from controls on average. Column 6 indicates whether the differentiation of that
subtype from controls was worse or better than the average differentiation of JIA samples
from controls.
Subtype Cases Mean GRS dif. P (sub/ctl) P (vs pred) Dir.
MHC included
Sys 280 0.21 1.08×10−03 < 1×10−4 Worse
PO 650 0.45 2.67×10−25 0.6 Worse
EO 390 0.68 1.61×10−36 < 1×10−4 Better
RF-poly 570 0.45 3.41×10−25 0.84 Better
RF+poly 200 0.44 7.87×10−10 0.88 Worse
ERA 180 0.51 1.23×10−10 0.67 Better
PsA 150 0.38 2.33×10−06 0.42 Worse
MHC excluded
Sys 280 −6.5×10−4 0.99 3.80×10−03 Worse
PO 650 0.20 1.04×10−05 0.39 Better
EO 390 0.21 1.36×10−04 0.32 Better
RF-poly 570 0.22 3.10×10−06 0.15 Better
RF+poly 200 0.28 1.97×10−04 0.083 Better
ERA 180 0.036 0.64 6.80×10−03 Worse
PsA 150 0.16 0.05 0.93 Better
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subtype. Tests of discrimination between each subtype and the remainder of the cases are
shown in table 6.8, which confirm this. PC1 scores for the Sys subtype were significantly
different from the JIA average (p = 4.68×10−10, not adjusted for multiple testing). The EO
subtype was again clearly discriminated from the average (p = 4.91×10−8, not adjusted),
with deviation in the opposite direction from the JIA mean to PC1 scores for Sys JIA. The
distribution of PC1 values for the ERA subtype appeared to be shifted from the mean scores
in the same direction as the EO subtype (figure 6.11) but evidence for this was inconclusive
(p = 0.089).
If we consider individual genotypes as points in a high-dimensional space in which each
dimension corresponds to a SNP, then the procedure of weighting variances according to
equation 6.29 is equivalent to a linear transformation on this space where the associated
matrix is diagonal, and the transformation is chosen to maximise the separation between
JIA samples and controls in the new space. The results above indicate that along the axis
in which points corresponding to JIA samples in this transformed space have the greatest
variance (PCA), EO and Sys samples tend to fall on opposite sides of the mean from the JIA
average.
PC1 scores with the MHC region removed were not able to differentiate subtypes in
general (p = 0.70) and no individual subtype was significantly differentiable from the mean
(table 6.7). This was relatively unsurprising, given that no individual non-MHC variant
reached Bonferroni-corrected significance for differentiating subtypes, and there was no
visible inflation of p-values on a Q-Q plot when the MHC region was removed (figure 6.9).
Although there was some evidence of inflation leveraged on JIA (figure 6.10) this was not
reflected in the GRS.
Supervised analysis
The cross-validated CD scores for which MHC was included had different means across
subtypes (ANOVA, p < 3×10−37). This was consistent with findings from the PC-based
GRS and the single-SNP analyses. The CD-based score was better able to differentiate
subtypes than the PC-based score, possibly due to being fitted specifically to differentiate
subtypes rather than to characterise the maximum variance in JIA genetics. Plots of densities
of CD scores are shown in figure 6.12 and results are tabulated in table 6.9. The CD with
MHC included showed striking differentiation between ERA samples and the JIA average
(p = 3.3×10−20), and again showed differentiation of the EO subtype from the JIA average.
The CD scores with MHC excluded did not have significantly different means across subtypes
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Fig. 6.11 Densities of PC1 for JIA subtypes, where PCs are computed weighting on
JIA/control status. Some evidence of separation of subgroups is seen, particularly for
systemic JIA (black solid line) and EO (green). The apparent trimodal distribution in the
lower panel is due to the small number of variants in the risk score.
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Table 6.8 Discrimination of JIA subtypes using the first PC weighted by z-score for
JIA/control. Column ‘Mean PC1 dif’ is the difference in average PC1 score for each
subtype from the overall mean PC1 score for JIA samples (note that these differences are
not independent). PC1 scores for Sys and EO subtypes are strongly differentiated from the
JIA overall average in the analysis with MHC included. Notably, PC1 scores for Sys and EO
subtypes deviate from the mean PC1 score in opposite directions.
Subtype Cases Mean PC1 dif P value
MHC included
Sys 280 -0.39 4.68×10−10
PO 650 0.061 0.18
EO 390 0.29 4.91×10−08
RF-poly 570 -0.022 0.64
RF+poly 200 -0.12 0.1
ERA 180 0.13 0.089
PsA 150 -0.15 0.065
MHC excluded
Sys 280 0.017 0.79
PO 650 -0.019 0.66
EO 390 0.058 0.29
RF-poly 570 0.052 0.28
RF+poly 200 -0.13 0.088
ERA 180 -0.028 0.71
PsA 150 −9.59×10−03 0.91
(ANOVA, p = 0.88) and no subtype had a significantly different mean CD score compared
to the other subtypes.
In the transformed space described in the previous subsection, the canonical discriminant
corresponds to the axis along which the predefined subgroups are best separated, as opposed
to the axis along which variance across samples is greatest (see figure 6.8). This suggests that
along this axis, ERA is strongly separated from other subtypes. It is not as well-separated on
the axis corresponding to the first PC.
6.4.7 Discussion
This series of analyses demonstrated evidence that genetic risk scores can be constructed
which differentiate certain JIA subgroups, principally involving variants in the MHC region,
and that JIA subtypes are differentiated in different ways according to the method used to
weight variants.
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Fig. 6.12 Densities of unbiased canonical discriminant for JIA subtypes, where CDs are
computed weighting on JIA/control status. Some evidence of separation of subgroups is seen,
particularly for the ERA (purple) and EO (green) subtypes.
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Table 6.9 JIA subtypes using the first CD weighted by z-score for JIA/control. Column
‘Mean CD1 dif’ is the difference in average CD1 score for each subtype from the overall
mean CD1 score for JIA samples (note that these differences are not independent). Mean CD
differences are correlated, but this effect is small. CD1 scores for EO and ERA subtypes are
strongly differentiated from the average scores for JIA in the analysis with MHC included.
The deviation of CD1 is in opposite directions for EO and ERA.
Subtype Cases Mean CD1 dif P value
MHC included
Sys 280 0.06 0.27
PO 650 -0.098 0.023
EO 390 -0.34 1.37×10−10
RF-poly 570 -0.092 0.041
RF+poly 200 -0.023 0.74
ERA 180 0.94 3.30×10−20
PsA 150 0.12 0.16
MHC excluded
Sys 280 0.029 0.65
PO 650 0.027 0.56
EO 390 -0.034 0.51
RFneg 570 1.05×10−03 0.98
RFpos 200 6.04×10−03 0.93
ERA 180 -0.011 0.88
PsA 150 -0.14 0.091
The improved predictive ability of a GRS for RA in the EO subtype suggests causative
processes may be shared to a greater extent between EO and RA than between other JIA
subtypes. This is consistent with the clinical observation that a symmetric distribution of
affected joints is associated with oligoarthritic extension [Al-Matar et al., 2002]. The GRS
for RA with MHC included was significantly less able to predict RF+poly than would be
expected if subtypes were genetically homogeneous, but with MHC excluded, a GRS for RA
was able to differentiate EO from controls about as well as expected under a null hypothesis
of genetic homogeneity. This suggests distinct disease mechanisms for EO and RA associated
with the MHC region, but potentially shared mechanisms controlled by elsewhere in the
genome.
The GRS for T1D also predicted EO better than expected. Prediction of systemic JIA was
significantly worse than expected, and the poor prediction remained in the GRS with the MHC
region removed. This suggests an absence of shared mechanisms between T1D and systemic
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JIA, which is notable given the good prediction of other JIA subtypes. The differentiation
between systemic JIA and other subtypes was also observed in the unsupervised analysis
using PCA, suggesting a fundamental difference in the mechanism of systemic JIA compared
to other subtypes. This is consistent with earlier findings [Ombrello et al., 2017].
The supervised analysis (LDA) was notable for the sharp discrimination of ERA. The
ERA subtype appeared to be moderately differentiated from other JIA subtypes on the basis
of the GRS for T1D and the PCA analysis, but to a much lesser extent. This suggests a
distinction between causative mechanisms of ERA and other JIA types, and highlights the
importance of considering both types of discriminants. Further analysis of ERA could involve
leverage on summary statistics for ankylosing spondylitis, a phenotypically similar adult
disease [Colbert, 2010].
As discussed in the introduction to this chapter, an important question regarding the ILAR
subtypes is whether they are the most clinically-relevant way to sub-classify the disease. The
results from the single-SNP analysis and the unsupervised GRS (PC-based) lend credence to
the current subtyping criteria by demonstrating the presence of genetic heterogeneity between
ILAR subtypes, in addition to that demonstrated for Sys JIA [Ombrello et al., 2017]. In
particular, the variation across subtypes observed in the first re-weighted principal component
indicates that the current subtyping may capture the ‘fundamental’ variance in JIA genetic
architecture to an extent. However, I noted that the between-subtype discrimination using the
canonical discriminant was larger than that using PCA. If the ILAR subtyping corresponded
to a maximum separation of subtypes in the transformed space described in section 6.4.6,
then (under the assumption that the variance in PC1 is due to inter-phenotypic heterogeneity
rather than identity by descent or other confounders) we would expect the PCA and LDA
axes to be approximately the same, and the separation of subgroups along these axes to be
similar. This suggests that other sub-classifications may better differentiate JIA cases on a
genetic basis than the current ILAR subtypes.
The risk scores developed in this section do not have the immediate potential clinical
application of those developed to differentiate EO and PO. Indeed, the findings of this section
may appear vague, and it is not clear why an assertion of ‘increased chance of similar disease
mechanisms’ should be useful either clinically or scientifically. Since studies of this sort do
not definitively associate any given pathway with any JIA subtype of interest, further studies
will be necessary in order to translate any assertion of disease similarity into a clinically
useful knowledge of disease pathology.
However, there are a vast range of processes potentially contributing to arthritis and
articular disease. In order to understand the action of a pathological process on a disease
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in broad terms, the activity of that process has to be monitored in individuals with the
disease. This is an expensive process, both in investigative resources and burden on the
patient population. The identification of probable shared processes between diseases enables
improved prior knowledge of the processes likely to be involved. By establishing similarities
with well-studied and common disease such as RA and T1D, knowledge already attained
about the common diseases can be used to reduce the burden of investigation in the rare one.
The PC- and CD- based analyses contribute to understanding the way subtypes separate on
the basis of JIA association itself, and may be useful in informing further clinically-useful
disease subtypings. This can ultimately contribute to improving treatment provision in
patients with JIA.

Chapter 7
Discussion
7.1 Conclusions and linking themes
In this thesis, I developed a range of methods for the comparison of case-control studies, with
application principally in the analysis of genomic data for complex diseases. This entailed
an important extension of a method for levering GWAS summary statistics in an asymmetric
way (chapter 2), with application to the analysis of underpowered datasets (chapter 3); the
development of a similar shared-control design in the context of study replication (chapter 4);
the development of a characterisation of patterns of genetic heterogeneity in disease subtypes
(chapter 5) and the specific investigation of heterogeneity patterns in JIA using predictive
risk scores (chapter 6). Recalling figure 1.1 in chapter 1, these topics are not sequential and
their goals are varied; however, they are linked by several underlying ideas.
Individual methods and findings are discussed in the relevant chapters. In this chapter, I
will begin by discussing the linking themes of this work, and their advantages and shortcom-
ings. I will then examine the wider context of this work and discuss how it can contribute
to scientific understanding of the genetics of complex disease. Finally, I will discuss the
implications of this work in the development of precision and personalised medicine, and
suggest several areas for further research.
7.1.1 Joint analysis of two traits
Every project in this thesis concerns the co-analysis of more than one trait or study; chapters 2
and 3 concern analysis of explicitly different diseases, chapter 4 different studies on the same
disease, and chapters 5 and 6 studies relating to heterogeneity within a disease.
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The advantage of co-analysis of related traits, as opposed to single-trait analyses or
meta-analysis of both traits together, is improved power for detecting association in one study
while minimally compromising the specificity of the trait under investigation. If one trait is
analysed at a time, this improved power is lost; if traits are meta-analysed as though they
were the same disease, it is difficult to ascribe a resulting association specifically to one of
the two traits.
However, the compromise is imperfect; some specificity and power are necessarily lost.
As discussed in chapter 3, section 3.4, the ordering of variants by ĉFDR is systematically
different to the ordering of variants by p-value when there is pleiotropy between the principal
and conditional phenotypes. Disregarding LD, the expected p-values of variants of a fixed
AF are monotonic to the effect sizes of those variants, but this is not true for the expected
ĉFDR values. The same is generally true for any procedure assessing association with one
phenotype conditioning on another. For instance, a test for association could be developed
based on the fitted coefficient for a SNP of interest in a GRS for the phenotype of interest
levered on a second phenotype such as those in chapter 6, section 6.3.3, but such a test would
be influenced both by association with the phenotype of interest and by association with the
levering phenotype. Thus, although the cFDR procedure and other association tests using
leverage can be used to identify the set of regions associated with a disease, it cannot be used
directly to assessing the relative effect sizes of variants.
If large enough datasets were available, co-analysis of traits would not be necessary,
and the compromises could be avoided. ‘Large enough’ is nonetheless intractable; even as
sample sizes increase through the hundreds of thousands of samples, new associations with
complex traits can still be discovered [Wood et al., 2014]. It is impossible that anywhere near
this power may be attainable when analysing rare diseases, and even if it were, the trend of
subdividing diseases into ever-finer subtypes [Robinson et al., 2008] will probably continue
as interest in ‘precision medicine’ develops [Collins and Varmus, 2015], so interest in small
studies is likely to persist. Furthermore, variant effect sizes for the same disease may differ
between cohorts of patients with different ethnicities, and as GWAS expand in scope past
the western world, comparison of results between populations will continue to be of medical
interest [Rosenberg et al., 2010].
The promise of co-analysis of two studies suggests a natural extension to more than two
studies. This extension could lead to deeper understanding of genetic relationships between
diseases; for example, the similarities and differences between JIA prediction using T1D and
RA in chapter 6, and the pleiotropy explored in chapter 3 suggests the presence of categories
of variants affecting only two of the three traits as well as all three. However, three- or
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more- trait analysis becomes difficult in terms of data requirements. All the methods for joint
analysis in this thesis require modelling distributions of effect sizes in some way, but this
becomes difficult for more than two diseases. In practical terms, given three traits i, j, k, a
cFDR analogue of the form
Pr(H i0|Pi < pi,Pj < p j,Pk < pk) (7.1)
would require estimation of densities of the three-dimensional random variable (pi, p j, pk),
which would become very erratic in regions where observations are sparse. However, this
may be an interesting avenue of further research, if sufficiently detailed datasets are available.
7.1.2 Adaptations to a shared control design
A second common theme in this thesis is the comparison of studies with shared controls.
As derived in chapters 2 and 4, sharing controls (or cases) induces a correlation between
resultant effect sizes. This is managed in different ways in different chapters; in 2, p-values
are transformed to account for the correlation; in 4, thresholds are adjusted to maintain
false-positive rates, and in 5 (in which all controls are ‘shared’ between analyses for each
subgroup), alternative summary statistics are used which are independent under the relevant
null hypotheses.
The obvious advantage of sharing controls is enlargement of the control cohort, increasing
power in univariate analyses (standard GWAS) and usually increasing power in bivariate
analyses. Chapters 2 (figure 2.2) and 4 (figure 4.2) explore the improvement in power in
several specific contexts. A disadvantage of sharing controls is the requirement for more
complex analyses, or the use of alternative summary statistics which are harder to interpret.
Chapter 4 explores more subtle advantages and disadvantages in the context of ‘aberrance’
in various cohorts. If some error in sampling or measurement leads to a systematic difference
between the expected value of some variable in a control cohort and the expected value of
the variable in the population the cohort ostensibly samples, then sharing the control cohort
between both studies will propagate this error into both studies. This could lead to loss
of control of type-1 error rate in the study replication setting (chapter 4) or inappropriate
leverage in the cFDR setting. In the cFDR setting in particular, errors in shared controls
could lead to loss of control of type 1 error rate in two ways; firstly, by lowering p-values
at affected variables in both the principal and conditional phenotypes, and secondly by
suggesting pleiotropy where there may not be any, inappropriately lowering the p-value
threshold for association at low conditional p-value thresholds, and increasing type 1 error
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rate at unaffected variables. Conversely, sharing controls can also improve control over
type-1 error rate if there is aberrance in other cohorts, explored in detail in chapter 4. This is
of importance if there is differential confidence in the representativeness of cohorts of their
respective populations.
Sharing controls is becoming common as datasets become more widely shared (eg [The
Wellcome Trust Case Control Consortium, 2007, UK Biobank, 2007, Canela-Xandri et al.,
2017]). Large GWAS meta-analyses frequently use controls from a range of sources, not
necessarily recruited specifically for the study (eg [Okada et al., 2014, Barrett et al., 2009,
Trynka et al., 2012], meaning that control subjects in such studies frequently overlap. This
can be a problem if comparisons between studies are performed naively, since p-values are
dependent between studies even for null SNPs. This provides a second important incentive
for the development of shared-control designs in association study comparison: the enabling
of type-1 error rate control in comparisons between large published datasets without the need
to recalculate summary statistics.
7.1.3 Using multi-SNP effects
Chapters 5 and 6 both involve statistical inference based on multiple variants, rather than
single-SNP effects. Chapters 2 and 3 search for single-SNP effects, but use the joint
distribution of effect sizes of genome-wide SNPs to inform association tests.
All methods assume that the genetic architecture of the disease in question involves a
large number of SNP-disease associations, with an approximately normal distribution of
effect sizes (appendix A.1.1 to chapter 2 includes an exploration of robustness to deviation of
effect sizes from a normal distribution). The method in chapter 5 is based on the assumption
that there is greater power to detect multi-SNP effects than to detect than single-SNP effects;
see figure 5.4.
From a biomedical perspective, the assumption of a large number of associated variants
is justifiable. Biochemical and metabolic pathways are complex, and many perturbations
could potentially lead to exacerbation of a pathological process. Variants strongly associated
with a disease are expected to be under negative selection, so disease-associated variants
typically have small effect sizes or are rare [Gibson, 2012]. An implication of this is that
individual SNP-disease associations are generally difficult to find, so analysis of combinations
of variants may be necessary in order to understand disease genetics in any way.
A problem with multi-SNP effects is difficulty in interpretation, with the result that the
best follow-up for investigating a positive result may be unclear. Positive results using the
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PLR test developed in chapter 5, for example, do not immediately suggest any lines of
follow-up (other than the single-SNP tests outlined in section 5.2.5, although they do not
require a positive result from the PLR test in order to be used). The clinical or scientific
usefulness of ‘similarity’ of subtypes of JIA based on various discriminants in chapter 6
is also not immediately obvious. The methods do, however, have important scientific uses,
which are discussed specifically in sections 6.4.7 and 7.1.5.
In general, many standard analyses of genomic data are focussed on finding single-
SNP effects because the long-term goal is to identify new drug targets (eg [Wolfs et al.,
2009, Zhang et al., 2008]). However, this is not the only way that genomics can contribute to
medical practice. An important prospect for clinical contribution is the use of genetic risk
scores as predictors of disease risk or disease outcome, as discussed in chapter 6 (though
the extent is debatable [Clayton, 2009]). I propose that determination of the likely cause
of subgroup heterogeneity in a disease (chapter 5) may also be useful in directing further
research on heterogeneity to investigating predominantly environmental, physiological or
pathological causes.
7.1.4 Efficient use of information
It is generally an important task in statistics to determine the best procedure to use for a given
problem. A typical metric used for performance in frequentist statistics is the maximisation
of power for a fixed type-1 error rate, as used in (for example) the Neyman-Pearson lemma.
Determination of the exact or asymptotic power of a procedure in general circumstances
is often mathematically intractable, particularly when trying to predict performances on
complex structures such as genomic data. However, a useful heuristic for performance is
whether the procedure incorporates everything we (the researcher) know about the data.
This heuristic is useful in several chapters. Chapter 2 is an adaptation of an existing
procedure to make use of the information that associated variants may be common to related
diseases (that is, show pleiotropy), which is otherwise not used in a standard GWAS analysis.
I extended it to allow for shared control samples, allowing for incorporation of the knowledge
that the expected value of variables under investigation is (generally) the same in both control
sets. This is also a key part of the incentive for the procedure in chapter 4.
A more subtle argument in the cFDR method concerns its comparison against a more
typical leverage procedure, in which only variants reaching a given p-value threshold in some
conditional phenotype are tested in the principal phenotype, with a threshold on p-value
for the principal phenotype determined using a Bonferroni correction (eg [Plagnol et al.,
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2011]). This has the advantage over the cFDR of easy control over the overall FDR (using the
Benjamini-Hochberg procedure) and an obvious advantage in simplicity of method. However,
it means that variants narrowly missing the conditional p-value threshold are excluded from
investigation, and variants with p-value thresholds reaching the threshold are treated the same
way, no matter how associated they are with the principal phenotype.
In this case, the information from the summary statistics for the principal phenotype
is reduced from a real-valued variable to a binary variable, representing a large sacrifice
of information. The reduction in information is slightly smaller if the threshold is chosen
according to the distribution of p-values for the conditional phenotype, but choosing a
threshold in this way is difficult without biasing results (the ‘Texas Sharpshooter problem’).
The cFDR requires no such sacrifice, and should in general circumstances have greater power
to detect variants at a fixed false-positive rate than methods based on a single-SNP cutoff.
The methods in chapters 5 and 6 both involve assessing within-subgroup association. The
single-SNP analysis using the cFDR in chapter 5 and the PC/LD scores in chapter 6 both
perform this analysis by levering on associations between the general disease and the control
group (Za, using the notation of chapter 5). In this way, more information is used than would
be under an isolated analysis of subtype differentiation.
An important caveat of increased information use is the question of whether the increased
information actually helps. In an analysis of T1D|PSO in chapter 2, no inflation is evident
for T1D after conditioning on association with PSO. In this case, intuitively, the inclusion
of PSO data in the analysis of T1D adds no extra information to the analysis, and should
not improve power to detect association with T1D at all. The analogue of this in the inter-
subgroup comparisons of chapters 5 and 6 is independence between subgroup associations
and case/control associations - the null hypothesis in chapter 5. This is one reason why
assessment of this null hypothesis is important
The heuristic of information use is not perfect. As demonstrated in chapter 4, the
improvements in power from using more information may be very small, and may come
at the cost of losing control of other error rates. However, I consider it an important
consideration in experimental and analytical design.
7.1.5 Genetic analysis of subgroups
In the introduction to this thesis, I proposed that the fields of medicine and medical research
have changed markedly in the past several centuries in the way that they classify diseases.
In the earliest medical records, patients are classified very specifically, only occasionally
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drawing links between similar presentations. As medical science and society progressed,
classifications of diseases grew broader, allowing greater power in assessing pathology and
treatment strategies. Finally, in the past several decades, the trend has been reversed, and
diseases are becoming ever more finely sub-classified. The merits of analysing diseases as
large but heterogeneous cohorts or small homogeneous cohorts is known as the ‘lumping-
splitting’ debate [McKusick, 1969].
The general reason for the subdivision of diseases is the hope for more specific treatment,
avoiding the use of unnecessary therapy. From a clinical perspective, patients are often
managed by successively trialling different therapies until one is effective (eg [Ravelli and
Martini, 2007]). The advantages of predicting response to therapy are thus in reducing the
time patients need to spend trialling therapies, and reducing the cost to the medical system
from temporary trials of ineffective medication. The advantages are naturally greatest for
medications which are effective in only a small (but identifiable) subset of disease cases, and
are expensive to produce.
From a practical perspective, sub-classifications of disease are used to characterise
patients who respond to a given therapy in a clinical trial. However, this is not simple. For
a cohort of N patients, there are 2N ways to select a patient subgroup. Even in a realistic
clinical context, there are a huge number of potentially clinically useful subgroupings; for
instance, by the presence or absence of any disease symptom or set of symptoms, by ethnicity
or country, by body habitus or physiological parameters, or by aspects of disease course. The
vast scope of potential subgroupings means that prior information on which subgroupings
are likely to be able to predict treatment response must be incorporated. This can be done
either by only considering subgroups likely to be predictive of treatment response (that is,
using a prior which has probability 0 for unused subgroups), or explicitly constructing a prior
over potential subgroupings.
The methods developed in chapters 5 and 6 are useful in producing such a prior. In
particular, the methods in chapter 5 are important in differentiating the types of heterogeneity
present in a subgrouping. This can enable more effective classification of patients who
respond to a given therapy, ultimately improving the efficiency of the medical system and
reducing harm to patients.
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7.2 Future directions
7.2.1 Conditional analysis
An important application of several methods in this thesis is the use of a large dataset to enable
a better analysis of a small one. In both chapter 2 and 6, the analysis is asymmetric, in that
the hypotheses of interest only concern the small dataset; chapter 3 the cFDR methodology
is used to investigate EGPA conditioning on a much larger dataset of GWAS association
statistics for eosinophil count in healthy individuals, and in chapter 6, association statistics
from a comparatively large study (RA/T1D/JIA) are used for both variable selection and
coefficient estimation in GRS for a smaller dataset on a rare phenotype (EO/PO). In both
the cFDR methodology and the methods in chapter 6, the association of variants with the
levering phenotype does not need to be investigated, and indeed, the phenotype used for
leverage does not need to be meaningful in itself.
This invites the possibility of assembling large GWAS datasets for the sole purpose of
leverage. An example may be an assimilation of all cohorts of autoimmune disease cases in
chapter 2. Given the widespread pleiotropy between autoimmune diseases, some of which
was explored in the chapter, this could enable the identification of variants which have too
small an effect size in any single phenotype. Importantly, a genetic association in such a
case cohort would mean little on its own, since the evidence of association with any one
disease may be poor - but the dataset as a whole could be an effective way to prioritise
autoimmune-associated regions for analysis. The ImmunoChip and similar custom arrays
were designed using similar reasoning.
The assembly of multiple case cohorts into one risks reducing effect sizes for variants
only associated with a subset of the constituent cohorts. This reduction of effect sizes may be
overcome by using a p-value based meta-analysis, as variants may have effects in opposite
directions in different cohorts ([Cotsapas and Hafler, 2013]). Another problem may be that a
meta-analysis of many diverse case-cohorts could identify too many associated variants to
effectively reduce dimensionality. Despite these potential shortcomings, I believe that some
assembly of some such cohorts could strengthen the power of standard GWAS analysis and
facilitate genomic analysis of rare disease in cases where it may not previously have been
possible. This is an example in which both the ‘lumping’ and ‘splitting’ philosophies could
be used together.
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7.2.2 Further characterisation of heterogeneity
The methodology presented in chapter 5 aimed to differentiate two particular classes of
heterogeneity between disease subtypes; namely, testing for the presence of a set of variants
associated both with subtype status and case/control status. As detailed in appendix D.1,
table D.1, this dichotomises a larger set of potential genetic architectures of disease subtypes.
A potentially useful line of further research would be to develop methods to differentiate
two-dimensional genetic architectures further.
There are several metrics which could be used to develop such a characterisation process.
An important starting point is assessing deviation of Zd from an N(0,1) distribution, to iden-
tify whether disease heterogeneity is completely environmentally-driven, with no heritability.
This is more difficult that it may initially seem. The EO/PO phenotype in chapter 6 is an
example; there is no evidence of deviation of pEO from a uniform distribution, but evidence of
deviation can be seen conditioning on other phenotypes, indicating that the EO/PO phenotype
has a degree of heritability. Other important metrics, explored in appendix D.1, table D.1,
include genetic correlation and the proposed ‘absolute correlation’.
Another important potential application of the subgroups methodology is in the investi-
gation of differential drug response. Different responses to therapy may be due (in varying
degrees) to individual differences in pharmacokinetics and to different disease mechanisms,
and the question of which of these is occurring is of importance in personalised medicine.
As discussed in section 7.1.5, if the goal is to characterise a subgroup of patients likely
to respond to a drug, a strong prior on likely subgroupings of patients is necessary. The
methodology of chapter 5 applied to this problem could determine if the best subgroupings
to look at are on the basis of disease symptomatology or individual pharmacokinetic and
physiological variation.
7.2.3 Personalised, precision, and ‘ballpark’ medicine
A large part of the motivation for the topics in this thesis, and the field of genomics in general,
is the development of precision medicine. This can be seen as the eventual goal of the move-
ment towards finer phenotypic subdivisions, and the incentive for precise characterisation of
the pathological processes for complex diseases.
Precision medicine is essentially the modulation of therapy and clinical management
between individuals in response to their specific physiology and disease type [Collins and
Varmus, 2015]. It is already a major part of many aspects of medical practice (for example,
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blood typing prior to transfusion) but it has the potential to expand in scope with the increased
clinical use of genomic data and -omics analysis methodology.
Incorporation of high dimensional data in medicine has several challenges. One important
difficulty concerns interpretation of tests in the context of different prior probabilities of
disease. Medical diagnosis is generally a Bayesian process; beginning with a prior on disease
probability based on epidemiological data, a clinician makes a set of initial observations
(history and examination), after which the probability distribution over potential diseases is
more informative. The next stage of diagnosis generally involves choosing a set of laboratory
investigations with the highest information content; hence clinicians generally observe the
results of biochemical and radiological investigations in the context of an already highly-
informative prior. Genetic data, by contrast, remains the same over the lifespan of a patient,
and may be used at any stage in the diagnostic procedure. To be useful in making a final
diagnosis, proposals for the use of genomic data in medicine must involve co-analysis with
other clinical data.
The major current use of genetic data in medicine is in the diagnosis of Mendelian
traits, such as Huntington’s disease or cystic fibrosis. Although this is a clinically-useful
application, the benefit is only to a small proportion of patients. For the large majority of
the patient population, their genomic data will not be able to accurately predict whether they
will develop a disease; but it may be able to inform ‘ballpark’ estimates of how their pattern
of disease risk differs from the population average. If genomic data is to be of use to such
patients, then there needs to be a way to meaningfully respond to small increases or decreases
in common disease risk. An example of data of this form may be a genetic risk score of the
type in chapter 6, section 6.3.5.
There are several ways in which clinical management may be slightly modulated in
response to risk scores. Since risk scores can be calculated at any stage in a patient’s life, one
potential clinical response would be to modulate individual thresholds on clinical parameters
needed to diagnose a disease. For instance, if a patient was judged by genomic data to be
at a 5% increased risk of coronary artery disease, their individual threshold on HbA1C for
diagnosis of type-2 diabetes could be slightly lowered, in response to a slightly increased
need to maintain normoglycaemia. The storage and access of patient-specific thresholds may
become more feasible with the development of electronic health record systems.
This type of intervention requires extensive comparison of results for different disease,
which is the area in which my work may contribute. Predictive scores for rarer phenotypes
are likely to benefit from leverage on common phenotypes, which can be facilitated using
the methods in chapters 2, 3 and 6. In the above example, the intervention would only be
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effective if the patient’s genetic coronary disease risk was not modulated through increased
genetic risk of T2D, which may require understanding the shared and distinct architectures
of the two diseases; the methods developed in 5 can help direct this.
The development of precision medicine is a potentially exciting new field, and the
introduction of statistical techniques for analysis of high-dimensional data will be vital to
its progress. In a sense, precision medicine represents the integration of a diverse range of
scientific disciplines into medical practice; some of which are discussed throughout this
thesis. The further introduction of genomics into medicine, along with rigorous statistical
methods and effective data management, will, I believe, come to be a milestone of the medical
field.
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Appendix A
Supplementary material for chapter 2
A.1 Supplementary note
A.1.1 Robustness of normality assumption in estimating distribution
of effect sizes
The computation of cFDR with shared control groups requires an estimate of the distribution
of true effect sizes η in the conditional phenotype; that is, the z values which would be
observed if the MAFs in controls and cases exactly matched the true MAFs in the relevant
populations. We assume that the values η are instances of a random variable H.
For any distribution of effect sizes which is non-increasing for positive effect sizes and
non-decreasing for negative effect sizes, the true cFDR is less than the ’naive’ cFDR obtained
from applying the Andreasson formula without adjustment (theorem A.1.3, section A.1.3).
That the distribution of true effect sizes should have this profile is essentially the assumption
that ’small’ effect sizes are more frequent than ’large’ effect sizes in polygenic phenotypes, a
hypothesis suggested by recent large GWAS [Wood et al., 2014].
In our algorithm, we assume the true effect sizes η follow a mixture distribution, being 0
with probability π0 and following a normal distribution with mean 0 and standard deviation
σ with probability 1− π0. This is largely for computational convenience, as it allows a
simplification of a triple integral to a double (see section 2.4, equation 2.18). However, the
formula can be applied for any distribution of H.
The information about the distribution of H is incorporated into the formula for ĉFDR
through the expression Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ). As shown in theorems 1 and A.1.3 in
section A.1.3 this is larger than pi for most reasonable distributions of H.
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If the true distribution of H is different to that assumed, the estimate of Pr(Pi ≤ pi|Pj ≤
p j,H
(i)
0 ) will be incorrect. Overestimation of Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) is a less serious prob-
lem, as it will lead to a (conservative) overestimate of ĉFDR. Since ĉFDR is a systematically
conservative estimate of cFDR anyway, the expected ĉFDR using the incorrect distribution of
H will still provide an upper bound on the true cFDR (= Pr(H(i)0 |Pi ≤ pi,Pj ≤ p j)), although
this would cause a loss in power.
If, however, an incorrect assumption on the distribution of H leads to an underestimation
of cFDR, the estimate may no longer be conservative, meaning that the expected value of
ĉFDR may not be a true upper bound on ĉFDR. While it is the true distribution of H is
generally unknown, I show in theorem A.1.4 in section A.1.3 that the distribution of H
for which Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) is highest is the degenerate distribution at 0; that is, if
π0 = 1, so the worst the underestimate can be is in the case in which all SNPs are null for the
conditional phenotype.
For a SNP with p values (pi, p j) for two phenotypes i, j, the percentage difference
in Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) when using the normal approximation compared to the ‘true’
distribution of H is equal to the percentage difference in ĉFDR(pi|p j) and indicates the
range of potential ĉFDR cutoffs for which the normal approximation will lead to a different
classification of the SNP. However, this does not account for the distribution of values of
(pi, p j); clearly some values of p j are far more likely than others, and in general the more
likely values of (pi, p j) tend to correspond to smaller errors. An implication of this is that
although an incorrect assumption of the distribution of H could theoretically lead to a 20%
over- or underestimation of the true ĉFDR, a much smaller error may be observed in the
actual number of SNPs for which ĉFDR is less than some threshold.
To show this, I simulated observed effect sizes for 10000 SNPs for a principal phenotype
i and a conditional phenotype j. The Z scores for the conditional phenotype were distributed
according to various non-Gaussian distributions, and the Z scores for the principal phenotype
were distributed as N(0,5), in order to generate values with a reasonable range. Z scores
were correlated with ρ = 0.3, corresponding to partial sharing of controls. Values of ĉFDR
were computed using first the true distribution of effect sizes for the conditional phenotype
and second a normal approximation. We compared the number of SNPs reaching a range of
a range of thresholds for ĉFDR.
The first four rows of figure A.1 show the amount by which Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) is
overestimated or underestimated using our technique for various distributions of H. The
leftmost panels show the percentage error which arises for possible values (pi, p j) (p values
for the principal and conditional phenotype respectively), and the middle pattern shows the
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number of SNPs with ĉFDR less than a given cutoff with cFDR calculated using either the
true distribution or the normal approximation of H. The rightmost panel shows the true
distribution of H and the normal approximation to it.
When H has a bimodal distribution, the error is almost universally below 5%. In general,
if the true distribution of H follows a heavy-tailed distribution, such as the T-distribution,
then because our approximation comparatively under-weights extreme H values, which
would otherwise lower the estimate of Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ), in favour of values nearer
zero, our approximation tends to overestimate rather than underestimate Pr(Pi ≤ pi|Pj ≤
p j,H
(i)
0 ), which, as discussed, is favourable. Except for very pathological distributions, the
overestimation or underestimation is rarely greater than 20%. For all tested distributions, the
effect on the number of SNPs with ĉFDR less than a cutoff is negligible.
The lowermost panel of figure A.1 simulates a scenario in which all SNPs are null for the
conditional phenotype, but in which our estimated distribution of H has parameters pi0 = 0.9,
σ = 2. In practice, the E-M algorithm for estimating the parameters of the distribution will
generally return π0 = 1, meaning such a scenario is unlikely to occur if the observed values
of Pj do not differ substantially from their underlying distribution. This figure indicates the
maximum possible underestimation of Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ), given incorrectly estimated
values of π0 and σ . Notably, it is highest when both pi and p j are very low.
Although the left-hand panel of figure A.1 E demonstrates that there is potential for major
underestimation of the expected quantile, the middle panel shows that in this scenario the
mis-estimation has minimal effect on the number of SNPs reaching various ĉFDR thresholds.
This is because the major underestimation occurs at very low p j values, which are very rare
under the true distribution H = 0.
I conclude from these results that a normal approximation to the distribution of H is
reasonable in most cases.
A.1.2 Estimation of the distribution of p values for the principal phe-
notype across SNPs null for the conditional phenotype
The distribution of p values for the principal phenotype across SNPs null for the conditional
phenotype can be derived from the distribution of Z scores given in the Methods section of
chapter 2.
(Zi,Z j|H(i)0 )∼
N((00
)
,
( 1 ρ
ρ 1
)
), p = π( j)0
N((00
)
,
( 1 ρ
ρ 1+σ2
)
), p = 1−π( j)0
(A.1)
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Fig. A.1 Figures showing the effect of incorrectly estimating the distribution of conditional
effect sizes. If the distribution of ’true’ effect sizes for the conditional phenotype (the effect
sizes which would be observed in a study of equal size if the observed MAFs exactly matched
population MAFs) is incorrectly assumed, the value Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) (proportional
to ĉFDR) will be incorrectly calculated. These figures demonstrate a range of possible
distributions for the true effect sizes, with an assumed value of π0 = 0.9 in each case. In all
cases, we simulated 105 samples from the ’true’ distribution and used our E-M algorithm
to find an approximating π0 and σ . For panels A-D, the right-hand plot shows the ’true’
conditional effect size distribution (uniform, T (df=5), and bimodal with near and far peaks
respectively) and our approximation and the left-hand plot the percentage error in the estimate.
Note that colours correspond to different values in the different graphs due to difficulties in
scaling. Panel E shows the maximum fold underestimation of cFDR, which occurs the true
effect sizes are all zero. The ’estimated’ distribution here is not what would be estimated by
our E-M algorithm (which would find the correct distribution in this case) but a simulated
incorrect distribution.
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While I previously computed a distribution (Zi,Z j|H(i)0 ) in order to compute the expected
quantile, here my motivation differs. When computing the expected quantile, the motivation
was to determine what the expected distribution for (Zi,Z j|H(i)0 ) would be if the SNP were
null for the principal phenotype; in this section, we aim to find the expected distribution only
for truly null SNPs. For this reason, while we fitted the earlier model to all values Z j; here, I
only fit the model to a subset of values Z j which I expect to correspond to null SNPs.
I fit the model to the Z j values for the SNPs corresponding to Pi ≥ 0.5. Because I expect
true effect sizes to be independent at SNPs which are null for the principal phenotype, this
will be a representative sample of the distribution of Z j for these SNPs. I expect that some
non-null SNPs will also have Pi ≥ 0.5; however, the proportion of such SNPs will be small,
and their inclusion would be expected to lead to an estimate of the distribution of Pj biased
toward low values, affecting the integral of f0 over L more than the integral over X and
making the estimate conservative.
I assume Pr(Pj ≤ p j|Pi ≥ 0.5,H(i)0 )≈ Pr(Pj ≤ p j|H(i)0 ) and fit π ′0, σ ′ to the model
Z j|H(i)0 ∼ Z j|Pi ≥ 0.5,H(i)0 ∼ π ′0N(0,1)+(1−π ′0)N(0,σ ′2) (A.2)
using expectation/maximisation.
Defining fρ,π0,σ (zi,z j) as
fρ,π ′0,σ ′(zi,z j) = π
′
0N(0
0
)
,
( 1 ρ
ρ 1
)(zi,z j)+(1−π ′0)N(0
0
)
,
( 1 ρ
ρ 1+σ ′2
)(zi,z j) (A.3)
the PDF of p value pairs (Pi,Pj) = (2 Φ(−|Zi|),2 Φ(−|Z j|)) can then be written as
pd f (pi, p j) = f0(pi, p j) =
(
fρ,π ′0,σ ′(−Φ
−1(
pi
2
),−Φ−1( p j
2
))
+ fρ,π ′0,σ ′(Φ
−1(
pi
2
),−Φ−1( p j
2
))
+ fρ,π ′0,σ ′(−Φ
−1(
pi
2
),Φ−1(
p j
2
))
+ fρ,π ′0,σ ′(−Φ
−1(
pi
2
),Φ−1(
p j
2
))
)
×π
2
exp(
1
2
(Φ−1(
pi
2
)2+Φ−1(
p j
2
)2)) (A.4)
where Φ(z) denotes as usual the normal CDF at z, and Φ−1(p) its inverse at p. If the upper
right vertex of M∗ is on the line Pj = 1, then the integral of this PDF over the rectangle M∗
is simply the area of M∗, as it corresponds to the area of the marginal PDF for Pi, which is
U(0,1) by assumption. The integral of the PDF over L is easiest to obtain by integrating
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expression A.3 over the analogue of L on the plane Zi× Z j. If σ ′ = 1 then the PDF is
identically 1 and this integral is the area of L.
A.1.3 Overestimation of expected quantile by raw p value
Theorem 1. Given two bivariate normal random variables (Zi,Z j) with means (0,0) and
covariance matrix
(
1 ρ
ρ 1+σ2
)
, define Pi = 2Φ(−|Zi|) and Pj = 2Φ(−|Z j|) (the p values
associated with Zi and Z j). Then for any pi, p j ≥ 0
Pr(Pi ≤ pi|Pj ≤ p j)≥ pi (A.5)
with equality if and only if ρ = 0, pi = 0, or p j = 0.
Proof. Define zi =Φ−1(pi/2), z j =Φ−1(p j/2), and let
fσ (x) =
1√
2π(1+σ2)
exp(− 1
2(1+σ2)
x2)
fσ (x,y,ρ) =
1
2π
√
1+σ2−ρ2 exp(−
1
2(1+σ2−ρ2)((1+σ
2)x2−2ρxy+ y2)) (A.6)
the univariate and bivariate normal PDFs corresponding to the distributions of Z j and (Zi,Z j)
respectively.
The statement to be proved is equivalent to
Pr(Pi ≤ pi,Pj ≤ p j)≥ piPr(Pj ≤ p j)
⇔ Pr(|Zi| ≥ zi, |Z j| ≥ z j)≥ Pr(|Zi| ≥ zi)Pr(|Z j| ≥ z j)
⇔
∫∫
|x|≥zi,|y|≥z j
fσ (x,y,ρ)dxdy≥
∫
|x|≥zi
f0(x)dx
∫
|y|≥z j
fσ (y)dy (A.7)
=
∫∫
|x|≥zi,|y|≥z j
fσ (x,y,0)dxdy
Due to the symmetry of the normal distribution and the four disjoint regions defined by
{|x| ≥ zi, |y| ≥ z j}, we may rewrite both integrals over the connected region in {R+}2 defined
by {x≥ zi,y≥ z j}:∫∫
x≥zi,y≥z j
fσ (x,y,ρ)+ fσ (x,y,−ρ)−2 fσ (x,y,0)dxdy≥ 0 (A.8)
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Rewriting fσ (x,y,ρ) as
1
2π
√
1+σ2−ρ2 exp(−
1+σ2
2(1+σ2−ρ2)(x−
ρ
1+σ2
)2)exp(− 1
2(1+σ2)
y2) (A.9)
and noting that
∫ ∞
zi
exp(− 1+σ
2
2(1+σ2−ρ2)(x−
ρ
1+σ2
)2y)dx =
√
2π
(1+σ2−ρ2
1+σ2
)Φ(
−zi+ ρ1+σ2 y√
1+σ2−ρ2
1+σ2
)
we can rewrite inequality A.8, after removing the common denominator 2
√
2π(1+σ2), as
∫ ∞
z j
(
Φ(
−zi+ ρ1+σ2 y√
1+σ2−ρ2
1+σ2
)+Φ(
−zi− ρ1+σ2 y√
1+σ2−ρ2
1+σ2
)−2Φ(−zi)
)
exp(− 1
2(1+σ2)
y2)dy > 0 (A.10)
If z j = 0, then the region integrated over in A.7 is two vertical strips defined by |x| ≥ zi,y∈R.
The integral of fσ (x,y,ρ) over this region is the integral of the marginal of Zi over |x| ≥ zi,
and is hence independent of ρ . Thus, in this case, the integral of fσ (x,y,ρ)+ fσ (x,y,−ρ)−
2 fσ (x,y,0) over this region is 0. The same clearly holds if zi = 0 or ρ = 0. Henceforth, we
will assume ρ > 0.
Define
g(y) =Φ(
−zi+ ρ1+σ2 y√
1+σ2−ρ2
1+σ2
)+Φ(
−zi− ρ1+σ2 y√
1+σ2−ρ2
1+σ2
)−2Φ(−zi)
h(y) = g(y)exp(− 1
2(1+σ2)
y2) (A.11)
Because Φ is monotonically increasing and (1+σ2−ρ2)/(1+σ2)< 1 we have g(0)< 0.
As y→ ∞, the first term in g tends to 1, and the second to 0. As Φ(−zi)< 0.5, g therefore
tends to the finite positive value 1−2Φ(−zi), and hence h(y) tends to 0 from above.
We have
g′zi(y) =C0
(
exp(−
(1+σ2)(− ρ1+σ2 y+ zi)2
2(1+σ2−ρ2) )− exp(−
(1+σ2)( ρ1+σ2 y+ zi)
2
2(1+σ2−ρ2) )
)
(A.12)
for a constant C0, which can only be 0 if the exponentiated terms are equal; that is, y = 0 or
zi = 0. Given that h is asymptotically positive and g(0)< 0, g is monotonically increasing
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on R+, and is 0 at exactly one positive value y0. Because the sign of h is the sign of g, h(y)
is likewise 0 if and only if y = y0.
For y > y0, g(y) is positive, so h(y) is uniformly positive across the region of integration,
and hence the integral A.10 is positive for z j > y0. Because the integral of h over the positive
reals is 0 we have, for any z j ≤ y0∫ ∞
z j
h(y)dy =
∫ y1
z j
h(y)dy+
∫ ∞
y1
h(y)dy
>
∫ y1
0
h(y)dy+
∫ ∞
y1
h(y)dy
=
∫ ∞
0
h(y)dy
= 0 (A.13)
as required.
Corollary 1. Suppose a SNP is null for two phenotypes i and j, and GWAS are performed for
i and j sharing some or all controls. Let pi be the p value obtained at the SNP for phenotype
i, p j be the p value for phenotype j, Pi, Pj the random variables from which pi and p j are
drawn, and H(i)0 the null hypothesis for the SNP for phenotype i. Then pi underestimates
the probability Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ), and hence leads to an unpredictably biased and
usually falsely low estimate of cFDR.
Proof. Due to a result of Zaykin et al [Zaykin and Kozbur, 2010, Lin and Sullivan, 2009] the
sharing of controls between studies induces a positive correlation between Z scores. Applying
the theorem with σ = 0 yields the result. The estimated cFDR is computed by dividing the
quantity Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) by an estimate of Pr(Pi ≤ pi|Pj ≤ p j). As discussed in the
methods section of chapter 2, the estimate is systematically slightly conservative (a slight
overestimate) as the quantity Pr(H(i)0 |Pj ≤ p j) is assumed to be 1. This conservatism is lost
if the estimate of Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) is systematically low (as is the case if pi is used
as the estimator); the assertion that E(ĉFDR)≥ ĉFDR no longer holds.
Corollary 2. Suppose a GWAS is performed for some phenotype j. For each SNP s define ηs
as the Z score which would have been obtained in the GWAS if the allele frequencies for that
SNP in the case and control group exactly matched the allele frequencies in the general case
and control populations. Consider the values ηs as observations of a continuous random
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variable H and suppose that
H ∼
0, p = π
( j)
0
N(0,σ2), p = 1−π( j)0
(A.14)
for some π0,σ . Suppose another GWAS is performed for some other phenotype i, sharing
some or all controls with phenotype j. Let pi and p j be the p values obtained in these
two studies for a randomly chosen SNP, and Pi, Pj the random variables associated with
pi and p j. Define H
(i)
0 as the hypothesis that the SNP is null for phenotype i. Then pi
(equal to Pr(Pi ≤ pi|H i0)) underestimates Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) , and hence leads to an
unpredictably biased and usually falsely low estimate of cFDR.
Proof. As in section 2.4.3, define
Λ(ρ,σ2)(zi,z j) =
∫∫
|x|>|zi|,|y|>|z j|
N(0
0
)
,
( 1 ρ
ρ 1+σ2
)(x,y)dxdy
λσ2(z j) =
∫
|y|>|z j|
N(0,1+σ2)(y)dy (A.15)
By the results obtained in the same section, the distribution of H implies that
Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) =
π( j)0 Λ(ρ,0)(zi,z j)+(1−π( j)0 )Λ(ρ,σ2)(zi,z j)
π( j)0 λ0(z j)+(1−π( j)0 )λσ2(z j)
(A.16)
for some ρ > 0. From corollary 1 we have Λ(ρ,0)(zi,z j)/λ0(z j)> pi and from theorem 1 we
have Λ(ρ,σ2)(zi,z j)/λσ2(z j)> pi. The result follows.
Theorem 2. Define i, j, (Zi,Z j), (pi, p j), (Pi,Pj), (pi, p j), η , and H as for corollary 2, but
suppose H is distributed according to some unknown distribution function k(x) which is
non-increasing on R+. Then pi underestimates Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ).
Proof. We prove the statement for H ∼U(0,ηmax) (the uniform distribution) for any ηmax.
Because any decreasing function can be arbitrarily closely approximated as a linear combina-
tion of such functions with non-negative coefficients, we conclude the result.
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We may assume without loss of generality that η is non-negative. Defining k again as the
PDF of H, we have
Pr(Pi ≤ pi|Pj ≤ p j,H(i)0 ) =
Pr(Pi ≤ pi,Pj ≤ p j,H(i)0 )
Pr(Pj ≤ p j,H(i)0 )
=
∫ ∞
0 Pr(Pi ≤ pi,Pj ≤ p j|H(i)0 ,H = η)k(η)dη∫ ∞
0 Pr(Pj ≤ p j|H(i)0 ,H = η)k(η)dη
(A.17)
so the statement is equivalent to proving that∫ ∞
0
k(η)
(∫∫
|x|>zi,|y|>z j
f0(x,y−η ,ρ)− f0(x,y−η ,0)dxdy
)
dη > 0 (A.18)
For brevity, let q(x,y,η) = f0(x,y−η ,ρ)− f0(x,y−η ,0). Assume that k(η) has the form
k(η) =
 1ηmax if η ≤ ηmax0 if η > ηmax (A.19)
for some ηmax. Then inequality A.18 is equivalent to
1
ηmax
∫ ηmax
0
(∫∫
|x|>zi,|y|>z j
q(x,y,ρ)dxdy
)
dη def=
1
ηmax
I(ηmax)> 0 (A.20)
Because f0(x,y,ρ) = f0(−x,−y,ρ) we have q(x,y,η) = q(−x,η ,y). Because of the symme-
try of the function q(x,y,η) about y = η , we have∫ ∞
0
∫∫
|x|>zi,|y|>z j
q(x,y,η)dxdydη =
1
2
∫ ∞
−∞
∫∫
|x|>zi,|y|>z j
q(x,y,η)dxdydη
=
1
2
∫
|y|>z j
∫∫
|x|>zi,η∈R
q(−x,η ,y)dxdydη
=
1
2
∫
|y|>z j
∫∫
|x|>zi,η ′∈R
f0(x,η ′,ρ)− f0(x,η ′,0)dxdηdy
= 0 (A.21)
setting η ′ = η− y, and again using the fact that the integral over the marginal is independent
of ρ . Thus I(ηmax)→ 0 as ηmax → ∞. Again using the symmetry of the function q(x,y,η)
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about y = η , we can write ∫∫
|x|>zi,|y|>z j
q(x,y,η)dxdy =
12(
∫∫
|x|>zi,|y|>η+z j q(x,y,0)dxdy−
∫∫
|x|>zi,|y|>η−z j q(x,y,0)dxdy), η > z j
1
2(
∫∫
|x|>zi,|y|>η+z j q(x,y,0)dxdy+
∫∫
|x|>zi,|y|>z j−η q(x,y,0)dxdy), η < z j
(A.22)
From the second of these cases it is clear that the integrand of I(ηmax) is always positive if
ηmax≤ z j. If the integrand of I(ηmax) (expression A.22) is to be zero, we must have∫∫
|x|>zi,|y|>η+z j
q(x,y,0)dxdy =
∫∫
|x|>zi,|y|>η−z j
q(x,y,0)dxdy)
⇔
∫
|y|>η+z j
∫
|x|>zi
q(x,y,0)dydx =
∫
|y|>η−z j
∫
|x|>zi
q(x,y,0)dydx
⇔
∫
y>η+z j
h(y)dy =
∫
y>η−z j
h(y)dy (A.23)
using the notation h(y) from theorem 1, and re-expressing the integrand over connected
regions. As discussed there, the integral of h(y) is negative for y less than some y0 and
positive thereafter, tending asymptotically to 0, so the integral of h(y) from y = z to ∞ is zero
at z = 0, increases to a maximum at z = x0, and decreases thereafter. If equality were to hold
in the above, we would need the integral of h(y) from z to ∞ to be equal at two values of z
which are 2zi apart. Because of the way the integral changes with z, the integral can only be
zero for one value of η .
This implies that expression A.22 is positive for η < z j, is zero at some value η = η0,
and is negative thereafter. Given that I(ηmax)→ 0 and is positive for ηmax < z j, it must be
positive for all ηmax. This proves the theorem for k(η) of the form A.19.
For any general PDF k(η)which is non-increasing onR+ and any ε > 0 we may construct
k0(η) as a linear sum of functions kηi of the form A.19:
k0(η) =∑
i
wikηi(η)
def
=∑
i
wi
 1ηmax if η ≤ ηi0 if η > ηi (A.24)
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with nonnegative wi, such that ∫ ∞
0
|k(η)− k0(η)|dη < ε (A.25)
Now∫∫
|x|>zi,|y|>z j
f0(x,y−η ,ρ)− f0(x,y−η ,0)dxdy≤ 2
∫∫
|x|>zi,|y|>z j
f0(x,y−η ,ρ)dxdy≤ 2
(A.26)
so ∫ ∞
0
k(η)
(∫∫
|x|>zi,|y|>z j
f0(x,y−η ,ρ)− f0(x,y−η ,0)dxdy
)
dη
−
∫ ∞
0
k0(η)
(∫∫
|x|>zi,|y|>z j
f0(x,y−η ,ρ)− f0(x,y−η ,0)dxdy
)
dη
≤ 2
∫ ∞
0
k0(η)dη ≤ 2ε (A.27)
The second term in the LHS sum above is positive for any linear combination with at least
one wi > 0, as it is a linear combination of integrals of the form A.20. Thus inequality A.18
holds for any k of the required form.
Remark 1. For certain pathological distributions, it may be the case that pi does not underes-
timate Pr(Pi ≤ pi|Pj ≤ p j). In general, however, most GWAS are across mostly null SNPs,
so in general the distribution of H (as per corollary 2) has a high mass at 0. In this case, the
situation in corollary 1 is dominant, and in practice pi is almost always an underestimate
of Pr(Pi ≤ pi|Pj ≤ p j) ≤ pi. Except in rare cases, pi ̸= Pr(Pi ≤ pi|Pj ≤ p j), and it is not
reasonable to use pi as an approximation in the current context if controls are shared between
studies.
A.1.4 Maximum possible overestimation of expected quantile
Theorem 3. Let H be a random variable taking real values, and suppose that two random
variables Zi and Z j are distributed as
(Zi,Z j)|H = η ∼ N(
(
0
η
)
,
( 1 ρ
ρ 1+σ2
)
) (A.28)
that is, normally distributed with mean (0,η) and correlation matrix
( 1 ρ
ρ 1+σ2
)
. Let Pi =
2Φ(−Zi), Pj = 2Φ(−Z j) as usual, and (pi, p j) be an instance of (Pi,Pj) with 0 < pi, p j < 1.
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Then across all distributions of H, the value of P(Pi ≤ pi|Pj ≤ p j) is maximised when H is
the degenerate distribution at 0; that is, H = 0 with probability 1.
Proof. We will show that amongst all values of η , the value P(Pi ≤ pi|Pj ≤ p j,H = η) is
maximised when η = 0, from which the result follows.
From earlier considerations, we have
P(Pi ≤ pi|Pj ≤ p j,H = η) =
∫∫
|x|>zi,|y|>z j N( 0η ),( 1 ρρ 1)(x,y)dxdy∫
|y|>z j N(η ,1)(y)dy
def
= Rη(zi,z j) (A.29)
where zi = −Φ−1(pi/2), z j = −Φ−1(p j/2), and N represents the normal PDF with the
subscripted parameters. We may assume η > 0.
As η increases from 0, the value of Rη(zi,z j) (holding (zi,z j) constant) tends to decrease
to a minimum, then increase to an asymptote as η → ∞ (figure A.2).
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Fig. A.2 Plot of Rη(zi,z j), or equivalently Pr(Pi ≤ pi|Pj ≤ p j,H = η), as a function of η .
The statement of theorem A.1.4 is that this function is maximised at η = 0, which is seen in
this plot. The function decreases from 0 to a minimum then increases to an asymptote as η
increases
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We rewrite Rη(zi,z j) as
Rη(zi,z j) =
∫
|x|>zi
∫
|y|>z j
1
2π
√
(1−ρ2) exp{( x y−η )
( 1 ρ
ρ 1
)−1( x
y−η
)}dydx∫
|y|>z j
1√
2π
exp{−(y−η)2}dy
=
1
2π
√
(1−ρ2)
∫
|x|>zi
∫
|y|>z j exp{− 12(1−ρ2)(x2−2ρx(y−η)+(y−η)2)}dydx
1√
2π
∫
|y|>z j exp{−12(y−η)2}dy
(A.30)
The numerator may be rewritten as
1
2π
√
(1−ρ2)
∫
|x|>zi
∫
|y|>z j
exp{− 1
2(1−ρ2)((y− (η+ xρ))
2+ x2(1−ρ2))}dydx
=
∫
|x|>zi
exp{−1
2
x2}
∫
|y|>z j
1
2π
√
(1−ρ2) exp{−
1
2(1−ρ2)(y− (η+ xρ))
2}dydx
=
∫
|x|>zi
exp{−12x2}√
2π
(
Φ(
η+ xρ− z j√
1−ρ2 )+Φ(
−η− xρ− z j√
1−ρ2 )
)
dx
=
∫ −zi
−∞
exp{−12x2}√
2π
(
Φ(
η+ xρ− z j√
1−ρ2 )+Φ(
η− xρ− z j√
1−ρ2 )
+Φ(
−η+ xρ− z j√
1−ρ2 )+Φ(
−η− xρ− z j√
1−ρ2 )
)
dx
def
=
∫ −zi
−∞
exp{−12x2}√
2π
K(x,z j,η)dx (A.31)
and the denominator simply as
1√
2π
∫
|y|>z j
exp{−1
2
(y−η)2}dy =Φ(−z j +η)+Φ(−z j−η)
def
= B(z j,η) (A.32)
Since B is independent of x, we may simply include a factor of 1/B(z j,η) in the integrand
of A.31.
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If zi = 0, then the numerator of A.30 is an integral over the marginal of y, and hence the
numerator and denominator are equal, so Rη(0,z j) = 1. Hence
Rη(zi,z j) =
∫ −zi
−∞
exp{−12x2}√
2π
K(x,z j,η)
B(z j,η)
dx
= 1−
∫ 0
−zi
exp{−12x2}√
2π
K(x,z j,η)
B(z j,η)
dx
= 1−
∫ zi
0
exp{−12x2}√
2π
K(x,z j,η)
B(z j,η)
dx
given the symmetry of K in x. The problem then reduces to showing that
∫ zi
0
exp{−12x2}√
2π
K(x,z j,η)
B(z j,η)
dx >
∫ zi
0
exp{−12x2}√
2π
K(x,z j,0)
B(z j,0)
dx (A.33)
for all η ̸= 0.
As zi → ∞, the numerator of A.30 tends to 0 while the denominator does not change.
Thus the above integral tends to 1 whatever the value of η .
For zi approaching 0, the ratio of the RHS integral to the LHS integral tends to the ratio
of the integrands at x = 0. This is equal to
K(0,z j,η)B(z j,0)
K(0,z j,0)B(z j,η)
=
(Φ( η−z j√
1−ρ2 )+Φ(
−η−z j√
1−ρ2 ))Φ(z j)
(Φ(η− z j)+Φ(−η+ z j))Φ( −z j√
1−ρ2 )
(A.34)
From the fact that Φ is convex on R− and from Φ(x) = 1−Φ(−x), it is clear that if
b > a ≥ 0, z > 0 and c1 and c2 are such that −z+a ≤ c1 ≤−z+b, −z−b ≤ c2 ≤−z+a,
then Φ′(c1)>Φ′(c2). Thus Φ(−z+b)−Φ(−z+a)>Φ(−z−a)−Φ(−z−b) and
Φ(
−z j +η√
1−ρ2 )−Φ(
−z j√
1−ρ2 +η)>Φ(
−z j√
1−ρ2 −η)−Φ(
−z j−η√
1−ρ2 )
⇔Φ( −z j +η√
1−ρ2 )+Φ(
−z j−η√
1−ρ2 )>Φ(
−z j√
1−ρ2 +η)+Φ(
−z j√
1−ρ2 −η) (A.35)
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We now define the function Φ∗(z) = Φ(z+η)/Φ(z), and note that the numerator of the
derivative is
1√
2π
e−
1
2 (z+η)
2
Φ(z)− 1√
2π
e−
1
2 z
2
Φ(z+m)
∝
∫ z
−∞
e−
1
2 (z+η)
2
e−
1
2 x
2 − e− 12 (x+η)2e− 12 z2dx
=
∫ z
−∞
e−
1
2 z
2
e−
1
2 x
2
e−
1
2η
2
(e−ηz− e−ηx)dx
< 0 (A.36)
as the integrand is always negative. Thus
Φ( η−z j√
1−ρ2 )+Φ(
−η−z j√
1−ρ2 )
Φ( −z j√
1−ρ2 )
>
Φ( −z j√
1−ρ2 +η)+Φ(
−z j√
1−ρ2 −η)
Φ( −z j√
1−ρ2 )
=
Φ( −z j√
1−ρ2 +η)
Φ( −z j√
1−ρ2 )
+
Φ( −z j√
1−ρ2 −η)
Φ( −z j√
1−ρ2 )
>
Φ(−z j +η)
Φ(−z j) +
Φ(−z j−η)
Φ(−z j)
=
Φ(−z j +η)+Φ(−z j−η)
Φ(−z j)
(A.37)
and, rearranging, we see that expression A.34 is greater than 1. Thus for sufficiently small zi,
inequality A.33 holds.
We now show that the integrands on either side of A.33 can be equal for at most one
positive value of x, which we denote x0. Since the integrals are equal as zi → ∞, they must in
fact intersect exactly once. For zi < x0 the inequality obviously holds as the LHS integrand
is strictly larger than the RHS integrand. For zi ≥ x0, the integral of the LHS integrand from
zi to ∞ is less than the integral of the RHS integrand over the same, so the integral of the
LHS integrand from 0 to zi is again greater than the integral of the RHS integrand from 0 to
zi. This is shown in figure A.3.
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Fig. A.3 Examples of integrands (left) and integrals (right) of LHS (blue) and RHS (pink)
sides of expression A.33, as functions of x and zi respectively. We show that the integrands
can only intersect once, as seen in the graph, so the integrals are never equal. This is seen on
the right-hand plot.
If the integrands are equal, then
K(x,z j,η)
K(x,z j,0)
=
B(z j,η)
B(z j,0)
so
⇔
Φ(η+xρ−z j√
1−ρ2 )+Φ(
η−xρ−z j√
1−ρ2 )+Φ(
−η+xρ−z j√
1−ρ2 )+Φ(
−η−xρ−z j√
1−ρ2 )
2Φ(−xρ−z j√
1−ρ2 )+2Φ(
xρ−z j√
1−ρ2 )
=
Φ(η− z j)+Φ(−η− z j)
2Φ(−z j)
(A.38)
For m > 0, the function Φ is convex on R− if −x+m < 0 and the line between (−x−
m,Φ(−x−m)) and (−x+m,Φ(−x+m)) lies strictly above Φ(y) for y < 0. Thus we have
(Φ(−x+m)+Φ(−x−m))/2 > Φ(−x), so the RHS above is greater than 1. Considering
the expression on the LHS as a function of x, we will show that it can take the required value
> 1 at most once on R+.
In analysing the LHS in isolation, the factor
√
1−ρ2 merely scales η , and z j, and the
expression is to be proved for all η ,z j > 0, so we may ignore the factor in this case. Likewise,
the factor ρ/
√
1−ρ2 simply scales x, so we may ignore it as well.
If the LHS is to take some value 1+ ε/2, then
Φ(−z j− x+η)+Φ(−z j + x−η)+Φ(−z j + x−η)+Φ(−z j− x+η)
− (2+ ε)(Φ(−z j− x)+Φ(−z j + x)) = 0 (A.39)
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Consider the function
Lε(x,η) = (2+ ε)Φ(x)−Φ(x−η)−Φ(x+η) (A.40)
so A.39 is equivalent to Lε(x− z j)+Lε(−x− z j) = 0. We have
∂
∂x
Lε(x,η)
def
= L′ε(x,η) ∝ (2+ ε)e
− 12 x2 − e− 12 (x−η)2 − e− 12 (x+η)2
= e−
1
2 x
2
((2+ ε)−2e− 12η2 cosh(ηx)) (A.41)
so L′ε(x,η) is zero only at only one non-negative value (and is symmetric). From the shape
of the normal PDF, we have L′ε(0,η)> 0 and because, for large enough x, we have
(2+ ε)e−
1
2 x
2
< e−
1
2 (x−η)2 (A.42)
L′ε(x,η) must be asymptotically negative. Clearly L′ε(x,η) = L′ε(−x,η), and L′ε(x,η)→ 0
as x→ ∞. Furthermore, the second derivative of Lε(x,η) with respect to x (which we will
call L′′ε (x,η)) is given by
L′′ε (x,η) ∝ (2+ ε)xe
− 12 x2 − (x+η)e− 12 (x+η)2 − (x−η)e− 12 (x−η)2
= e−
1
2 x
2
((2+ ε)x− e− 12η2(2xcosh(ηx)−2η sinh(−ηx))) (A.43)
The curve y= xcosh(ηx)−η sinh(−ηx) can only intersect the line y= x(2+ε)/(2exp(−m2/2))
at one positive value of x, and given the antisymmetry of the curve and the line, the function
L′′ε (x,η) considered as a function of x has only three zeros. Given this and the earlier asymp-
totic properties, L′ε(x,η) (as a function of x) must be positive and maximal at 0, decrease
monotonically to a negative minimum value, and increase monotonically thereafter. If we
consider a superimposition of the curve transposed left and the curve transposed right, the
transposed curves can only intersect at five points, one of which is x = 0.
The curves L′ε(x− z j,η) and L′ε(−x− z j,η) = L′ε(x+ z j,η) constitute two such trans-
posed curves and thus
∂
∂x
(Lε(x− z j,η)+Lε(−x− z j,η)) = L′ε(x− z j,η)−L′ε(x+ z j,η) (A.44)
can have at most two positive zeros. Because L′ε(x) is asymptotically increasing as x→ ∞,
the difference L′ε(x− z j,η)−L′ε(x+ z j,η) is asymptotically negative, so the derivative of
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Fig. A.4 The top left plot shows Lε(x− z j,η)+Lε(x+ z j,η) as a function of x. We demon-
strate that it is symmetric, asymptotically positive, has two stationary points for positive x,
is negative at 0, and crosses zero once. These properties can be seen in this plot. The top
right plot shows Lε(x,η) and its derivative with respect to x. The bottom right plot shows
the derivative of Lε(x,η) transposed to the right and left by z j. Note the limited number of
points at which the two curves can cross. The bottom right plot shows the derivative with
respect to x of Lε(x− z j,η)+Lε(x+ z j,η)
Lε(x− z j,η)+Lε(−x− z j,η) is asymptotically increasing as x→ ∞. Writing
Lε(x,η) = 2Φ(x)−Φ(x−η)−Φ(x+η)+ εΦ(x) (A.45)
we see that as x → ∞, Lε(x,η) → εΦ(x) → ε , so Lε(x− z j,η) + Lε(−x− z j,η) → 2ε .
Because the derivative of Lε(x− z j,η)+Lε(−x− z j,η) is asymptotically increasing toward
0, it must be asymptotically negative. Plots of Lε , L′ε are shown in figure A.4.
We now show that Lε(x− z j,η)+Lε(−x− z j,η) is negative at x = 0. If it were to be
positive, then
Lε(−z j,η)+Lε(−z j,η)> 0
⇔ (2+ ε)Φ(x− z j)−Φ(−z j−η)−Φ(−z j +η)> 0
⇔ 1+ ε
2
>
Φ(−z j−η)+Φ(−z j +η)
2Φ(−z j) (A.46)
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Recalling, however, that the value of 1+ ε/2 of interest is given by the RHS of A.38,
which can be rewritten as
Φ(γ(−z j−η))+Φ(γ(−z j +η))
2Φ(−γz j) (A.47)
with γ =
√
1−ρ2 < 1, we see that we must have
Φ(γ(−z j−η))+Φ(γ(−z j +η))
2Φ(−γz j) >
Φ(−z j−η)+Φ(−z j +η)
2Φ(−z j) (A.48)
which is impossible as, given the shape of Φ, the LHS is strictly increasing with γ for γ > 0.
Thus for the value of ε of interest, Lε(x− z j,η)+Lε(−x− z j,η) is negative at x = 0,
asymptotically positive and decreasing as x→ ∞, and has as most two stationary points for
x > 0. Consequently, it can cross any y value between its height at 0 and its limit as x→ ∞
exactly once, and the result follows.
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Table A.1 Details of FDR calculation for cFDR hits
Me f f Max p Eq uFDR FDR bound
T1D 1.4 1.15×10−6 6.4×10−5 7.32×10−6
ATD 1.2 1.6×10−6 3.37×10−4 1.02×10−5
CEL 1.3 4.15×10−7 2.44×10−5 5.77×10−6
MS 1.4 9.85×10−7 7.91×10−5 1.19×10−5
NAR 3.3 7.86×10−8 3.51×10−4 3.05×10−4
PBC 1.5 1.43×10−6 1.71×10−4 2.09×10−5
PSO 1.9 3.11×10−6 9.32×10−4 5.45×10−5
RA 2.2 2.75×10−6 5.63×10−4 6×10−5
UC 1.3 6.98×10−7 4.67×10−5 6.73×10−6
CRO 1.1 2.8×10−7 9.9×10−6 2.73×10−6
Calculation of false discovery rates for SNPs reaching ĉFDR significance levels. Me f f gives
the ‘effective number of tests’, relating to the multiple testing adjustment for the multiple
phenotypes conditioned upon (see Methods section for chapter 2). Max p is the maximum
principal p value at which a SNP was able to be declared significant using ĉFDR. Eq FDR
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shows the false-discovery rate we would be forced to control at in order to detect all these
SNPs the principal p value alone. The FDR bound (bold) is the false discovery rate at which
the set of SNPs discovered by the ĉFDR method is controlled.
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Table A.2 SNPs associated with T1D
RSID Region Pos P val uFDR cFDR CP
rs3842727 11p15.5 2141424 8.81e-168 1.07e-115 4.9e-116 UC
rs6679677 1p13.2 114105331 4.24e-105 1.81e-100 6.1e-102 ATD
rs7396243 11p15.5 2162468 1.05e-46 1.88e-43 1.84e-43 CRO
rs3184504 12q24.12 110368991 2.67e-38 2.36e-35 1.67e-35 ATD
rs72853903 11p15.5 2155241 2e-34 1.42e-31 1.42e-31 T1D
rs61839660 10p15.1 6134703 8.42e-34 5.9e-31 5.42e-31 ATD
rs705705 12q13.2 54721771 1.19e-27 6.68e-25 5.64e-25 ATD
rs7073236 10p15.1 6146558 2.4e-20 9.09e-18 5.55e-19 RA
rs773588 1p13.2 113646347 4.68e-19 1.7e-16 7.93e-18 RA
rs12927355b 16p13.13 11102272 7.1e-19 2.56e-16 1.5e-17 MS
rs3087243 2q33.2 204447164 4.75e-18 1.63e-15 6.11e-17 RA
rs8056814 16q23.1 73809828 1.14e-16 3.54e-14 2.3e-14 MS
rs6578997 11p15.5 2176990 2.1e-16 6.39e-14 5.76e-14 ATD
rs2111485 2q24.2 162818782 1e-15 2.95e-13 8.66e-14 ATD
rs117693013 11p15.5 2155055 2e-15 5.81e-13 4.92e-13 CRO
rs6669008 1p13.2 113968084 4.79e-15 1.38e-12 5.9e-13 RA
rs7925375 11p15.5 2147731 7.52e-14 1.93e-11 1.74e-11 ATD
rs1893217 18p11.21 12799340 1.42e-13 3.57e-11 3.48e-12 RA
rs11203203 21q22.3 42709255 2.94e-13 6.94e-11 6.64e-12 ATD
rs34536443b 19p13.2 10324118 4.19e-13 9.62e-11 4.4e-12 RA
rs7068821 10q23.31 90041015 4.96e-13 1.12e-10 3.32e-11 NAR
rs72853956 11p15.5 2178847 5.76e-13 1.29e-10 8.68e-11 UC
rs1503836 1p13.2 114343021 1.74e-12 3.61e-10 1.4e-11 RA
rs516246 19q13.33 53897984 3.49e-12 6.99e-10 3.82e-10 CRO
rs72928038 6q15 91033489 4.14e-12 8.25e-10 3.11e-11 ATD
rs34843303 15q25.1 77021525 7.62e-12 1.47e-09 2.03e-10 NAR
rs3842759 11p15.5 2136445 2.23e-11 3.94e-09 3.43e-09 UC
rs72687939 1p13.2 113812829 2.83e-11 4.88e-09 3.14e-10 RA
rs7511816 1p13.2 114019237 5.12e-11 8.6e-09 3.24e-10 RA
rs2412975 22q12.2 28870590 1.35e-10 2.05e-08 1.47e-09 ATD
rs6827756 4q27 123403861 1.86e-10 2.7e-08 1.35e-08 MS
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rs56994090 14q32.2 100376200 3.48e-10 4.81e-08 4.18e-08 NAR
rs4929968 11p15.5 2234264 3.63e-10 4.97e-08 2.79e-08 RA
rs7239671 18q22.2 65674240 5.19e-10 6.92e-08 9e-09 RA
rs2611215+ 4q32.3 166793717 5.25e-10 6.99e-08 5.73e-08 UC
rs2304256b 19p13.2 10336652 9.48e-10 1.2e-07 6.71e-09 RA
rs151233 16p11.2 28413929 1.21e-09 1.5e-07 1.71e-08 ATD
rs736202 1p13.2 113620903 1.31e-09 1.62e-07 7.75e-09 RA
rs151181 16p11.2 28398018 5.29e-09 5.44e-07 1.3e-07 NAR
rs6043409 20p13 1564206 5.78e-09 5.82e-07 2.46e-07 NAR
rs72727394 15q14 36634314 6.72e-09 6.73e-07 5.61e-08 RA
rs193778b 16p13.13 11258712 8.12e-09 7.97e-07 1.47e-07 PBC
rs2045258 6q22.32 126716047 1.26e-08 1.18e-06 9.33e-07 CRO
rs6476839 9p24.2 4280823 1.67e-08 1.5e-06 4.54e-07 MS
rs77347828* 10p15.1 6208296 5.24e-08 4.05e-06 3.68e-06 MS
rs57582212* 10p15.1 6119041 9.91e-08 7.36e-06 1.62e-06 MS
rs12453507* 17q12 35306733 1.23e-07 8.93e-06 7.87e-07 RA
rs229533* 22q12.3 35917057 1.94e-07 1.34e-05 2.98e-06 ATD
Associated SNPs for T1D, ordered by best cFDR. P values shown are after adjustment for
genomic inflation. Chromosome positions are from the NCBI36 assembly. The conditional
phenotype shown is the phenotype for which the cFDR was most below the relevant cutoff.
Column CP is the conditional phenotype for which corrected cFDR was lowest. SNPs with p
value greater than 5×10−8 for the principal phenotype are asterisked, and SNP-disease
associations not previously known are suffixed with a ’+’
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Table A.3 SNPs associated with ATD
RSID Region Pos P val uFDR cFDR CP
rs1023586 14q31.1 80532036 1.83e-26 5.82e-22 2.87e-22 UC
rs6679677 1p13.2 114105331 2.58e-24 1.54e-20 5.46e-22 T1D
rs11571297 2q33.2 204453248 1.38e-21 7.75e-18 5.73e-19 T1D
rs77130284* 2q33.2 204513456 3.1e-07 7.36e-05 6.69e-06 T1D
rs72928038* 6q15 91033489 4.11e-07 9.73e-05 3.2e-06 T1D
rs2030519* 3q28 189602595 7.05e-07 0.000162 5.58e-06 CEL
rs706779* 10p15.1 6138830 8.46e-07 0.000194 9.29e-06 T1D
Associated SNPs for ATD, ordered by best cFDR. P values shown are after adjustment for
genomic inflation. Chromosome positions are from the NCBI36 assembly. The conditional
phenotype shown is the phenotype for which the cFDR was most below the relevant cutoff.
Column CP is the conditional phenotype for which corrected cFDR was lowest. SNPs with p
value greater than 5×10−8 for the principal phenotype are asterisked, and SNP-disease
associations not previously known are suffixed with a ’+’
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Table A.4 SNPs associated with CEL
RSID Region Pos P val uFDR cFDR CP
rs4686484 3q28 189601266 1.53e-47 2.04e-43 5.76e-44 ATD
rs13132308 4q27 123770564 2.6e-37 7.35e-34 5.58e-34 MS
rs6927172 6q23.3 138043868 4.29e-29 7.27e-26 2.84e-26 UC
rs76830965 3q25.33 161120372 1.61e-26 2.51e-23 7.4e-24 UC
rs1359062 1q31.2 190808095 1.39e-24 1.99e-21 1.14e-21 NAR
rs3184504 12q24.12 110368991 2.17e-20 2.03e-17 1.04e-17 MS
rs2097282 3p21.31 46353029 4.43e-20 4.05e-17 2.13e-17 CRO
rs55743914 6q22.33 128335255 3.9e-18 2.04e-15 1.5e-15 NAR
rs1250552 10q22.3 80728033 2.38e-16 1.07e-13 2.01e-14 MS
rs990171 2q12.1 102453202 3.61e-16 1.61e-13 6.97e-14 UC
rs4525910 3q25.33 161129306 5.56e-16 2.28e-13 3.83e-14 MS
rs1018326 2q31.3 181716045 8.78e-16 3.5e-13 2.42e-13 CRO
rs13003464 2p16.1 61040333 1.23e-15 4.76e-13 8.31e-14 MS
rs6441991 3p21.31 46459287 1.83e-15 6.8e-13 5.3e-13 NAR
rs1353248 3q25.33 161106253 2.2e-15 8.04e-13 3.99e-13 NAR
rs182429 6q25.3 159389562 2.36e-15 8.56e-13 1.43e-13 MS
rs1980422 2q33.2 204318641 3.9e-15 1.35e-12 3.33e-13 MS
rs77027760 6q23.3 138043754 8.3e-15 2.46e-12 5.4e-13 MS
rs61907765 11q24.3 127897147 7.93e-13 1.52e-10 5.82e-11 CRO
rs1929848+ 6p21.31 35308328 1.17e-12 2.19e-10 2.09e-10 PSO
rs4445406 1p36.32 2529260 1.15e-11 1.83e-09 4.23e-10 MS
rs7104791 11q23.1 110702068 3.87e-11 5.7e-09 3.26e-09 MS
rs73001429 11q23.3 118108375 5.05e-11 7.36e-09 2.53e-09 MS
rs16896780+ 6p21.31 35139530 5.99e-11 8.65e-09 7.76e-09 PSO
rs76733709 3p21.31 46256465 6.16e-11 8.86e-09 5.65e-09 UC
rs4821124 22q11.21 20309289 1.13e-10 1.55e-08 4.81e-09 CRO
rs12068671 1q24.3 170947654 2.69e-10 3.54e-08 2.26e-08 RA
rs11875687 18p11.21 12833137 3.66e-10 4.66e-08 1.52e-08 UC
rs72975916 6q22.33 128335748 6.16e-10 7.46e-08 2.27e-08 MS
rs6498114 16p13.13 10871619 1.08e-09 1.23e-07 6.12e-08 NAR
rs1050976 6p25.3 353079 3.27e-09 3.31e-07 2.82e-07 RA
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rs3087243 2q33.2 204447164 4.64e-09 4.52e-07 2.79e-07 ATD
rs1893592 21q22.3 42728136 5.2e-09 5.02e-07 1.76e-07 UC
rs17602709 3q28 189553102 5.43e-09 5.22e-07 4e-07 MS
rs12142280 1q24.3 171131275 6.4e-09 6.09e-07 4.15e-07 UC
rs7616215 3p21.31 46180690 1.24e-08 1.13e-06 5.05e-07 UC
rs1107943 6q25.3 159418255 1.35e-08 1.22e-06 4.55e-07 MS
rs7162232 15q24.1 72902948 1.36e-08 1.22e-06 3.86e-07 MS
rs6715106 2q32.3 191621279 1.42e-08 1.27e-06 3.37e-07 RA
rs692890 3q25.33 161182267 1.47e-08 1.31e-06 4.52e-07 RA
rs61579022 3q13.33 120605968 1.68e-08 1.48e-06 5.65e-07 MS
rs9355697 6q25.3 159427336 2.66e-08 2.24e-06 3.18e-07 MS
rs59867199 4q27 123671681 3.11e-08 2.58e-06 5.89e-07 CRO
rs2387397 10p15.1 6430198 3.2e-08 2.66e-06 6.9e-07 RA
rs10238927 7p14.1 37400062 3.55e-08 2.92e-06 4.41e-07 MS
rs10800746 1q32.1 199148015 4.22e-08 3.43e-06 4.76e-07 MS
rs11851414* 14q24.1 68329255 7.59e-08 5.81e-06 2.37e-06 MS
rs6691768*+ 1p31.3 61564451 8.56e-08 6.45e-06 2.93e-06 CRO
rs78560100* 4q27 123260921 1.13e-07 8.25e-06 1.75e-06 RA
rs6032606*+ 20q13.12 44029614 1.31e-07 9.42e-06 2.89e-06 MS
rs9610686*+ 22q13.1 35963797 1.9e-07 1.3e-05 3.48e-06 ATD
rs6705577*+ 2p21 43212779 3.61e-07 2.17e-05 3.29e-06 MS
rs7753008* 6q15 90866360 4.15e-07 2.44e-05 3.72e-06 MS
Associated SNPs for CEL, ordered by best cFDR. P values shown are after adjustment for
genomic inflation. Chromosome positions are from the NCBI36 assembly. The conditional
phenotype shown is the phenotype for which the cFDR was most below the relevant cutoff.
Column CP is the conditional phenotype for which corrected cFDR was lowest. SNPs with p
value greater than 5×10−8 for the principal phenotype are asterisked, and SNP-disease
associations not previously known are suffixed with a ’+’
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Table A.5 SNPs associated with MS
RSID Region Pos P val uFDR cFDR CP
rs6677309 1p13.1 116881689 7.06e-27 7.54e-22 2.64e-23 PBC
rs12928537 16p13.13 11098901 4.06e-25 8.67e-21 1.66e-22 T1D
rs2104286 10p15.1 6139051 1.63e-21 5.29e-18 1.2e-18 T1D
rs1813375 3p24.1 28053575 6.15e-17 6.57e-14 4.9e-14 PSO
rs8070345 17q23.1 55171539 4.39e-15 4.07e-12 1.82e-12 PBC
rs1800693 12p13.31 6310270 5.51e-15 5.03e-12 2.31e-12 PBC
rs41286801 1p22.1 92748052 6.25e-15 5.61e-12 1.62e-12 T1D
rs212405 6q25.3 159390547 1.09e-14 9.15e-12 6.25e-13 T1D
rs1131265 3q13.33 120705146 1.47e-14 1.19e-11 5.34e-12 PBC
rs1920296 3q13.33 123026267 4.67e-14 3.12e-11 2.49e-11 PBC
rs4780348 16p13.13 11197993 1.12e-13 6.66e-11 7.77e-12 T1D
rs9989735 2q37.1 230823698 4.66e-13 2.5e-10 2e-10 PSO
rs1359062 1q31.2 190808095 1.04e-12 5.33e-10 4.18e-11 T1D
rs11554159 19p13.11 18146944 1.42e-12 7.14e-10 3.27e-10 PBC
rs1077667 19p13.3 6619972 1.92e-12 9.31e-10 1.07e-10 T1D
rs2255214 3q13.33 123253229 2.81e-12 1.28e-09 1e-09 PSO
rs4976646 5q35.3 176721176 5.27e-12 2.28e-09 4.98e-10 T1D
rs3748817 1p36.32 2515525 6.64e-12 2.73e-09 2.62e-10 PBC
rs12087340 1p22.3 85519581 2.36e-11 8.45e-09 4.56e-09 PBC
rs17066096 6q23.3 137494601 2.69e-11 9.46e-09 5.24e-10 PBC
rs11172342 12q14.1 56474025 4.18e-11 1.44e-08 9.82e-10 PBC
rs74796499 14q31.3 87502081 3.27e-10 8.18e-08 2.4e-08 CEL
rs9282641 3q13.33 123279458 6.44e-10 1.46e-07 4.84e-08 PBC
rs6498184 16p13.13 11343491 7.58e-10 1.7e-07 8.1e-09 PBC
rs1021156 8q21.12 79738359 1.93e-09 3.98e-07 2.8e-08 PBC
rs1870071 19p13.11 16366106 1.95e-09 4.02e-07 2.34e-07 ATD
rs34383631 11q12.2 60549906 1.96e-09 4.02e-07 1.96e-07 RA
rs2288904 19p13.2 10603170 3.19e-09 6.15e-07 2.63e-07 RA
rs1014486 3q25.33 161173806 3.82e-09 7.18e-07 4.15e-08 PBC
rs706015 7p15.2 26981513 4.22e-09 7.8e-07 4.67e-07 PBC
rs2364482 12p13.31 6372392 4.56e-09 8.37e-07 1.09e-07 T1D
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rs9967792 2q32.3 191682680 5.77e-09 1.02e-06 5.44e-07 CEL
rs35730213 1q32.1 199140852 6.25e-09 1.09e-06 9.25e-08 PBC
rs4410871 8q24.21 128884211 6.31e-09 1.1e-06 3.9e-07 NAR
rs11154801 6q23.3 135781048 7.41e-09 1.26e-06 1.16e-07 T1D
rs71624119 5q11.2 55476487 8.44e-09 1.4e-06 1.83e-07 T1D
rs1177209 2p16.1 60931074 1.17e-08 1.85e-06 2.03e-07 CEL
rs941816 6p21.31 36483282 1.36e-08 2.09e-06 5.24e-07 PBC
rs7923837 10q23.33 94471897 1.39e-08 2.13e-06 9.73e-07 PBC
rs11052877 12p13.31 9796957 1.61e-08 2.43e-06 2.35e-07 T1D
rs7717955 5p13.2 35898598 1.61e-08 2.43e-06 1.59e-07 PBC
rs34536443b 19p13.2 10324118 3.53e-08 4.58e-06 2.8e-07 PBC
rs11865086 16p11.2 30037994 4.93e-08 5.9e-06 6.22e-07 PBC
rs4796791* 17q21.2 37784289 5.04e-08 6.02e-06 2.62e-06 T1D
rs917116* 7p15.1 28139264 5.72e-08 6.68e-06 2.52e-06 RA
rs2445610* 8q24.21 128266270 6.75e-08 7.59e-06 2.53e-06 CEL
rs60600003* 7p14.1 37348990 6.9e-08 7.72e-06 5.86e-07 PBC
rs5884150* 7p12.2 50296113 7.87e-08 8.63e-06 3.06e-06 T1D
rs6896969* 5p13.1 40460183 8.23e-08 8.99e-06 9.24e-07 CRO
rs10892299* 11q23.3 118232053 1.07e-07 1.13e-05 1.47e-06 PBC
rs67297943* 6q23.3 138286509 1.27e-07 1.31e-05 3.63e-06 PSO
rs793108* 10p11.22 31455112 1.46e-07 1.48e-05 2.26e-06 T1D
rs2163226* 2p21 43214760 1.8e-07 1.78e-05 4.51e-06 CEL
rs7120737* 11p11.2 47658971 1.94e-07 1.9e-05 4.86e-06 CEL
rs35929052* 16q24.1 84551985 7.74e-07 6.35e-05 4.46e-06 PBC
Associated SNPs for MS, ordered by best cFDR. P values shown are after adjustment for
genomic inflation. Chromosome positions are from the NCBI36 assembly. The conditional
phenotype shown is the phenotype for which the cFDR was most below the relevant cutoff.
Column CP is the conditional phenotype for which corrected cFDR was lowest. SNPs with p
value greater than 5×10−8 for the principal phenotype are asterisked, and SNP-disease
associations not previously known are suffixed with a ’+’
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Table A.6 SNPs associated with NAR
RSID Region Pos P val uFDR cFDR CP
rs1154155 14q11.2 22072524 2.68e-28 2.63e-23 4.22e-24 UC
rs4916312 1q25.1 171412980 7.76e-11 9.54e-07 6.89e-08 CRO
rs34843303 15q25.1 77021525 9.06e-09 5.94e-05 2.3e-06 T1D
Associated SNPs for NAR, ordered by best cFDR. P values shown are after adjustment for
genomic inflation. Chromosome positions are from the NCBI36 assembly. The conditional
phenotype shown is the phenotype for which the cFDR was most below the relevant cutoff.
Column CP is the conditional phenotype for which corrected cFDR was lowest. SNPs with p
value greater than 5×10−8 for the principal phenotype are asterisked, and SNP-disease
associations not previously known are suffixed with a ’+’
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Table A.7 SNPs associated with PBC
RSID Region Pos P val uFDR cFDR CP
rs72678531 1p31.3 67571033 2.58e-34 2.76e-29 2.21e-30 CRO
rs574808 3q25.33 161215677 9.17e-20 2.52e-16 4.36e-17 MS
rs35188261 7q32.1 128470775 1.11e-19 2.97e-16 5.67e-17 MS
rs3024921 2q32.3 191651517 1.79e-16 2.49e-13 4.87e-14 RA
rs17122453 11q23.3 118188774 2.88e-14 3.42e-11 4.54e-12 RA
rs13092998 3q13.33 120727734 3.62e-14 4.08e-11 5.35e-12 MS
rs4728142b 7q32.1 128361203 4.62e-14 5.1e-11 2.17e-11 MS
rs1646019b 16p13.13 11267181 1.98e-13 1.83e-10 3.75e-11 MS
rs1800693 12p13.31 6310270 3.27e-13 2.89e-10 1.03e-10 MS
rs12708715 16p13.13 11085325 1.15e-12 8.29e-10 6.41e-11 MS
rs7665090 4q24 103770651 1.9e-12 1.32e-09 1.22e-10 MS
rs9303277 17q12 35229995 2.12e-12 1.46e-09 2.03e-10 MS
rs909685 22q13.1 38077617 3.37e-12 2.24e-09 4.19e-10 RA
rs6871748 5p13.2 35921739 4.57e-12 2.85e-09 2.44e-10 MS
rs1675497 3q25.33 161065076 9.82e-12 5.28e-09 6.14e-10 MS
rs34536443b 19p13.2 10324118 2.07e-11 9.5e-09 5.1e-10 MS
rs2488393 1q31.3 195988863 6.31e-11 2.55e-08 3.84e-09 MS
rs17753961 3q25.33 161142977 9.83e-11 3.7e-08 3.3e-09 MS
rs911263 14q24.1 67823346 1.04e-09 2.98e-07 2.9e-08 RA
rs6693065 1p31.3 67572606 1.18e-09 3.31e-07 6.79e-08 UC
rs11117433 16q24.1 84577017 1.11e-08 2.46e-06 1.66e-07 MS
rs17564829 17q21.31 41362429 1.62e-08 3.43e-06 3.91e-07 T1D
rs1498736 3q25.33 161177252 1.74e-08 3.63e-06 1.45e-06 CEL
rs7574865 2q32.3 191672878 2.23e-08 4.45e-06 1.11e-06 MS
rs34725611 19p13.2 10338067 2.98e-08 5.76e-06 3.48e-07 MS
rs7302763* 12q24.12 110311952 7.31e-08 1.23e-05 1.32e-06 T1D
rs1034920*+ 1p13.1 116877922 1.43e-06 0.000173 3.55e-06 MS
Associated SNPs for PBC, ordered by best cFDR. P values shown are after adjustment for
genomic inflation. Chromosome positions are from the NCBI36 assembly. The conditional
phenotype shown is the phenotype for which the cFDR was most below the relevant cutoff.
Column CP is the conditional phenotype for which corrected cFDR was lowest. SNPs with p
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value greater than 5×10−8 for the principal phenotype are asterisked, and SNP-disease
associations not previously known are suffixed with a ’+’
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Table A.8 SNPs associated with PSO
RSID Region Pos P val uFDR cFDR CP
rs2474524+ 10p11.21 35699658 3.76e-22 3.85e-17 8.47e-18 MS
rs76930577+ 8q21.12 79722985 1.49e-18 7.65e-14 3.38e-14 NAR
rs57995211+ 1q23.3 159607415 5.7e-17 1.95e-12 1.3e-12 T1D
rs78623400+ 6q22.33 127278089 2.43e-16 6.22e-12 3.89e-12 T1D
rs33980500 6q21 112019955 2.5e-16 5.12e-12 4.81e-13 UC
rs143726108+ 5q35.2 173175476 5.76e-16 9.84e-12 4.54e-12 UC
rs34413922+ 16p11.2 28479506 6.14e-16 8.98e-12 8.98e-12 PSO
rs9525864+ 13q14.11 43355611 8.28e-16 1.06e-11 1.06e-11 PSO
rs116054851+ 3p21.2 50787356 1.51e-15 1.71e-11 1.71e-11 PSO
rs111251548 16p13.13 10974929 7.79e-15 7.99e-11 7.99e-11 PSO
rs114557151+ 3p24.1 27794143 2.81e-14 2.62e-10 2.62e-10 PSO
rs3818818+ 13q14.11 43352455 3.77e-14 3.22e-10 3.22e-10 PSO
rs13394291+ 2q37.1 234166479 7.05e-14 5.55e-10 5.55e-10 PSO
rs1581803 1q21.3 150858905 4.46e-13 2.23e-09 9.28e-10 RA
rs77520588+ 1p13.1 117088877 8.73e-13 3.08e-09 3.08e-09 PSO
rs17728338 5q33.1 150458511 1.05e-12 3.59e-09 2.02e-09 RA
rs10424919+ 19p13.2 11697587 1.75e-12 5.61e-09 4.55e-09 NAR
rs17066690 6q23.3 138025674 2.32e-12 7.19e-09 7.19e-09 PSO
rs113866081+ 6p25.3 320823 4e-12 1.05e-08 1.05e-08 PSO
rs7130650+ 11q13.5 75877226 6.2e-12 1.55e-08 1.25e-08 NAR
rs34536443b 19p13.2 10324118 8.6e-12 2e-08 1.94e-09 RA
rs7722096 5q33.3 158754495 9.09e-12 2.07e-08 5.94e-09 CRO
rs456865 6q21 111739621 9.75e-12 2.17e-08 2.12e-08 RA
rs12188300 5q33.3 158762105 1.78e-11 3.8e-08 2.15e-08 UC
rs58973750+ 110949512 1.06e-10 1.84e-07 1.57e-07 MS
rs117135073+ 10q21.2 64025171 1.27e-10 2.13e-07 7.52e-08 UC
rs74237645+ 12q24.13 111388614 4.25e-10 4.74e-07 4.04e-07 MS
rs78636848+ 1q31.3 195820925 6.66e-10 7.11e-07 4.9e-07 MS
rs1416173 6q23.3 138170539 7.04e-10 7.36e-07 4.92e-07 PBC
rs114835245+ 5p13.1 40548527 8.77e-10 8.9e-07 5e-07 CRO
rs57939339+ 11p15.5 491841 9.87e-10 9.82e-07 4.58e-07 CRO
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rs11681704+ 2q37.1 234003141 1.27e-09 1.25e-06 5.73e-07 CRO
rs7865117+ 9p13.3 34848595 2.89e-09 2.65e-06 2.6e-06 MS
rs6714339 2p15 61278697 5.83e-09 4.63e-06 3.3e-06 MS
rs77840275 7p14.1 37377990 8.02e-09 5.96e-06 4.47e-06 MS
rs72832931+ 17q12 35246237 8.52e-09 6.24e-06 4.7e-06 MS
rs892085 19p13.2 10679092 1.05e-08 7.24e-06 6.66e-06 RA
rs30376 5q15 96146015 1.25e-08 8.03e-06 3.73e-06 UC
rs11648503+ 16q22.1 67156439 1.74e-08 1.01e-05 8.43e-06 MS
rs2304256b 19p13.2 10336652 2.29e-08 1.27e-05 4.01e-06 RA
rs73246593+ 8q21.12 79696198 2.3e-08 1.27e-05 2.22e-06 UC
rs57009492+ 17q12 34880189 3.17e-08 1.68e-05 1.35e-05 MS
rs75430970+ 11q13.5 75907370 3.62e-08 1.88e-05 8.75e-06 UC
rs75929100+ 4q27 123651035 4.46e-08 2.24e-05 9.32e-06 CRO
rs11209026* 1p31.3 67478546 1.01e-07 4.8e-05 6.16e-07 UC
rs1990760* 2q24.2 162832297 2.69e-07 0.000122 1.21e-05 UC
Associated SNPs for PSO, ordered by best cFDR. P values shown are after adjustment for
genomic inflation. Chromosome positions are from the NCBI36 assembly. The conditional
phenotype shown is the phenotype for which the cFDR was most below the relevant cutoff.
Column CP is the conditional phenotype for which corrected cFDR was lowest. SNPs with p
value greater than 5×10−8 for the principal phenotype are asterisked, and SNP-disease
associations not previously known are suffixed with a ’+’
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Table A.9 SNPs associated with RA
RSID Region Pos P val uFDR cFDR CP
rs6679677 1p13.2 114105331 3.16e-63 1.67e-58 7.89e-61 ATD
rs71624119 5q11.2 55476487 1.81e-20 3.14e-17 2.7e-18 ATD
rs34536443b 19p13.2 10324118 1.31e-13 1.05e-10 9.01e-13 T1D
rs13524 1p13.2 114029723 1.65e-11 1.2e-08 2.43e-10 T1D
rs6920220 6q23.3 138048197 1.06e-10 7.01e-08 3e-09 T1D
rs932036 4p15.2 25699960 1.15e-10 7.59e-08 2.89e-09 T1D
rs13426947 2q32.3 191641499 4.29e-10 2.32e-07 4.16e-08 T1D
rs8026898 15q23 67778471 1.36e-09 6.92e-07 9.62e-08 ATD
rs58721818 6q23.3 138285432 2.54e-09 1.25e-06 2.75e-07 T1D
rs10209110 2q11.2 100039124 7.21e-09 3.54e-06 1.43e-07 ATD
rs2812378 9p13.3 34700260 8.4e-09 4.06e-06 1.65e-06 UC
rs2228145 1q21.3 152693594 8.46e-09 4.07e-06 4.74e-07 ATD
rs2301888 1p36.13 17545317 8.77e-09 4.19e-06 2.66e-06 CRO
rs12049447 1p13.2 113724368 1.8e-08 8.29e-06 1.16e-07 T1D
rs1503836 1p13.2 114343021 3.16e-08 1.37e-05 1.65e-07 T1D
rs72685699 1p13.2 113673353 3.34e-08 1.44e-05 2.3e-07 T1D
rs39984* 5q21.1 102625191 6.29e-08 2.51e-05 7.94e-06 T1D
rs55686954* 2q33.2 204294760 8.13e-08 3.2e-05 1.96e-06 T1D
rs3087243* 2q33.2 204447164 9.27e-08 3.61e-05 3.31e-07 T1D
rs8043085* 15q14 36615432 1.12e-07 4.25e-05 1.37e-06 T1D
rs28532547* 1p36.32 2551146 1.58e-07 5.79e-05 2.81e-06 ATD
rs12936409* 17q12 35297175 2.61e-07 8.38e-05 2.59e-06 T1D
rs736202* 1p13.2 113620903 3.55e-07 0.00011 2.13e-06 T1D
rs72928038*+ 6q15 91033489 5.89e-07 0.000167 2.9e-06 T1D
rs2304256b* 19p13.2 10336652 1.48e-06 0.000348 8.18e-06 T1D
rs10795791* 10p15.1 6148346 2.22e-06 0.000478 6.93e-06 T1D
Associated SNPs for RA, ordered by best cFDR. P values shown are after adjustment for
genomic inflation. Chromosome positions are from the NCBI36 assembly. The conditional
phenotype shown is the phenotype for which the cFDR was most below the relevant cutoff.
Column CP is the conditional phenotype for which corrected cFDR was lowest. SNPs with p
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value greater than 5×10−8 for the principal phenotype are asterisked, and SNP-disease
associations not previously known are suffixed with a ’+’
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Table A.10 SNPs associated with UC
RSID Region Pos P val uFDR cFDR CP
rs4654925 1p36.13 20100310 7.56e-37 8.15e-32 2.16e-32 NAR
rs7547569 1p31.3 67503956 1.56e-34 3.36e-30 2.88e-32 PSO
rs9808651 21q22.2 39388338 6.99e-28 2.79e-24 1.98e-24 PBC
rs6017342 20q13.12 42498442 3.51e-27 1.08e-23 8.64e-24 PBC
rs3024493 1q32.1 205010591 8.69e-24 2.46e-20 9.56e-21 CRO
rs10800314 1q23.3 159739413 3.1e-21 7.43e-18 3.96e-18 CRO
rs3806308+ 1p36.13 20015453 1.01e-20 2.32e-17 1.35e-17 PBC
rs3197999 3p21.31 49696536 1.04e-20 2.28e-17 5.54e-18 CRO
rs10883361 10q24.2 101272958 4.21e-20 8.56e-17 1.77e-17 CRO
rs11465802 1p31.3 67458186 5.27e-20 1.05e-16 1.56e-17 CRO
rs4655215+ 1p36.13 20010301 9.37e-17 7.01e-14 3.23e-14 PSO
rs12946510 17q12 35165903 4.92e-16 3.35e-13 3.88e-14 CRO
rs10758669 9p24.1 4971602 7.91e-16 5.23e-13 5.74e-14 CRO
rs11614178 12q15 66794389 1.78e-15 1.1e-12 6.66e-13 T1D
rs10781499 9q34.3 138386226 1.91e-15 1.17e-12 2.41e-13 CRO
rs12126806 1q32.1 199230448 6.27e-15 3.69e-12 3.08e-13 CRO
rs56167332 5q33.3 158760347 7.31e-14 2.52e-11 4.78e-12 CRO
rs7608910 2p16.1 61058360 3.06e-13 8.97e-11 6.65e-12 CRO
rs4366152 9q32 116604696 3.72e-13 1.08e-10 7.64e-12 CRO
rs6702254 1q32.1 205031575 7.19e-13 1.94e-10 2.38e-11 CRO
rs6466198 7q31.1 107267362 2.63e-12 6.38e-10 5.33e-10 PBC
rs1250563+ 10q22.3 80717389 1.01e-11 2.16e-09 8.97e-10 CRO
rs2816958 1q32.1 198368543 1.67e-11 3.33e-09 2.46e-09 NAR
rs2823259 21q21.1 15711341 1.8e-11 3.54e-09 4.64e-10 CRO
rs17229679 2q33.1 199269002 2.55e-11 4.7e-09 3.7e-09 PBC
rs4676406 2q37.3 241227781 4.79e-11 8.35e-09 5.01e-09 CEL
rs928722 6q23.3 138015525 5.5e-11 9.49e-09 1.95e-09 CEL
rs12244675 10q21.2 64070058 6.81e-11 1.16e-08 1.95e-09 CRO
rs17085007 13q12.13 26429267 1.14e-10 1.86e-08 1.36e-08 CRO
rs4845604 1q21.3 150068304 1.29e-10 2.08e-08 5.58e-09 CRO
rs6897260 5q33.3 158735664 2.07e-09 2.45e-07 2.65e-08 CRO
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rs4746475 10q21.2 64028691 2.08e-09 2.46e-07 3.7e-08 NAR
rs17229285 2q33.1 199231367 2.23e-09 2.63e-07 1.96e-07 PBC
rs115800677+ 1q23.3 159635622 2.31e-09 2.71e-07 1.6e-07 CRO
rs798544 7p22.3 2729628 4.77e-09 5.19e-07 3.68e-07 PBC
rs2143178 22q13.1 37990775 4.78e-09 5.19e-07 7.93e-08 CRO
rs6062496 20q13.33 61799543 5.53e-09 5.93e-07 5.3e-08 CRO
rs7805114+ 7q31.1 107237269 6.71e-09 7.08e-07 5.65e-07 PBC
rs1003643 22q13.1 38006440 7.42e-09 7.77e-07 7.4e-08 CRO
rs10891692 11q23.2 113898862 8.94e-09 9.31e-07 7.79e-07 PBC
rs11641184+ 16p13.13 11612152 9.31e-09 9.67e-07 1.16e-07 CRO
rs17401847 1p36.13 20111053 9.59e-09 9.93e-07 6.01e-07 PBC
rs1893217 18p11.21 12799340 1.08e-08 1.11e-06 1.08e-07 CRO
rs3774937 4q24 103653283 1.18e-08 1.21e-06 1.01e-07 PBC
rs72684721 4q27 123197786 1.39e-08 1.4e-06 1.31e-07 CRO
rs4494327 11q13.5 75972484 2.24e-08 2.15e-06 4.84e-07 CRO
rs80243484 9q34.3 138425458 2.36e-08 2.26e-06 2.18e-07 CRO
rs12727925+ 1p36.13 20014907 2.87e-08 2.71e-06 2.25e-06 PBC
rs34963268 1p36.12 22583464 3.06e-08 2.87e-06 2.08e-06 NAR
rs6088747* 20q11.22 33218265 5.69e-08 5.09e-06 2.14e-06 T1D
rs7808907* 7q32.1 128371320 1.2e-07 1.01e-05 1.5e-06 PBC
rs1479918* 4q27 123570881 1.36e-07 1.12e-05 1.86e-06 CRO
rs1790932* 18q22.2 65684380 1.38e-07 1.14e-05 3.39e-06 RA
rs79248157*+ 2q32.1 185209310 1.53e-07 1.25e-05 3.55e-06 CRO
rs281423* 19p13.2 10296493 2.42e-07 1.86e-05 1.82e-06 CRO
Associated SNPs for UC, ordered by best cFDR. P values shown are after adjustment for
genomic inflation. Chromosome positions are from the NCBI36 assembly. The conditional
phenotype shown is the phenotype for which the cFDR was most below the relevant cutoff.
Column CP is the conditional phenotype for which corrected cFDR was lowest. SNPs with p
value greater than 5×10−8 for the principal phenotype are asterisked, and SNP-disease
associations not previously known are suffixed with a ’+’
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Table A.11 SNPs associated with CRO
RSID Region Pos P val uFDR cFDR CP
rs5743289 16q12.1 49314275 1.03e-86 1.11e-81 6.62e-82 CEL
rs11209026 1p31.3 67478546 1.55e-74 2.77e-70 8.62e-72 PSO
rs7517847 1p31.3 67454257 5.59e-67 2.87e-63 2.87e-63 CRO
rs6451493 5p13.1 40446692 1.1e-39 1.8e-36 7.1e-37 MS
rs11749040 5p13.1 40432182 2.02e-30 1.43e-27 6.71e-28 MS
rs3792111 2q37.1 233844429 6.24e-29 3.41e-26 2.33e-26 PSO
rs17622378 5q31.1 131806351 5.83e-27 2.35e-24 2.27e-24 PSO
rs9673419 16q12.1 49218774 1.07e-24 3.83e-22 2.94e-22 RA
rs11791262 9q34.3 138391740 9.65e-24 3.34e-21 2.81e-21 ATD
rs11236797 11q13.5 75977297 2.96e-23 1e-20 7.83e-21 RA
rs10995271 10q21.2 64108492 7.91e-23 2.63e-20 1.96e-20 RA
rs56167332 5q33.3 158760347 1.37e-21 4.27e-19 3.43e-19 RA
rs79139810+ 1p31.3 67646635 1.54e-21 4.79e-19 4.06e-19 ATD
rs4957310 5p13.1 40531137 5.86e-20 1.72e-17 1.13e-17 PSO
rs4409764 10q24.2 101274227 3.64e-19 9.87e-17 9.14e-17 ATD
rs1990623+ 16q12.1 49123471 3.49e-18 8.9e-16 7.91e-16 ATD
rs11597184 10p11.21 35437402 3.65e-18 9.28e-16 7.12e-16 RA
rs2143178 22q13.1 37990775 6.5e-18 1.6e-15 8.44e-16 UC
rs4958426 5q33.1 150258539 8.26e-18 2.01e-15 1.5e-15 RA
rs11646242 16q12.1 49329618 1.24e-17 2.94e-15 2.32e-15 RA
rs10758669 9p24.1 4971602 1.65e-17 3.73e-15 2.21e-15 UC
rs2823256 21q21.1 15706577 1.81e-17 4.05e-15 1.92e-15 UC
rs56735814 5q33.3 158746694 2.66e-17 5.59e-15 2.73e-15 UC
rs4643314+ 16q12.1 48933456 2.36e-15 3.76e-13 3.28e-13 T1D
rs12946510 17q12 35165903 1.61e-14 2.36e-12 1.36e-12 UC
rs73818239 3p24.3 18730835 2.5e-14 3.62e-12 3.14e-12 T1D
rs9889296 17q12 29594660 4.16e-14 5.87e-12 4.24e-12 UC
rs11585473+ 1p31.3 67678880 1.08e-13 1.37e-11 6.44e-12 UC
rs3197999 3p21.31 49696536 1.24e-13 1.53e-11 1.34e-11 PSO
rs6561151 13q14.11 43382706 1.3e-12 1.25e-10 9.07e-11 UC
rs10889680+ 1p31.3 67541181 1.36e-12 1.3e-10 6.32e-11 UC
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rs181207 16p11.2 28421031 1.53e-12 1.46e-10 9.58e-11 UC
rs7869487 9q32 116620735 3.75e-12 3.41e-10 9.81e-11 UC
rs13407913 2p23.3 24951148 3.82e-12 3.47e-10 1.91e-10 UC
rs28701841 6q21 106637023 4.08e-12 3.7e-10 2.88e-10 UC
rs34920518 18p11.21 12773086 4.49e-12 4.04e-10 1.16e-10 UC
rs55838263 1q32.1 199141351 9.52e-12 8.33e-10 2.54e-10 UC
rs2945412 17q11.2 22867770 1.44e-11 1.22e-09 1.18e-09 PSO
rs4432939 5p13.1 40706856 1.77e-11 1.46e-09 1.01e-09 UC
rs11145765 9q34.3 138523101 2.34e-11 1.89e-09 4.96e-10 UC
rs6500315+ 16q12.1 49065602 3.11e-11 2.47e-09 2.15e-09 PSO
rs6062496 20q13.33 61799543 3.65e-11 2.87e-09 6.79e-10 UC
rs529866 16p13.13 11280821 5.78e-11 4.42e-09 2.33e-09 T1D
rs10191951 2p16.1 61051294 5.79e-11 4.43e-09 9.46e-10 UC
rs1558620 2q12.1 102297827 6.03e-11 4.59e-09 2.9e-09 UC
rs4807569 19p13.3 1074378 6.37e-11 4.83e-09 4.79e-09 PSO
rs1004234 5q31.1 131785000 6.95e-11 5.24e-09 3.49e-09 NAR
rs1250573 10q22.3 80712481 1.05e-10 7.62e-09 3.6e-09 T1D
rs4311543 6q21 106609325 1.08e-10 7.84e-09 6.07e-09 UC
rs780094 2p23.3 27594741 2.44e-10 1.64e-08 1.27e-08 T1D
AMBIG_3_18793384 18793384 3.15e-10 2.07e-08 4.84e-09 UC
rs118097399 6q22.33 128319926 3.48e-10 2.28e-08 9.3e-09 T1D
rs4880099 9q34.3 138530410 3.98e-10 2.58e-08 1.01e-08 UC
rs4768236 12q12 39042739 5.24e-10 3.32e-08 1.98e-08 NAR
rs925255 2p23.2 28468298 6.7e-10 4.15e-08 8.29e-09 NAR
rs5757584 22q13.1 37992496 7.74e-10 4.72e-08 1.04e-08 UC
rs1842076 5p13.1 40272775 9.97e-10 5.92e-08 2.84e-08 UC
rs9457268 6q27 167423629 1.32e-09 7.61e-08 1.66e-08 NAR
rs2284553 21q22.11 33698565 1.38e-09 7.93e-08 5.23e-08 T1D
rs3024493 1q32.1 205010591 1.43e-09 8.19e-08 2.56e-08 T1D
rs74956615 19p13.2 10288721 1.96e-09 1.09e-07 2.07e-08 PBC
rs4796793 17q21.2 37795736 2.51e-09 1.38e-07 4.58e-08 UC
rs6651252 8q24.21 129636363 2.55e-09 1.4e-07 6.1e-08 RA
rs6074022 20q13.12 44173603 3.25e-09 1.74e-07 7.39e-08 RA
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rs12565884 1q32.1 199300895 4.42e-09 2.29e-07 1.38e-07 UC
rs7097656 10q23.1 82240811 5.07e-09 2.59e-07 1.26e-07 UC
rs1734907 7q22.1 100153453 5.42e-09 2.75e-07 1.62e-07 T1D
rs2074452 19p13.3 1058160 1.02e-08 4.78e-07 3.88e-07 UC
rs12041056 1p31.3 67399848 1.18e-08 5.48e-07 5.06e-07 NAR
rs2270395 16q12.1 49404333 1.21e-08 5.61e-07 5.02e-07 ATD
rs78686200 5q31.1 131550934 1.23e-08 5.7e-07 2.05e-07 UC
rs35256947 2q37.1 230869270 1.31e-08 6.04e-07 1.93e-07 T1D
rs1582515 5q33.3 158713930 2.06e-08 9.2e-07 1.82e-07 UC
rs4663340 2q37.1 233807430 2.07e-08 9.25e-07 8e-07 NAR
rs12340801+ 9q31.3 113671146 2.1e-08 9.33e-07 2.8e-07 UC
rs11641016 16q24.1 84572382 2.92e-08 1.27e-06 2.75e-07 PBC
rs174535 11q12.2 61307932 3.27e-08 1.41e-06 4.7e-07 T1D
rs679574 19q13.33 53897920 3.43e-08 1.47e-06 5.5e-07 CEL
rs68143871 1q24.3 171122199 4.18e-08 1.77e-06 6.75e-07 CEL
rs72684721 4q27 123197786 4.99e-08 2.07e-06 4.27e-07 UC
rs8127691* 21q22.3 44439288 5.33e-08 2.2e-06 5.36e-07 UC
rs12924003*+ 16q12.1 49637715 5.82e-08 2.38e-06 2e-06 NAR
rs10463350* 5q31.3 141514362 6.7e-08 2.69e-06 7.14e-07 UC
rs2451258* 6q25.3 159426588 8.79e-08 3.47e-06 1.03e-06 CEL
rs2476601* 1p13.2 114179091 9.49e-08 3.71e-06 3.15e-07 T1D
rs80243484* 9q34.3 138425458 1.15e-07 4.42e-06 9.04e-07 UC
rs34266232* 19p13.2 10363968 1.26e-07 4.81e-06 1.34e-06 UC
rs9358372* 6p22.3 20920567 1.38e-07 5.2e-06 2.05e-06 UC
rs79829650* 10q21.2 64050130 1.44e-07 5.4e-06 1.05e-06 NAR
rs71624119* 5q11.2 55476487 1.46e-07 5.47e-06 1.91e-06 ATD
rs12075255* 1q32.1 205028251 1.54e-07 5.77e-06 1.22e-06 UC
rs2042097* 1q31.3 195737973 2.55e-07 9.09e-06 1.58e-06 PBC
Associated SNPs for CRO, ordered by best cFDR. P values shown are after adjustment for
genomic inflation. Chromosome positions are from the NCBI36 assembly. The conditional
phenotype shown is the phenotype for which the cFDR was most below the relevant cutoff.
Column CP is the conditional phenotype for which corrected cFDR was lowest. SNPs with p
258 Supplementary material for chapter 2
value greater than 5×10−8 for the principal phenotype are asterisked, and SNP-disease
associations not previously known are suffixed with a ’+’
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Fig. A.5 Effect of adjusting ĉFDR for shared controls. This plot shows the ratio between the
true ĉFDR (computed using our method) to the ’naive’ ĉFDR (computed by naively applying
the existing split-control approach to shared-control data without adjustment) for a range of
p values for the principal phenotype. The p values forming the x-coordinates were obtained
from the shared-control design.
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Fig. A.6 Summary of pleiotropy between phenotypes. The colour for phenotype i (horizontal)
and phenotype j (vertical) corresponds to the p-value cutoff for significance for phenotype i,
given that a p-value cutoff for phenotype j is less than 5×10−6.
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Fig. A.7 Distribution of log(M) amongst null SNPs. M is proportional to the variance of the
log odds ratio from TDT data, defined as σˆ2 f (1− f )), where f is the minor allele frequency
amongst null SNPs, and σˆ is the standard error. Equating the median of M with a known
expression for variance of the log odds ratio in a case-control study enables back-calculation
of the effective number of cases and controls. This technique was used for computing the
number of cases and controls in the T1D study, for which p values were obtained from a
meta-analysis of case-control and TDT data.
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Fig. A.8 Q-Q plots labelled "i| j", where i is the principal phenotype and j the conditional
phenotype. Y axes show log10(p
′
i); X axes show log quantile (rank) of p values in various
sets of SNPs. Each colour corresponds to the Q-Q plot for pi amongst only SNPs such that
p j is less than a certain cutoff, with the black line corresponding to the Q-Q plot for all
SNPs. P values for the principal phenotype are adjusted for the effect of shared controls
between studies. A leftward shift with decreasing p j cutoff indicates enrichment of SNP sets
from conditioning on degrees of association with a conditional phenotype, probably due to
pleiotropic effects between phenotypes. Because the studies used the ImmunoChip, which
covers only potential autoimmune-associated regions, the black line also shows considerable
enrichment compared to quantiles.
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Appendix B
Supplementary work for chapter 4
B.1 Supplementary note
B.1.1 Covariance between Z scores due to shared samples
The matching of type-1 error rates between methods relies on establishing the covariance
between triples of z-scores under H∩0 . The covariance can be readily estimated when z-scores
are assumed to be derived from tests of equality of binomial random variables mi.
If strata or covariates are used, either an assumption must be made that computed z-scores
are well-approximated by comparisons of binomial proportions, or covariances must be
estimated allowing for the covariate or strata structure. Estimates can be made analytically in
some circumstances, but can also be made empirically either by using known non-associated
variants or by simulating variants with the same covariate structure.
The presence of strata or covariates also affects the values ζi, and if the effects of
covariates are large, the approximations in equations 4.9 in the main paper may be poor.
Values ζi can be estimated as functions of allelic differences by simulating variants with the
same covariate structure.
No covariates or stratification
Assume study i and j have ni0, n
j
0 controls and n
i
1, n
j
1 cases respectively, of which n
i j
0 controls
and ni j1 cases are shared between both studies. Let m0,m1,m
′
0,m
′
1, denote the observed allele
frequencies of a SNP in the respective cohort, and µ0,µ1,µ ′0,µ
′
1 the expected allele frequency.
As for section 4.4 in chapter 4, define zx for x ∈ {d,r,s,m,c} as the signed z-score
(±Φ−1(px/2)) corresponding to px, and zx for x ∈ α,β ,β ∗,γ as the positive corresponding
threshold −Φ−1(x/2), where Φ,Φ−1 are the standard normal CDF and quantile functions.
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If no strata or covariates are used in the calculation of summary statistics, z scores
zd,zr,zs,zm are asymptotically proportional to the allelic differences m1 −m0, m′1 −m′0,
m′1− m
′
0n
′
0+m0n0
n0+n′0
, m1n1+m
′
1n
′
1
n1+n′1
− m′0n′0+m0n0n0+n′0 respectively, since z scores are monotonic with allelic
differences and allelic differences are asymptotically normal. Since m0,m1,m′0,m
′
1 are
independent and asymptotically normal the multivariate random variables (zd,zr,zm) and
(zd,zs,zm) have multivariate normal distributions.
For studies i on n0i, n1i controls and cases and j on n0 j, n1 j controls and cases in which
n0i j and n1i j controls and cases are shared between studies, the correlation between the
observed allelic differences m1i−m0i, m1 j−m0 j is asymptotically given by
cor(m1i−m0i,m1 j−m0 j) = n0in0 jn1i j +n1in1 jn0i j
n0in0 jn1in1 j
√
1
n0i
+ 1n0 j
√
1
n0 j
+ 1n1 j
(B.1)
This holds under H∩0 (no allelic differences between cohorts) and approximately holds in
general. Expressions for ρds, ρdm, ρrm and ρsm may be derived in terms of n0, n1, n′0, and n
′
1.
Specifically
det(ΣA) = 1−ρ2dm−ρ2rm
=
(n0n′1−n′0n1)2
(n0+n′0)(n1+n
′
1)(n0+n1)(n
′
0+n
′
1)
(B.2)
det(ΣB) = 1−ρ2dm−ρ2ds−ρ2sm+2ρdmρdsρsm
=
n′0n
2
1
(n0+n1)(n0+n′0+n
′
1)(n1+n
′
1)
(B.3)
so ΣA is singular if n0n1 =
n′0
n′1
, and ΣB if n′0n1 = 0.
Z scores with stratification
If computation of Z scores is performed with correction for strata or covariates, formula B.1
will not asymptotically hold under H∩0 and may be a poor approximation to the true covariance.
The true covariance can be computed in some cases.
If samples are divided into strata 1,2, ...s, and nrpi, m
r
pi, µrpi denote the number of samples
and observed and expected minor allele frequencies in cohort p, study i, stratum r respectively,
then the z score zi for study i is asymptotically given by
zi =
s
∑
r=1
αir (mr1i−mr0i) (B.4)
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for positive values αir depending on the values nrpi. If the Cochran-Mantel-Hanszel test is
used, then
αir ∝
nr0in
r
1i
nr0i+n
r
1i
(B.5)
Suppose that nr0i j controls and n
r
1i j cases are shared between studies i and j in stratum r.
Since the values mrpi are dependent only within the same values of p and r, the correlation
between zi and z j under the null hypothesis µr0i ≡ µr1i,µr0i ≡ µr1i is given by
cor(zi,z j) =
∑αirα jrcov(mr1i−mr0i,mr1 j−mr0 j)√
var(mr1i−mr0i)var(mr1 j−mr0 j)
≈
∑αirα jr
( nr0i j
nr0in
r
0 j
+
nr1i j
nr1in
r
1 j
)
√(
∑α2ir
(
1
nr0i
+ 1nr1i
))(
∑α2jr
(
1
nr0 j
+ 1nr1 j
)) (B.6)
where all sums are implicitly only over the values of r ∈ 1..s for which the relevant values of
nrpi are positive.
Z scores with covariates
If z scores are computed adjusting for one or more covariates, the estimation of correlation
is more difficult. Assume that in a case cohort C1 and a control cohort C0 the values of
some covariate(s) x have different known distributions f1, f0, and that numerical genotypes g
(g ∈ {0,1,2}) at some SNP of interest may vary with x. Assume the cohorts are large and
that f1, f0, and E(g|x) are continuous functions of x.
Let gkp denote the genotype of individual k in cohort p (p∈C0,C1) and xkp denote covariate
value(s), where gkp is an observation of a random variable g. An idealised z-score testing
association of g with case/control status can be considered a function of the values gkp, x
k
p
which should be monotonic with each gkp and have expectation under H
∩
0 if x is independent of
case/control status, whatever the form of the function E(g|x). Because individual genotypes
are assumed to be independent between individuals, cross-terms of the form∏i gi should carry
no additional information from singleton genotypes, so I assume that z can be decomposed
into a weighted linear sum of individual genotypes:
z ∝
1
|C1| ∑k∈C1
ck1g
k
1−
1
|C0| ∑k∈C0
ck0g
k
0 (B.7)
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where the (positive) values ck1,c
k
0 depend only on the values x
·
1,x
·
0; that is, not on the relation-
ship between g and x, and the constant of proportionality depends on only on the observed
allele frequency. Let function c0(x),c1(x) denote the values of ci corresponding to covariate
value(s) x in C0, C1.
For a null SNP, E(g|x) is independent of case/control status, but may take any (continuous)
form. We have
E(z) ∝ E
(
1
|C1| ∑i∈C1
cigi− 1|C0| ∑i∈C0
cigi
)
lim
|C0|,|C1|→∞
E(z) ∝
∫
c1(x) f1(x)E(g|x)dx−
∫
c0(x) f0(x)E(g|x)
∝
∫
(c1(x) f1(x)− c0(x) f0(x))E(g|x)dx (B.8)
From a standard result from the calculus of variations, E(z) = 0 implies that
c1(x) f1(x)− c0(x) f0(x)≡ 0 =⇒ c1(x) ∝ f (x)f1(x) ,c0(x) ∝
f (x)
f0(x)
(B.9)
for some function f , so the values ck1,c
k
0 must effectively re-weight the contribution of
individuals to a common density f (x) across x. The procedure of weighting observation k in
this way is analogous to a limiting case of stratification, in which weights are defined by the
frequency of stratum r (see discussion of strata above). For a constant allelic difference across
the range of x, the best common distribution to ‘map to’ does not depend on the relationship
between g and x, and hence the best values of ci should be constant for all functions E(g|x).
Let zq denote a z-score for study q; npq, fpq = fpq(x) and Cpq denote the number of
samples, density function of x, and set of samples in cohort p, study q; gipq and c
k
pq denote the
normalised genotype of sample k in cohort p, study q and its coefficient in zq; n0s, n1s, f0s,
f1s and Cs0, C
s
1 the number of shared controls/cases between studies, the density of x amongst
the shared samples, and the sets of shared samples; and fq the common density function to
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which cases and controls are weighted in study q (equation B.9). Then
cov(zi,z j)≈
1
n0in0 j ∑k∈Cs0 c
k
0ic
k
0 j +
1
n1in1 j ∑k∈Cs1 c
k
1ic
k
1 j√
1
n21i
∑k∈C1i(c
k
1i)
2+ 1
n20i
∑k∈C0i(c
k
0i)
2
√
1
n21 j
∑k∈C1 j(c
k
1 j)
2+ 1
n20 j
∑k∈C0 j(c
k
0 j)
2
(B.10)
→
n0s
n0in0 j
∫
f0s(x)
fi(x) f j(x)
f0i(x) f0 j(x)
dx+ n1sn1in1 j
∫
f1s(x)
fi(x) f j(x)
f1i(x) f1 j(x)dx√
1
n0i
∫ fi(x)2
f0i(x)
dx+ 1n1i
∫ fi(x)2
f1i(x)
dx
√
1
n0 j
∫ f j(x)2
f0 j(x)
dx+ 1n1 j
∫ f j(x)2
f1 j(x)
dx
(B.11)
with integrals over the domain of x, and the limit as sample sizes tend to infinity while ratios
between them remain constant.
Logistic regression models with continuous covariates can only model simple (generally
linear) relationships between ci and xi, and property B.9 may not hold. If the values ckpq are
known, the correlation can be determined using equation B.10. If not, some methods for
estimating correlation are outlined below.
Practical estimation of covariance
Although the asymptotic correlation between z scores may be intractable, as long as the z
score permits an expansion of the form B.7, the correlation will be nearly invariant with
allele frequency and change only minimally for SNPs associated with the covariate.
In practical terms, one method to estimate the correlation between z scores is to simply
use the sample correlation at a set of variants presumed to be not associated with the main trait
of interest. This approach may be unreliable and have limited accuracy due to the difficulty of
identifying such variants Another option is to permute existing genotypes without permuting
covariates, and compute correlation between resultant z scores. This has the disadvantage
that it is difficult to permute whilst maintaining potential relationships between genotypes
and confounders.
Since the correlation should only depend on the sample sizes and structure of covariate
distributions, a more convenient and powerful method is to simply simulate sets of genotypes
un-associated with the trait, but potentially associated with covariates in a range of different
ways, and compute correlation between the resultant z scores. Given the shortcomings of
standard methods such as logistic regression in fully accounting for covariate effects, this is
an advisable procedure in any analysis including covariates.
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All results in the main paper which require conditions on sample sizes are only approxi-
mate when using studies with stratification or covariates, with the approximation worsening
with greater differences in covariate values between groups and lower effective sample sizes.
B.1.2 Properties of β ∗
Asymptotic properties of β ∗
In this appendix, an asymptotic approximation is established for β ∗and it is shown that
β ∗ > β for all ni0, n
j
0, n
i
1, n
j
1, zα , zγ . Define ΣA and ΣB as per equations 4.1 in the main paper,
and note that ΣA and ΣB only differ in their middle row/column. Further define
Σdm = var
(
(zd zm)t |H∪0
)
=
(
1 ρdm
ρdm 1
)
(B.12)
Let (z′α z′γ) be the point in {zd > zα ,zm > zγ} at minimal Mahalanobis distance from the origin
with respect to Σdm (ie, minimal (zd zm)Σ−1dm(zd zm)
t). Then for z′γ −ρdmz′α held constant, we
have
lim
z′γ→∞/z′α→∞
√|ΣA|((ρdsρdm−ρsm)z′γ +(ρdmρsm−ρds)z′α + |Σdm|zβ ∗)√|ΣB|(−ρrmz′γ +ρdmρrmz′α + |Σdm|zβ) = 1 (B.13)
Specifically, for β ∗ defined as per equation 4.3, we have
lim
α→0
zβ ∗√
1−ρ2dszβ +ρdszα
= 1 (B.14)
and zβ ∗ >max(β ,
√
1−ρ2dszβ +ρzα) for all zα . To show this, I firstly establish the following
lemma and corollary:
Lemma 1. Let Σ be a positive definite matrix of dimension N, x be the vector (x1 x2...xn)t , A1,
A0, and Z = (z1 z2...zn)t constant vectors of dimension N with A1 ̸= A0 ̸= 0, C0 a constant,
and R the (closed) region x1 ≥ z1,x2 ≥ z2, , ,xN ≥ zN .
Define C as the (unique) value satisfying∫
R
e−
1
2 x
tΣ−1x (Φ(At1x+C)−Φ(At0x+C0))dx1dx2...dxN = 0 (B.15)
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Denote y = (y1 y2...yN) as the point in R at minimal Mahalanobis distance M(y) from the
origin with respect to Σ (usually, y = Z). Consider all regions R for which the corresponding
value of y lies on the hyperplane At0y+C
′
0 = 0, C
′
0 ̸=C0. Then
lim
M(y)→∞|At0y+C′0=0
At1y+C
At0y+C0
= lim
M(y)→∞|At0y+C′0=0
At1y+C
C0−C′0
= 1 (B.16)
Proof. The value C is unique since the functionΦ(At1x+C) is continuous and monotonically
increasing in C for all x, and hence so is the integrand (and integral).
I proceed from the formal definition of a limit
∀ε > 0 ∃Y |
(
M(y)> Y =⇒
∣∣∣∣ At1y+CAt0y+C0 −1
∣∣∣∣< ε) (B.17)
Because At0y+C
′
0 = 0, the right-hand side is equivalent to
(1− ε)(C0−C′0)−At1y≤C ≤ (1+ ε)(C0−C′0)−At1y (B.18)
I will show that there exists Y such that M(y)> Y implies that when C takes values at the
endpoints of the interval in the integral B.18, the integral B.15 takes different signs. Since
the integral is increasing in C and must be 0, C must lie in the interval in B.18 for M(y)> Y .
If C takes the upper value, then at x = y, the value of the integrand is
e−
1
2 M(y)
(
Φ((1+ ε)(C0−C′0))−Φ(C0−C′0)
)
(B.19)
the sign of which depends on the sign of C0 −C′0. I shall assume it is positive (with
analogous arguments if it is negative). Because ε > 0, point y does not lie on the hyperplane
(At1−At0)x+(1+ ε)(C0−C′0)−At1y−C0 = 0 (on which the integrand of B.15 is 0). The
distance from y to the hyperplane is given by
D =
|(At1−At0)y+(1+ ε)(C0−C′0)−At1y−C0|
||At1−At0||
=
|(1+ ε)(C0−C′0)−C0−C′0|
||At1−At0||
(B.20)
which is independent of y. Consider a hypersphere centred at y of radius d < D. Each point
in the hypersphere can be expressed as y+κ with |κ| ≤ d, so within the hypersphere we
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have
Φ(At1x+C)−Φ(At0x+C0) =Φ(At1(y+κ)+(1+ ε)(C0−C′0)−At1y)
−Φ(At0(y+κ)+C0)
=Φ
(
(1+ ε)(C0−C′0)+At1κ
)
+Φ
(
(C0−C′0)+At0κ
)
≥Φ((1+ ε)(C0−C′0)+ |At1|d)
+Φ
(
(C0−C′0)−|At0|d
)
(B.21)
Thus d can be chosen independently of y such that Φ(At1x+C)−Φ(At0x+C0) is bounded
below in the hypersphere by a constant X also independent of y. The function Φ(At1x+
C)−Φ(At0x+C0) is obviously bounded by ±2. Let R′ be the intersection of R and the
hypersphere. The integral B.15 now satisfies∫
R
e−
1
2 x
tΣ−1x (Φ(At1x+C)−Φ(At0x+C0))dx1dx2...dxN
=
∫
R′
e−
1
2 x
tΣ−1x (Φ(At1x+C)−Φ(At0x+C0))dx1dx2...dxN
+
∫
R\R′
e−
1
2 x
tΣ−1x (Φ(At1x+C)−Φ(At0x+C0))dx1dx2...dxN
> X
∫
R′
e−
1
2 x
tΣ−1xdx1dx2...dxN
−2
∫
R\R′
e−
1
2 x
tΣ−1xdx1dx2...dxN (B.22)
Because d (the radius of the hypersphere) does not depend on y, by the properties of the
Gaussian integral a value M+ can be chosen such that M(y)> M+ implies that the ratio
∫
R′ e
− 12 xtΣ−1xdx1dx2...dxN∫
R\R′ e
− 12 xtΣ−1xdx1dx2...dxN
(B.23)
is arbitrarily large (namely, > 2/X), and hence integral B.22 is positive. In a similar way, a
value M− can be chosen such that if C takes the lower value of interval B.18, the integral
is negative for M(y)> M−. For M(y)> max(M+,M−), the value of C satisfying equation
B.15 lies within the interval B.18, and the limit is established.
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Corollary 3. Given b,c,y ∈ R+, define a such that∫ ∞
y
e−
x2
2 (Φ(c)−Φ(a−bx))dx = 0 (B.24)
then
lim
y→∞
a
by+ c
= 1 (B.25)
and a > by+ c ∀y
Proof. Note firstly that the function Φ(c)−Φ(a−bx) is increasing for all x. If the integral is
0, the (smooth) integrand must cross 0 at some finite x ∈ (y,∞), and hence its value at x = y
must be negative. As Φ is increasing, we have Φ(a−by)>Φ(c) =⇒ a > by+ c
The proof of the limit proceeds in a similar way to the proof of the lemma above.
Now (recalling definition 4.2 in the main paper)∫ ∞
zα
∫ ∞
zγ
∫ ∞
zβ∗
NΣB
(
(zd zs zm)t
)
dzsdzmdzd
=
∫ ∞
zα
∫ ∞
zγ
∫ ∞
zβ
NΣA
(
(zd zr zm)t
)
dzrdzmdzd
=⇒
∫ ∞
zα
∫ ∞
zγ
NΣdm
(
(zd zm)t
)
(Φ(a1zd +b1zm+ c1)
−Φ(a0zd +b0zm+ c0))dzddzm = 0 (B.26)
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where
a0 =− ρdmρrm√|Σdm||ΣA|
b0 =
ρrm√|Σdm||ΣA|
c0 =−
√
|Σdm|
|ΣA| zβ
a1 =
ρds−ρdmρsm√|Σdm||ΣB|
b1 =
ρsm−ρdsρdm√|Σdm||ΣB|
c1 =−
√
|Σdm|
|ΣB| zβ ∗ (B.27)
The asymptotic property of β ∗ follows from corollary 3.
If γ = 1, we have from definition 4.3 in the main paper
∫ ∞
zα
∫ ∞
zβ∗
1
2π
√
1−ρ2ds
exp
(
− 1
2(1−ρ2ds)
(
x2+ y2−2ρxy))dxdy
=
∫ ∞
zα
∫ ∞
zβ
1
2π
exp
(
−1
2
(
x2+ y2
))
dxdy
=⇒
∫ ∞
zα
e−
y2
2 Φ
zβ ∗−ρdsy√
1−ρ2ds
dy = ∫ ∞
zα
e−
y2
2 Φ(zβ ) (B.28)
from which the result follows from an application of lemma 1.
Size of β , β ∗ and β⊥
To show that β ∗ < β , I show that if we replace zβ with zβ ∗ in the definition of c0 in
equation B.27, then the integral B.26 is positive. Since the value of the integral is decreasing
with z∗β (as Φ(x) is monotonically increasing in x) we must have z
∗
β > zβ if the integral is to
be 0. A similar argument can be used to show that β⊥ < β ∗. Denote by I(zd,zm) the value
of the integrand of B.26 with zβ ∗ = zβ .
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Consider the line a1zd +b1zm+ c1 = a0zd +b0zm+ c0 on the (zd,zm) plane on which the
integrand of B.26 is 0. The gradient of this line is
a0−a1
b0−b1 =
√
ni0(n0+n
′
0)n1(n0+n1)√
(n1+n′1)(n0+n
′
0+n1+n
′
1)
× (B.29)
n′0n1(n0+n
′
0+n1+n
′
1)− (n0+n′0)|n′0n1−n0n′1|
n′0(n0+n
′
0)n1(n0+n1)− (n20+n0n′0+n′0n1)|n′0n1−n0n′1|
(B.30)
Since |n′0n1−n0n′1| ≥ (n′0n1−n0n′1) the numerator of the second fraction is greater than or
equal to
n′0n1(n0+n
′
0+n1+n
′
1)− (n0+n′0)(n′0n1−n0n′1) = n20n′1+n′0(n21+n0n′1+n1n′1)
> 0 (B.31)
and similarly the denominator is greater than or equal to
n0(n20n
′
1+n
′
0(n
2
1+n0n
′
1+n1n
′
1))> 0 (B.32)
so the gradient is positive. If b1−b0 > 0, I(zd,zm) is positive if (zd,zm) falls above the line,
and negative if below it; if b1−b0 < 0, the other way around. Assume for the moment that
b1−b0 < 0.
If the point (zα ,zγ) lies above the line, then since I(zd,zm) is negative in the region
(−∞,zα)× (zγ ,∞), we have∫ ∞
zα
∫ ∞
zγ
I(zd,zm)dzddzm ≥
∫ ∞
zα
∫ ∞
zγ
I(zd,zm)dzddzm
+
∫ zα
−∞
∫ ∞
zγ
I(zd,zm)dzddzm
=
∫ ∞
∞
∫ ∞
zγ
I(zd,zm)dzddzm (B.33)
If the point lies below the line, let z′γ > zγ be defined such that the point (zα ,z′γ) lies on the
line. Since I(zd,zm) is positive in the region (zα ,∞)× (zγ ,z′γ) and negative in the region
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(−∞,zα)× (zγ ,∞), we have∫ ∞
zα
∫ ∞
zγ
I(zd,zm)dzddzm ≥
∫ ∞
zα
∫ ∞
zγ
I(zd,zm)dzddzm
−
∫ ∞
zα
∫ z′γ
zγ
I(zd,zm)dzddzm
+
∫ zα
−∞
∫ ∞
z′γ
I(zd,zm)dzddzm
=
∫ ∞
−∞
∫ ∞
z′γ
I(zd,zm)dzddzm (B.34)
so it is sufficient to prove that the integral is positive when the range (zα ,∞) is replaced with
(−∞,∞). Similar arguments can be used when b1−b0 > 0, in which case it is sufficient to
prove positivity when zγ = 0.
This enables zd (or zm) to be integrated out, namely reducing to showing that∫ ∞
zβ
∫ ∞
zγ
N( 1 ρsm
ρsm 1
)((zs zm)t)−N( 1 ρrm
ρrm 1
)((zs zm)t)dzmdzs > 0
⇔
∫ ∞
zβ
1
2π
exp
(
1
2
z2s
)(
Φ
(
ρsmzs− zγ
1−ρ2sm
)
−Φ
(
ρrmzs− zγ
1−ρ2rm
))
> 0 (B.35)
The second part of the integrand is monotonically increasing in zs as ρsm > ρrm. Thus the
integral is minimised as zβ →−∞, at which the value is Φ(zγ), which is positive.
B.1.3 SNPs with aberrant allele frequency in one group
RB < RA for SNPs with aberrance in C1
If SNPs have aberrant MAF in C1 only, we have E(zd) = ζd ̸= 0, E(zm) = ζm ̸= 0 and
E(zs) = E(zr) = 0. As noted in the main text, as ζd → 0, RB,RA → P0 (equation 4.2 in the
main paper) and
lim
ζd→∞
RB = lim
ζd→∞
(∫ ∞
zα−ζd
∫ ∞
zβ∗
∫ ∞
zγ−ζm
NΣB
(
(zd zs zm)t
)
dzsdzmdzd
+
∫ ∞
zα+ζd
∫ ∞
zβ∗
∫ ∞
zγ+ζm
NΣB
(
(zd zs zm)t
)
dzsdzmdzd
)
=Φ(−z∗β ) =
β ∗
2
(B.36)
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and similarly, RA → β2 , RB → β
∗
2 as ζd →±∞, with β ∗ < β as shown above. For β ∗ defined
by 4.3 in the main paper, I show here that RA > RB for all ζd . For the more general definition
of β ∗ (equation 4.2 in the main paper), the inequality RB < RA may not hold for all ζd .
However, in practice, the inequality holds for almost all ζd and any deviation is small and
near ζd = 0.
Define the shorthand Nρ(x,y) as the value at (x,y) of the bivariate normal PDF with
mean
(
0
0
)
and variance
(
1 ρ
ρ 1
)
, and erfc(x) = 2
(
1−Φ(√2x)
)
as the complementary error
function. In this section, ρ refers to ρds.
Consider the value RA−RB as a function of ζd . I will show that the partial derivative
δ
δζd
(RA−RB) is zero only when ζd = 0. Because RA−RB passes through the origin and is
asymptotically positive in both directions, it is positive for all ζd ̸= 0. We have
RA−RB =
(∫ ∞
zβ
∫ ∞
zα−ζd
N0(x,y)dxdy−
∫ ∞
zβ∗
∫ ∞
zα−ζd
Nρ(x,y)dxdy
)
+
(∫ −zβ
−∞
∫ −zα+ζd
−∞
N0(x,y)dxdy−
∫ −zβ∗
−∞
∫ −zα+ζd
−∞
Nρ(x,y)dxdy
)
(B.37)
δ
δζd
(RA−RB) =
(∫ ∞
zβ
δ
δζd
∫ ∞
zα−ζd
N0(x,y)dxdy−
∫ ∞
zβ∗
δ
δζd
∫ ∞
zα−ζd
Nρ(x,y)dxdy
)
+
(∫ ∞
zβ
δ
δζd
∫ ∞
zα+ζd
N0(x,y)dxdy−
∫ ∞
zβ∗
δ
δζd
∫ ∞
zα+ζd
Nρ(x,y)dxdy
)
=
1
2
√
2π
erfc
(
zβ√
2
)(
e−
1
2 (ζd−zα )2 − e− 12 (ζd+zα )2
)
− 1
2
√
2π
(
e−
1
2 (ζd−zα )2erfc
(
zβ ∗+ρ(ζd− zα)√
2(1−ρ2)
)
− e− 12 (ζd+zα )2erfc
(
zβ ∗−ρ(ζd + zα)√
2(1−ρ2)
))
Showing that δδζd (RA−RB)> 0 when ζd > 0 is equivalent to showing that (a−b)− (pa−
qb)> 0 where
a = e−
1
2 (ζd−zα )2 b = e−
1
2 (ζd+zα )
2
p =
erfc
(
zβ∗+ρ(ζd−zα )√
2(1−ρ2)
)
erfc
(
zβ
2
) q = erfc
(
zβ∗+ρ(ζd−zα )√
2(1−ρ2)
)
erfc
(
zβ
2
) (B.38)
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Since (ζd− za)2 < (ζd + za)2 for ζd > 0, we have a > b. Because erfc is strictly decreasing,
we have p < q. Because δ pδζd < 0, we have
p <
erfc
(
zβ∗−zα )√
2(1−ρ2)
)
erfc
(
zβ
2
) < 1 (B.39)
where the second inequality arises because zβ ∗ >
√
1−ρ2zβ +ρzα . Thus pa−qb < pa−
pb = p(a−b)< a−b, and δδζd (RA−RB)> 0 as required.
B.1.4 Upper bound on RB−RA with aberrance in C′1
For SNPs with aberrance in C′1, we have E(zd) = 0, E(zr) = ζr ̸= 0, E(zs) = ζs ̸= 0 and
E(zm) = ζm ̸= 0. As above RA,RB → P0 as ζr → 0, and by similar arguments to the section
above, RA,RB → α2 as ζr →±∞.
For β ∗ defined as per equation 4.3 in the main paper, it is possible to derive an approximate
(asymptotically accurate) upper bound on RB−RA, corresponding to the most serious increase
in FPR. The approach is not readily applied to the general definition of β ∗, but again the
difference is typically small in practice.
To first order
ζs
ζr
=
(
µ ′1−µ ′0
SE(m′1−m′0)
)
 µ ′1−µ0
SE
(
m′1−
m0n0+m
′
0n
′
0
n0+n
′
0
)
 =
√
(n0+n′0)(n
′
0+n
′
1
n′0(n0+n
′
0+n
′
1)
def
= k (B.40)
Now
RB−RA =
(∫ ∞
zβ∗−ζs
∫ ∞
zα
Nρ(x,y)dxdy−
∫ ∞
zβ−ζr
∫ ∞
zα
N0(x,y)dxdy
)
+
(∫ ∞
zβ∗+ζs
∫ ∞
zα
Nρ(x,y)dxdy−
∫ ∞
zβ+ζr
∫ ∞
zα
N0(x,y)dxdy
)
(B.41)
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Define z+r , z
−
r such that∫ ∞
z−r
∫ ∞
zα
N0(x,y)dxdy =
∫ ∞
zβ∗−ζs
∫ ∞
zα
Nρ(x,y)dxdy∫ ∞
z+r
∫ ∞
zα
N0(x,y)dxdy =
∫ ∞
zβ∗+ζs
∫ ∞
zα
Nρ(x,y)dxdy (B.42)
From equation B.14 in Appendix B.1.2, we have zβ ∗−ζs ≈
√
1−ρ2z−r −ρzα and zβ ∗+ζs ≈√
1−ρ2z+r −ρzα .
Noting that
∫ ∞
a
∫ ∞
b N0(x,y)dxdy =Φ(−a)Φ(−b) and Φ(x) = 1−Φ(−x) we now have
RB−RA =Φ(−zα)
(
Φ(zβ −ζr)−Φ(z−r )+Φ(zβ +ζr)−Φ(z+r )
)
(B.43)
Applying the identity Φ(−zα) = α2 and approximations z∗β ≈
√
1−ρ2zβ +ρzα , ζs ≈ kζr,
yields
z−r ≈
zβ ∗−ζs+ρzα√
1−ρ2 ≈ zβ −
k√
1−ρ2ζr
z+r ≈ zβ +
k1√
1−ρ2 z
′
0 (B.44)
RB−RA≈ α2
(
Φ
(
zβ −
k√
1−ρ2ζr
)
−Φ(zβ −ζr)+Φ
(
zβ +
k√
1−ρ2ζr
)
−Φ(zβ +ζr)
)
(B.45)
Considered as a function of ζr, the value RB−RA will be 0 at ζr = 0 and tend to 0 as
ζr →±∞. It will be maximised approximately at the points where Φ(zβ −ζr) or Φ(zβ +ζr)
are changing most rapidly; that is, ζr = ±zβ . At ζr = zβ , the contribution to the value
RB−RA from the difference Φ
(
zβ +
k√
1−ρ2ζr
)
−Φ(zβ + ζr) is negligible (and similarly
for the other difference when ζr =−zβ ). Using the first-order approximation for Φ(zβ −ζr)
about ζr = zβ yields
max(RB−RA)≈ α
2
√
2π
(
k√
1−ρ2 −1
)
zβ (B.46)
In general, this value is substantially less than α .
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B.1.5 Aberrance in C′0
For SNPs aberrant in C′0, again E(zd)= 0, E(zr)= ζr ̸= 0, E(zs)= ζs ̸= 0 and E(zm)= ζm ̸= 0.
As above RA,RB → P0 as ζr → 0, and RA,RB → α2 as ζr →±∞. In this case, RB is typically
less than RA.
B.1.6 General aberrance in replication cohorts
For β ∗ defined according to 4.3 in the main paper, the increase in FPR RB−RA for method
B for a SNP with aberrance in C′1 is generally smaller than the decrease in FPR RA−RB for
a SNP with a similarly-sized aberrance in C′0, in that the integral of the difference over the
range of ζr is generally smaller in the former.
Define k as in the section above and k1 =
ζs
ζr
∣∣C′0 aberrant =√ n′0(n′0+n′1)(n0+n′0)(n0+n′0+n′1) similarly.
Now for C′0 aberrant
RA−RB≈ α2
(
Φ(zβ −ζr)−Φ
(
zβ −
k1√
1−ρ2ζr
)
+Φ(zβ +ζr)−Φ
(
zβ +
k1√
1−ρ2ζr
))
(B.47)
Since
∫ x
0 Φ(z)dz = xΦ(x)+
1√
2π
(
e−
x2
2 −1
)
, we have
∫ ∞
0
(Φ(h− z)−Φ(h− kz))dz =
(
1− 1
k
)(
1√
2π
e−
1
2 h
2
+hΦ(h)
)
(B.48)∫ ∞
0
(Φ(h+ z)−Φ(h+ kz))dz =
(
1− 1
k
)(
− 1√
2π
e−
1
2 h
2
+hΦ(−h)
)
(B.49)
Thus with aberrant C′0
∫ ∞
0
(RA−RB)dζr = α2
(
1−
√
1−ρ2
k1
)
zβ (B.50)
Comparing RA and RB under the two aberrance scenarios with the same ζd
∫ ∞
0 (RA−RB)dζd [C′0 aberrant]∫ ∞
0 (RB−RA)dζd [C′1 aberrant]
=
1−
√
1−ρ2
k1√
1−ρ2
k −1
(B.51)
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For this to be > 1, a necessary condition is
(
1−
√
1−ρ2
k2
)
>
(√
1−ρ2
k1
−1
)
From the defini-
tions of ρds (Appendix B.1.1), k (equation B.40) and k1, this is equivalent to√
n0+n′0+n
′
1
n′0+n
′
1
√
1− n0n1n
′
1
(n0+n′0)(n0+n1)(n0+n
′
0+n
′
1)
√ n′0
n0+n′0
+
√
n0+n′0
n0
> 2
The final term in this product is of the form x+ 1x so is greater than 2. A sufficient condition
is thus
n0+n′0+n
′
1
n′0+n
′
1
(
1− n0n1n
′
1
(n0+n′0)(n0+n1)(n0+n
′
0+n
′
1)
)
≥ 1
⇐⇒ n20+n0(n′0+n1)+n1(n′0−n′1)≥ 0 (B.52)
which holds in most study designs.
B.2 Supplementary figures
Please see following page
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Fig. B.1 Power difference (%) between methods C and A. Mean power difference is taken as
the integral of power difference between methods (see methods section) over R with respect
to log-odds ratio. In all cases, 20 000 samples are used overall for a SNP with MAF 0.1, with
cutoffs α = 5×10−6, β = 5×10−4, γ = 5×10−8. Method C is almost universally more
powerful.
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Fig. B.2 Power difference (%) between methods C and B. Mean power difference is taken as
the integral of power difference between methods (see methods section) over R with respect
to log-odds ratio. In all cases, 20 000 samples are used overall for a SNP with MAF 0.1, with
cutoffs α = 5×10−6, β = 5×10−4, γ = 5×10−8.

Appendix C
Supplementary note for chapter 5
C.1 Disease models in H1 and H0
I define ‘differential causative pathology’ (the alternative hypothesis, H1) to mean that
some subset of disease-associated variants have different population effect sizes in the
case subgroups in question. My method tests against the null hypothesis H0 that all disease
associated variants have the same effect sizes in both subgroups. An equivalent formulation of
H0 is that the (possibly empty) sets of SNPs which have different minor allele frequencies in
case and control groups and which have different minor allele frequencies in case subgroups
are non-intersecting.
The multitude of potential causes for disease heterogeneity necessitate that both H0 and
H1 encompass a range of such causes. I list several below, with illustration in appendix D.1,
table D.1. I define the ’genetic architecture’ of a trait as a set of variants and corresponding
effect sizes (log-odds ratios or asymptotically similar statistics) between populations with
and without the trait. In general, most effect sizes are zero or negligibly small.
C.1.1 Disease models in H1
The simplest model of disease heterogeneity in H1 is the scenario in which some variants are
associated with one case subgroup, but not the other. For such a variant the effect size in one
subgroup is zero, and in the other nonzero. This would be expected to arise if some of the
pathological processes giving rise to the disease were specific to one case subgroup.
A second potential model in H1 is when the same variants are associated with both
subgroups, but the relative effect sizes differ. This may arise in a situation where pathological
processes differ in relative impact between subgroups. For instance, if two pathological
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processes may lead to a disease of interest, and one process is likely to occur during the
neonatal period while the another is likely to occur during adolescence, a division of a case
group into neonatal-onset and adolescent-onset would likely show variants associated with
the first process as being more important in the first subgroup, and variants associated with
the second process as being more important in the second, although the set of associated
variants may be the same in both subgroups. The scenario may also arise if the cases can be
split into subgroups like those described in the first paragraph, but the subgrouping criterion
is only an approximation to this split.
A third model is when the same variants are associated with both subgroups with but
where the effect sizes in one subgroup are a constant factor larger than in the other subgroup.
This corresponds to differential heritability between subgroups, with the same pathological
processes present. In a liability threshold model where some environmental variable has
an additive effect with genetic risk, we would expect that defining subgroups based on the
environmental variable would lead to this scenario (figure C.1). In this case, the environment
modulates the effect of the genetic risk. As an example, under the assumption that a dietary
risk factor has an additive effect with genetic risk factors in type 2 diabetes, a disease
subgroup with the dietary risk factor would be expected to have lower disease heritability
than a subgroup without it.
C.1.2 Disease models in H0
Under H0, all disease associated variants have the same effect size in both subgroups. This
may take the form of an absence of any systematic genetic difference between case subgroups,
in which case the population allelic frequencies of disease-associated SNPs, and hence the
effect sizes of such SNPs between controls and each case subgroup, are equal.
Hypothesis H0 also allows the presence of genetic differences between subgroups at
different SNPs to those associated with the disease. This may be particularly prominent
if variation in the disease depends on how the disease process acts on different individual
physiologies, in which case genetic variation between subgroups is at different SNPs to those
involved in disease causality.
C.1.3 Subgrouping by a risk factor
Partitioning a case group by a known disease risk factor may lead to subgroupings in either H0
or H1 dependent on the interaction between the genetic and environmental risk factors. If the
risk factor on which the subgrouping is based has a multiplicative effect on disease risk with
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Gen. risk Env. risk 
H: p = α 
L: p = 1-α 
H: p = β 
L: p = 1-β 
H: p = β 
L: p = 1-β 
Pr(D|G,E) 
Pop. 
p1A 
p1B 
p2A 
p2B 
Pr(D,G,E) 
αβp1A 
α(1-β)p1B 
(1-α)βp2A 
(1-α)(1-β)p2B 
Fig. C.1 In a simplistic disease model, consider two levels of genetic risk G with frequencies
α , 1−α and an independent two-level environmental risk factor E with frequencies β , 1−β ,
and a disease D. In cases with the environmental risk factor, we would expect the ratio
of high-genetic risk to low-genetic risk cases to be α1−α
p1A
p2A
, and in cases without, α1−α
p1B
p2B
.
Assume we define subgroups based on the environmental risk factor. If the risk factor has a
multiplicative effect on Pr(D|G,E), so p1Ap2A =
p1B
p2B
, the prevalences of genetic risk groups are
identical in the groups, and the heritability of D is the same. If the effect of the environmental
risk factor on Pr(D|G,E) changes with G, so the environmental risk factor modulates the
genetic risk, this will not hold.
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genetic factors, then we expect the subgrouping to be in H0 (figure C.1). This may take the
form of a binary risk factor: if a disease is triggered by an environmental event (for example,
a particular mutation driven by environmental mutagens), with susceptibility to that event
determined genetically (for instance, impaired ability to repair the mutation), conditioning
on environment will not affect the distribution of genetic risk, and the subgrouping will be
in H0. The genetic risk may also be binary; for example, the development of a disease may
require the knock-out of a particular cellular process, with the genetic risk for the disease
solely involved in risk of the knock-out.
However, deviation from a locally multiplicative model can also lead to a subgrouping in
H1. One instance this may occur is if disease risk approaches 1. A current model of T1D
pathogenesis requires the presence of an environmental insult to trigger genetic susceptibility
([Rodriguez-Calvo et al., 2016]), which could be expected to lead to a locally multiplicative
relationship between age-at-diagnosis and genetic risk (figure C.2). However, if genetic
risk can be high enough that some individuals are almost sure to get the disease, this will
lead to the subgrouping being in H1 - a potential reason for the observation regarding
age-at-diagnosis in T1D in the main text.
Finally, cases may be sub-grouped according to non-causative clinical disease associa-
tions. Assume some binary clinical marker M has non-zero frequency in healthy individuals
and has some set of associated genetic variants G0. Let D be a genetically homogeneous
disease with a set of associated variants G1 such that G0∩G1 = /0 and D (or a necessary
precursor of D) probabilistically causes M to occur more often than in the general population.
Then when we condition on case status (and hence any necessary precursors of D) the only
variants which are associated with M-status in cases will be in G0, and a subgrouping based
on M will be in H0, despite M being associated with D. If, however, subtypes of D with
differential genetic basis induce M to different degrees, and hence M serves as an index of
such subtypes of D, then a subgrouping of M will fall in H1.
C.2 Distribution of Z scores
In this section, I define the test statistics (Z scores) used to characterise allelic differences
between groups and describe the rationale for my probabilistic model.
I partition SNPs into three theoretical categories:
1. SNPs which are not associated with case/control status or case subgroup status
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Insult 
incidence 
Low risk  
Mid risk  
High risk  
f(A) 
r1(A) 
r2(A) 
r3(A) 
X Y 
Age (A) 
Fig. C.2 In a simplified model of incidence of type 1 diabetes or a similar autoimmune
disease, I consider the disease to be triggered by an environmental ‘insult’; for instance
(eg, a viral illness) and three levels of genetic susceptibility to such insults. Denoting by
f (A) the density of such insults at age A (red vertical lines show a possible example for one
individual), I expect that for individuals at low or moderate genetic risk the densities r1(A),
r2(A) of disease incidence are proportional to f (A), with lifetime risk
∫
r1(A)dA,
∫
r2(A)dA
respectively. The risk of disease at age A can be considered a product of f (A) and a genetic
risk score. In a high-risk group for a disease such as type 1 diabetes, it is possible that the
lifetime risk
∫
r3(A)dA approaches 1, the high-risk group becomes ’saturated’ with disease
cases, and there are fewer non-affected individuals in the group at higher age groups, leading
to a lower constant of proportionality with f (A) at higher ages (dotted/solid lines). In the
absence of the high-risk group, a subgrouping of patients into those with age-at-onset X and
those with age-at-onset Y (vertical lines) would be expected to contain the same proportion of
low- and mid- genetic risk samples in each subgroup, with correspondingly equal heritability
of disease in each subgroup. With the high-risk group, the multiplicative effect of f (A)
on disease risk breaks down, inducing an environmental influence on the genetic risk, and
changing the heritability between groups.
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2. SNPs which are associated with the main phenotype but have the same effect size in
both case subgroups
3. SNPs which are associated with the difference between case subgroups
I consider SNP effect sizes between subgroups and between cases and controls to be
realisations of bivariate random variables, which have different distributions in each category.
C.2.1 Definitions
Unstratified groups
Let x be a random sample of size nx from patient population X, and y a sample of size ny
from a population Y . Denote by mx, my the allele frequencies of some SNP of interest in x
and y, and by µx, µy the allele frequencies in X and Y . Assume for the moment that x and y
are unbiased samples, so µx = E(mx) and µy = E(my).
In general, I compute Z scores from GWAS -defined p-values Pxy using the formula
Znx,ny(mx,my) =−Φ−1(Pxy/2)sign(mx−my) (C.1)
Although there are several ways in which a GWAS p-value may be computed, the resultant
Z scores all have several common asymptotic properties. In general, I assume a Z score
Znx,ny(mx,my) is a smooth function of allele frequencies mx, my, nx, ny with the following
properties
1. For fixed observed overall allele frequency nxmx+nymynx+ny , Znx,ny(mx,my) is monotonic to
the allelic difference mx−my
2. Under the null hypothesis µx = µy,
(a) E(Znx,ny(mx,my)) = 0
(b) var(Znx,ny(mx,my)) = 1
(c) Znx,ny(mx,my)→d N(0,1) as nx,ny → ∞
These properties imply that the first-order expansion of Z about (mx,my) = (µ,µ) is:
Znx,ny(mx,my) =
√
2nxny
nx+ny
mx−my√
µ(1−µ) +O((mx−µ)(my−µ)) (C.2)
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since √
2nx(mx−µx)→d N(0,µx(1−µx))√
2ny(my−µy)→d N(0,µy(1−µy))
(C.3)
and if µx = µy = µ √
2nxny
nx+ny
mx−my√
µ(1−µ) →d N(0,1) (C.4)
and only one linear function of mx, my can be asymptotically N(0,1).
If µx ̸= µy and
λ =
µx−µy√
µx(1−µx)
2nx
+
µy(1−µy)
2ny
(C.5)
remains finite as nx,ny → ∞, we have
Znx,ny(mx,my)≈
mx−my√
mx(1−mx)
2nx
+
my(1−my)
2ny
=
(mx−my)− (µx−µy)√
mx(1−mx)
2nx
+
my(1−my)
2ny
+
µx−µy√
mx(1−mx)
2nx
+
my(1−my)
2ny
→d N(0,1)+λ
= N(λ ,1) (C.6)
For a randomly chosen SNP, let µc be the population allele frequency (AF) in controls,
and µ1, µ2 the population AFs in case subgroups 1 and 2 respectively, for the same allele.
Define ν as the relative prevalence of subgroup 1 and 1− ν as the relative prevalence of
subgroup 2. The population AF across all cases is µ12 = νµ1+(1−ν)µ2.
Denote by mc, m1, m2 the corresponding observed AFs in a study with nc, n1, n2 controls
and samples in subgroup 1 and subgroup 2 respectively. Define m12 = n1m1+n2m2n1+n2 as the AF
in the whole case group and n12 = n1+n2. Assume that n1n1+n2 ≈ ν; that is, the case group
is an unbiased sample of the case population. I later describe how this assumption can be
relaxed.
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The values Za and Zd are defined as
Zd = Zn1,n2(m1,m2) (C.7)
Za = Zn1+n2,nc(m12,mc) (C.8)
where, as in the main paper, nc, n1, n2 refer to cohort sizes and mc, m1, m2 to observed allele
frequencies in controls, subgroup 1 and subgroup 2 respectively, and m12 is the observed
allele frequency across all cases (subgroups 1 and 2).
Adjustment for strata
If the distribution of some categorical variable (for example, country of origin) associated
with allele frequency varies systematically between x and y, stratification may be needed
when computing GWAS p-values. This may mean that E(mx) ̸= E(my), even if the expected
allele frequency is the same in x and y in each stratum. I proceed in a similar way to the
approach in appendix B in determining correlation between Z scores with shared controls.
Assume x is divided into k strata 1..k, and let n1x , n
2
x ,..., n
k
x be the number of samples, m
1
x ,
m2x ,..., m
k
x the observed allele frequencies and µ1x , µ2x ,..., µkx the expected allele frequencies
for a SNP of interest in each stratum (and analagously for y).
Assume the Z score Z{nx},{ny}({mx},{my}) in this case is a smooth function of {nix},{niy},{mix},{miy},
which has a first-order expansion about µ1, µ2, ... µk of the form
Z{nx},{ny}({mx},{my}) =
1√
∑
i∈1..k
k2i
nix+niy
2nixniy
µ i(1−µ i)
∑
i∈1..k
ki(mix−miy)+O
(
∑
i∈1..k
ki(mix−miy)2
)
(C.9)
≈ ∑ki(m
i
x−miy)√
var
(
∑ki(mix−miy)|µ ix = µ iy
) +O(∑ki(mix−miy)2) (C.10)
where coefficients ki depend only on the values {nx}, {ny}. For example, if the Cochran-
Mantel-Haenszel test is used, ki =
2nixn
i
y
nx+ny
.
Using analogous definitions to those under subheading ‘Unstratified groups’, we now
define
Zd = Z{n1},{n2}({m1},{m2}) (C.11)
Za = Z{n1+n2},{nc}({m12},{mc}) (C.12)
C.2 Distribution of Z scores 301
I term the coefficients of the allelic differences mi1−mi2, mi12−mic in the decomposition of
Zd and Za above as kdi, kai respectively.
Adjustment for covariates
If some continuous variable associated with the allele frequencies of some variant (for exam-
ple, height) has a systematically different distribution in x and y, adjustment for covariates
may be needed when computing GWAS p-values. In a similar approach to that in appendix B,
section B.1.1 we set G(i) as the numerical genotype of sample i (0,1,or 2) and wi as the
covariate value(s) for individual i. I consider wi to be a sample from a random variable Z
with PDF fx in x and fy in y.
Define the Z score Zx,y({G},{w}) in this case as a function of observed genotypes which
permits a first-order expansion
Zx,y({G},{w}) = 1√
m¯(1− m¯)
(
1
nx
∑
i∈x
hx(wi)G(i)− 1ny ∑j∈y
hy(w j)G( j)
)
(C.13)
where hx and hy are functions of covariate scores, depending on the distribution of w in x and
y, and parameter m¯ is some measure of the overall allele frequency. The expected genotype of
an individual may depend on their covariate value; for an individual i with covariate value(s)
wi in x set gx(wi) = E(G(i)), and set gy similarly. Under the null hypothesis that the SNP of
interest is not associated with x/y status, gx ≡ gy, and the expectation of Z must be 0. As in
appendix B, section B.1.1, if the adjustment is to correct for every possible relation of the
covariate to allelic frequencies (that is, have expectation 0 whenever gx = gy, whatever the
form of gx), we must have
hx(w) fx(w) = hy(w) fy(w) (C.14)
for all covariate values w.
The sums of genotypes on the right of equation C.13 can be considered as ‘effective’
allele frequencies, and we define
m′x =
1
nx
∑
i∈x
hx(wi)G(i)
m′y =
1
ny
∑
j∈y
hy(w j)G( j) (C.15)
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with expected values µ ′x, µ ′y respectively. Define ‘effective’ sample sizes n′x =
µ ′x(1−µ ′x)
var(m′x)
,
n′y =
µ ′y(1−µ ′y)
var(m′y)
so that, like allele frequencies (and under appropriate assumptions on the forms
of fx, fy, gx, gy):
m′x−µ ′x√
µ ′x(1−µ ′x)
n′x
→d N(0,1) (C.16)
and similarly for m′y.
Now define
Zd = Zcase 1,case 2({G},{w}) (C.17)
Za = Zcases,controls({G},{w}) (C.18)
C.2.2 Zd and Za are conditionally independent in categories 1 and 2
Unstratified or stratified groups
For SNPs in categories 1 and 2, µ1 = µ2. Hence
cov(Zd,Za) ∝ cov(m12−mc,m1−m2)
= cov
(
n1m1+n2m2
n1+n2
−mc,m1−m2
)
=
1
n1+n2
(cov(n1m1,m1)− cov(n2m2,m2))
=
1
n1+n2
(µ1(1−µ1)−µ2(1−µ2))
(C.19)
which is 0 in categories 1 and 2.
For stratified groups, the same holds for each stratum; that is, cov(mi12−mic,mi1−mi2) = 0.
The independence of Zd and Za follows from the expression of Zd and Za as proportional to
sums of allelic differences within strata and independence of the allelic differences in each
stratum.
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Adjustment for covariates
If we are adjusting for covariates, then using the definitions above, and noting that g1 = g2
for SNPs in categories 1 and 2, and h1 f1 = h2 f2 we have (defining D(w) as the domain of w)
cov(Zd,Za) ∝ cov
(
1
n12
∑
j∈cases
h12(w j)G( j)− 1nc ∑i∈ctl
hc(wi)G(i),
1
n1
∑
i∈c1
h1(wi)G(i)− 1n2 ∑j∈c2
h2(w j)G( j)
)
∝
1
n1
∑
i∈c1
h12(wi)h1(wi)var(G(i))− 1n2 ∑j∈c2
h12(w j)h2(w j)var(G( j))
→
∫
D(w)
h12(w)(h1(w) f1(w)−h2(w) f2(w))g1(w)(1−g1(w))dw
= 0 (C.20)
The simplifications are possible because genotypes vary independently in each cohort; that is,
∑
i∈ctl
hc(wi)G(i) ⊥ ∑
i∈c1
h1(wi)G(i), ∑
j∈c2
h2(w j)G( j), and ∑
i∈c1
h12(wi)G(i) ⊥ ∑
j∈c2
h2(w j)G( j),
∑
j∈c2
h12(w j)G( j)⊥ ∑
i∈c1
h1(wi)G(i).
C.2.3 SNPs in category 3
Under H0, SNPs in category 3 have the same allele frequency in cases and controls but differ-
ent population allele frequencies between subgroups. Such a set may arise if subgrouping is
based on some partially genetically-determined trait which is independent of the main phe-
notype has the same prevalence in case and control groups. An example may be subgroups
defined by heterogeneity in treatment response arising only from individual pharmacokinetic
variation. Under this assumption, the marginal variance of the joint distribution of Zd,Za in
the direction of Za is 1, and Zd , Za are uncorrelated.
Under H1 we expect SNPs in category 3 to be associated both with case/control status
and with subgroup status. It is therefore expected that the marginal variances of the joint
distribution to be greater than 1 in both the Za and Zd directions, and possible correla-
tion/anticorrelation between Za and Zd .
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Define ζ (µx,µy) as the population normalised log odds ratio between µx and µy:
ζ (µx,µy) =
√
µ¯(1− µ¯) log
(
µx(1−µy)
µx(1−µy)
)
(C.21)
=
µx−µy√
µ¯(1− µ¯) +O
(
(µx−µy)2
)
where µ¯ = 12(µx+µy). For a set of SNPs of interest, we consider µ1, µ2, µc to be distributed
such that ζd = ζ (µ1,µ2) and ζa = ζ (µ12,µc) can be considered to be random variables with
joint PDF:
Fσ2a ,σ2d ,ρ0 =
1
2
N((
0
0
)
,
(
σ2d ρ0
ρ0 σ2a
))+N((
0
0
)
,
(
σ2d −ρ0
−ρ0 σ2a
))
 (C.22)
with σd , σa, and ρ0 independent of n1, n2, nc. Under H0, σa = 0 (same MAFs in cases/controls)
and ρ0 = 0. I assume that ζd and ζa are conserved across strata and covariates.
Unstratified groups
Combining equation C.2 and expanding about µ¯:
ζ (µx,µy) =
µx−µy√
µ¯(1− µ¯) +O
(
(µx−µy)2
)
≈
√
nx+ny
2nxny
Znx,ny(µx,µy) (C.23)
so defining µ¯d = 12(µ1+µ2) and µ¯a =
1
2(µ12+µc), we note (defining ca and cd):
E(Zd|µ¯d,ζd) = E(Zd|µ1,µ2)
= Zn1,n2(µ1,µ2)
=
√
2n1n2
n1+n2
ζd
def
= cd ζd
E(Za|µ¯a,ζa) =
√
2n12nc
n12+nc
ζa
def
= ca ζa (C.24)
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Set µ = (µ1,µ2,µc). Since m1, m2 and mc are conditionally independent given µ we have
cor(Za,Zd|µ) = cor(m12−mc,m1−m2|µ)
=
cov(n1m1+n2m2n1+n2 −mc,m1−m2|µ)
σ(ms−mc|µ)σ(m1−m2|µ)
=
cov(n1m1,m1|µ)− cov(n2m2,m2|µ)
(n1+n2)σ(ms−mc|µ)σ(m1−m2|µ)
=
µ1(1−µ1)−µ2(1−µ2)
(n1+n2)σ(ms−mc|µ)σ(m1−m2|µ)
≈ 0
From equation C.6, var(Zd|µ1,µ2) = var(Za|µ1,µ2,µc) = 1. Thus approximately:(
Zd
Za
)
|ζd,ζa ∼ N
((
cd ζd
ca ζa
)
, I2
)
(C.25)
and the PDF of (Za Zd)t at (x,y) has value∫∫
R2
N(cdζd caζa)t ,I2(x,y)Fσ2a ,σ2d ,ρ0(ζd,ζa) dζd dζa
=F1+c2aσ2a ,1+c2d σ2d ,cacdρ0(x,y)
=
1
2
(
N((
0
0
)
,
(
1+c2dζ
2
d cacdρ0
cacdρ0 1+c2aζ 2a
))(x,y)+N((
0
0
)
,
(
1+c2dζ
2
d −cacdρ0
−cacdρ0 1+c2aζ 2a
))(x,y)) (C.26)
which is a symmetric two-Gaussian distribution. Under H0, the marginal variance in the
direction of Za (fitted σ23 ) is 1, and the covariance between Zd and Za is zero.
Adjustment for strata
For stratified groups, we assume ζa and ζd are conserved across strata, and set µ¯ id =
1
2(µ
i
1+
µ i2), µ¯
i
a =
1
2(µ
i
12+ µ
i
c), kdi as the coefficient of m
i
1−mi2 in the first-order expansion of Zd
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(equation C.9), and kai as the coefficient of mi12−mic in the first-order expansion of Za to find
E(Zd|{µ¯d},ζd) = E(Zd|{µ¯1},{µ¯2})
≈ 1√
∑
i∈1..k
k2di
ni1+n
i
2
2ni1n
i
2
µ¯ id(1− µ¯ id)
∑
i∈1..k
kdi(µ i1−µ i2)
≈
∑kdi
√
µ¯ id(1− µ¯ id)√
∑k2di
ni1+n
i
2
2ni1n
i
2
µ¯ id(1− µ¯ id)
ζd
≈ ∑kdi√
∑k2di
ni1+n
i
2
2ni1n
i
2
ζd
def
= c′dζd (C.27)
and
E(Za|{µ¯1a , µ¯2a , ..., µ¯ka},ζa)≈ ∑
kai√
∑k2ai
ni12+n
i
c
2ni12n
i
c
ζa
def
= c′aζa (C.28)
assuming that for most SNPs the values µ¯ id , µ¯
i
a do not differ markedly across strata. If the
Cochran-Mantel-Haenszel test is used,
c′d =
√
∑kdi
=
√
∑ 2n
i
1n
i
2
ni1+n
i
2
c′a =
√
∑ 2n
i
12n
i
c
ni12+n
i
c
(C.29)
and the PDF of Zd , Za is then as for equation C.26 with c′d , c
′
a in place of cd , ca.
Adjustment for covariates
The expression for Zx,y({G},{w}) can be rewritten as:
Zx,y({G},{w}) = 1√
m¯(1− m¯)(m
′
x−m′y) (C.30)
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As above, I assume that whatever the dependence of E(G(i)) on covariates, the allelic
difference between case subgroups is constant, so g1(w)−g2(w) is constant for all w. Define
the analogue of ζ (µx,µy) given covariate(s) w
ζ (µx,µy)|w =
√
µ¯(w)(1− µ¯(w)) log
(
µ ′x(w)(1−µy(w))
µx(w)(1−µy(w))
)
(C.31)
and define c′′d , c
′′
a analogously to the previous section:
c′′d =
E{Zd}
ζd
c′′a =
E{Za}
ζa
The joint distribution of Zd and Za is then given by the analogue of equation C.26 with
appropriate analogues of cd , ca.
C.2.4 Unequal subgroup prevalences
Motivation
The criteria by which subgroups are defined may have a different distribution in the population
than in the case group, with the consequence that the disease subtype corresponding to one
of the subgroups may be oversampled relative to its true prevalence in the population.
This leads to inaccuracies in the inferred genetic architecture recovered from a case-
control study (ie, a typical GWAS), which may take the form of false-positive associations.
If there exist variants which differentiate subgroups, oversampling of one subgroup will
bias the the observed overall variant effect sizes toward the effect size in the oversampled
subgroup, even if the variants are un-associated with the phenotype overall.
In serious cases, this could lead to false identification of variants associated only with
subgroup status as associated with the disease as a whole. For example, a GWAS on
rheumatoid arthritis (RA) in which the case group had a high prevalence of obesity may
identify purely obesity-associated variants as RA-associated.
For stratified and covariate-adjusted analyses, the equivalent problem is failure of popula-
tion subgroup prevalences to match study subgroup prevalences within each strata or across
covariates. This could be a result of ascertainment bias; different geographic locations could
report different frequencies of disease subtypes due to differences in clinic specialities.
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As well as affecting conventional GWAS analyses, I show below that subgroup oversam-
pling can cause false-positives in my test. I show a modification to the method to account for
this.
Behaviour of standard approach
I demonstrate the effect of mismatched sample and population subgroup frequencies in the
scenario where no strata or covariates are used. The extension to the generalised cases is
similar.
Assume that in the disease population, the ‘true’ prevalences of subgroups 1 and 2 are
ν , 1−ν , and define µ12 = νµ1+(1−ν)µ2 as the underlying MAF across all cases in the
population. In the hypothesis test to compute Pa, the hypothesis Ha : µc = n1m1+n2m2n1+n2 is not
equivalent to H : µc = µ12.
Since E(m12) = E
(
n1m1+n2m2
n1+n2
)
= n1µ1+n2µ2n1+n2 ̸= µ12, equation C.25 becomes(
Zd
Za
)
|ζd,ζa ∼ N
((
Zn1,n2(µ1,µ2)
Zn12,nc(
n1µ1+n2µ2
n1+n2
,µc)
)
, I2
)
(C.32)
Now
Zn12,nc
(
n1µ1+n2µ2
n1+n2
,µc
)
≈ ca√
µ¯(1− µ¯)(
n1µ1+n2µ2
n1+n2
−µc)
=
ca√
µ¯(1− µ¯)
(
(µ12−µc)+
(
n1
n1+n2
−ν
)
(µ1−µ2)
)
≈ ca(ζa+ kζd) (C.33)
where k = ( n1n1+n2 −ν), so the unconditional distribution of (Za Zd)t in this case is given by∫∫
R2
N(cdζd ca(ζa+cζd))t ,I2(x,y)Fσ2a ,σ2d ,ρ0(ζd,ζa) dζd dζa
=
1
2
(
N((0
0
)
,Σ2
)(x,y)+N((0
0
)
,Σ3
)(x,y)
)
(C.34)
where
Σ2 =
(
1+ c2dζ
2
d cacd(ρ0+ kζ
2
d )
cacd(ρ0+ kζ 2d ) 1+ c
2
a(ζ 2a + k2ζ 2d +2kρ0)
)
Σ3 =
(
1+ c2dζ
2
d cacd(−ρ0+ kζ 2d )
cacd(−ρ0+ kζ 2d ) 1+ c2a(ζ 2a + k2ζ 2d −2kρ0)
)
(C.35)
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Distribution C.34 consists of the sum of two Gaussians which are not mirror images in the x
and y axes. Conceptually, the aberrance between prevalences of subgroups in the population
and in the study induces a bias in Za toward either Z1 or Z2, whichever is comparatively
over-represented in the study compared to the population.
This effect is demonstrated in figure C.3, with simulated data and approximate distribution
as per C.34. As the discrepancy between the relative proportions grows, the distributions
precess around the origin. Importantly, under H0 (σa = 0, ρ0 = 0) the distribution of Zd,Za
will not satisfy σ3 = 1, ρ = 0, and my standard approach is inappropriate.
Fig. C.3 Distribution of (Za,Zd) for SNPs in category 3 when observed subgroup frequency
(n1/n2) does not match underlying subgroup frequency in the population (ν1/ν2 = ν/(1−ν)).
Red and blue points correspond to the two Gaussian distributions comprising the underlying
distribution of effect sizes. Contour lines of distributions are shown. Note the precession in
the axes of the distributions as the difference between ν1/ν2 and n1/n2 increases, and loss of
symmetry when ν1/ν2 ̸= n1/n2
Adaptation
If the true proportion of case subgroups in the population are known, the problem of over-
sampled subgroups can be overcome by a recalculation of Za. The problem broadly arises
because the expected value of the observed allele frequency in cases, E(m12), is different
from the true allele frequency µ12 in cases in the population, for SNPs in category 3.
This can be addressed by using an unbiased estimate of the true population allele fre-
quency m′12 = νm1+(1−ν)m2 in place of m12. The resultant Z score, Z′a, is obtained by
adjusting Za by subtracting a multiple of Zd:
Z′a =
1√
1+β 2
(Za−βZd) (C.36)
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so, given a between-subgroup effect size ζd , var(Z′a|ζd) = 1. I choose β so that E(Z′a) = 0
for SNPs in category 3 (see below). The adjustment leads to systematic nonzero covariance
between Zd and Z′a.
Za and Zd are independent conditioned on ζa, ζd and µ¯ . Thus under H0 and conditioning
on µ¯
cov(Z′a,Zd|ζa,ζd) =
1√
1+β 2
E(Zd(Za−βZd)|ζa,ζd)
=
1√
1+β 2
(
E(ZdZa|ζa,ζd)−βE(Z2d |ζa,ζd)
)
=
−β√
1+β 2
var(Z2d |ζd)
=
−β√
1+β 2
(C.37)
and because ζd and ζa are independent under H0, cov(Z′a,Zd) =
−β√
1+β 2
in every category. I
denote this consistent covariance by ρc
Hence the overall model for Zd,Za changes to
PDFZd ,Za|Θ(d,a) =π1N( 1 ρc
ρc 1
)(d,a) (category 1)
+π2N( 1 ρc
ρc σ22
)(d,a) (category 2)
+π3
1
2
N( τ2 ρ+ρc
ρ+ρc σ23
)(d,a)+ 1
2
N( τ2 −ρ+ρc
−ρ+ρc σ23
)(d,a)
 (category 3)
(C.38)
where, under H0, ρ = 0 and σ3 = 1. This requires a slight modification of the fitting algorithm.
My R package at https://github.com/jamesliley/subtest contains an implementation.
No stratification of covariates
If no strata nor covariates are used, set
β =
(
n1
n1+n2
−ν
)
ca
cd
def
= k
ca
cd
(C.39)
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recalling the definitions of ca and cd from equation C.24, and that ν is the proportion of
cases of subgroup 1 in the population while n1n1+n2 is the proportion in the study. The value
k =
(
n1
n1+n2
−ν
)
thus corresponds to the dissimilarity between subgroup prevalences in the
case group and in the population.
Under H0, for SNPs in category 3 we have
E(Z′a|ζd) ∝ E
(
Za− k cacd Zd
)
=
ca√
m¯(1− m¯)E
((
n1m1+n2m2
n1+n2
−mc
)
−
(
n1
n1+n2
−ν
)
(m1−m2)
)
=
ca√
m¯(1− m¯)E (νm1+(1−ν)m2−mc)
= 0 (C.40)
since E(νm1+(1−ν)m2) = νµ1+(1−ν)µ2 = µc = E(mc) for all SNPs under H0.
Adjustment for strata
In the equivalent adjustment for stratified groups, define
β =
√√√√√√∑k2di
ni1+n
i
2
2ni1n
i
2
∑k2ai
ni12+n
i
c
2ni12n
i
c
∑kai
(
ni1
ni1−ni2
−ν
)
∑kdi
(C.41)
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so, assuming µ i1−µ i2 are conserved and µ¯ ia, µ¯ id are close to conserved across strata, and given
µ¯ ia ≈ µ¯ id|H0:
E(Z′a|H0) =
∑kai(µ i12−µ ic)√
∑k2ai
ni12+n
i
c
2ni12n
i
c
µ¯ ia(1− µ¯ ia)
+β ∑
kdi(µ i1−µ i2)√
∑k2di
ni1+n
i
2
2ni1n
i
2
µ¯ id(1− µ¯ id)
≈ ∑kai(µ
i
12−µ ic)√
µ¯a(1− µ¯a)
√
∑k2ai
ni12+n
i
c
2ni12n
i
c
+β ∑
kdi(µ i1−µ i2)√
µ¯d(1− µ¯d)
√
∑k2di
ni1+n
i
2
2ni1n
i
2
=
1√
µ¯a(1− µ¯a)
√
∑k2ai
ni12+n
i
c
2ni12n
i
c
(
∑kai
(
ni1µ
i
1+n
i
2µ
i
2
ni1+n
i
2
−µ ic
)
−
(
ni1
ni1+n
i
2
−ν
)
(µ i1−µ i2)
)
=
1√
µ¯a(1− µ¯a)
√
∑k2ai
ni12+n
i
c
2ni12n
i
c
(
∑kai((νµ i1+(1−ν)µ i2)−µ ic)
)
= 0 (C.42)
Adjustment for covariates
If covariates are used, define the functions h12, h1, f1, f2 in the same way as in subheading
‘Adjustment for covariates’ and set
β =
∫
D(w) h12(w)((1−ν) f1(w)−ν f2(w))dw∫
D(w) h1(w) f1(w)dw
(C.43)
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so
E(Z′a|H0) ∝
√
µ¯(1− µ¯)E(Za−βZd)
=
(
1
n12
∑
i∈c1
h12(wi)G(i)+
1
n12
∑
i∈c2
h12(wi)G(i)− 1nc ∑i∈controls
hc(wi)G(i)
)
−β
(
1
n1
∑
i∈c1
h1(wi)G(i)− 1n2 ∑i∈c2
h2(wi)G(i)
)
→
∫
D(w)
h12(w)( f1(w)g1(w)+ f2(w)g2(w))−hc(w) fc(w)gc(w)dw
−β (g1(w)−g2(w))
∫
D(w)
h1(w) f1(w)dw
=
∫
D(w)
h12(w)( f1(w)+ f2(w))(νg1(w)+(1−ν)g2(w))−hc(w) fc(w)gc(w)dw
=
∫
D(w)
h12(w) f12(w)(νg1(w)+(1−ν)g2(w)−gc(w))dw
=0 (C.44)
since h12 f12 = hc fc and h1 f1h2 f2 in the same way as under subheading ‘Adjustment for
covariates’ in section C.2.1, g1−g2 is constant by assumption, and the expected population
genotypes at covariate value w are the same in cases (νg1(w)+(1−ν)g2(w)) and controls
(gc(w)) under H0.
C.3 Testing procedure
C.3.1 Algorithm
For testing a subgrouping S of interest, I use the following protocol (recalling definitions
from chapter 5, section 5.4.2):
1. Compute Za scores between cases and controls
2. For the proposed subgrouping S
(a) Compute scores ZSd corresponding to S,
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(b) Fit parameters of full and null models
θ S1 = arg maxθ∈H1PLda(Z
S
d ,Za|θ)
θ S0 = arg maxθ∈H0PLda(Z
S
d ,Za|θ)
(c) Compute
uPLR = log{PLda(ZSd ,Za|θ S1 )}− log{PLda(ZSd ,Za|θ S0 )}
and adjusting factor
f (Za|θ S1 ,θ S0 ) = log{PLa(Za|θ S1 )}− log{PLa(Za|θ S0 )}
(d) Compute PLRS = uPLR− f (Za|θ S1 ,θ S0 )
3. Fix πˆ2 and σˆ2 as per equation 5.16
4. For > 1000 random subgroups R of the case group
(a) Compute scores ZRd corresponding to R
(b) Fit parameters
θR1 = arg maxθ∈H1|π2=πˆ2,σ2=σˆ2
cPL(ZRd |Za,θ)
θR0 = arg maxθ∈H0|π2=πˆ2,σ2=σˆ2
cPL(ZRd |Za,θ)
noting the difference between maximising PLda over all parameters in step 2b
and maximising cPL over all parameters except π2 and σ2 here.
(c) Compute
cPLRR = log{cPL(ZRd |Za,θR1 )}− log{cPL(ZRd |Za,θR0 )} (C.45)
5. Estimate parameters γ , κ of the null distribution of cPLRR values (of the form
γ
(
κχ21 +(1−κ)χ22
)
)
6. Compute p-value for PLRS by comparison to the distribution in step 5.
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In summary, I compare an adjusted pseudo-log likelihood ratio for a subgrouping of
interest to conditional pseudo-log likelihood ratios for randomly-chosen subgroupings. As
discussed in section 5.4.2, an easier potential approach would be to compare PLRS to PLR
values PLRR from random subgroups, but this is problematic.
Define one distribution F as ‘majorising’ another distribution G if, for X ∼ F , Y ∼ G,
and all x > 0, we have Pr(X > x) > Pr(Y > x) (with ‘minorising’ defined in the obvious
way). If F majorises G and we wish to estimate the value Pr(Y > x|X ∼ G), then the value
Pr(X > x|X ∼ F) is an overestimate. In the sense that Pr(Y > x|X ∼ G) is a p-value, the
value Pr(X > x|X ∼ F) provides a conservative estimate of this p-value (that is, retaining
control of the type-1 error rate).
For fixed parameters θ ∈ H0, the uPLR and cPLR both asymptotically have the same
mixture-χ2 distribution, which I will denote M. Because PLR < uPLR (as f is positive), the
distribution (asymptotic and empirical) of uPLR majorises the distribution of PLR, although
the majorisation is slight when τ ≫ 0 (section C.4).
Unfortunately, parameter sets with τ = 1 may not be in H0 (see figure C.4) although such
parameters correspond to no genetic differences between subgroups and are not of interest.
Because of this, the distribution of uPLR|τ ≈ 1 may depart substantially from M and in
general will majorise it (see figure C.5 in chapter 5). Departures from H0 with τ = 1 do not,
however, tend to affect the cPLR, since it effectively ‘removes’ the contribution of Za alone
to the PLR (section C.3.3, final two paragraphs). Indeed the cPLR tends to have a similar
distribution both when τ = 1 and when τ ≫ 1 (section C.4). The distribution of PLR with
τ ≈ 1, by contrast, will minorise the distribution of uPLR and will generally also minorise
the distribution of cPLR (see section C.3.3).
Since by resampling random subgroups, we can only sample the subspace of the parameter
space with τ = 1 and Za fixed, we are restricted to testing a PLR value from a subtyping of
interest against the empirical distributions of one of PLR|τ = 1, uPLR|τ = 1, or cPLR|τ = 1,
bearing in mind that the subtyping of interest may have τ = 1 or τ ≫ 1. Testing against the
empirical distribution of uPLR|τ = 1 will generally have little power when the value of τ in
the subtyping of interest is ≫ 1 since the distribution of uPLR|τ = 1 substantially majorises
the distribution of uPLR|τ ≫ 1. Testing against the empirical distribution of PLR|τ = 1 may
lead to loss of control of the type-1 error rate when the value of τ in the subtyping of interest
is ≫ 1, since the distribution of PLR|τ = 1 minorises the distribution of cPLR|τ = 1 and
generally the distribution of PLR|τ > 1. This leaves testing the PLR against the distribution
of cPLR, which is slightly conservative when the value of τ in the subgrouping of interest is
≈ 1, and appropriate type-1 error control otherwise. This conservatism is in fact somewhat
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desirable (see section 5.3, chapter 5), and hence this which was the approach I eventually
took.
C.3.2 Use of uPLR for testing
A problem arises with the behaviour of the unadjusted pseudo-log likelihood ratio statistic
uPLR= log{PLda(ZSd ,Za|ΘS1)}− log{PLda(ZSd ,Za|ΘS0)when the true value of τ (the marginal
variance of Zd in group 3) is near 1, corresponding to an absence of SNPs which differentiate
subgroups.
If τ = 1, there can be no differential genetic architecture between the subgroups, as there
are no systematic genetic differences between them at all. However, the joint distribution of
Zd,Za may still be in H1; if Za has an equally weighted three-Gaussian mixture distribution
with variances 1,a2,b2, and Zd ∼N(0,1), the true parameter values are (π2,π3,τ,σ2,σ3,ρ)=
(13 ,
1
3 ,1,a,b,0) ∈ H1 \H0 (figure C.4).
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σ3= 1, τ= 1
Zd
Za
Fig. C.4 Potential for false positives when τ = 1. Black/grey points and contours cor-
respond to category 1, blue to category 2, and red/pink to category 3. Top two fig-
ures show potential distributions of Zd,Za with σ3 > 1; bottom two figures distribu-
tions with σ3 = 1. A test based on the unadjusted pseudo-log likelihood ratio uPLR =
log{L(ZSd ,Za|ΘS1)}− log{L(ZSd ,Za|ΘS0)} will reject H0 for both of the top two scenarios.
However, we do not want to reject H0 for the top right figure, in which τ = 1 (no genetic
difference between subgroups). This scenario is possible in real data, as the distribution of
Za is only approximately normal and may more closely resemble a three-Gaussian mixture
distribution (where components have variances σ22 , σ
2
3 and 1) than a two-Gaussian mixture
distribution (where components have variances σ21 and 1).
This problem is particularly prevalent in randomly-chosen subgroups, since τ = 1 by
assumption in this case. If the distribution of Zd,Za from a test subgrouping is to be
compared against corresponding distributions from random subgroupings, this problem must
be addressed.
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C.3.3 Rationale for approach
Consider the function
cPL(Zd|Za,θ) = log{PLda(Zd,Za|θ)}− log{PL(Za|θ)} (C.46)
As per chapter 5, define
θ̂1 = arg max
θ∈H1
PLda(Zd,Za|θ)
θ̂0 = arg max
θ∈H0
PLda(Zd,Za|θ)
and given fixed values πˆ2, σˆ2, define
θ̂ c1 = arg maxθ∈H1|π2=πˆ2,σ2=σˆ2
cPL(Zd|Za,θ)
θ̂ c0 = arg maxθ∈H0|π2=πˆ2,σ2=σˆ2
cPL(Zd|Za,θ)
Now
cPLR = log{cPL(Zd|Za, θˆ c1)}− log{cPL(Zd|Za, θˆ c0)}
PLR = log{cPL(Zd|Za, θˆ1)}− log{cPL(Zd|Za, θˆ0)}
Under H0, with τ ≈ 1, I argue below (heuristically) that log{cPL(Zd|Za, θˆ c1)≥ log{cPL(Zd|Za, θˆ1)}
and log{cPL(Zd|Za, θˆ c0)≈ log{cPL(Zd|Za, θˆ0)}, so cPLR≥ PLR. This implies that for τ ≈ 1,
we have Pr(PLR < x|H0) < Pr(cPLR < x|H0). If τ ≫ 1 then both PLR and cPLR have a
mixture chi2 distribution under H0, of the form in equation 5.2 in chapter 5. The scaling factor
γ arises from LDAK weights, common to both PLR and cPLR, and the mixing parameter κ
tends to be approximately 1/2, so if τ ≫ 1, Pr(PLR < x|H0)≈ Pr(cPLR < x|H0).
The value PLa(Za|θ) can be considered an expected value with fixed values Za of
PLda(Zd,Za|θ) over observations of Zd . Since the parameters π2, σ2 characterise only the Za
distribution, which is common to both PLa(Za|θ) and PLda(Zd,Za|θ), we have
∂
∂π2
log{PLda(Zd,Za|θ)} ≈ ∂∂π2{PLa(Za|θ)}
∂
∂σ2
log{PLda(Zd,Za|θ)} ≈ ∂∂σ2{PLa(Za|θ)} (C.47)
318 Supplementary note for chapter 5
so ∂cPL∂π2 ≈ 0 and
∂cPL
∂σ2
≈ 0, and the value of cPL changes only slightly with changes in π2,
σ2. Denote θˆ ′1 = arg maxθ∈H1|π2=πˆ2,σ2=σˆ2 PLda(Zd,Za|θ) (defined similarly to θˆ1 but with
π2 and σ2 fixed). Now 1
cPL(Zd|Za, θˆ1)≈ cPL(Zd|Za, θˆ ′1) (C.48)
≤ max
θ∈H1|π2=πˆ2,σ2=σˆ2
cPL((Zd|Za,θ)
= cPL((Zd|Za, θˆ c1) (C.49)
Now recalling the definition of PLa(Za|θ):
PLa(Za|Θ) = ∏
Z(i)a ∈Za
(
π1N0,1(Z
(i)
a )+π2N0,σ22 (Z
(i)
a )+π3N0,σ23 (Z
(i)
a )
)
(C.50)
we see that under H0, the value of PLa(Za|θ) is fixed if π2 and σ2 are fixed, since σ3 = 1
and ρ = 0. Defining θˆ ′0 analogously to above, the constancy of PLa implies that maximising
PLda is equivalent to maximising cPL under H0, so θˆ ′0 = θˆ
c
0 and hence
cPL(Zd|Za, θˆ0)≈ cPL(Zd|Za, θˆ ′0) = cPL((Zd|Za, θˆ c0) (C.51)
as required.
A rough explanation of this argument is that contributions to the unadjusted PLR can
come from either the distribution of Za or the interaction between Za and Zd , and inflation
in the unadjusted PLR when τ = 1 arise only from the former. If the former effect is large,
the parameters in θ1 will tend to be values which maximise the former effect, somewhat
compromising the latter. By eliminating the former effect, using the adjustment, only
this compromised contribution of the latter is allowed to contribute to the adjusted PLR.
The compromise is why the distribution of PLR > x|τ ≈ 1) approximately minorises the
distribution of cPLR > x|τ ≈ 1) (see section C.3.1). When τ is larger, the SNPs in categories
2 and 3 can be more easily distinguished, and the two effects above are more separate, so the
compromise is lower. By contrast, the values which maximise the cPLR effectively take into
account the adjustment for Za (by maximising cPL rather than PLda), and the compromise of
the latter effect does not occur.
1Note that log{PLda(Zd ,Za|θˆ1)}− log{PLda(Zd ,Za|θˆ ′1) has a χ2 distribution with 2 degrees of freedom
under H0 if πˆ2 and σˆ2 are the true values of π2 and σ2, and hence it is not generally near 0. The argument
applied in equation C.48 derived from equation C.47 is that log{PLda(Zd ,Za|θˆ1)}− log{PLda(Zd ,Za|θˆ ′1) ≈
log{PLa(Za|θˆ1)}− log{PLa(Za|θˆ ′1), from which approximation C.48 is reasonable.
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As discussed in section ??, if we were to use the adjusted uPLR to generate the null
distribution using random subgroups, the majorisation of the observed distribution by the
mixture-χ2 may lead to loss of FDR control in test subgroups with τ > 1. However, using
the slightly anti-conservative distribution of cPLR to fit the null distribution overcomes this
problem. Indeed, some conservatism is desirable when τ = 1 as a double guard against
rejecting H0. The power of cPLR to reject H0 is, however, somewhat lower than the power of
the PLR, so I test using adjusted uPLR and fit the null distribution with cPLR.
C.4 Details of simulations
C.4.1 Simulations of random genotypes
Firstly, I simulated genotypes at independent SNPs to establish the distributions of PLR and
cPLR under H0 with τ = 1 and τ > 1.
I simulated the following scenarios:
1. (a) (Zd,Za) under H0 with τ = 1
(b) (Zd,Za) under H0 with τ allowed to vary
2. (Zd,Za) under H1
In each case, Za and Zd were calculated from simulated genotypes at 5×104 independent
autosomal SNPs in Hardy-Weinberg equilibrium. Because the sample size only affects PLR
through the size of the fitted parameters (section C.4.3) I fixed the sample size at 2000
controls and 1000 cases of each subgroup and varied the underlying effect size distribution.
Larger sample sizes correspond to larger deviations of underlying values of σ2, σ3, τ from 1
(table C.1).
For all simulations, I computed the uPLR and PLR (with adjustment f (Za)). For sce-
nario 1a (τ = 1, corresponding to random subgroups) I additionally computed the cPLR.
Simulations 2 functioned as power calculations; the results from these are shown in the main
text.
I tested over values of π3 from {10−3,10−2,0.1,0.2}. Values of σ2, σ3, τ were chosen
corresponding to 97.5% quantiles of odds ratios in {1.5,2,2.5} for case/control comparison
(Za) or {1,1.2,1.5,2} for between-subgroups comparison (Zd), table C.1.Values of ρ were
chosen corresponding to correlations in {0,0.1,0.5}.
I compared the observed distributions of PLR from simulations 1a,1b with the observed
distribution of cPLR from simulation 1a. Q-Q plots are shown in figure C.5. The distribution
320 Supplementary note for chapter 5
97.5% quantile of odds ratios
n1, n2 1.2 1.5 2 2.5
500, 500 1.20 1.75 2.66 3.41
1000, 500 1.25 1.94 3.02 3.89
1000, 1000 1.36 2.27 3.62 4.71
Table C.1 Approximate expected standard deviations of observed Z scores for given odds-
ratio distributions at various study sizes. For instance, if a study had 500 cases of each
subgroup, and 95% of ’true’ odds ratios (corresponding to population MAFs) for SNPs in
category 3 were less than 1.5, the expected value of τ (the standard deviation of Z scores for
SNPs in category 3) would be 2.66.
of cPLR agrees well with a mixture-χ2 distribution, as does the distribution of PLR for simu-
lation 1b. The distributions of PLR for simulations 1a,1b are minorised by the distribution of
cPLR, more so for simulations 1a (τ = 1), leading to a conservative test overall. Using cPLR
to fit a null distribution, and using a significance cutoff p < 0.05, leads to a false-discovery
rate of 0.048 (95% CI 0.039-0.059) in subgroups with τ > 1 and 0.033 (95% CI 0.022-0.045)
in subgroups with τ = 1.
I also show the distribution of unadjusted PLR (uPLR) for simulations 1a and 1b. The
distribution for 1a markedly majorises the mixture-χ2 distribution, and has a very different
distribution to that for 1b. Thus, if a test subgroup with τ >> 1 was compared to random
subgroups using unadjusted PLR, the test would have very low power to reject H0. Finally,
I plotted the estimated null distribution for all tests of real disease datasets, and found that
the empirical distributions of cPLR from random subgroups agreed well with the proposed
mixture χ2 distribution (appendix D.2, figure D.5a, D.5b, D.5c).
C.4.2 Simulation on GWAS case group subgroups
To check the extensibility of these results to real data, I performed a similar set of simulations
on data generated from subgroups of an ATD case group. In order to simulate scenarios in
which τ > 1, I selected subgroups for which groups of ≈ 50 SNPs differentiated subgroups
without being associated with the disease in general.
Specifically, I repeatedly polled the overall dataset for sets of 2000 SNPs in linkage
equilibrium, then clustered them hierarchically using a Euclidean distance metric. I then
chose the first-appearing cluster of 50 SNPs, and hierarchically clustered the individuals in
the case group according to a metric based on similarity across the 50 SNPs. When there
were two clusters of individuals left, I denoted the two clusters as subgroup 1 and subgroup
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Fig. C.5 Q-Q plots comparing distributions of PLR and cPLR for subgroups based on
simulated genotypes with a random variable distributed as 12(χ
2
1 +χ
2
2 ) (that is, γ = κ =
1
2).
In both plots, the black points correspond to conditional PLR (cPLR) values for ’random’
subgroups (τ = 1). The observed distribution is well-approximated by the asymptotic mixture-
χ2. The left-hand plot shows the distributions of unadjusted and adjusted PLR for subgroups
with τ = 1. The distribution of unadjusted PLR markedly majorises the mixture-χ2, but
the adjustment largely fixes this. The right-hand plot compares the distribution of cPLR
for random subgroups with PLR for subgroups with τ > 1. The distribution of cPLR is
well-approximated by the mixture-χ2 whether τ = 1 (black) or τ > 1 (red). In both plots,
the distribution of cPLR and the mixture-χ2 distribution slightly majorise the distribution of
PLR, leading to a conservative test.
2. The mean resultant fitted value of τ was ≈ 5 and standard deviation of fitted values was
≈ 1.5.
For simulated subgroups with τ = 1 (randomly chosen) and with τ > 1 I computed PLR
and cPLR. As for simulated genotypes, the resultant distributions showed good agreement
with the proposed mixture-χ2 distributions (figure C.6), with the approximation of the null
distribution of PLR with the distribution of cPLR again leading to a conservative test, as
expected. The type 1 error rate corresponding to α = 0.05 was 0.52 (95% CI 0.043-0.061) in
subgroups with τ > 1 and 0.012 (95% CI 0.007-0.016) in subgroups with τ = 1.
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Fig. C.6 Comparison of distributions of PLR and cPLR for subgroups of an ATD case group,
chosen so τ = 1 or τ > 1. The distribution of cPLR for random subgroups (τ = 1) and the
distribution of PLR for subgroups with τ >> 1 are both well-approximated by a random
variable distributed as 12(χ
2
1 +χ
2
2 ); red dashed lines show 99% pointwise confidence intervals.
The distribution of PLR when τ = 1 is minorised by the mixture-χ2 leading to a conservative
test if a subgroup with τ = 1 is tested using PLR against the observed distribution of cPLR
for random subgroups. Because τ = 1 implies no genetic difference between subgroups, this
is reasonable behaviour for the test.
C.4.3 Distributions of parameter values for simulation and power cal-
culations
I assume a distribution of summary statistics parametrised by six variables: π1, π2, σ2, σ3,
τ , and ρ (the value of π3 is determined by π1 and π2). The space of all parameter values is
too large to meaningfully assess performance of my test across it, so for each simulation, I
draw the value of underlying parameters from sets of potential values chosen to reflect values
which may arise in real data.
For a SNP S in two groups of size n1, n2, denote the population allele frequencies as µ1,
µ2 and the corresponding observed allele frequencies as m1, m2. Set µ = µ1n1+µ2n2n1+n2 as the
overall observed MAF, r = log
(
µ1(1−µ2)
µ2(1−µ1)
)
and R = log
(
m1(1−m2)
m2(1−m1)
)
as the ’underlying’ and
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observed log-odds ratios respectively. To first order
SE{R}=
√
1
2m1n1
+
1
2(1−m1)n1 +
1
2m2n2
+
1
2(1−m2)n2
≈
√
1
2m(1−m)
√
1
n1
+
1
n2
(C.52)
The observed Z score is, to first order, Z = RSE(R) . Now
E(Z|µ,r)≈ r
√
2µ(1−µ)n1n2
n1+n2
SD(Z|µ,r)≈ 1 (C.53)
Consider r as a N(0,σ2) random variable, and fix µ . Now, to first order
Z|µ ∼ N
(
0,1+
2µ(1−µ)σ2n1n2
n1+n2
)
(C.54)
Assuming µ to have an approximately uniform distribution on (0,0.5], this gives
Z ∼ N
(
0,1+
σ2n1n2
3(n1+n2)
)
(C.55)
An interpretable description of the underlying odds-ratio distribution is the 0.975 quantile of
‘true’ odds ratios (approximately 2 standard deviations). If 97.5% of ‘true’ odds ratios r fall
in [1/α,α], then σ ≈ log(α)2 and the expected value of the corresponding observed standard
deviation of Z (that is, σ2, σ3, or τ) is√
1+
log(α)2n1n2
12(n1+n2)
(C.56)
Some examples are shown in table C.2:
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Study size (n1/ n2)
α SD 100/100 100/500 500/500 500/1000 1000/1000 2000/2000
1.1 0.05 1.02 1.03 1.09 1.12 1.17 1.32
1.2 0.09 1.07 1.11 1.30 1.39 1.54 1.94
1.3 0.13 1.13 1.22 1.56 1.71 1.97 2.60
1.5 0.20 1.30 1.46 2.10 2.36 2.80 3.83
2 0.35 1.73 2.08 3.31 3.79 4.58 6.41
Table C.2 Correspondence between odds-ratio distribution and standard deviation of observed
Z score for various study sizes. Column α is the 97.5 % quantile of population odds-ratios
for SNPs with non-zero effect sizes (approximately two standard deviations). Column SD is
the corresponding standard deviation of the underlying log-odds ratio distribution (assumed
to be normal). Entries in the table correspond to expected standard deviations of observed
Z scores; that is, σ2, σ3 or τ . I allow different odds-ratio distributions between cases and
controls for SNPs in categories 2 and 3 (corresponding to σ2 and σ3 respectively). For σ2 or
σ3, n1 is the number of cases and n2 the number of controls; for τ ; n1 and n2 are the number
of cases in each disease subgroup.
C.5 Genetic correlation as an alternative to PLR test
C.5.1 Overview
The presence of genetic heterogeneity between disease subgroups could be tested for by
adapting several known methods, although to my knowledge no specific method has yet been
developed. One potential approach is to estimate the narrow-sense genetic correlation (rg)
across a set of SNPs between case/control traits of interest, either between Z scores derived
from comparing the control group to each case subgroup, testing under the null hypothesis
rg = 1 (method 1); or between the familiar Za and Zd , under the null hypothesis rg = 0
(method 2).
This approach should have the advantage of characterising heterogeneity using a single
widely-interpretable metric. However, both methods have, in this naive application, have
multiple shortcomings which preclude their general use to subgroup testing. The most
important of these are systematic false-positives arising in method 1, and false-negatives
arising in method 2. I demonstrate this theoretically and in simulations. In addition, genetic
correlation is a signed test statistic; genetic effects in the same direction contribute positively,
and opposite directions contribute negatively, causing a loss of power in situations where
pleiotropy between the phenotypes involves shared effects of both types. Finally, I found that
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tests involving rg were less powerful than the PLR in rejecting the null hypothesis in real
genetic data (ATD; GD vs HT).
Genetic correlation is an estimate of the similarity in genetic basis of two traits. A useful
formal definition is given by Bulik-Sullivan et al [Bulik-Sullivan et al., 2015]. Let S be a
set of SNPs and X denote a vector of additively coded genotypes (0, 1 or 2) for a random
individual at the SNPs in S. For traits Y1, Y2 set
β = arg maxα∈R|S|,||α||=1 cor(Y1, X
tα)
γ = arg maxα∈R|S|,||α||=1 cor(Y2, X
tα) (C.57)
where the maximum is taken across the entire population. The genetic correlation between
traits across SNPs in S, rg, is then given by
rg =
β tγ
||β || ||γ|| =∑i∈S
βiγi (C.58)
C.5.2 Method 1: control-subgroup 1 vs control-subgroup 2
Expected behaviour
I firstly consider method 1. In this approach, I consider two case-control comparisons:
1. Case subgroup 1 vs control group
2. Case subgroup 2 vs control group
I denote Z scores derived from GWAS p-values comparing between controls and subgroup
1 by Z1 and scores between controls and subgroup 2 by Z2 (figure C.7). An estimated genetic
correlation significantly less than 1 (or at least significantly less than estimates from random
subgroups) may indicate different causative architectures for the subgroups, in the form of
differing relative effect sizes for disease-associated variants.
However, using this method will not distinguish between different disease-causative
architectures and genetic differences between subgroups unrelated to the overall phenotype.
In terms of the parameters of my three-categories model, method 1 will be liable to reject the
null whenever τ > 1, regardless of whether σ3 > 1 (that is, regardless of whether subgroup-
differentiating SNPs are in general disease-associated). Indeed, for a set value of τ , the
negative contribution of SNPs in group 3 to the observed rg will often be maximised when
H0 holds; that is, σ3 = 1.
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Consider a SNP in category 3. Under a simple model in which case subgroups are the
same size, I denote by µc the population MAF of the SNP in controls, and µ1 and µ2 the
population AF of the same allele in cases. To first order Z1 ∝ µ1− µc and Z2 ∝ µ2− µc.
Assume µ1− µ2 is set at some constant m > 0. Because m > 0, the SNP is associated
with at least one of the subgroups, and hence contributes to the genetic correlation. The
value of this contribution to the correlation is proportional to Z1Z2, which is proportional to
(µ1−µc)(µ2−µc).
This is minimised when µc = 12(µ1 + µ2). This is exactly the scenario in which the
genetic subgroup differences are unrelated to the phenotype as a whole. In other words,
dividing the case group on an arbitrary genetically-associated phenotype (ie hair colour,
ethnicity, presence of a second unrelated disease) would lead to a lowering of rg more than
would a differential disease process with the same heritability (figure C.7).
Simulations
I demonstrated this on the ATD dataset by using the subgroups generated under H0 as in
simulation 1b (see section C.4.2). These subgroups had a true value of τ greater than 1, but
σ3 = 1 and ρ = 0.
For each simulated subgroup, I computed the genetic correlation between the two studies
using two methods - LD score regression (LDSC) [Bulik-Sullivan et al., 2015] and genome-
wide complex trait analysis (GCTA) [Lee et al., 2012] - and computed the PLR statistic. I
also computed genetic correlation and PLR scores for multiple random subgroups of the ATD
case group. Significance of the genetic correlation was assessed by either comparing the
observed rg to the values observed in random subgroups (LDSC) or comparing the likelihood
of the observed data with an alternative model in which rg ≡ 1.
As expected, rg estimates using both methods were markedly lower in subgroups with
simulated genotypic differences than they were in random subgroups (figure C.8). In the
LDSC method, a cutoff of p < 0.05 led to rejecting the null in of 45% (SE 2%) of cases, and
in GCTA in in 29% (SE 5%) of cases. The PLR method did not reject the null more often
than expected, rejecting the null in 4% (SE 1%) of cases.
Application to real data
I also used both LDSC and GCTA to test the hypothesis of differential genetic architecture in
GD and HT. The GCTA method was unable to reject the null hypothesis (p = 0.217), using a
likelihood ratio test against a null model with rg = 1. The LDSC method was able to reject
C.5 Genetic correlation as an alternative to PLR test 327
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Fig. C.7 One way to test for phenotypic heterogeneity using genetic correlation (rg) is
to estimate rg for two separate case-control studies; each comparing the control group to
one of the disease subgroups, and test whether the estimated rg is significantly less than
1. I denote by Z1, Z2 the sets of Z- scores corresponding to allelic differences between
controls and cases of subtype 1 and between controls and cases of subtype 2 respectively
(top panel) in contrast to the usual Za and Zd scores. A shortcoming of this method is that
rg is decreased by the presence of SNPs which show allelic differences between subtypes,
but are unrelated to the phenotype overall. In this sense, the test rg < 1 is responsive to any
genetic difference between subtypes - not just those which correspond to differing disease
pathology. This scenario would arise if subgroups were defined based on a phenotype with
non-zero heritability which was unrelated to the disease; eg, subgroups of T1D defined
by hair colouring. The lower two panels demonstrate this scenario. The left panel shows
(simulated) Za and Zd scores for a set of SNPs under H0, where grey corresponds to category
1, red to category 2, and blue to category 3. The right lower panel shows the corresponding
sets of Z1 and Z2 values. SNPs in the grey circles, and generally SNPs coloured blue, will
contribute negatively to the overall genetic correlation, which is asymptotically proportional
to the sum of Z1Z2 over all SNPs coloured red or blue.
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Fig. C.8 Density of estimated rg (LDSC method) for method 1. Estimates for random
subgroups generated under H0 are shown in black. Estimates for subgroups with a simulated
difference (τ > 1) are shown in red. A test based on method 1 would reject H0 if rg was
significantly less than 1; however, as the plot shows, this would lead to systematic false
positives in the scenario where τ > 1. Some estimated values of rg are greater than 1 due to
the way the statistic is estimated under the LDSC method.
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the null at p < 0.05, though not at the same significance as the PLR (LDSC: p = 0.012, PLR
p = 2.2×10−15). This suggests that the rg based methods are less powerful than the PLR in
this context. This is likely due to the PLR responding to an additional degree of freedom
(σ3) between the null and full models.
C.5.3 Method 2: Zd (case vs control) vs Za (subgroup 1 vs 2)
Expected behaviour, and relation of ρg to ρ
In method 2, I consider the two case-control comparisons:
1. Combined case group vs control group
2. Case subgroup 1 vs case subgroup 2
analogous to my approach in the PLR method, with the two comparisons corresponding
to Za and Zd respectively. I estimate rg between these two traits, and test against the null
hypothesis that rg = 0.
The value of rg relates to the estimated value of ρg in the full model. For a set S of
disease-associated SNPs with additive (non-epistatic) effects in linkage equilibrium, and a
binary trait y, we have
cor(y,X tα) =∑
i∈S
cor(y,αiXi) =∑
i∈S
αicor(y,Xi) (C.59)
This is maximised when αi ∝ cor(y,Xi). If µ1(i) denotes the AF of SNP i in S amongst the
population with y = 1 , µ0(i) the corresponding µc(i) the overall AF of SNP i and p the
incidence of the trait in the population (that is, Pr(y = 1)), we have
cor(y,Xi) =
√
2p(1− p) µ1(i)−µ0(i)√
µc(i)(1−µc(i))
(C.60)
Given observed allele frequencies m1(i), m0(i) at SNP i in a GWAS between traits 1 and 2
with n1 and n0 samples respectively, the Z score for significance of that SNP is
Z(i) =
m1(i)−m0(i)
SE(m1(i)−m0(i)) +O((m1(i)−m0(i))
2)
=
m1(i)−m0(i)√
m1(i)(1−m1(i))
n1
+ m0(i)(1−m0(i))n0
+O((m1(i)−m0(i))2) (C.61)
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so
lim
n1,n0→∞
|µ1−µ0|→0
(
1
n1
+
1
n0
)
Z(i)
cor(y,Xi)
=
√
p(1− p) (C.62)
Amongst SNPs in LE with small effect sizes (µ1−µ0 small), expression C.59 is maximised
for αi ∝ limn1,n0→∞Z(i). If we denote by Z1i, Z2i the GWAS Z scores for SNP i in phenotypes
1 and 2 respectively in studies with all group sizes Θ(n), the genetic correlation between the
phenotypes is
rg ≈ lim
n→∞
∑
i∈S
Z1iZ2i√
∑
i∈S
Z21i ∑
i∈S
Z22i
(C.63)
The sum is over all SNPs S, but the only SNPs with non-vanishing contributions to rg are
those which are associated with both phenotypes. For the two traits in method 2, these SNPs
are exactly those which are in my (idealised) category 3 in the full model. Writing Ci as the
category of the SNP i we can rewrite the above as
rg ≈ lim
n→∞
∑
i∈S
I(Ci = 3)Z1iZ2i√
∑
i∈S
I(Ci = 3)Z21i ∑
i∈S
I(Ci = 3)Z22i
(C.64)
for which an obvious estimator is
rˆg =
∑
i∈S
Pr(Ci = 3)Z1iZ2i√
∑
i∈S
Pr(Ci = 3)Z21i ∑
i∈S
Pr(Ci = 3)Z22i
(C.65)
If we were to define the full model such that Za, Zd for SNPs in category 3 were distributed as
a single bivariate Gaussian distribution with covariance ρ ′ (as opposed to my current model
of two symmetric Gaussians), the updating step for ρ in the E-M algorithm would have a
similar form. Indeed, if Θn−1 is the set of estimates for {π1,π2,σ2,σ3,τ,ρ ′} after step n−1
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of the E-M algorithm, the updating steps for ρ ′, τ , σ3 are
(ρ ′)n ←
∑
i∈S
Pr(Ci = 3|Θn−1)Za(i)Zd(i)
∑
i∈S
Pr(Ci = 3|Θn−1)
(σ3)n ←
√√√√√ ∑i∈S Pr(Ci = 3|Θn−1)Za(i)2
∑
i∈S
Pr(Ci = 3|Θn−1)
(τ)n ←
√√√√√ ∑i∈S Pr(Ci = 3|Θn−1)Zd(i)2
∑
i∈S
Pr(Ci = 3|Θn−1) (C.66)
and hence when the E-M algorithm converges, ρ ′/(σ3τ) is an estimator for rg. Testing rg ̸= 0
in this scenario is broadly equivalent to testing whether ρ ′ ̸= 0 in the adapted full model.
When developing the PLR method, I chose not to use this simpler model, opting for a
more complex two-Gaussian distribution of (Za,Zd) for SNPs in category 3. There were
several reasons for this choice. Importantly, ρ ′ ̸= 0 implies ρ > 0, so the test rg ̸= 0 tests a
more specific proposition than the PLR.
Testing for ρ ′ ̸= 0 or rg ̸= 0 is weakened when Za and Zd are correlated at some group of
SNPs and anticorrelated at others. I note that this simultaneous correlation and anticorrelation
is likely in many biological scenarios. Given two disease subgroups 1 and 2, deleterious vari-
ants associated only with subgroup 1 will have correlated Za, Zd values, whereas deleterious
variants associated only with subgroup 2 will have anticorrelated Za and Zd .
In addition, the presence of between-subgroup heterogeneity, as characterised by the
presence of SNPs with simultaneously high |Zd| and |Za| values, does not require that Za
and Zd have to be correlated or anticorrelated at all. The presence of a set of SNPs whose
marginal variances of Za and Zd are simultaneously significantly larger than 1 is sufficient
evidence for heterogeneity of disease basis. This was the impetus for including the additional
parameter σ3 in the full model.
Uncorrelated Za and Zd may well occur in situations where the main sources of variation
between the subgroups are only weakly associated with the overall phenotype, while less
associated variants are strongly associated. This would be expected to occur in situations
where the subtypes have known genetic differences. If, for example, a subgrouping phenotype
was based on visual acuity in the phenotype of symptomatic Type 2 diabetes, variants
associated with general macular degeneration would have large |Zd| scores with low |Za|
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scores, while variants associated with microvascular glucose sensitivity would have larger
|Za| scores and smaller (but still overdispersed) |Zd| scores.
The behaviours of rg/ρ ′, ρ , τ and σ in various scenarios are summarised in appendix D.1,
table D.1. Overall, I consider that while ρg is a useful statistic, it does not capture the variety
of forms that disease heterogeneity can take.
Simulations
I tested the ability of GCTA to reject the null hypothesis rg = 0 on simulated data. I simulated
genotypes for 4000 controls and 2000 cases in each of two subgroups at 10000 SNPs in
linkage equilibrium. Genotypes were simulated in such a way that Za and Zd scores would
have the distributions
(
Zd
Za
)
∼ N
((
0
0
)
,
(
1 0
0 1
))
at 7000 SNPs (π1 = 0.7)(
Zd
Za
)
∼ N
((
0
0
)
,
(
1 0
0 4
))
at 2000 SNPs (π2 = 0.1)(
Zd
Za
)
∼ N
((
0
0
)
,
(
4 ρ
ρ 4
))
at ξ ∗1000 SNPs (π3 = 0.2)(
Zd
Za
)
∼ N
((
0
0
)
,
(
4 −ρ
−ρ 4
))
at (1−ξ )∗1000 SNPs (π3 = 0.2)
The value ξ represents the degree to which Za, Zd scores can show both correlation
and anticorrelation, and ρ represents the extent of the correlation/anticorrelation. I ran
simulations at ρ = 0 and for ρ ∈ {0,0.5,1,2} for ξ = 0 (no anticorrelation), ξ = 0.2 (mostly
correlation, some anticorrelation) and ξ = 0.5 (equal correlation and anticorrelation). The
large value of π3 was to ensure that both PLR and GCTA should be well-powered to reject
the null hypothesis where able, but not so well-powered as to be incomparable.
I estimated rg using the GCTA method [Lee et al., 2012]. Significance was assessed using
the provided likelihood-ratio test comparing the fitted model with a null model in which
rg = 0.
I did not test LDSC in this scenario, as it estimates rg based on phenomena arising
from the LD matrix, and simulation would entail setting an inherent effect size for these
phenomena through specifying an LD matrix. Since the shortcomings I identify are with the
use of rg itself, rather than the method used to simulate it, I considered this reasonable.
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ρ ξ GCTA PLR
0 0 0.09 (0.002) 1 (-)
0 0.2 0.12 (0.002) 1 (-)
0 0.5 0.06 (0.002) 1 (-)
0.5 0 0.55 (0.006) 1 (-)
0.5 0.2 0.13 (0.004) 1 (-)
0.5 0.5 0.06 (0.001) 1 (-)
1 0 0.96 (0.002) 1 (-)
1 0.2 0.59 (0.005) 1 (-)
1 0.5 0.07 (0.002) 1 (-)
2 0 1 (-) 1 (-)
2 0.2 1 (-) 1 (-)
2 0.5 0.04 (0.001) 1 (-)
Table C.3 Power of tests to reject the null hypothesis at α = 0.05 in simulated data. Brackets
show standard error. Value ρ is the degree of correlation/anticorrelation between Zd and Za.
Value ξ is the degree of split between correlation and anticorrelation; ξ = 0 corresponds to
correlation only, ξ = 0.2 to mostly correlation with some anticorrelation, and ξ = 0.5 to a
half/half mix. Testing for subgroup heterogeneity using GCTA is adequately powerful when
correlation ρ is present, but declines markedly when both correlation and anticorrelation are
present, and is effectively zero when p = 0.5 or ρ = 0. The PLR-based test was able to reject
H0 universally in all cases.
As expected, the test based on rg = 0 was not able to reject the null hypothesis when
ρ = 0 or ξ = 0.5, and power was markedly reduced when some anticorrelation was present,
at ξ = 0.2 (figure C.9, table C.3). While the test was able to systematically reject the
null hypothesis when ξ ∈ {0,0.2}, ρ > 0, the power was universally lower than that of the
PLR test (table C.3). This was likely due to information gained from the additional degree
of freedom (σ3) between the full and null models in the PLR test. I did not simulate any
scenarios where σ3 = 1, as this would imply that SNPs in category 3 were not systematically
associated with the subgrouping phenotype, and hence correlation with Za would be spurious.
Application to real data
Finally, I assessed whether I could reject H0 by testing against rg = 0 on my ATD dataset
(MHC removed), with subtypes GD and HT. I used both the LDSC and GCTA methods to do
this. While both were able to reject the null hypothesis (LDSC: rg =−0.579, p = 0.04, from
known null distribution of ρg; GCTA: rg =−0.580, p = 1×10−3 from likelihood-ratio test)
neither could do so as confidently as the PLR test (p = 2.2×10−15).
334 Supplementary note for chapter 5
llll
l
llllll
ll
llll
lll
ll
llll
llll
ll
lll
lll
ll
ll
llll
ll
ll
ll
ll
ll
l
l
l
lll
ll
lll
lll
l
lll
lll
lll
lll
l
llll
ll
ll
ll
ll
ll
ll
llllll
l
lll
llllll
ll
ll
l
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Relative rank
P 
va
lu
es
 (G
CT
A)
, s
ort
ed
lllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllllll
lllll
lllll
ll
lll
l
ll
ll
ll
l
l
l
l
l
l
l
ll ll ll ll ll llll
llllll
lllll
lll
lll
llll
l
l
llll
lll
ll
ll
lll
l
l
l
lll
ll
l
l
ll
l
l
ll
l
ll
l
l
l
llll
l l
l
lllll
lll
l
lll
l
lll
lll
ll
lllll
llll
ll
llll
ll
l
llll
ll
ll
l
lll
lll
lll
l
lll
ll
l
llll
lll
l
ll
ll
lll
llll
l
l
llll
ll
lll
lllll
lll
ll l
lll
ll
llll
llll
ll
llll
l
l
l
l
l
ρ = 0
ρ > 0, ξ = 0
ρ > 0, ξ = 0.2
ρ>  0, ξ = 0.5
Fig. C.9 Sorted p values from test of null hypothesis rg = 0 under simulations in which
ρ ∈ {0,0.5,1,2} and ξ ∈ {0,0.2,0.5}. In all simulations, H0 is false (with σ3 > 0). GCTA
is able to reject the null hypothesis only if ρ > 0 and p ̸= 0.5, and power is reduced (ie,
p-values are higher) if p = 0.2 compared to p = 0. If ρ = 0 or ξ = 0.5, the p-values show
effectively no deviation from U(0,1). Thus a test based on rejecting ρg = 0 is not suitable
for my purposes.
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Unfortunately I was unable to obtain meaningful estimates of rg in comparisons relating
to type 1 diabetes subgroups; the standard error of the estimate was such that I was never able
to reject the null hypothesis rg = 1 (method 1) or rg = 0 (method 2), with all adjusted p-values
greater than 0.2. Given this, I do not consider the estimated rg values to be informative in
this case.
Our proposed test is complex, and parametrises disease heterogeneity using several
variables (namely π3, σ3, τ and ρ) rather than providing a single metric. I consider this
complexity to be necessary; heterogeneity in a phenotype can arise in many ways and the
heterogeneous genetic architecture can take many forms. A test specifically to detect SNPs
with large, genome-wide significant effect sizes in one disease subgroup but not the other
may miss heterogeneity characterised by subtle effect size differences across many SNPs
with small effects. My method can ideally detect heterogeneity in a general sense in multiple
situations, and give insight into the architecture in the form of the fitted parameters.
C.6 Other
C.6.1 Alternative test statistics for retrospective single-SNP analysis
I propose four summary statistics for testing the degree to which single SNPs have differential
effect sizes in disease subgroups. The fourth of these, the Bayesian conditional false discovery
rate (cFDR) is discussed in the methods section of the main text. The three alternative
statistics (which I term X1, X2, X3) test against slightly different null hypotheses. The
alternative statistic for testing the overall H0 described in section 5.5.2 can also be adapted
to retrospective single-SNP analysis, although it is difficult to interpret its meaning for
individual SNPs.
The first, X1, is the posterior probability of membership of the third category of SNPs
under the full model; that is, for a SNP of interest with Z scores za, zd and given fitted
parameters Θ1 = {π1,π2,π3,σ2,σ3,τ,ρ}:
X1 = Pr(SNP ∈ category 3|Θ1)
=
1
2π3
N
0,
(
τ2 ρ
ρ σ23
)(za,zd)+N
0,
(
τ2 −ρ
−ρ σ23
)(za,zd)

PDFΘ1(za,zd)
(C.67)
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This test statistic has the advantage of straightforward FDR control against the null hypothesis
H0 = {SNP ∈ category 1/2|Θ1}, assuming the validity of Θ1. It also reflects the overall
shape of the distribution. A disadvantage is the dependence on the model implied by Θ1; in
circumstances where σ3 >> σ2, the test statistic X1 will be high for high values of |Za| even
when |Zd| is low (appendix D.2, figures D.8). This is a particular problem if tested regions
include very strong associations; for example, the MHC region in autoimmune phenotypes.
Our second statistic, X2, is the difference in pseudo-log likelihood of a given SNP under
the full and null models; that is, given fitted parameters Θ1 under H1 and Θ0 under H0
X2 = log{PL(za,zd|Θ1)}− log{PL(za,zd|Θ0)} (C.68)
This has the advantage that high values of X2 directly identify the SNPs contributing to a
higher pseudo-likelihood ratio. A disadvantage is the sensitivity to the behaviour of the fitted
parameters under H0, which may be variable (see chapter 5, section 5.2.3 and table 5.2), and
absence of direct FDR control. Because X1 and X2 tend to highlight uninteresting SNPs in
differing circumstances, I found a combination of both to be useful to find SNPs which are
’unusual’ (high X1) and contribute to the PLR (high X2).
The third test statistic is defined as X3 = zαa z
1−α
d , α ∈ (0,1). I chose this test statistic as I
am broadly searching for evidence of correlation between Za and Zd , and SNPs contribute to
measures of correlation principally through the value of ZaZd . This test statistic identifies
SNPs with concurrently high Za and Zd in an obvious way, so is of most use when SNPs
which differentiate subgroups are not of interest unless they are also associated with the
overall phenotype.
The value of α is set in order to prioritise SNPs with high Zd over those with high Za; for
instance, with α = 0.5 will give equal weight to a SNP with Za = 10, Zd = 1 and a SNP with
Za = 1, Zd = 10, but in general the second SNP will be of far greater interest. To determine
the best value of α , I consider how much I may expect Za and Zd to deviate from 0, using
both the full and null models.
I set τ ′ as the largest value of τ across both models, and σ ′ as the largest of σ2 (null
model) and σ2, σ3 (full model). Given fitted values τ ′, σ ′, I suggest the value
α =
log(σ ′)
log(τ ′)+ log(σ ′)
(C.69)
so that the statistic X3 has the same value at the points (1,τ ′) and (σ ′,1). The rationale for
this is that SNPs which have the true underlying distributions N
0,
(
τ ′2 0
0 1
) or N
0,
(
1 0
0 σ ′2
) are
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uninteresting; I seek deviance from both of these distributions. A hypothesis test for X3 can
then be computed, using the appropriate values of π(0,1,2).
Contour plots of the test statistics for several datasets are shown in appendix D.2, fig-
ures D.8, D.9.
C.6.2 Independence of PLR distribution on subgroup sizes
PLR and cPLR values for randomly chosen subgroups are all derived from data with the
same Za values, with the distribution of Zd expected to be N(0,1) and independent of Za
regardless of the relative sizes of random subgroups. Therefore I expect that the asymptotic
distribution (chapter 5, equation 5.2 does not depend on relative subgroup size. An important
consequence of this is that if several subgroupings of a phenotype are being simultaneously
assessed, the empirical distribution of cPLR need only be calculated once.
I demonstrate this assertion by simulation. Using the autoimmune thyroid disease dataset,
I simulated random subgroups from the combined case group (GH+HT) for a range of relative
sizes, repeating the simulation 1000 times for each subgroup size. Figure C.10 shows the
observed distributions of PLR and cPLR as compared to the overall distribution. These plots
are consistent with independence of empirical PLR and cPLR distributions on subgroup size.
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Fig. C.10 Distributions of PLR and cPLR for various relative sizes of subgroups. Simulations
are on ATD data. Legend shows the proportion of cases in the smaller subgroup. Leftmost
plot shows distribution of observed cPLR, rightmost distribution of PLR. Red dotted lines
show empirical 99% confidence limits. Distributions are similar for all relative subgroup
sizes.
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C.6.3 Number of simulations necessary to fit null distribution
I assessed the number of simulated random subgroups required to estimate the parameters γ ,
κ of the null distribution of the cPLR. I took bootstrap samples of various sizes from my list
of simulated random subgroups (τ = 1) of the ATD data. For each sample, I computed the
fitted values of γ and κ and the observed p-values associated with observed PLR values of 2,
3, 5, and 10, i.e. expected p values 0.08, 0.03, 0.004 and 1.5×10−6 respectively (figure C.11)
This suggests that 1000 simulations is generally adequate, and it is difficult to improve
accuracy markedly past this point. For this number of simulations, 95% of computed
values for κ , γ , Pr(PLR > 2|κ,γ) and Pr(PLR > 5|κ,γ) were in [0.44,0.56], [0.46,0.72],
[0.069,0.97] and [0.0021,0.0057] respectively. As expected, consistency of p-value estimates
is poorer for lower p-values, as these correspond to greater extrapolations of the distribution.
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Fig. C.11 Distributions of estimated parameters γ and κ and various corresponding p-values,
using various sizes of simulated random subgroups. Blue lines show quantiles of observed
distribution corresponding to ±2σ ; red lines show quantiles corresponding to ±σ . Errors in
γ and κ are shown as percentage errors as compared to median. Errors in p-values are shown
as log10 fold changes from median. Values of the median value of each variable are shown.
Observed values are shown as grey dots.
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Zd
Za
  
1/ <
1
≫ 0 ≫ 0 > 1 > 1
H1: Zd , Za correlated; eg.
same pathways; different heri-
tability (age-of-onset)
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< 1 > 0 ≫ 0 > 1 > 1
H1: Zd , Za mostly correlated,
some anticorrelation; eg. most
variants associated with sub-
group 1, some with subgroup
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Zd
Za
  
< 1 0 ≫ 0 > 1 > 1
H1: Zd , Za both correlated and
anticorrelated; eg. variants ei-
ther associated only with sub-
group 1 or only with subgroup
2
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Zd
Za
  
< 1 0 0 > 1 > 1
H1: var(Zd) > 1 and
var(Za) > 1 but not cor-
related; general shared
genetic architecture between
subgrouping phenotype and
main phenotype, effect sizes
independent
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H1: shared genetic architec-
ture between subgrouping phe-
notype and main phenotype,
effect sizes dependent but not
correlated or anticorrelated
Table D.1 Heterogeneity between case subgroups may arise in multiple ways, some of which
are illustrated here. Plots show the distribution of Zd and Za for SNPs in category 3 (those
which differentiate subgroups). Column r(1)g corresponds to genetic correlation in method 1
(between Z scores for control vs subgroup 1 and control vs subgroup 2), and column r(2)g to
genetic correlation in method 2 (between Za and Zd); see appendix C, section C.5. SNPs in
category 1 (not differentiating cases/controls and not differentiating subgroups) are shown in
grey for reference, and SNPs in category 2 are omitted. In the first two rows, the pathology
leading to heterogeneity is genetically independent of the pathology leading to the main
phenotype; the main null hypothesis. The test r(1)g < 1 will reject H0 for the scenario in
row 2, as well as other scenarios. The test r(2)g ̸= 0 rejects H0 for the scenario in row 3,
but is weakened in the scenario in row 4 due to the anticorrelation, and will not be able to
reject H0 for rows 5-7. Since ρ detects correlation and anticorrelation simultaneously, it will
additionally reject H0 for row 4 and will not be weakened in row 3. However, it is necessary
to test for σ3 > 1 to reject H0 for rows 5 and 6.
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SNP details Z scores
SNP Chr Pos Gene |Zd|(p) |Za|
rs12045559 1 113708908 PTPN22 2.892 (3.8×10−3) 3.217
rs415024 5 9445358 3.051 (2.3×10−3) 2.941
rs1010599 5 35944231 IL7R 3.367 (7.6×10−4) 2.881
rs4024109 5 35955375 IL7R 3.307 (9.4×10−4) 2.792
rs17085170 5 95198087 4.291 (1.8×10−5) 2.365
rs3114834 7 109192112 2.649 (8.1×10−3) 3.787
rs12549890 8 21045174 3.535 (4.1×10−4) 2.459
rs16874205 8 107271324 4.428 (9.5×10−6) 3.565
rs4076319 10 85129122 4.124 (3.7×10−5) 2.165
rs10736277 10 121705898 3.415 (6.4×10−4) 3.411
rs7912574 10 121717404 3.265 (1.1×10−3) 2.957
rs2065660 10 121754185 3.557 (3.8×10−4) 3.031
rs6578252 11 2226817 INS 3.481 (5×10−4) 2.576
rs705698 12 54670954 IKZF4 5.058 (4.2×10−7) 2.016
rs705702 12 54676903 IKZF4 5.135 (2.8×10−7) 2.086
rs2292239 12 54768447 IKZF4 5.651 (1.6×10−8) 3.278
rs4766443 12 109864518 3.372 (7.5×10−4) 3.644
rs10774613 12 110008885 SH2B3 3.929 (8.5×10−5) 2.614
rs1265566 12 110179096 SH2B3 3.612 (3×10−4) 3.975
rs17696736 12 110949538 SH2B3 3.867 (1.1×10−4) 6.409
rs16961362 15 33731898 3.799 (1.5×10−4) 3.23
rs1711029 15 51491702 5.178 (2.2×10−7) 4.201
rs12924729 16 11095284 DEXI 3.741 (1.8×10−4) 3.784
rs1942707 18 60768535 4.279 (1.9×10−5) 1.642
SNP details Values (rank)
SNP Chr X1 X2 X3 X4
rs12045559 1 0.332 0.383 3.003 0.061 (15)
rs415024 5 0.344 0.394 3.012 0.083 (20)
rs1010599 5 0.538 0.72 (15) 3.186 (16) 0.078 (18)
rs4024109 5 0.456 0.561 (18) 3.115 (19) 0.107
rs17085170 5 0.832 1.353 (9) 3.477 (10) 0.022 (12)
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rs3114834 7 0.308 0.351 3.005 0.072 (17)
rs12549890 8 0.449 0.519 (19) 3.11 (20) 0.141
rs16874205 8 0.994 4.48 (3) 4.102 (4) 6.669×10−4 (3)
rs4076319 10 0.656 0.773 (14) 3.285 (15) 0.066 (16)
rs10736277 10 0.775 1.434 (8) 3.413 (12) 0.021 (11)
rs7912574 10 0.499 0.648 (16) 3.153 (17) 0.084
rs2065660 10 0.73 1.23 (11) 3.361 (14) 0.036 (13)
rs6578252 11 0.473 0.572 (17) 3.13 (18) 0.113
rs705698 12 0.934 0.871 (13) 3.656 (8) 1.241×10−3 (6)
rs705702 12 0.956 1.067 (12) 3.737 (6) 8.403×10−4 (4)
rs2292239 12 1 4.991 (2) 4.663 (2) 8.184×10−6 (1)
rs4766443 12 0.813 1.623 (7) 3.466 (11) 0.016 (10)
rs10774613 12 0.769 1.279 (10) 3.403 (13) 0.055 (14)
rs1265566 12 0.942 2.764 (5) 3.736 (7) 6.384×10−3 (8)
rs17696736 12 0.237 0.256 4.622 (3) 9.922×10−4 (5)
rs16961362 15 0.896 2.123 (6) 3.588 (9) 0.011 (9)
rs1711029 15 1 7.503 (1) 4.809 (1) 8.759×10−6 (2)
rs12924729 16 0.952 2.92 (4) 3.756 (5) 3.989×10−3 (7)
rs1942707 18 0.411 0.108 3.052 0.083 (19)
SNP details Summary statistics
SNP Chr p-val (X3) FDR (X4)
rs12045559 1 5.593×10−5 0.169
rs415024 5 5.415×10−5 0.247
rs1010599 5 2.092×10−5 0.23
rs4024109 5 3.072×10−5 0.357
rs17085170 5 4.695×10−6 0.046
rs3114834 7 5.504×10−5 0.213
rs12549890 8 3.154×10−5 0.48
rs16874205 8 2.768×10−7 3.612×10−3
rs4076319 10 1.269×10−5 0.186
rs10736277 10 6.581×10−6 0.045
rs7912574 10 2.528×10−5 0.25
rs2065660 10 8.529×10−6 0.091
rs6578252 11 2.87×10−5 0.374
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rs705698 12 2.016×10−6 6.997×10−3
rs705702 12 1.371×10−6 4.78×10−3
rs2292239 12 2.35×10−8 2.586×10−5
rs4766443 12 5.058×10−6 0.069
rs10774613 12 6.902×10−6 0.152
rs1265566 12 1.373×10−6 0.027
rs17696736 12 2.823×10−8 5.809×10−3
rs16961362 15 2.769×10−6 0.052
rs1711029 15 1.187×10−8 2.748×10−5
rs12924729 16 1.278×10−6 0.015
rs1942707 18 4.376×10−5 0.247
Table D.6 Top 20 SNPs differentiating T1D and RA (MHC removed), considered as sub-
groups of a general autoimmune phenotype, for each of four summary statistics. Positions
are in NCBI build 36. Because of the large number of SNPs with evidence for differentiating
the subgroups, only SNPs with non-zero weights after applying the LDAK procedure are
included in this table. Ranks in X2 (bracketed) are only amongst SNPs with X1 > 0.7; ranks in
X3 and X4 are amongst all SNPs. The value X1 is the posterior probability of category 3 mem-
bership (SNPs differentiating subgroups); X2 is the contribution to the pseudo-likelihood ratio
from the SNP; X3 is a weighted geometric mean of Za and Zd and X4 is the conditional false
discovery rate for observations za and zd at the SNP; that is, Pr(H ′0
∣∣|Zd| ≤ |zd|, |Za| ≤ |za|),
where H ′0 is the hypothesis that the SNP has the same population minor allele frequencies
in subgroups. P-values are computed based on X3, under the null hypothesis that (Za,Zd)
has a joint mixture bivariate Gaussian distribution consistent with H0. A value X4 = α does
not correspond to a false-discovery rate of α amongst SNPs with X4 ≤ α; the correspond-
ing value, P(H ′0|X4 < α) is given in the rightmost column. Potential gene associations are
marked.
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SNP details Z scores
SNP Chr Pos Gene |Zd|(p) |Za|
rs17013326 1 113801358 PTPN22 3.007 (2.6×10−3) 4.509
rs1230666 1 113885452 PTPN22 4.327 (1.5×10−5) 6.265
rs6679677 1 114015850 PTPN22 6.52 (7×10−11) 7.437
rs6661817 1 114159076 PTPN22 3.372 (7.5×10−4) 3.26
rs3811019 1 114183625 PTPN22 3.353 (8×10−4) 3.609
rs12061474 1 201120971 PIK3C2B 3.252 (1.1×10−3) 3.153
rs903228 2 53603700 0.077 (0.94) 5.085
rs7666328 4 116140909 0.425 (0.67) 5.593
rs2544677 5 86435018 3.272 (1.1×10−3) 3.661
rs2112168 5 86440646 3.199 (1.4×10−3) 3.335
rs7917983 10 114722872 TCF7L2 4.357 (1.3×10−5) 3.303
rs7901275 10 114722896 TCF7L2 4.331 (1.5×10−5) 3.287
rs7901695 10 114744078 TCF7L2 7.691 (1.5×10−14) 2.215
rs12243326 10 114778805 TCF7L2 6.645 (3×10−11) 1.889
rs3741939 12 3517792 4.885 (1×10−6) 0.473
rs705698 12 54670954 IKZF4 4.494 (7×10−6) 2.569
rs705702 12 54676903 IKZF4 4.554 (5.3×10−6) 2.624
rs2292239 12 54768447 IKZF4 5.026 (5×10−7) 3.78
rs4766443 12 109864518 SH2B3 3.44 (5.8×10−4) 3.025
rs10774613 12 110008885 SH2B3 4.415 (1×10−5) 2.223
rs1265566 12 110179096 SH2B3 3.398 (6.8×10−4) 3.276
rs17696736 12 110949538 SH2B3 4.981 (6.3×10−7) 4.788
rs12924729 16 11095284 SH2B3 4.236 (2.3×10−5) 3.563
rs7193144 16 52368187 FTO 4.493 (7×10−6) 2.139
rs8050136 16 52373776 FTO 4.442 (8.9×10−6) 2.127
rs9926289 16 52378004 FTO 4.19 (2.8×10−5) 1.985
rs2542151 18 12769947 PTPN2 5.278 (1.3×10−7) 2.866
SNP details Values (rank)
SNP Chr X1 X2 X3 X4
rs17013326 1 0.957 3.169 (7) 3.741 (9) 3.431×10−3 (13)
rs1230666 1 1 14.651 (2) 5.283 (2) 1.512×10−5 (6)
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rs6679677 1 1 22.963 (1) 6.999 (1) 7.052×10−11 (1)
rs6661817 1 0.573 0.801 3.311 (17) 0.021
rs3811019 1 0.768 1.413 (14) 3.489 (11) 9.448×10−3 (17)
rs12061474 1 0.422 0.511 3.198 (20) 0.036
rs903228 2 0.726 1.425 (13) 0.738 ≥ 0.5
rs7666328 4 0.954 3.307 (6) 1.706 ≥ 0.5
rs2544677 5 0.753 1.36 (15) 3.476 (12) 9.796×10−3 (18)
rs2112168 5 0.503 0.664 3.272 (18) 0.03
rs7917983 10 0.973 2.988 (8) 3.752 (8) 8.059×10−4 (9)
rs7901275 10 0.969 2.895 (9) 3.732 (10) 8.347×10−4 (10)
rs7901695 10 1 1 (16) 3.93 (5) 1.566×10−10 (2)
rs12243326 10 1 0.447 (20) 3.372 (14) 7.82×10−8 (3)
rs3741939 12 0.713 0 1.386 0.016 (19)
rs705698 12 0.907 1.492 (12) 3.324 (16) 2.223×10−3 (12)
rs705702 12 0.932 1.673 (11) 3.383 (13) 1.886×10−3 (11)
rs2292239 12 1 5.14 (4) 4.31 (4) 1.186×10−5 (5)
rs4766443 12 0.474 0.586 3.21 (19) 0.032
rs10774613 12 0.783 0.804 (17) 3.049 6.221×10−3 (16)
rs1265566 12 0.601 0.867 3.332 (15) 0.021
rs17696736 12 1 8.774 (3) 4.876 (3) 2.532×10−6 (4)
rs12924729 16 0.98 3.46 (5) 3.859 (6) 4.771×10−4 (8)
rs7193144 16 0.803 0.747 (18) 3.011 4.761×10−3 (14)
rs8050136 16 0.768 0.689 (19) 2.986 5.919×10−3 (15)
rs9926289 16 0.519 0.337 2.8 0.018 (20)
rs2542151 18 0.998 2.619 (10) 3.797 (7) 7.514×10−5 (7)
SNP details Summary statistics
SNP Chr p-val (X3) FDR (X4)
rs17013326 1 9.501×10−7 0.026
rs1230666 1 9.121×10−10 8.1×10−5
rs6679677 1 3.583×10−14 2.658×10−10
rs6661817 1 7.411×10−6 0.128
rs3811019 1 3.046×10−6 0.057
rs12061474 1 1.366×10−5 0.234
rs903228 2 0.372 ≥ 0.5
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rs7666328 4 0.021 ≥ 0.5
rs2544677 5 3.278×10−6 0.059
rs2112168 5 9.241×10−6 0.192
rs7917983 10 9.129×10−7 5.483×10−3
rs7901275 10 9.996×10−7 5.325×10−3
rs7901695 10 4.229×10−7 5.471×10−10
rs12243326 10 5.464×10−6 3.365×10−7
rs3741939 12 0.066 0.096
rs705698 12 7.058×10−6 0.016
rs705702 12 5.177×10−6 0.013
rs2292239 12 8.463×10−8 6.252×10−5
rs4766443 12 1.264×10−5 0.208
rs10774613 12 3.07×10−5 0.042
rs1265566 12 6.733×10−6 0.126
rs17696736 12 6.675×10−9 1.263×10−5
rs12924729 16 5.72×10−7 3.029×10−3
rs7193144 16 3.735×10−5 0.033
rs8050136 16 4.257×10−5 0.041
rs9926289 16 1.203×10−4 0.109
rs2542151 18 7.456×10−7 4.5×10−4
Table D.9 Top 20 SNPs differentiating T1D and T2D (MHC removed), considered as
subgroups of a general diabetic phenotype, for each of four summary statistics. Positions are
in NCBI build 36. Because of the large number of SNPs with evidence for differentiating the
subgroups, only SNPs with non-zero weights after applying the LDAK procedure are included
in this table. Ranks in X2 (bracketed) are only amongst SNPs with X1 > 0.7; ranks in X3 and
X4 are amongst all SNPs. The value X1 is the posterior probability of category 3 membership
(SNPs differentiating subgroups); X2 is the contribution to the pseudo-likelihood ratio from
the SNP; X3 is a weighted geometric mean of Za and Zd and X4 is the conditional false
discovery rate for observations za and zd at the SNP; that is, Pr(H ′0
∣∣|Zd| ≤ |zd|, |Za| ≤ |za|),
where H ′0 is the hypothesis that the SNP has the same population minor allele frequencies
in subgroups. P-values are computed based on X3, under the null hypothesis that (Za,Zd)
has a joint mixture bivariate Gaussian distribution consistent with H0. A value X4 = α does
not correspond to a false-discovery rate of α amongst SNPs with X4 ≤ α ; the corresponding
value, P(H ′0|X4 < α) is given in the rightmost column. Potential gene associations are
marked.
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SNP details Z scores
SNP Chr Pos Gene |Zd|(p) |Za|
rs10858002 1 113794974 PTPN22 2.997 (2.7×10−3) 3.44
rs17013326 1 113801358 PTPN22 2.465 (0.01) 4.223
rs1230666 1 113885452 PTPN22 5.326 (1×10−7) 5.801
rs6679677 1 114015850 PTPN22 7.137 (9.5×10−13) 6.9
rs3811019 1 114183625 PTPN22 2.943 (3.3×10−3) 3.132
rs10931347 2 189007813 3.014 (2.6×10−3) 2.984
rs6846031 4 178394297 3.474 (5.1×10−4) 2.908
rs11970411 6 138220854 TNFAIP3 3.601 (3.2×10−4) 2.402
rs3114834 7 109192112 3.092 (2×10−3) 3.204
rs16874205 8 107271324 3.042 (2.4×10−3) 3.866
rs2104286 10 6139051 IL2RA 3.911 (9.2×10−5) 2.842
rs7917983 10 114722872 TCF7L2 2.296 (0.02) 3.823
rs7901275 10 114722896 TCF7L2 2.064 (0.04) 4.016
rs7901695 10 114744078 TCF7L2 5.689 (1.3×10−8) 2.203
rs12243326 10 114778805 TCF7L2 4.592 (4.4×10−6) 2.087
rs10736277 10 121705898 TCF7L2 2.992 (2.8×10−3) 3.064
rs770738 12 10034164 DEXI 2.364 (0.02) 3.698
rs1495377 12 69863368 TSPAN8 4.302 (1.7×10−5) 2.063
rs7961581 12 69949369 TSPAN8 3.715 (2×10−4) 2.935
rs551714 13 20436464 2.381 (0.02) 3.659
rs1711029 15 51491702 2.742 (6.1×10−3) 4.722
rs1054028 16 22834715 3.063 (2.2×10−3) 3.222
rs7193144 16 52368187 FTO 2.469 (0.01) 3.622
rs8050136 16 52373776 FTO 2.575 (0.01) 3.548
rs896136 17 35904973 IKZF3 3.02 (2.5×10−3) 3.122
SNP details Values (rank)
SNP Chr X1 X2 X3 X4
rs10858002 1 0.413 0.472 (11) 3.171 (11) 0.042 (11)
rs17013326 1 0.743 0.933 (6) 3.072 (15) 0.029 (8)
rs1230666 1 1 10.802 (2) 5.515 (2) 1.508×10−7 (2)
rs6679677 1 1 19.721 (1) 7.039 (1) 9.563×10−13 (1)
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rs3811019 1 0.207 0.199 3.019 (19) 0.11
rs10931347 2 0.17 0.163 3.002 (20) 0.14
rs6846031 4 0.324 0.379 (13) 3.23 (9) 0.053 (12)
rs11970411 6 0.161 0.181 3.052 (17) 0.162
rs3114834 7 0.305 0.328 (14) 3.137 (12) 0.07 (14)
rs16874205 8 0.748 1.213 (5) 3.355 (7) 0.013 (6)
rs2104286 10 0.554 0.804 (8) 3.433 (4) 0.03 (9)
rs7917983 10 0.356 0.283 (16) 2.828 0.08 (16)
rs7901275 10 0.407 0.268 (17) 2.709 0.093
rs7901695 10 0.987 4.345 (3) 3.861 (3) 6.625×10−5 (3)
rs12243326 10 0.587 0.912 (7) 3.326 (8) 0.01 (4)
rs10736277 10 0.194 0.188 3.021 (18) 0.113
rs770738 12 0.298 0.236 2.838 0.084 (19)
rs1495377 12 0.369 0.483 (10) 3.186 (10) 0.032 (10)
rs7961581 12 0.486 0.655 (9) 3.373 (6) 0.025 (7)
rs551714 13 0.28 0.221 2.838 0.086 (20)
rs1711029 15 0.971 2.145 (4) 3.424 (5) 0.011 (5)
rs1054028 16 0.302 0.322 (15) 3.127 (13) 0.074 (15)
rs7193144 16 0.29 0.245 2.888 0.081 (18)
rs8050136 16 0.287 0.255 2.936 0.081 (17)
rs896136 17 0.23 0.231 3.061 (16) 0.094
SNP details Summary statistics
SNP Chr p-val (X3) FDR (X4)
rs10858002 1 1.492×10−5 0.27
rs17013326 1 2.656×10−5 0.172
rs1230666 1 6.511×10−11 1.391×10−6
rs6679677 1 3.084×10−15 8.924×10−12
rs3811019 1 3.64×10−5 ≥ 0.5
rs10931347 2 3.952×10−5 ≥ 0.5
rs6846031 4 1.041×10−5 0.326
rs11970411 6 2.948×10−5 ≥ 0.5
rs3114834 7 1.822×10−5 0.452
rs16874205 8 5.053×10−6 0.077
rs2104286 10 3.19×10−6 0.185
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rs7917983 10 1.079×10−4 0.478
rs7901275 10 2.092×10−4 ≥ 0.5
rs7901695 10 3.159×10−7 5.521×10−4
rs12243326 10 6.013×10−6 0.056
rs10736277 10 3.562×10−5 ≥ 0.5
rs770738 12 1.021×10−4 0.478
rs1495377 12 1.37×10−5 0.197
rs7961581 12 4.576×10−6 0.145
rs551714 13 1.021×10−4 0.49
rs1711029 15 3.406×10−6 0.058
rs1054028 16 1.903×10−5 0.458
rs7193144 16 7.761×10−5 0.491
rs8050136 16 5.855×10−5 0.489
rs896136 17 2.826×10−5 ≥ 0.5
Table D.12 Top 20 SNPs differentiating T2D and RA (MHC removed), considered as
subgroups of a general phenotype, for each of four summary statistics. Positions are in
NCBI build 36. Because of the large number of SNPs with evidence for differentiating the
subgroups, only SNPs with non-zero weights after applying the LDAK procedure are included
in this table. Ranks in X2 (bracketed) are only amongst SNPs with X1 > 0.7; ranks in X3 and
X4 are amongst all SNPs. The value X1 is the posterior probability of category 3 membership
(SNPs differentiating subgroups); X2 is the contribution to the pseudo-likelihood ratio from
the SNP; X3 is a weighted geometric mean of Za and Zd and X4 is the conditional false
discovery rate for observations za and zd at the SNP; that is, Pr(H ′0
∣∣|Zd| ≤ |zd|, |Za| ≤ |za|),
where H ′0 is the hypothesis that the SNP has the same population minor allele frequencies
in subgroups. P-values are computed based on X3, under the null hypothesis that (Za,Zd)
has a joint mixture bivariate Gaussian distribution consistent with H0. A value X4 = α does
not correspond to a false-discovery rate of α amongst SNPs with X4 ≤ α ; the corresponding
value, P(H ′0|X4 < α) is given in the rightmost column. Potential gene associations are
marked.
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SNP details Z scores
SNP Chr Pos Gene |Zd|(p) |Za|
rs6679677 1 114105331 PTPN22 2.568 (0.01) 9.84
rs2476601 1 114179091 PTPN22 2.649 (8.1×10−3) 9.88
rs7554023 1 160162988 ATF6?? 3.625 (2.9×10−4) 1.855
X2-204400444- 2 204400444 CTLA4 2.142 (0.03) 8.822
CA-DELETION
X2-204408002- 2 204408002 CTLA4 2.103 (0.04) 8.879
CCT-DELETION
rs58716662 2 204423821 CTLA4 2.447 (0.01) 5.968
rs78960870 2 204458162 CTLA4 2.171 (0.03) 6.143
rs13030124 2 204402508 CTLA4 2.091 (0.04) 8.871
rs3997876 2 179005067 PRKRA 7.863 (3.8×10−15) 10.102
rs3997878 2 179004872 PRKRA 7.358 (1.9×10−13) 9.467
rs6720771 2 154461782 4.091 (4.3×10−5) 0.428
rs6723546 2 154617139 4.137 (3.5×10−5) 0.76
rs12638263 3 187278549 BCL6 3.459 (5.4×10−4) 2.263
rs34244025 9 138290559 ESP33 4.649 (3.3×10−6) 1.426
rs34775390 9 138293196 ESP33 4.595 (4.3×10−6) 1.508
rs6582394 12 40972456 3.247 (1.2×10−3) 2.504
rs10220315 14 80197971 CEP128 2.947 (3.2×10−3) 4.818
rs10136185 14 80210225 CEP128 2.954 (3.1×10−3) 4.579
rs78304225 14 80276765 CEP128 2.853 (4.3×10−3) 4.249
rs327443 14 80291769 CEP128 3.331 (8.7×10−4) 6.025
rs327465 14 80299793 CEP128 4.731 (2.2×10−6) 6.653
rs55957493 14 80539807 CEP128 5.634 (1.8×10−8) 9.916
rs17545310 14 80540892 CEP128 2.844 (4.5×10−3) 6.223
rs2284734 14 80623486 CEP128 2.81 (5×10−3) 4.358
rs2284735 14 80623539 CEP128 2.99 (2.8×10−3) 3.781
SNP details Values (rank)
SNP Chr X1 X2 X3 X4
rs6679677 1 1 1.994 (8) 4.019 (7) 0.01 (14)
rs2476601 1 1 2.224 (7) 4.109 (5) 8.063×10−3 (11)
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rs7554023 1 0.11 0.064 2.899 0.012 (18)
X2-204400444- 2 1 1.015 (11) 3.435 (10) 0.044
CA-DELETION
X2-204408002- 2 1 0.907 (12) 3.399 (12) 0.041
CCT-DELETION
rs58716662 2 1 1.93 (9) 3.294 (14) 0.02
rs78960870 2 1 1.335 (10) 3.071 (20) 0.043
rs13030124 2 1 0.879 (13) 3.385 (13) 0.042
rs3997876 2 1 25.336 (1) 8.548 (1) 3.008×10−14 (1)
rs3997878 2 1 22.077 (2) 8.003 (2) 1.777×10−12 (2)
rs6720771 2 0.05 0.051 1.927 0.015 (20)
rs6723546 2 0.07 0.065 2.352 8.97×10−3 (12)
rs12638263 3 0.176 0.116 3.003 0.011 (17)
rs34244025 9 0.414 0.497 3.135 (19) 6.905×10−4 (6)
rs34775390 9 0.414 0.494 3.169 (18) 6.897×10−4 (5)
rs6582394 12 0.199 0.126 2.977 0.014 (19)
rs10220315 14 0.999 2.934 3.472 (9) 5.334×10−3 (8)
rs10136185 14 0.996 2.85 3.419 (11) 5.943×10−3 (9)
rs78304225 14 0.977 2.341 3.258 (15) 0.011 (16)
rs327443 14 1 4.141 (5) 4.059 (6) 1.628×10−3 (7)
rs327465 14 1 8.77 (4) 5.301 (4) 7.38×10−6 (4)
rs55957493 14 1 13.509 (3) 6.803 (3) 2.346×10−8 (3)
rs17545310 14 1 2.882 (6) 3.692 (8) 7.092×10−3 (10)
rs2284734 14 0.984 2.366 3.253 (16) 0.011 (15)
rs2284735 14 0.899 1.764 3.234 (17) 9.448×10−3 (13)
SNP details Summary statistics
SNP Chr p-val (X3) FDR (X4)
rs6679677 1 2.433×10−6 0.045
rs2476601 1 1.784×10−6 0.035
rs7554023 1 1.529×10−4 0.054
X2-204400444- 2 1.803×10−5 0.193
CA-DELETION
X2-204408002- 2 2.047×10−5 0.179
CCT-DELETION
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rs58716662 2 3.026×10−5 0.089
rs78960870 2 7.274×10−5 0.188
rs13030124 2 2.146×10−5 0.184
rs3997876 2 8.23×10−17 1.046×10−13
rs3997878 2 5.231×10−15 6.2×10−12
rs6720771 2 0.011 0.065
rs6723546 2 1.833×10−3 0.039
rs12638263 3 9.761×10−5 0.05
rs34244025 9 5.625×10−5 2.932×10−3
rs34775390 9 4.904×10−5 2.923×10−3
rs6582394 12 1.093×10−4 0.061
rs10220315 14 1.576×10−5 0.024
rs10136185 14 1.912×10−5 0.027
rs78304225 14 3.453×10−5 0.047
rs327443 14 2.122×10−6 7.152×10−3
rs327465 14 1.677×10−8 2.329×10−5
rs55957493 14 8.75×10−12 7.965×10−8
rs17545310 14 7.401×10−6 0.031
rs2284734 14 3.53×10−5 0.047
rs2284735 14 3.782×10−5 0.041
Table D.15 Top 20 SNPs differentiating Graves’ disease and Hashimoto’s thyroiditis (MHC
removed), considered as subgroups of autoimmune thyroid disease, for each of four summary
statistics. Positions are in NCBI build 37. Because of the density of the genotyping chip used
and the large number of SNPs with evidence of differentiating the subgroups, with non-zero
weights after applying the LDAK procedure are included in this table. The column ’LDAK’
gives the weight attributed to the SNP by the LDAK procedure. Ranks in X2 (bracketed) are
only amongst SNPs with X1 > 0.7; ranks in X3 and X4 are amongst all SNPs. The value X1
is the posterior probability of category 3 membership (SNPs differentiating subgroups); X2
is the contribution to the pseudo-likelihood ratio from the SNP; X3 is a weighted geometric
mean of Za and Zd and X4 is the conditional false discovery rate for observations za and
zd at the SNP; that is, Pr(H ′0
∣∣|Zd| ≤ |zd|, |Za| ≤ |za|), where H ′0 is the hypothesis that the
SNP has the same population minor allele frequencies in subgroups. P-values are computed
based on X3, under the null hypothesis that (Za,Zd) has a joint mixture bivariate Gaussian
distribution consistent with H0. A value X4 = α does not correspond to a false-discovery
rate of α amongst SNPs with X4 ≤ α ; the corresponding value, P(H ′0|X4 < α) is given in the
rightmost column. Potential gene associations are marked.
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SNP details Z scores
SNP Chr Pos Gene |Zd|(p) |Za|
rs231790 2 204408819 CTLA4 3.465 (5.3×10−4) 5.584
rs231797 2 204414352 CTLA4 3.466 (5.3×10−4) 5.567
rs231804 2 204416891 CTLA4 3.046 (2.3×10−3) 6.22
rs11571304 2 204417021 CTLA4 3.047 (2.3×10−3) 6.22
rs3087243 2 204447164 CTLA4 3.355 (7.9×10−4) 6.606
rs6748358 2 204465150 CTLA4 3.395 (6.9×10−4) 5.887
rs7596727 2 204491827 CTLA4 3.578 (3.5×10−4) 5.065
rs2352551 2 204503002 CTLA4 3.558 (3.7×10−4) 5.247
rs3757247 6 91014184 BACH2 4.037 (5.4×10−5) 3.683
rs11755527 6 91014952 BACH2 4.105 (4×10−5) 3.936
rs619192 6 91025670 BACH2 3.135 (1.7×10−3) 4.791
rs1847472 6 91029880 BACH2 3.465 (5.3×10−4) 4.389
rs604912 6 91043041 BACH2 3.144 (1.7×10−3) 4.762
rs17251453 12 91026211 4.26 (2×10−5) 2.593
rs12426486 12 91052228 4.433 (9.3×10−6) 2.671
rs7334298 13 41359622 4.442 (8.9×10−6) 2.566
rs9525555 13 41408305 4.44 (9×10−6) 2.525
rs9532960 13 41443676 4.377 (1.2×10−5) 2.418
rs16967120 15 36707739 RASGRP1 3.088 (2×10−3) 4.359
rs2839511 21 42721590 UBASH3A 3.533 (4.1×10−4) 4.47
SNP details Values (rank)
SNP Chr X1 X2 X3 X4
rs231790 2 0.979 2.672 (6) 3.825 0.047
rs231797 2 0.979 2.677 (5) 3.824 0.047
rs231804 2 0.925 1.764 3.531 0.031 (6)
rs11571304 2 0.925 1.764 3.532 0.032 (7)
rs3087243 2 0.94 2.163 (10) 3.86 (7) 0.036
rs6748358 2 0.969 2.471 (9) 3.805 0.044
rs7596727 2 0.987 2.958 (2) 3.845 (9) 0.044
rs2352551 2 0.986 2.904 (3) 3.856 (8) 0.043
rs3757247 6 0.952 2.611 (7) 3.961 (4) 0.015 (2)
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rs11755527 6 0.98 3.265 (1) 4.069 (1) 0.015 (1)
rs619192 6 0.971 2.124 3.423 0.03 (5)
rs1847472 6 0.975 2.579 (8) 3.638 0.02 (3)
rs604912 6 0.971 2.137 3.426 0.033 (9)
rs17251453 12 0.674 0.831 3.844 (10) 0.071
rs12426486 12 0.788 1.171 3.992 (2) 0.053
rs7334298 13 0.752 1.013 3.965 (3) 0.066
rs9525555 13 0.735 0.948 3.951 (5) 0.037
rs9532960 13 0.657 0.727 3.871 (6) 0.033 (8)
rs16967120 15 0.949 1.896 3.317 0.035 (10)
rs2839511 21 0.981 2.76 (4) 3.709 0.029 (4)
SNP details Summary statistics
SNP Chr p-val (X3) FDR (X4)
rs231790 2 2.179×10−6 0.067
rs231797 2 2.204×10−6 0.069
rs231804 2 1.07×10−5 0.034
rs11571304 2 1.064×10−5 0.036
rs3087243 2 1.812×10−6 0.044
rs6748358 2 2.45×10−6 0.062
rs7596727 2 1.946×10−6 0.062
rs2352551 2 1.845×10−6 0.059
rs3757247 6 1.046×10−6 0.017
rs11755527 6 5.814×10−7 0.016
rs619192 6 1.913×10−5 0.032
rs1847472 6 5.968×10−6 0.024
rs604912 6 1.866×10−5 0.039
rs17251453 12 1.951×10−6 0.12
rs12426486 12 8.797×10−7 0.079
rs7334298 13 1.017×10−6 0.107
rs9525555 13 1.102×10−6 0.048
rs9532960 13 1.696×10−6 0.038
rs16967120 15 3.361×10−5 0.043
rs2839511 21 4.072×10−6 0.03
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Table D.18 Top ten SNPs differentiating TPOA positive and negative T1D (MHC removed),
for each of four summary statistics. Positions are in NCBI build 36. Only SNPs with
positive weights after applying the LDAK procedure (and therefore used in fitting the model)
were considered here. Ranks in X2 (bracketed) are only amongst SNPs with X1 > 0.7;
ranks in X3 and X4 are amongst all SNPs. The value X1 is the posterior probability of
category 3 membership (SNPs differentiating subgroups); X2 is the contribution to the
pseudo-likelihood ratio from the SNP; X3 is a weighted geometric mean of Za and Zd
and X4 is the conditional false discovery rate for observations za and zd at the SNP; that
is, Pr(H ′0
∣∣|Zd| ≤ |zd|, |Za| ≤ |za|), where H ′0 is the hypothesis that the SNP has the same
population minor allele frequencies in subgroups. P-values are computed based on X3, under
the null hypothesis that (Za,Zd) has a joint mixture bivariate Gaussian distribution consistent
with H0. A value X4 = α does not correspond to a false-discovery rate of α amongst SNPs
with X4 ≤ α; the corresponding value, P(H ′0|X4 < α) is given in the rightmost column.
Potential gene associations are marked.
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SNP details Z scores
SNP Chr Pos Gene |Zd|(p) |Za|
rs231790 2 204408819 CTLA4 2.815 (4.9×10−3) 5.584
rs231797 2 204414352 CTLA4 2.795 (5.2×10−3) 5.567
rs11571293 2 204425958 CTLA4 2.834 (4.6×10−3) 5.995
rs6748358 2 204465150 CTLA4 2.847 (4.4×10−3) 5.887
rs7596727 2 204491827 CTLA4 2.944 (3.2×10−3) 5.065
rs2352551 2 204503002 CTLA4 2.949 (3.2×10−3) 5.247
rs1560418 3 159972335 4.541 (5.6×10−6) 1.21
rs1560417 3 159972476 4.543 (5.5×10−6) 1.213
rs511198 4 116234541 4.685 (2.8×10−6) 1.858
rs506851 4 116234970 4.746 (2.1×10−6) 1.956
rs503256 4 116244902 4.645 (3.4×10−6) 1.832
rs473989 4 116246844 4.687 (2.8×10−6) 1.781
rs505277 4 116248257 4.634 (3.6×10−6) 1.81
rs1507935 4 116368809 4.586 (4.5×10−6) 1.514
rs867036 4 116381578 4.581 (4.6×10−6) 1.515
rs7694946 4 116413588 4.693 (2.7×10−6) 1.963
rs706781 10 6126391 IL2RA 3.098 (1.9×10−3) 4.515
rs907092 17 35175785 IKZF3 3.746 (1.8×10−4) 4.221
rs11078927 17 35317931 IKZF3 3.774 (1.6×10−4) 4.168
rs4795400 17 35320546 IKZF3 3.569 (3.6×10−4) 4.106
SNP details Values (rank)
SNP Chr X1 X2 X3 X4
rs231790 2 0.971 1.953 (7) 2.978 0.143
rs231797 2 0.971 1.924 (8) 2.957 0.117
rs11571293 2 0.966 2.044 (4) 3.013 0.271
rs6748358 2 0.968 2.048 (3) 3.022 0.282
rs7596727 2 0.978 1.977 (6) 3.078 0.204
rs2352551 2 0.978 2.042 (5) 3.091 0.364
rs1560418 3 5.957×10−3 0.11 4.075 (10) 0.082
rs1560417 3 5.988×10−3 0.11 4.078 (9) 0.09
rs511198 4 0.025 0.131 4.344 (3) 0.039 (4)
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rs506851 4 0.033 0.141 4.413 (1) 0.07 (10)
rs503256 4 0.023 0.128 4.305 (5) 0.037 (3)
rs473989 4 0.021 0.128 4.33 (4) 0.045 (7)
rs505277 4 0.022 0.127 4.29 (6) 0.033 (1)
rs1507935 4 0.011 0.116 4.188 (7) 0.055 (8)
rs867036 4 0.011 0.115 4.184 (8) 0.056 (9)
rs7694946 4 0.032 0.138 4.37 (2) 0.088
rs706781 10 0.964 1.862 (10) 3.195 0.401
rs907092 17 0.958 2.227 (1) 3.783 0.045 (6)
rs11078927 17 0.951 2.175 (2) 3.805 0.045 (5)
rs4795400 17 0.927 1.868 (9) 3.61 0.035 (2)
SNP details Summary statistics
SNP Chr p-val (X3) FDR (X4)
rs231790 2 7.2×10−4 0.146
rs231797 2 7.831×10−4 0.117
rs11571293 2 6.162×10−4 0.447
rs6748358 2 5.989×10−4 0.494
rs7596727 2 4.648×10−4 0.276
rs2352551 2 4.349×10−4 ≥ 0.5
rs1560418 3 3.168×10−6 0.275
rs1560417 3 3.108×10−6 0.088
rs511198 4 6.607×10−7 0.137
rs506851 4 4.33×10−7 0.227
rs503256 4 8.292×10−7 0.131
rs473989 4 7.184×10−7 0.166
rs505277 4 9.08×10−7 0.113
rs1507935 4 1.644×10−6 0.168
rs867036 4 1.709×10−6 0.172
rs7694946 4 5.593×10−7 0.096
rs706781 10 2.764×10−4 ≥ 0.5
rs907092 17 1.565×10−5 0.163
rs11078927 17 1.392×10−5 0.161
rs4795400 17 3.785×10−5 0.121
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Table D.21 Top ten SNPs with differing effect sizes with age at diagnosis in T1D (MHC
removed), for each of four summary statistics. Positions are in NCBI build 36. Only SNPs
with positive weights after applying the LDAK procedure (and therefore used in fitting
the model) were considered here. Ranks in X2 (bracketed) are only amongst SNPs with
X1 > 0.7; ranks in X3 and X4 are amongst all SNPs. The value X1 is the posterior probability
of category 3 membership (SNPs differentiating subgroups); X2 is the contribution to the
pseudo-likelihood ratio from the SNP; X3 is a weighted geometric mean of Za and Zd
and X4 is the conditional false discovery rate for observations za and zd at the SNP; that
is, Pr(H ′0
∣∣|Zd| ≤ |zd|, |Za| ≤ |za|), where H ′0 is the hypothesis that the SNP has the same
population minor allele frequencies in subgroups. P-values are computed based on X3, under
the null hypothesis that (Za,Zd) has a joint mixture bivariate Gaussian distribution consistent
with H0. A value X4 = α does not correspond to a false-discovery rate of α amongst SNPs
with X4 ≤ α; the corresponding value, P(H ′0|X4 < α) is given in the rightmost column.
Potential gene associations are marked.
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Fig. D.1 Top plot shows Zd scores arising from geography-based subgroups compared with
expected normal. Leftmost plot shows quantiles of Z scores from geography based subgroups;
two-region subgroups in light grey and one-region subgroups in dark grey. Considerable
inflation is seen compared to Z-scores arising from random subgroups, in rightmost figure.
Lower plots show distribution of cPLR values from random subgroups against observed
PLR values from geographically-defined subgroups. Leftmost plot shows cPLR values from
random subgroups plotted in ascending with PLR values from random subgroups shown
in blue. Rightmost plot is Q-Q plot comparing null cPLR distribution with the asymptotic
mixture-χ2.
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Fig. D.2 Summary of test statistics (PLR) from geographically-defined subgroups, based
on WTCCC data [The Wellcome Trust Case Control Consortium, 2007] for controls and
type 1 diabetes (T1D). In each instance, one subgroup was defined as the controls coming
from either one or two geographic regions, and the other subgroup as the controls coming
from the remaining nine or ten geographic regions. I also generated > 2000 randomly
allocated subgroups and computed the cPLR. The left panel shows a Q-Q plot of cPLR values
from random subgroups against the asymptotic mixture-χ2 distribution, with blue points
representing the PLRs of geographic subgroups. The right panel shows cPLR values plotted
in ascending order with the PLR values from geographic subgroups included as blue points.
The minimum Bonferroni-corrected empirical p value was > 0.5
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N = 500 (pi3 = 0.01)
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N = 5000 (pi3 = 0.1)
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Fig. D.3 Estimates of power to reject H0 for subgrouping problem (α = 0.05) for various
values of π3, σ3, τ , and ρ . The value N is the approximate number of SNPs in category 3,
corresponding to π3. In total, each simulation was on 5×104 simulated autosomal SNPs in
linkage equilibrium. The value ρ/(σ3τ) is the correlation (rather than covariance) between
Za and Zd in category 3.
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N = 5000 (pi3 = 0.1)
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Fig. D.4 Estimates of power of alternative test statistic (K) to reject H0 (α = 0.05) for
subgrouping problem for various values of π3, σ3, τ , and ρ . The value N is the approximate
number of SNPs in category 3, corresponding to π3. In total, each simulation was on 5×104
simulated autosomal SNPs in linkage equilibrium. The value ρ/(σ3τ) is the correlation
(rather than covariance) between Za and Zd in category 3.
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(a) T1D/T2D/RA data
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(b) ATD:GH/HT data
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(c) T1D (AAB) data
Fig. D.5 Q-Q plot of the distribution of observed test statistics (cPLR) for random subgroups
of tested phenotypes (T1D/RA/T2D combined, GH/HT combined, T1D) against a mixture
χ2 distribution of the form γ ∗ (κχ21 +(1−κ)χ22 ). A 99% confidence interval is shown by
the dashed red lines. The distribution is well-approximated by the asymptotic mixture-χ2 in
all cases.
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Category
Fig. D.6 Observed Za and Zd scores (grey) for T1D subtypings based on autoantibody
positivity, including or excluding the MHC region, and contours of parameters of fitted
models (coloured ellipses). Full models are shown for the comparisons involving TPO-Ab,
GAD-Ab, and IA2-Ab, and null models for PCA-Ab (for which the null hypothesis could
not be rejected). Note the differing X-axis scales. The plots illustrate the rationale for the
three-category model; for TPO-Ab, GAD-Ab and IA2-Ab, a tendency is seen for SNPs
associated with autoantibody positivity (high |Zd|) to be associated with T1D also (high |Za|).
This tendency is not seen for PCA-Ab, and is minimal for non-MHC SNPs in GAD-Ab.
Further analysis of the plot for TPOAb positivity (top left) is shown below.
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Fig. D.7 Observed Za and Zd scores for T1D subclassified by age at diagnosis. Non-MHC
SNPs are shown in red.
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(a) T1D/RA comparison
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l ll
l
llll
l
l l
ll
l
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
ll
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l l
l
ll
l
l
l
l
ll
l
ll
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
ll
ll ll ll
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
ll
ll
l
l
l
l
l
l l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
ll ll
l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
ll
l
l
l
l l
ll
l l
l
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
llll
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
ll
l
ll
l
l
l l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll l
l
lll
l
l
l
ll
lll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
ll ll l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
lll
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
ll l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l l
l
l
l
l
l
l
l l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
ll
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l l ll
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
ll
ll
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l l
l
ll
l
l
l
l
l
ll
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
lll
l
l l
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l l
l
ll
l
l
l
ll
l
l
l
l
l
l l l
l
ll
l
l
l
l
l
l ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
ll
l l
l
l
l l
l
l
l
l
l l
l
l
l
l
ll
ll
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l ll
l
ll
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
lll
l
ll
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l l
l
ll
l
l
l
l
l
l
l
l
l
l
lll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
l
0 2 4 6 8
0
2
4
6
8
10
12
X1
Zd (between subgroups)
Z a
 
(ca
se
 vs
 co
ntr
ol)
l
l
l
l l
l
ll
l
ll
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
 
1e−05
 
 
1e−
04 
 
0.00
1 
 0.1  0.2  0.5  0.7 
 0.9 
Bl
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l ll
l
llll
l
l l
ll
l
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
ll
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l l
l
ll
l
l
l
l
ll
l
ll
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
ll
ll ll ll
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
ll
ll
l
l
l
l
l
l l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
ll ll
l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
ll
l
l
l
l l
ll
l l
l
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
llll
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
ll
l
ll
l
l
l l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll l
l
lll
l
l
l
ll
lll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
ll ll l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
lll
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
ll l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l l
l
l
l
l
l
l
l l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
ll
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l l ll
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
ll
ll
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l l
l
ll
l
l
l
l
l
ll
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
lll
l
l l
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l l
l
ll
l
l
l
ll
l
l
l
l
l
l l l
l
ll
l
l
l
l
l
l ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
ll
l l
l
l
l l
l
l
l
l
l l
l
l
l
l
ll
ll
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l ll
l
ll
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
lll
l
ll
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l l
l
ll
l
l
l
l
l
l
l
l
l
l
lll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
l
0 2 4 6 8
0
2
4
6
8
10
12
X2
Zd (between subgroups)
Z a
 
(ca
se
 vs
 co
ntr
ol)
l
l
l
l l
l
ll
l
ll
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l l
l
l l
ll
l
l
l
l
l  −0.5
 
 0 
 
0 
 0.5  1 
 2 
 4 
Bl
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l ll
l
llll
l
l l
ll
l
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
ll
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l l
l
ll
l
l
l
l
ll
l
ll
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
ll
ll ll ll
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
ll
ll
l
l
l
l
l
l l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
ll ll
l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
ll
l
l
l
l l
ll
l l
l
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
llll
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
ll
l
ll
l
l
l l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll l
l
lll
l
l
l
ll
lll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
ll ll l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
lll
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
ll l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l l
l
l
l
l
l
l
l l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
ll
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l l ll
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
ll
ll
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l l
l
ll
l
l
l
l
l
ll
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
lll
l
l l
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l l
l
ll
l
l
l
ll
l
l
l
l
l
l l l
l
ll
l
l
l
l
l
l ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
ll
l l
l
l
l l
l
l
l
l
l l
l
l
l
l
ll
ll
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l ll
l
ll
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
lll
l
ll
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l l
l
ll
l
l
l
l
l
l
l
l
l
l
lll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
l
0 2 4 6 8
0
2
4
6
8
10
12
X3
Zd (between subgroups)
Z a
 
(ca
se
 vs
 co
ntr
ol)
l
l
l
l l
l
ll
l
ll
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
 1  2 
 3 
 4 
 5 l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l ll
l
llll
l
l l
ll
l
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
l
l
l
ll
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l l
l
ll
l
l
l
l
ll
l
ll
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
ll
ll ll ll
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
ll
ll
l
l
l
l
l
l l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
ll ll
l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
ll
l
l
l
l l
ll
l l
l
l
l
l
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
llll
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l l
l
l
l
l
l
ll
l
ll
l
ll
l
l
l l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll l
l
lll
l
l
l
ll
lll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
ll ll l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l l
l
l
l
l
l
l ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
lll
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
ll l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l l
l
l
l
l
l
l
l l l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
ll
l
l
l
l
ll
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
ll l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l l ll
ll
l
l
l
l
l
l
l
l
l
l
l l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
ll
ll
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
ll
l
l l
l
ll
l
l
l
l
l
ll
l
l
l
ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
ll
ll
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
lll
l
l l
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l l
l
ll
l
l
l
ll
l
l
l
l
l
l l l
l
ll
l
l
l
l
l
l ll
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
ll
l l
l
l
l l
l
l
l
l
l l
l
l
l
l
ll
ll
ll
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l ll
l
ll
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
ll
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
lll
l
ll
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
ll
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l l
l
ll
l
l
l
l
l
l
l
l
l
l
lll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
lll
l
l
l
l
0 2 4 6 8
0
2
4
6
8
10
12
X4
Zd (between subgroups)
Z a
 
(ca
se
 vs
 co
ntr
ol)
l
l
l
l l
l
ll
l
ll
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll
l
l
l
l
l
l
l
ll
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
ll
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l ll
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l ll
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
lll l
ll
l
l l
 1e−05 
 1e−04 
 0.001 
 0.1 
 0.2 
 0.5 
D.2 Supplementary figures 379
(b) T1D/T2D comparison
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D.2 Supplementary figures 381
(d) GD/HT (ATD) comparison
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382 Supplementary tables and figures for chapter 5
Fig. D.8 I demonstrate all four test statistics for single-SNP effects in the comparisons betwen
T1D/T2D/RA, and between GD and HT (preceding pages). The top 100 SNPs for each test
statistic are highlighted, with larger symbols corresponding to SNPs with non-zero weights
after applying LDAK [Speed et al., 2012]; that is, the SNPs which contributed to the model
fit. Contours of each test statistic are shown in grey.
Differences are evident in the behaviour of the test statistics X1 and X2 between the two
datasets; X3 and X4 are more robust. The different null hypotheses between X3 and X4 are
responsible for the difference in shape near the line Za = 0. Contours of X4 are jagged due to
the dependence of this statistic on the distribution of Z scores.
All methods primarily identified SNPs with both high |Za| and |Zd| scores as contributors.
As evident from the comparison between GH and HT, the statistic X1 is vulnerable to falsely
declaring SNPs as subgroup-differentiating despite low |Zd| scores (labelled ’A’, top left
panel, GD/HT). This arises due to the full model having a markedly higher value of σ3 than
σ2, leading to SNPs with very high |Za| values having a high posterior probability of category
3 membership.
This is partially able to be overcome by combining the test statistics X1 and X2 into one,
which I typically do by only considering X2 scores in SNPs with X1 greater than some cutoff.
However, this is not always effective, as is evident from the above figure for T1D/T2D.
In this case, as discussed in the main paper, almost all SNPs with high Za also had high
Zd , meaning that the two distributions forming categories 2 and 3 under the null model
were essentially the same. This led to the fitted parameters of the null model supporting
SNPs falling into two distributions; one with identity covariance matrix, and the other with
var(Zd)> 1, var(Za) = 1 (see fitted parameters).
The different alternative hypothesis for X4 (different population MAFs in subgroups without
requiring association with the phenotype overall) meant that SNPs with low |Za| scores may
be identified by X4 in addition to those identified by X1, X2 and X3 (contour lines on bottom
right panel, both figures). SNPs which are isolated may be missed by both X1 and X2 (label
’B’, top two panels, T1D/RA), due to the fitted distribution of SNPs in category 3 tending to
be driven by clusters of SNPs.
Given these results, I consider X3 and X4 to generally be the most appropriate measure
for single SNP effects, although in appropriate circumstances X2 can be used alone or
conditionally on X1.
D.2 Supplementary figures 383
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Fig. D.9 I assessed the SNPs responsible for the observed difference in pseudo-likelihood
ratio for my analysis of TPOAb positivity in T1D. SNPs in the MHC region were removed
from the analysis (co-ordinates 25-38 Mb, GChR build 37). I combined X1 and X2 into a
single test statistic, by only considering SNPs with X1 > 0.7 and then considering the top
SNPs for X2. The top ten SNPs for X2|X1 > 0.7 (blue, top two panels), X3 (purple, bottom
left panel), and X4 (red, bottom right panel) are shown. Contours of each summary statistic
are shown as black lines. Details of SNPs are shown in appendix D.1.
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Fig. D.10 I assessed the SNPs responsible for the observed difference in pseudo-likelihood
ratio for my analysis of age at diagnosis in T1D. SNPs in the MHC region were removed
from the analysis (co-ordinates 25-38 Mb, GChR build 37). I combined X1 and X2 into a
single test statistic, by only considering SNPs with X1 > 0.7 and then considering the top
SNPs for X2. The top ten SNPs for X2|X1 > 0.7 (blue, top two panels), X3 (purple, bottom
left panel), and X4 (red, bottom right panel) are shown. Contours of each summary statistic
are shown as black lines. Details of SNPs are shown in appendix D.1.
